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Summary 
α-Galactosylceramide (α-GalCer), a structurally optimized glycosphingolipid derived from 
extracts of the marine sponge Agelas mauritianus, is nowadays known as the prototypical 
ligand for invariant natural killer T (iNKT) cells. Following complexation with the antigen 
presenting glycoprotein CD1d, α-GalCer is recognized by the T cell receptor (TCR) of iNKT 
cells, resulting in the rapid release of both T helper 1 (Th1) and T helper 2 (Th2) cytokines. 
Th1 cytokines, such as IFN-γ, are involved in antitumor, antiviral and antibacterial responses, 
while Th2 cytokines, like IL-4, can ameliorate autoimmune diseases. Unfortunately, both 
types of cytokines tend to antagonize each other’s biological effect, limiting the clinical 
effectiveness of α-GalCer. Hence, analogues capable of inducing a Th1/Th2 biased response 
are highly awaited. Towards this end, numerous modifications of all parts of α-GalCer, i.e. the 
galactose, the phytosphingosine and the acyl moieties, have already been investigated. An 
overview is given in Chapter 1. 
S.A.R. studies revealed a wide variety of possible alterations in the ceramide part resulting in 
a shifted cytokine profile. By contrast, successful modifications of the galactose moiety are 
rather scarce and chiefly limited to the 6”-position. Encouraged by the Th1 biased response of 
certain C-6”-derivatised analogues, designed earlier in our laboratory, we decided to further 
explore modifications at this position. A divergent synthetic approach was developed that 
provides access to both 6”-O- and 6”-N-altered as well as 5”-modified α-GalCer analogues, 
and that allows late-stage introduction of alternative acyl chains. The elaboration of our 
methodology is described in Chapter 3, together with its application for the synthesis of two 
known Th1-featuring compounds, α-D-fucopyranosylceramide and α-D-galacturonosyl-
ceramide, as well as two C6Ph acyl variants. 
Chapter 4 describes the introduction of several new C-5” and C-6”-modifications, starting 
from a common key intermediate. A first group consists of seven aromatic-substituted 
uronamides and three C-6”-carbamates. With one exception, in vivo activation of mice iNKT 
cells by these compounds results in a Th1 polarization. The strongest Th1 antigens are found 
in the class of C-6”-carbamates, which also contains a Th2 polarizer. These C-6”-carbamates 
exhibit significantly enhanced antimetastatic effects in a B16 melanoma mouse model. 
Compared to α-GalCer, they were shown to interact much longer with CD1d. For two 
compounds this is reflected by the formation of more intimate contacts with CD1d. Strikingly, 
these additional contacts were not found for the strongest Th1 polarizer that, by contrast, 
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showed a novel interaction with the TCR. Hence, a clear relationship with the observed iNKT 
cell responses could not be established. 
Secondly, a series of six α-GalCer analogues with differently 4-substituted 1,2,3-triazol-1-yl 
moieties connected to the 6”-position were synthesized. Both the phenyl-substituted 
derivatives as well as the butyl- and non-substituted compounds were able to stimulate iNKT 
cells better than α-GalCer in an in vitro mouse setting. We inferred that this increase in 
antigenic activity is mainly due to the triazole functionalization. 
Additionally, a Th1-featuring C-5” and C-6”-modification was combined with an OCH 
ceramide moiety. Biological evaluation of these analogues demonstrated a reduced IFN-γ 
potential compared to their parent C-5”/C-6”-modified compounds. 
The synthetic route was also utilized for the preparation of two C-6”-labeled α-GalCer 
derivatives, to be used in competition binding experiments. 
Finally, Chapter 5 is dedicated to the synthesis of a potential iNKT cell antagonist that might 
be useful in the treatment of allergic inflammatory diseases, such as asthma, and other 
disorders characterized by inappropriate or excessive iNKT cell activation. Several attempts 
were needed to acquire the envisioned C-6”-naphthylurea α-mannosylceramide. The eventual 
succesful synthetic route also allowed late-stage conversion to the corresponding α-glucosyl 
derivative. Unfortunately, the preliminary biological experiments with NU-α-ManCer failed 
to show any antagonistic potential. 
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Samenvatting 
α-Galactosylceramide (α-GalCer) is een structureel geoptimaliseerd glycosfingolipide, 
gebaseerd op extracten van de zeespons Agelas mauritianus, en wordt beschouwd als het 
prototype ligand voor de invariant natural killer T (iNKT) cellen. Na complexatie met het 
antigen-presenterend glycoproteïne CD1d wordt α-GalCer herkend door de T cel receptor 
(TCR) van deze iNKT cellen, die vervolgens gestimuleerd worden tot de productie van zowel 
T helper 1 (Th1) als T helper (Th2) cytokines. Th1 cytokines, zoals IFN-γ, spelen een rol in 
antitumorale, antivirale en antibacteriële responsen. Th2 cytokines daarentegen, zoals IL-4, 
kunnen auto-immuunziekten tegengaan. Helaas werken beide types cytokines elkaars 
biologisch effect tegen waardoor de klinische effectiviteit van α-GalCer beperkt is. Bijgevolg 
zijn analogen die de iNKT cel respons kunnen sturen naar een Th1 of Th2 richting dan ook 
sterk gewenst. Hiervoor werden reeds verschillende wijzigingen aangebracht aan de drie 
structurele onderdelen van α-GalCer, met name het galactosegedeelte, de fytosfingosineketen 
en de acylstaart. Een overzicht hiervan wordt weergegeven in Hoofdstuk 1. 
Studies naar de structuur-activiteits-relatie (S.A.R.) hebben aangetoond dat het 
ceramidegedeelte op verschillende plaatsten kan veranderd worden teneinde een gepolariseerd 
cytokineprofiel te bekomen. Succesvolle wijzigingen aan het galactosegedeelte daarentegen 
zijn eerder schaars en voornamelijk beperkt tot de 6”-positie. Geïnspireerd door de Th1 
polarizerende eigenschappen van bepaalde C-6”-derivaten die eerder in ons laboratorium 
gesynthetiseerd werden, hebben we besloten bijkomende modificaties aan deze positie te 
verkennen. Hiervoor werd een divergente syntheseroute ontwikkeld, die de mogelijkheid 
biedt om zowel 6”-O- als 6”-N-gemodifeerde α-GalCer analogen te bekomen, alsook 
analogen gewijzigd ter hoogte van C-5”. Bovendien kunnen in een laat stadium van de 
synthese wisselende acylketens ingevoerd worden. De uitwerking van deze methode staat 
beschreven in Hoofdstuk 3, samen met de toepassing ervan op de synthese van twee gekende 
Th1-polarizerende analogen, namelijk α-D-fucopyranosylceramide en α-D-galacturonosyl-
ceramide. Daarnaast werden ook twee nieuwe varianten van deze verbindingen bereid, waarin 
de conventionele acylketen vervangen werd door een 6-phenylhexanoylketen (C6Ph). 
Hoofdstuk 4 beschrijft de invoering van verscheidene nieuwe C-5” en C-6”-modificaties, 
vertrekkende vanuit een gemeenschappelijk sleutelintermediair. Een eerste groep bestaat uit 
zeven aromatisch gesubstitueerde uronamiden en drie C-6”-carbamaten. Op één uitzondering 
na induceren al deze verbindingen een Th1 gepolarizeerde respons in vivo in muizen. De 
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sterkste Th1 antigenen bevinden zich in de klasse van de C-6”-carbamaten, die daarnaast ook 
een Th2 polarizerende verbinding bevat. Deze C-6”-carbamaten oefenen significant betere 
antimetastatische effecten uit in een B16 melanoma muis model. In vergelijking met α-GalCer 
interageren deze analogen veel langer met CD1d. Voor twee componenten wordt dit 
weerspiegeld door de vorming van meer en betere contacten met CD1d. Dit werd echter niet 
teruggevonden voor de sterkste Th1 polarizer, die daarentegen een nieuwe interactie met de 
TCR vertoonde. Bijgevolg was het niet mogelijk om een algemeen verband te leggen met de 
waargenomen iNKT cel responsen. 
In tweede instantie werd een serie van zes α-GalCer analogen gesynthetiseerd met 
verschillende 4-gesubstitueerde 1,2,3-triazool-1-yl groepen ter hoogte van de 6”-positie. In 
een in vitro experiment met muis iNKT cellen vertoonden zowel de derivaten met een 
fenylsubstituent en een butylgroep, alsook de niet-gesubstitueerde variant, een betere 
stimulerende capaciteit dan α-GalCer. Hieruit hebben wij geconcludeerd dat de verhoogde 
antigene activiteit van deze analogen voornamelijk te wijten is aan de ingevoerde 
triazoolgroep. 
Bijkomend werden twee analogen bereid die een C-5” en C-6”-modificatie combineren met 
een OCH-ceramide. Biologische evaluatie van deze verbindingen heeft aangetoond dat hun 
IFN-γ potentieel significant verlaagd is ten opzichte van de C-5”/C-6”-gemodificeerde 
referentieverbindingen. 
Verder werd de syntheseroute ook nog aangewend voor de bereiding van twee C-6”-gelabelde 
analogen. Deze verbindingen zullen toegepast worden in bindingscompetitie experimenten. 
Tot slot wordt in Hoofdstuk 5 de synthese van een mogelijke iNKT cel antagonist beschreven. 
Een dergelijke antagonist zou nuttig kunnen zijn voor de behandeling van inflammatoire 
allergiën zoals astma, alsook van andere aandoeningen die gekenmerkt worden door een 
overmatige activatie van iNKT cellen. Om het beoogde C-6”-naftylureum-α-
mannosylceramide derivaat te kunnen bekomen waren verschillende pogingen nodig. De 
uiteindelijk succesvolle syntheseroute liet toe om in een laat stadium het α-mannosylderivaat 
om te vormen naar het overkomstige α-glucosylderivaat. Helaas konden preliminaire 
biologische experimenten met NU-α-ManCer geen antagonistische eigenschappen aantonen. 
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1 Introduction 
The immune system, classically divided into two arms, provides protection of the organism 
from invading pathogens and is responsible for the elimination of modified or altered cells. 
The innate immune system acts as a first line of defense associated with a rapid nonspecific 
response to a variety of microorganisms. By contrast, the acquired or adaptive immune system 
is rather slow-responding and reacts upon recognition of specific antigens. Furthermore it is 
characterized by the generation of immunological memory, ensuring a more rapid and 
effective response on subsequent exposure to the same pathogen. 
Basically, microbial invasion is prevented by anatomical barriers such as the skin and the 
mucosal epithelia lining the respiratory, gastrointestinal and urogenital tracts. However, once 
infectious agents have penetrated tissues, both cellular as well as humoral components of the 
nonspecific system are brought into play causing an inflammatory response. Thereby, the first 
encountered immune cells are macrophages. Together with neutrophiles and dendritic cells 
(DCs) they belong to the family of phagocytic cells, capable of engulfing and digesting many 
pathogens. In addition, macrophages and DCs act as antigen-presenting cells (APC), 
necessary for initiating the adaptive immune response at a later stage. Other innate immune 
cells are eosinophils, basophils and mast cells, primarily exhibiting a secretory function. 
Finally, natural killer (NK) cells can recognize and kill modified cells through the release of 
lytic granules. The major humoral barrier of the innate arm is the complement system, 
composed of over twenty soluble proteins which induce a rapid killing response. This 
involves a catalytic cascade resulting in an increase of the vascular permeability, opsonization 
and recruitment of immune cells as well as direct killing of the microorganism through 
membrane lysis. 
Detection of an altered homeostatic state by the innate immune system occurs through a 
limited repertoire of proteins, known as pattern recognition receptors (PRRs). These receptors 
are able to identify conserved components among a broad range of microorganisms in 
addition to alarm signals send out by stressed or damaged cells. Recognition of a so-called 
pathogen- or damage-associated molecular pattern (PAMP or DAMP) triggers the innate 
immune cells and proteins to eliminate the threat via their various effector mechanisms. Some 
activated cells including macrophages and DCs also release cytokines, which serve as 
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chemical mediators to attract other innate immune cells to the site of infection and contribute 
to the activation of the adaptive immune system. 
An adaptive immune response is initiated when the innate system fails to eliminate the 
infectious agent and is achieved by specialized leucocytes, called lymphocytes. Among them, 
B cells are involved in humoral immune responses, while T cells mediate cellular immune 
responses. Both cell types express highly pathogen-specific receptors and are characterized by 
clonal expansion and differentiation into effector cells upon exposure to specific peptide 
antigens. A subset of the proliferating cells also differentiates into memory cells that persist 
after the infection, forming the basis of immunological memory. 
Naive T lymphocytes constitute two major subtypes, CD4
+
 and CD8
+
 T cells. In contrast to B 
cells they cannot recognize soluble antigens but require association of the antigen with a 
major histocompatibility complex (MHC). In particular for CD4
+
 T cells, antigens are 
displayed on MHC II molecules at the surface of antigen-presenting molecules (macrophages, 
DCs and B cells), while CD8
+
 T cells recognize antigens presented by MHC I molecules, for 
example at the surface of virus-infected cells or tumor cells. As a result of their activation, the 
naive T cells differentiate into either Th1 and Th2 cells in case of CD4
+
 T cells or cytotoxic T 
(Tc) cells in case of CD8
+
 cells. In turn, Th1 cells release pro-inflammatory cytokines such as 
interferon-γ (IFN-γ) and tumor necrosis factor (TNF), thereby activating macrophages and 
NK cells. By contrast, Th2 cells produce anti-inflammatory cytokines including interleukine-4 
(IL-4) leading to the activation of B cells. CD8
+
 Tc cells on the other hand destroy viral-
infected or tumor cells by means of perforine and granzyme secretion. 
B cells are generally activated upon recognition of soluble proteins by their B cell receptor 
(BCR) in combination with stimulatory signals provided by Th2 cells. The BCR-bound 
antigen will be internalized followed by degradation to peptide fragments which can be 
presented by MHC II molecules at their cell surface. Furthermore, B-cell proliferation and 
differentiation generates plasma cells that secrete neutralizing antibodies. 
In contrast to the conventional B and T cells described above, some B and T cells share innate 
characteristics, blurring the boundaries between both systems. These cells are referred to as 
innate-like B and T lymphocytes. Among them, natural killer T (NKT) cells are a prominent 
population in mouse and human shown to bridge the innate and acquired immune system. 
Whereas conventional T cells recognize peptide antigens displayed on MHC I or II molecules, 
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the majority of NKT cells recognize lipids or glycolipids presented by CD1d molecules. Other 
dissimilarities are their extremely rapid cytokine production following activation, and their 
lack of immunological memory. Because of their important functions in microbial and tumor 
immunity as well as autoimmune diseases, they have been the subject of extensive research in 
the past two decades. Hereby, α-galactosylceramide (α-GalCer) is often utilized as 
prototypical glycolipid for their activation. 
1.1 NKT cells 
NKT cells, first discovered in 1987, represent a unique thymus-derived lymphocyte 
subpopulation, originally characterized by the co-expression of the natural killer receptor 
NK1.1 (CD161) and a T-cell receptor (TCR).
1,2,3,4
 In mice they localize preferentially to the 
liver (20-30% of the total lymphocytes), bone marrow (20-30%) and thymus (10-20%), 
whereas in human the frequency is much lower with a high degree of variability between 
individuals. Since the NK1.1 marker is not uniformly expressed by all NKT cells and 
additionally, some conventional T cells upregulate this marker upon activation, the 
elementary definition that NKT cells are NK1.1
+
 T cells is inaccurate. Therefore, these 
heterogeneous cells are subdivided into at least three categories mainly based on their TCR 
phenotype and CD1d restriction.
2,3,5
 
1.1.1 Classification 
Type 1 NKT cells are defined as cells having an invariant TCR Vα chain rearrangement 
(Vα14-Jα18 in mice, Vα24-Jα18 in humans) conjugated with a limited Vβ chain repertoire 
(Vβ8.2, Vβ7 or Vβ2 in mice, Vβ11 in humans). As a consequence they are often referred to as 
‘invariant’ NKT (iNKT) cells (Figure 1.1). They show high affinity for the glycosphingolipid 
α-GalCer presented by CD1d and are sometimes subdivided into a CD4+ and a CD4-CD8- or 
DN population, although human iNKT cells can be CD8
+ 
as well. Not all these cells express 
the NK1.1 marker and therefore, some authors prefer the term Vα14iT rather than iNKT cells. 
Type 2 NKT cells express more diverse TCR Vα chains and recognize different ligands, such 
as sulphatide and phospholipids, in the context of CD1d. Similar to type 1 NKT cells, they 
can be CD4
+
 or DN and comprise both NK1.1
+
 and NK1.1
-
 subsets. Another population, 
classified as NKT-like cells, is also characterized by the expression of diverse TCRs but is 
CD1d-independent. Much less is known about these cells. 
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The analogues synthesized in this work are aimed at targeting iNKT cells. Hence only this 
type is considered hereafter. 
 
Figure 1.1 iNKT cells compared with conventional T cells. 
(Van Kaer, 2005, Nat. Rev. Immunol.) 
1.1.2 TCR structure 
The structure of the iNKT TCR generally resembles that of other αβ TCRs. These 
heterodimeric receptors consist of an α and β chain, each subdivided into a constant (C) and 
variable (V) domain. Both chains have a transmembrane region by which the molecule is 
anchored in the cell membrane followed by a short cytoplasmic tail. The V segment is 
composed of three complementarity determining regions (CDRs). Together, these six 
hypervariable loops make up the antigen-recognition site of the TCR. Among them, CDR3β 
displays extensive junctional diversity resulting in slightly different conformations and 
variable loop lengths.
6,7
 
1.2 Cluster of differentiation 1d (CD1d) 
CD1d belongs to a third family of antigen-presenting molecules, the CD1 molecules.
8,9,10
 
These non-polymorphic glycoproteins are related to major histocompatibility complex (MHC) 
molecules and can be divided into two groups by sequence homology. Group I consists of 
CD1a, CD1b and CD1c isotypes, and group II comprises CD1d. CD1e on the other hand is 
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considered as an intermediate isotype thought to play an intracellular trafficking role. While 
humans express all isoforms, mice and rats contain only CD1d. They can be found at the 
surface of cortical thymocytes, macrophages, DCs and B cells where they present 
hydrophobic antigens, mostly glycolipids, for recognition by the TCR.  
Analogous to MHC class I molecules, CD1 proteins are composed of a heavy chain with three 
extracellular domains (α1-α3) that are non-covalently associated with β2-microglobulin (β2m) 
(Figure 1.2). The α1 and α2 domains form the antigen-binding region that sit atop a six-
stranded anti-parallel β-sheet platform. The α3 domain is attached to the cell membrane by a 
transmembrane segment, followed by a short cytoplasmic tail. The binding groove of CD1d is 
more narrow but substantially deeper compared to that of MHC-I and has two major pockets 
that connect directly to the surface, designated A’ and F’ in mice and A’ and C’ in humans. 
Their walls are made up of almost entirely hydrophobic residues, with the only polar residues 
situated at the bottom of the A’ pocket and at the entrance of the groove. Hence, these 
molecules are highly suitable for the binding of lipid or glycolipid antigens. 
 
Figure 1.2 Crystal structure of mouse CD1d 
(Zeng et al., 1997, Science). 
1.3 The immunological role of iNKT cells 
In response to antigen stimulation, iNKT cells are able to rapidly release massive amounts of 
cytokines, including pro-inflammatory Th1 cytokines such as IFN-γ and TNF-α, and anti-
inflammatory Th2 cytokines such as IL-4, IL-10 and IL-13 (Figure 1.3).
11 , 12
 This rapid 
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release, within 1-2 hours after TCR ligation, is thought to be due to the presence of high levels 
mRNAs encoding IL-4 and IFN-γ in resting iNKT cells.13 This might also explain the initial 
Th0 cytokine profile induced by these cells in contrast to conventional T cells.
14
 The produced 
cytokines in turn can activate several other cell types such as DCs, NK cells, macrophages 
and neutrophiles in the innate immune system and conventional B and T cells in the acquired 
immune system (Figure 1.3). Furthermore, iNKT cells can exhibit cytotoxic activities 
mediated by Fas-FasL interaction and the expression of granzyme B and perforin. However, it 
is still unclear whether all iNKT cells have this capability and trans-activated NK cells 
definitely play a predominant role herein. In tandem with their vigorous cytokine secretion, 
iNKT cells undergo surface receptor downregulation, followed by extensive cell expansion by 
days 2-3, before returning to homeostatic levels.
15,16 
 
Figure 1.3 Cytokine release by activated iNKT cells inducing trans-activation of other leukocytes 
(Brennan et al., 2013, Nat. Rev. Immunol.). 
Depending on the elicited cytokine profile, iNKT cells can mediate a wide range of protective 
and regulatory immune functions.
17
 Th1 cytokines promote enhanced cell-mediated 
immunity, associated with tumor surveillance and host protection from a variety of infectious 
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agents including bacteria, viruses and parasites.
18,19
 Th2-type cytokines on the other hand 
support humoral immunity through upregulation of antibody production and induce 
immunosuppressive responses essential for the prevention of autoimmune diseases as well as 
the maintenance of tolerance.
20,21
 Homeostasis requires a carefully controlled balance between 
both types of cytokines and as a consequence any dysregulation can induce disease. 
Accordingly, a decreased number and/or impaired cytokine function of iNKT cells has been 
correlated with attenuated immune responses to pathogens and predisposition to the 
development of several autoimmune diseases as well as certain cancers.
22
 However, whether 
the defect is a cause or consequence of the disease, or may in some cases simply reflect the 
accumulation of iNKT cells at sites of inflammation remains to be determined. Nevertheless, 
iNKT cells represent an important immunotherapeutic target with broad clinical potential. 
The mechanisms controlling the outcome of iNKT cell activation are still poorly understood. 
Two independent studies showed that different human iNKT cell subsets are characterized by 
distinct cytokine profiles. Whereas CD4
+
 iNKT cells are able to produce both Th1 and Th2 
cytokines, CD4
-
 subsets primarily produce Th1 cytokines.
23,24
 In addition, the iNKT cell 
cytokine secretion is determined by the tissue of origin as well as by environmental aspects 
such as surrounding cytokines, chemokines and co-stimulatory molecules. Finally, distinct 
lipid antigens may also influence the resulting effector functions (see 1.7). 
1.4 Distinct modes of iNKT cell activation 
iNKT cells can respond to an array of different lipid-based antigens in complex with CD1d. 
The first discovered CD1d-binding iNKT cell ligand is the synthetic glycolipid α-GalCer. 
Since then, many more iNKT cell antigens have been described, classifiable into endogenous 
or self-antigens, microbial ligands and synthetic derivatives. 
1.4.1 α-Galactosylceramide 
During a screen for compounds that could prevent tumor metastases in mice, extracts derived 
from the marine sponge Agelas mauritianus elicited promising biological activities. Their 
antitumor properties were later attributed to a glycosphingolipid family called agelasphins, 
from which α-GalCer was structurally optimized (Figure 1.4).25,26,27 Today this glycolipid, 
also known as KRN7000, is the most extensively studied antigen for iNKT cells. 
α-GalCer contains a D-galactosyl head group attached to a ceramide, which in turn is 
composed of a C18 phytosphingosine base linked to a saturated C26 fatty acyl chain. A 
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striking structural feature is the α-anomeric linkage, as most mammalian glycolipids possess a 
β-glycosidic bond. Instead, the α-anomeric linkage is considered as a microbial signature. 
 
Figure 1.4 Structural comparison of agelasphins and α-GalCer  
(agelasphins with branched alkyl chains are not shown). 
Activation of iNKT cells by strong agonists such as α-GalCer is suggested to occur in three 
distinct steps (Figure 1.5).
28
 At first, interaction with the TCR leads to the secretion of 
primarily IL-4 and only a little IFN-γ. Secondly, upregulation of CD40 ligand (CD40L) by the 
activated iNKT cell followed by interaction with CD40 present on the DC cell induces DC 
maturation and secretion of IL-12. Subsequently, DC-derived IL-12 activates NK and iNKT 
cells for a second wave of IFN-γ production. This last step is required for maximal release of 
IFN-γ. 
 
Figure 1.5 α-GalCer-mediated activation of iNKT cells 
(adapted from Brennan et al., 2013, Nat. Rev. Immunol.). 
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1.4.2 Endogenous ligands 
A remarkable feature of iNKT cells is their CD1d-restricted autoreactivity. Not only do self-
lipids drive iNKT cell development in the thymus, they also contribute to peripheral iNKT 
cell activation implicated in many infectious and non-infectious diseases such as cancer or 
autoimmunity. However, the nature of these self-ligands remains a controversial issue. 
Initially, isoglobotrihexosyl ceramide (iGb3), composed of three serially linked glycosides β-
linked to a ceramide, was proposed as the natural ligand essential for both thymic selection 
and peripheral activation of iNKT cells (Figure 1.6).
29
 Meanwhile it is known that iGb3 
cannot be the unique physiological antigen and although it is definitely an agonist for iNKT 
cells, its role as a natural selecting ligand has been questioned.
30,31
 In the further search for 
specific self-lipids, other cellular glycosphingolipids have been identified as potential self-
ligands such as the ganglioside GD3
32
 and β-GlcCer (Figure 1.6).33 Additionally, it has been 
demonstrated that self-antigens may not be restricted to GSLs but are likely more diverse in 
structure.
34
 Consistent with this, several membrane phospholipids have been found associated 
with CD1d including phosphatidylinositol, phosphatidylcholine, sphingomyeline, 
phosphatidylglycerol and phosphatidylethanolamine.
35,36,
 Recently, lysophosphatidylcholine 
has been suggested as a self-antigen for human iNKT cells (Figure 1.6).
37
 Yet, this 
phospholipid does not appear to stimulate mouse iNKT cells indicating that self-antigens for 
mouse and human iNKT cells may be different.
34
 Furthermore, the lipid self-antigens 
contributing to the thymic selection of iNKT cells may differ from those involved in iNKT 
cell activation in the periphery. 
 
Figure 1.6 Structures of endogenous iNKT cell ligands. 
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1.4.3 Microbial activation 
iNKT cells can become activated early in infection either through direct stimulation by 
microbe-specific CD1d-presented lipids or alternatively via an indirect pathway driven by 
TLR engagement of the APC.
38
 Both mechanisms lead to Th1 type effector responses, 
including potent IFN-γ secretion. 
1.4.3.1 Direct pathway 
Microbial lipid antigens that activate iNKT cells have been identified in a broad range of 
microorganisms. For example Sphingomonas spp. bacteria express α-glucuronosylceramide 
(GSL-1) and α-galacturonosylceramide (GSL-1’) shown to stimulate murine and human 
iNKT cells in a CD1d-dependent manner (Figure 1.7).
39,40,41
 During infection with these 
bacteria in mice, iNKT cells appear to control both bacterial clearance and the septic shock 
response, providing evidence of a significant role for iNKT cells in antimicrobial defense. A 
second type of microbe containing cognate glycolipid antigens is Borrelia burgdorferi, the 
causative agent of Lyme disease.
42
 The diacylglycerol-based lipids isolated from this bacteria 
are referred to as B. burgdorferi glycolipid-2 (BbGl-II), the fatty acids of which vary in length 
from C14 to C18 (Figure 1.7). Likewise, a direct role for iNKT cells in host defense and 
clearance of these microbes has been demonstrated.
43,44
 Other iNKT cell stimulating lipids are 
likely present in Plasmodium falciparum,
45
 Trypanosoma spp.,
45
 Leishmania spp.,
46
 Ehrlichia 
spp.,
39
 Streptococcus pneumoniae,
47
 Helicobacter pylori
48
 and Mycobacterium bovis BCG.
49
 
 
Figure 1.7 Structures of microbial iNKT cell ligands. 
1.4.3.2 Indirect pathway 
In a second pathway of iNKT cell activation during microbial infection, a unique mechanism 
is used that does not require TCR-mediated cognate recognition of bacterial lipid antigens. 
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Instead, IL-12 released by DCs in response to PAMPs or DAMPs such as Toll-like receptor 
(TLR) ligands, in concert with weak responses to CD1d-presented self-antigens is capable of 
stimulating iNKT cells (Figure 1.8). This has first been demonstrated in studies with 
Salmonella typhimurium and Staphylococcus aureus bacteria.
50
 However, it remains to be 
determined which of the proposed self-lipids actually contribute to the activation of iNKT 
cells in this context. Furthermore, stimulation of iNKT cells independent of CD1d-mediated 
self-recognition has also been reported, for example in the case of E. coli where exposure to 
IL-12 and IL-18 produced by activated APCs is sufficient for iNKT cell activation.
51
 
 
Figure 1.8 Microbial activation of iNKT cells: the left panel shows direct activation through iNKT TCR ligation 
by a microbial lipid ligand. By contrast, the right panel shows cytokine-dominated activation following TLR 
engagement whether or not combined with TCR stimulation by an endogenous lipid antigen (Cerundolo et al., 
2009, Nat. Rev. Immunol.). 
1.5 Structural basis for lipid antigen recognition 
Binding of α-GalCer to CD1d is realized through accommodation of the acyl chain and 
sphingosine chain into the A’ and F’/C’ pockets respectively, giving rise to three hydrogen 
bonds with the glycolipid (Figure 1.9).
52,53
 Specifically, the 3-OH on the sphingosine chain 
interacts with Asp80, the 2”-OH of the galactose ring with Asp151 (Asp153 in mice) and 
finally, the glycosidic oxygen is hydrogen-bonded to Thr154 (Thr156 in mice). These 
interactions are believed to contribute to the proper orientation of the galactose ring above the 
surface of CD1d for optimal recognition by the TCR. 
Structural comparison of CD1d with and without α-GalCer reveals conformational changes in 
the F’ pocket upon binding of α-GalCer, i.e. Leu84 and Leu150 are reoriented, leading to the 
formation of a closed ‘roof’ above the F’ pocket.53 This in turn affects the position of other 
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amino acids such as Arg79, known to be important for interaction with the TCR. As a result 
of the F’ roof closure, the phytosphingosine chain is tightly tugged underneath by forming 
additional van der Waals interactions. Furthermore, the preformed F’ roof allows binding of 
the TCR without significant accommodation of the CD1d/α-GalCer complex. 
 
 
Figure 1.9 Presentation of α-GalCer by human CD1d: The left panel shows binding of the α-GalCer lipid chains 
in the A’ and C’ pocket of hCD1d. The right panel shows the hydrogen bonds formed between residues of 
hCD1d and α-GalCer (Koch et al., 2005, Nat. Immunol.). 
Since mouse and human CD1d are highly homologous, the binding mode of α-GalCer in 
CD1d is very similar in both species. Nevertheless, a non-conservative polymorphism results 
in a different positioning of the galactose head group.
54
 More specifically, a bulky 
tryptophane residue at position 153 in human CD1d, in contrast to a glycine residue at 
position 155 in mouse CD1d, pushes the galactose ring away causing a shift of up to 3Å 
(Figure 1.10). 
 
Figure 1.10 Species polymorphism in the presentation of α-GalCer by mouse and human CD1d leads to a small 
shift of the galactose ring. Orientation of α-GalCer when presented by human CD1d is depicted in blue and is 
superimposed on α-GalCer when complexed to mouse CD1, shown in yellow (Godfrey et al., 2005, Nat. 
Immunol.). 
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Despite the above mentioned difference in sugar head position, crystal structures of both 
mouse and human TCRs in complex with α-GalCer/CD1d show a highly conserved lock-and-
key binding mode by the TCR (Figure 1.11).
55,56
 In contrast to the diagonal footprint adopted 
by MHC-restricted TCRs, the iNKT TCR docks on a parallel manner to CD1d. Whereas the 
TCR-α chain sits above the opening of the CD1d binding groove, the TCR-β chain is situated 
above the closed end of the F’ pocket. Consequently, recognition by the iNKT TCR is 
dominated by the invariant α-chain, contacting both CD1d and α-GalCer via several hydrogen 
bonds and van der Waals interactions. In particular for α-GalCer, these hydrogen bonds are 
formed between the 2”, 3” and 4” hydroxyl groups of the galactose ring and Gly96 located in 
the CDR3α loop and Ser30 and Phe29 in the CDR1α loop respectively (in mice the 2”-OH 
and 3”-OH are both bound by Asn30 of CDR1α) (Figure 1.11). Additionally, the 3-OH group 
of the sphingosine base interacts with Arg95 in the CDR3α loop. The α1 and α2 helices of 
CD1d on the other hand interact with CDR3α and CDR2β. 
 
 
Figure 1.11 The left panel shows the ternary complex of α-GalCer with hCD1d and the TCR; the right panel 
shows the hydrogen bonds formed between residues of the TCR and α-GalCer (Borg et al., 2007, Nature). 
The TCR footprint onto the CD1d/glycolipid complex is not only conserved between humans 
and mice, conferring reciprocal cross-species reactivity, but is also independent of the TCR-β 
composition and the lipid antigen associated with CD1d.
57 , 58
 An explanation for this 
conserved docking mode is provided by mutational analyses of the individual CDR residues, 
revealing a “hot spot” composed of germline-encoded amino acids within CDR1α, CDR3α 
and CDR2β. 59  Conversely, the hypervariable CDR3β loop can fine tune the interaction, 
thereby modulating the TCR affinity.
60
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Comparison of the ternary complex with α-GalCer to the one with GSL-1’ and BbGl-IIc 
learns that the TCR can induce structural changes in both CD1d and the ligand orientation to 
maintain the conserved binding mode, probably causing the weaker potencies of these 
microbial antigens.
61
 When GSL-1’ and BbGl-IIc are bound by CD1d without the TCR, the 
roof over the F’ pocket is not closed due to their different lipid chain structures. Closure does 
occur, however, upon binding by the TCR implicating structural changes above the F’ pocket. 
This is associated with an energetic penalty, likely accounting for the reduced TCR affinities 
compared to α-GalCer. Furthermore, in case of BbGl-IIc, the sugar is rotated 60° 
counterclockwise from the optimal position when bound to CD1d without the TCR, attributed 
to a different binding orientation to CD1d. Hence, apart from conformational changes over the 
F’ roof, binding of the TCR also involves a reorientation of the sugar head group by 60° in 
clockwise direction. This might explain the nearly tenfold weaker binding affinity compared 
to GSL-1’.62 Together, these findings indicate that, even though the lipids are buried in the 
CD1d groove and do not directly contact the TCR, they are important in the formation of a 
TCR epitope and consequently can determine the antigenic potency. 
1.6 Therapeutic potential and limitations 
The therapeutic potential of harnessing iNKT cell responses has been demonstrated in various 
experimental models of human diseases. α-GalCer treatment showed antitumor effects against 
a broad range of experimental tumor lines including melanoma, sarcoma, colon carcinoma 
and lymphoma,
63
 and can protect against spontaneous as well as carcinogen-induced primary 
tumor formation in mice.
64
 Stimulation of iNKT cells via repeated administration of α-GalCer 
has also been reported to exhibit therapeutic effects in certain autoimmune diseases such as 
type 1 diabetes, experimental allergic encephalomyelitis (EAE), arthritis, lupus and 
experimental colitis.
65
 Furthermore, α-GalCer-mediated activation of iNKT cells significantly 
increases immune responses to co-injected antigens providing opportunities for the generation 
of new adjuvant strategies to enhance the efficacy of various vaccines against infectious 
diseases and cancer.
66
 
Despite these promising preclinical data, the clinical effectiveness of α-GalCer is rather 
limited. In a first phase I study consisting of IV administration of α-GalCer to patients with 
refractory solid tumors, only marginal therapeutic effects were observed.
67
 Since 
administration of α-GalCer-pulsed DCs showed enhanced antitumor effects in murine models 
compared to free α-GalCer and additionally circumvent activation-induced anergy owing to 
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iNKT cell overstimulation, subsequent clinical trials were conducted following this 
approach.
68,69
 Depending on the employed APC platform, modest to strong expansion of 
iNKT cells and secondary activation of NK and T cells following an initial drop in cell 
numbers were reported.
70
 Moreover, increased levels of IFN-γ and IL-12 were seen. 
Nonetheless, no tumor regression could be observed except for one clinical trial utilizing 
intranasal administration of α-GalCer-pulsed APCs. These poor clinical responses are 
attributed to the opposing activities of simultaneous secreted Th1 and Th2 cytokines. Hence, 
-GalCer analogues capable of inducing a biased Th1 or Th2 response are believed to afford 
superior clinical effectiveness. 
1.7 Structure-activity relationship studies 
In order to selectively induce Th1- or Th2-type cytokine production and to better understand 
the interaction mechanism of the CD1d/glycolipid/iNKT complex, many research groups have 
been generating new iNKT cell ligands by modification of the structure of α-GalCer. These 
alterations can be subdivided into four categories, i.e. variation of the ceramide part, 
modification of the configuration and the nature of the glycosidic bond, variation of the sugar 
moiety and finally polymodified compounds. Below, a brief overview of notable and/or 
relevant analogues is given. 
1.7.1 Modifications of the ceramide moiety 
An extensively studied modification in the ceramide moiety comprises truncation of the lipid 
chains, generally resulting in a Th2 bias. The best known analogue in this context is OCH 
containing a C9 phytosphingosine chain and a C24 acyl chain (Figure 1.12). Upon injection in 
mice, this compound induces a weak immune response with predominant IL-4 production, 
associated with a significant increased suppression of EAE and protection against diabetes 
and collagen-induced arthritis compared to α-GalCer.71 Extended evidence of a correlation 
between acyl or phytosphingosine chain-shortened glycolipids and a Th2 cytokine-release 
profile has been provided by the group of Savage.
72
 Yet, mere shortening of the acyl chain 
from C26 to C20 goes along with a significant decrease in overall potency. By introduction of 
insaturations into the latter, the stimulatory activity is augmented with retention of the Th2 
skewing capacity.
73
 The optimized compound among this class is C20:2 (Figure 1.12), a much 
stronger iNKT cell agonist compared to OCH. 
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Figure 1.12 Structures of lipid chain-modified α-GalCer analogues. 
With regard to the numerous aromatic side chains lining the binding groove of CD1d, the 
group of Wong introduced terminal aromatic rings into the fatty acyl chain of α-GalCer 
(Figure 1.12).
74
 Interestingly, analogues C6Ph, C8Ph and C11Ph are four times more potent 
and biased for IFN-γ secretion, attributed to additional interactions with CD1d. For C8PhF, 
these effects are even more pronounced.
75
 Recently, a more comprehensive screening of those 
and related analogues led to the identification of 7DW8 as a lead candidate with superior 
adjuvant activity on HIV and malaria vaccines in mice, and C34 as an adjuvant candidate for 
a breast cancer vaccine.
76,77
 
In early structure-activity relationship (S.A.R.) studies of the polar part of the ceramide, 
comparison of the 4-deoxy and the 3,4-dideoxy analogues of α-GalCer indicated the 
importance of the 3-OH group, while the 4-OH group appeared to be less essential.
27,78,79
 This 
is in accordance with the crystal structure of the ternary complex, where the 3-OH interacts 
with Asp80 of CD1d as well as with Arg95 of the TCR. However, more recently the 3-deoxy 
compound was found to be similarly effective at inducing iNKT cell responses as α-GalCer 
and 4-deoxy-α-GalCer.80 A docking study suggested that the 4-OH group compensates for the 
role of the 3-OH group in making a hydrogen-bond network with CD1d, explaining the very 
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weak activity of the 3,4-dideoxy analogue. A 4,4-difluoro analogue showed moderate and 
slightly Th1 biased activity and thus confirms that the 4-OH group is not required for iNKT 
cell recognition.
81
 Park et al. demonstrated via evaluation of all eight α-GalCer stereoisomers 
that the configuration of the C2-NH and the C3-OH group are crucial for the biological 
activity, while the stereochemistry of the C4-OH is less significant.
82
 Strikingly, our group 
found earlier that the configuration of the C4-OH group appears to be more important than 
that of C3.
83
 Finally, replacement of the 2-amide functionality with a 1,2,3-triazole moiety 
resulted in comparable stimulatory effects as α-GalCer and a pronounced Th2 response.84 
1.7.2 Modifications of the glycosidic bond 
The α-anomeric configuration of the glycosidic bond was previously assumed to be a crucial 
feature for iNKT cell recognition as β-GalCer (Figure 1.13) didn’t show any TCR affinity in 
in vitro experimental settings and accordingly was unable to stimulate iNKT cell 
hybridomas.
78
 However, other studies did reveal biological activities induced by β-anomeric 
GalCer albeit at much lower potency than α-GalCer.85 Though low-level contamination with 
α-anomeric forms cannot be excluded, the different behavior of both type of analogues 
provides evidence that β-GalCer can be recognized by the TCR. Furthermore, recent crystal 
structure elucidation of the TCR/β-GalCer/CD1d complex showed that β-GalCer adopts a flat 
orientation after TCR ligation similar to α-anomeric compounds.86 This allows the TCR to 
dock in an analogous manner onto CD1d/β-GalCer. Yet, flattening of the conformation 
presumably implicates a considerable energetic penalty, accounting for the much lower TCR 
affinity. A similar induced-fit recognition model has been demonstrated for iGb3.
87
 
 
 
Figure 1.13 Structures of α-GalCer analogues modified at the glycosidic bond. 
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α-C-GalCer (Figure 1.13), characterized by a methylene group instead of the glycosidic 
oxygen, is definitely one of the best documented Th1 polarizers, shown to stimulate 
prolonged IL-12 secretion from DCs followed by long-lasting IFN-γ release from NK cells.88 
Due to the stable ether group, this compound displays higher resistance towards enzymatic 
and chemical degradation, resulting in a more stable presentation by CD1d despite its lower 
binding affinity. In in vivo mice experiments, the C-glycoside was 100 times more potent than 
α-GalCer against lung metastases and even 1000 times more effective against malaria. 
Unfortunately, it is not capable of significantly stimulating human iNKT cells, ruling out 
clinical benefits.
89
 However, replacement of the glycosidic CH2 by an E-olefin linker, e.g. in 
vinyl analogues GSK127 and GSK152 (Figure 1.13) leads to potent stimulatory activity of 
human iNKT cells biased towards a Th1 response.
89
 Remarkably, these vinyl derivatives 
show a dichotomy in their potency of activating mouse versus human iNKT cells, i.e. 
GSK152 elicits a strong biological activity in human iNKT cells but is far less active in 
murine assays while GSK127 exhibits greater cytokine production in mice than in humans. 
1.7.3 Modifications of the sugar moiety 
Several studies have been performed to assess the S.A.R. of the galactose part of -GalCer. 
Regarding the stabilizing hydrogen bonds with CD1d and the TCR, it is not surprising that the 
2”-OH group is found critical for bioactivity. Upon substitution with a methoxy 90  or 
acetamide group,
91
 the cytokine response is dramatically decreased. Likewise, removal of the 
hydroxyl group
92
 or replacement by a fluoro group abolishes all activity.
93
 Alteration of the 
3”- and 4”-OH groups by contrast seems less destructive, yet weakens the bioactivity. This is 
exemplified in the 3”- or 4”-deoxy and -fluoro analogues of α-GalCer, which are still able to 
stimulate some iNKT cell hybridoma though less potent than α-GalCer.94 Exceptions are 3”-
O-sulfo--GalCer and some 4”-arylalkyl substituted derivatives (Figure 1.14), which afford 
activities comparable to or even better than the parent compound.
95,96
 Inversion of the 4”-OH 
resulting in a glucosyl derivative (α-GlcCer) partially affects the activity,97,98 while α-ManCer 
is unable to induce any activity, highlighting the importance of 2”-OH configuration.78,98 
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Figure 1.14 Structures of galactose-modified α-GalCer analogues. 
In contrast to the secondary alcohol groups of the galactose, its primary 6”-OH group does not 
make any hydrogen bond with residues of CD1d nor the TCR, suggesting that modifications 
of this hydroxyl group may be well-tolerated. First evidence herefore was provided by a series 
diglycosylceramide analogues. Gal(1→6)GalCer was able to stimulate iNKT cells without 
conversion to the parent monoglycosylceramide, as opposed to the corresponding 
diglycosylceramides at the other OH-groups (Gal(1→2)GalCer, Gal(β1→3)GalCer and 
Gal(1→4)GalCer), which lost their activity if the additional sugar cap was not enzymatically 
processed.
98,99
 Later, Savage et al. demonstrated that attachment of small fluorophores or an 
acetamide group at the 6”-position resulted in modified -GalCers that retained the capacity 
to stimulate iNKT cells.
100,101
 These findings triggered the further exploration of this position 
and incited several research groups to synthesize 6”-modified analogues in the quest for 
polarizable iNKT cell ligands. For example Guzman and coworkers used a 6”-amide group to 
construct a water-soluble pegylated -GalCer analogue which showed an increased biological 
activity skewed towards a Th2 response.
102
 Mori and coworkers on the other hand reported a 
series of 6”-modified analogues of -GalCer including a 6”-O-methylated (RCAI-61, Figure 
1.14) and -D-fucopyranosyl analogue (RCAI-58, Figure 1.14), both found superior to -
GalCer in inducing IFN- in mice.103 Finally, our group recently reported a series of 6”-amide 
and 6”-urea derivatives that retained or even surpassed the antigenic potency of KRN7000 
and, as an additional benefit, proved capable of producing a significant Th1-skewed cytokine 
response in vivo.
104
 Among them, a urea compound referred to as NU-α-GalCer (Figure 1.14) 
showed marked in vivo antitumor effects and will be discussed in more detail below. 
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Apart from the numerous α-GalCer analogues modified at one of the glycosidic hydroxyl 
groups, also some nonglycosidic derivatives have been examined. Among them, 
threitolceramide (ThrCer, Figure 1.15), lacking the alcohol moieties at C-5” and C-6” of the 
galactose, is demonstrated to effectively activate iNKT cells.
105
 Regarding the observed 
antigen-specific T and B cell response upon coinjection with OVA, ThrCer is considered a 
promising adjuvant for vaccination strategies, in particular because its weaker TCR binding 
affinity minimizes overstimulation of iNKT cells associated with the induction of anergy. A 
neoglycoside analogue, α-carba-GalCer (Figure 1.15), shares the stable ether structure of α-C-
GalCer while retaining the H-bonding capacity of the glycosidic oxygen with the α2 helix of 
CD1d and is therefore believed to make a more stable complex with CD1d.
106
 This compound 
results in a remarkably enhanced and prolonged IFN-γ production in vivo in mice and induces 
only half the amount of IL-4 compared to α-GalCer. Importantly, this potent Th1 polarizer 
can also stimulate human iNKT cells as opposed to α-C-GalCer.107 
 
Figure 1.15 Structures of non-glycosidic α-GalCer analogues. 
1.7.4 Polymodified α-GalCer analogues 
With regard to the beneficial Th2 polarizing properties of OCH, Toba et al. prepared a series 
of phytosphingosine-altered OCH derivatives, including aliphatic, aromatic and ethereal 
compounds.
108
 Compared to OCH most of these analogues induced a similar or reduced Th2 
profile at the expense of antigenicity. In order to obtain a more potent Th2 immunomodulator, 
they also synthesized the C-glycoside variant of OCH (Figure 1.16). Remarkably, this 
compound was shown to have no cytokine production effect in vitro nor in vivo. 
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Figure 1.16 Structures of polymodified α-GalCer analogues. 
Combination of a C20:2 acyl tail with an α-L-fucosyl head group also abrogates all activity 
(Figure 1.16).
109
 Given the extremely potent biological activity exhibited by the α-GalCer 
variant of C20:2, this indicates that modification of the carbohydrate moiety can significantly 
alter the influence of the lipid moiety of the ligand on CD1d presentation and iNKT cell 
responses. 
Finally, the group of Wong synthesized various α-GalCer analogues bearing differently 
substituted aromatic rings on both the acyl chain and the galactosyl 6”-position, including a 
C-6”-naphthylurea compound with an 11-(3,4-difluorophenyl)undecanoyl acyl chain (Figure 
1.16), two Th1 featuring modifications.
110
 This derivative retained or even surpassed the Th1 
selectivity of the parent compounds although its potency was significantly decreased. This 
again illustrates that combination of two favorable modifications does not necessarily afford 
compounds with enhanced biological profiles. 
1.8 Hypotheses concerning the polarization mechanism 
As illustrated by the numerous synthetic α-GalCer analogues, the balance of Th1-Th2 
cytokines can be affected by structurally different lipid antigens, representing a valuable tool 
for new immunotherapeutic strategies. However, the mechanisms by which alteration in 
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glycolipid structure controls the outcome of iNKT cell activation still remain unclear. Several 
explanations have been suggested including different binding affinities and pharmacokinetics, 
distinct cellular sites of antigen loading, and antigen targeting to different APCs. 
1.8.1 Stability of the ternary complex 
A well-established theory relates the induced cytokine pattern to the duration of TCR 
signaling, which in turn is influenced by the overall stability of the CD1d/glycolipid/TCR 
complex, i.e. the affinity of the TCR interaction, the half-life of the glycolipid/CD1d complex 
as well as the in vivo stability of the glycolipid. Oki et al. demonstrated that IFN-γ production 
by the iNKT cell requires longer TCR stimulation than for IL-4 production.
111
 Furthermore, 
the mainstream IFN-γ following α-GalCer injection originates from trans-activated NK cells, 
also demanding a longer period of iNKT cell activation.
28
 Consequently, ligands leading to 
long-lasting TCR signaling such as α-C-GalCer tend to induce a more pronounced Th1 
polarization, while analogues with a short interaction time like OCH result in a Th2 bias 
(Figure 1.17). 
 
Figure 1.17 Correlation between TCR interaction time and the induced cytokine profile: Th2 polarizing 
analogues are characterized by a short interaction time while compounds with a Th1-skewed cytokine pattern 
induce long-lasting TCR signaling (Berkers and Ovaa, 2005, Trends in Pharmacol. Sci). 
The reduced duration of TCR signaling by OCH is suggested to be the result of a decreased 
half-life of binding to CD1d as well as a reduced TCR affinity.
111,112
 Indeed, McCarthy et al. 
demonstrated that shortening either the phytosphingosine or the acyl chain decreases the 
stability of the CD1d/glycolipid complex.
113
 Interestingly, only for analogues with a truncated 
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phytosphingosine chain, but not for those with a shortened acyl chain, a reduced TCR affinity 
was observed. This is presumed to be a consequence of conformational changes within the 
incompletely filled F’ pocket, altering the CD1d T cell recognition surface. On the other hand, 
CD1d molecules bound to analogues with a phenyl group in the acyl chain such as 7DW8 are 
characterized by a better binding avidity and stability for the TCR than α-GalCer, accounting 
for their Th1-skewed iNKT cell responses.
114
 However, Sullivan et al. argued that differing 
CD1d/glycolipid half-lifes and TCR affinities do not provide a simple explanation for the 
altered cytokine profiles as α-C-GalCer binding to CD1d tends to be even shorter-lived 
compared to OCH and exhibits weaker binding to the TCR.
115
 Conversely, C-glycoside forms 
long-lived functional complexes on the surfaces of APCs in vivo owing to its improved 
metabolic stability, yet allowing for a sustained activation of iNKT cells. Hence, they propose 
that in some cases the in vivo stability of the glycolipid may also be a critical determinant for 
the induction of polarized cytokine responses. 
1.8.2 Cellular site of antigen loading 
Another plausible explanation for the different cytokine profiles induced by altered glycolipid 
antigens involves their distinct uptake and presentation properties. It has been demonstrated 
that multiple analogues inducing Th2 cell-type cytokine responses are faster presented by 
CD1d and without requirement for intracellular loading than analogues with a mixed cytokine 
profile.
73,116
 This might be attributed to the increased polarity and reduced hydrophobicity, 
which typically characterize Th2-polarizing analogues, as increased solubility facilitates 
access to the lipid binding site of cell surface expressed CD1d molecules. Furthermore, it has 
been shown that intracellular loading of a compound followed by lysosomal processing leads 
to accumulation of the glycolipid/CD1d complex into lipid rafts, whereas direct loading of 
CD1d molecules on the surface of the cell results in exclusion from such domains (Figure 
1.18).
116
 This might promote distinct TCR signaling, effectuating different iNKT cell 
responses. 
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Figure 1.18 CD1d loading and intracellular processing affects the iNKT cell response: mixed Th1/Th2 inducers 
require internalization prior to CD1d loading, followed by lysosomal processing and preferential presentation in 
lipid rafts as opposed to Th2 polarizers, which are directly loaded onto CD1d molecules at the surface of APCs 
(Venkataswamy and Porcelli, 2010, Sem. Immunol.). 
1.8.3 Presentation by different APCs 
A third, alternative mechanism suggests that the different cytokine production of α-GalCer 
variants might be the consequence of presentation by different types of APCs. This 
assumption relies on a study in which iNKT cells stimulated by α-GalCer displayed by CD1+ 
Schwann cells predominantly secrete Th2 cytokines.
117
 Similarly, Besbradica et al. found that 
presentation of α-GalCer by B cells skews the iNKT cell outcome towards a Th2-type 
response.
118
 Although other studies could not provide evidence for a correlation with the APC 
type used, a more recent study demonstrated that α-GalCer presentation requires CD1d 
expression by DCs, while presentation of Th2 variants is rather promiscuous.
119
 Since the 
second and long-lasting wave of IFN-γ secretion is dependent on IL-12 derived from DCs, 
these analogues fail to induce a sustained IFN-γ production, accounting for the observed Th2 
bias. 
1.9 A closer look at NU-α-GalCer 
NU-α-GalCer, one of the C-6”-modified compounds previously synthesized in our lab, is 
nowadays known as a strong Th1 polarizer, characterized by a markedly elevated IFN-γ and 
IL-12 production in mice compared to α-GalCer.120 Additionally, in a B16 melanoma long 
Introduction 
27 
metastases model, NU-α-GalCer provided superior antitumor effects, in particular when 
loaded onto BMDCs. Interestingly, its Th1-skewing capacity was also observed in cultures of 
human peripheral blood mononuclear cells (PBMC) and purified human iNKT cells, in 
contrast to α-C-GalCer. 
In order to gain more insight into the mechanism underlying the observed Th1 polarization, 
the crystal structure of NU-α-GalCer in complex with CD1d and the TCR was examined and 
compared to that of α-GalCer. This study demonstrated that all hydrogen bond interactions 
with the TCR and CD1d described for α-GalCer are conserved (Figure 1.19). Moreover, an 
additional H-bond is formed between the carbonyl oxygen of the urea linker and a threonine 
residue of CD1d. Strikingly, whereas the naphthyl group was expected to be exposed into the 
solvent, it was found facing down towards CD1d. 
 
Figure 1.19 Crystal structure of the ternary complex with NU-α-GalCer: The left panel shows the binding of 
NU-α-GalCer (yellow) with CD1d and the TCR superimposed on α-GalCer (blue), highlighting the conserved H-
bond interactions with the TCR and the downwards orientation of the naphthyl ureum group to CD1d. The right 
panel shows the conserved H-bond interactions with CD1d and the additional H-bond with Thr159. 
A more detailed view of the binding mode of the galactose substituent learned that, in order to 
accommodate the naphthyl group, the α1 and α2 helices of CD1d are opened laterally, 
creating a small hydrophobic pocket on top of the A’ roof (Figure 1.20). This binding pocket, 
also referred to as a third anchor, provides additional hydrophobic interactions with CD1d 
and, together with the additional hydrogen bond, enhances the stability of the complex with 
CD1d. This is clearly reflected by the higher affinity measured for CD1d and is proposed to 
account for the predominant Th1 cytokine secretion, in agreement with the first hypothesis. 
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Figure 1.20 The left panel shows the binding of α-GalCer in CD1d with the galactosyl head group protruding at 
the surface of the antigen binding groove. The right panel shows the same for NU-α-GalCer illustrating the 
induction of the additional hydrophobic pocket by the naphthyl group. 
1.10 Synthetic pathways towards α-GalCer 
The small amount of agelasphins present in the marine sponge Agelas mauritianus prompted 
Morita and coworkers in 1993 to the initial synthesis of agelasphin 9b, the main compound 
among these active substances.
121
 The difficult scale-up, however, incited the search for 
another candidate that could be synthesized more easily, and soon led to the first synthesis of 
α-GalCer by the same group (Scheme 1.1).27 Since then, a wide variety of different synthetic 
strategies have been explored to optimize the synthesis of α-GalCer and related analogues. 
Preparation of α-GalCer roughly involves the connection of three fragments, i.e. the galactose 
part, the D-ribo-phytosphingosine moiety and the acyl chain. Herefore, the two most 
convenient pathways are coupling of a properly protected sugar moiety with a totally 
functionalized ceramide part, or with a phytosphingosine building block followed by N-
acylation.
122
 Although less convergent, insertion of both fatty chains after the glycosidation 
step has also been described, allowing the development of α-GalCer analogues with various 
structural motifs in the lipid chain. Regardless of the chosen methodology, the major 
difficulty is the stereoselective formation of the glycosidic bond (vide infra), constituting the 
subject of many optimization attempts. 
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Scheme 1.1 First synthesis of α-GalCer by Morita et al. 
The procedures found in the literature for the synthesis of D-ribo-phytosphingosine and its 
azido derivative are mainly based on two approaches, i.e. the chiral pool approach and the 
asymmetric induction approach.
123
 In the former method, stereoselective synthesis of D-ribo-
phytosphingosine starts from a naturally occurring chiral precursor, typically carbohydrates 
including D-galactose, D-lyxose and D-galactal. Other popular chiral starting materials 
comprise serine derivatives such as Garner’s aldehyde. Asymmetric synthesis procedures by 
contrast use chiral auxiliaries and enantioselective catalytic reactions to introduce the desired 
chirality. Nowadays, however, D-ribo-phytosphingosine is commercially available as a 
derivative resulting from a yeast fermentation process, and therefore, these methods will not 
be discussed into more detail. 
A drawback associated with the direct glycosylation of ceramide derivatives is the low 
product yield due to unfavorable hydrogen bond formation between the amide and the 
primary hydroxyl group, diminishing the nucleophilicity of the latter.
124
 This can be 
ameliorated either by using a phytospingosine precursor as acceptor or by increasing the 
reactivity of the galactosyl donor. For example, Schmidt and coworkers elaborated a highly 
regio- and stereoselective glycosylation procedure with a 1,3,4-O-unprotected 
phytosphingosine derivative, taking advantage of the α-directing effect of a 4,6-O-
benzylidene-protected trichloroacetimidate donor (Scheme 1.2, A).
125
 Likewise, 4,6-di-tert-
butylsilylene (DTBS)-protected galactosyl donors have been successfully applied in the 
synthesis of α-GalCer, for instance by the group of Kiso (Scheme 1.2, B).126 This donor type 
Chapter 1 
30 
is reported as a powerful α-galactosylating agent, allowing the coupling of both ceramide and 
phytosphingosine derivatives. 
 
Scheme 1.2 (A) Synthesis of α-GalCer by Schmidt et al. (B) Synthesis of α-GalCer by Kiso et al. 
Another highly reactive glycosyl donor, recently introduced by Gervay-Hague in the 
convergent synthesis of α-GalCer, is per-O-silylated galactosyl iodide (Scheme 1.3, top).127 α-
Glycosylation with this donor involves in situ anomerization mediated by 
tetrabutylammonium iodide (TBAI). A similar methodology can be applied on a benzyl-
protected galactosyl iodide in the glycosylation with azidophytosphingosine, affording the 
desired α-product in excellent yield and stereoselectivity (Scheme 1.3, bottom).128 Inspired by 
the work of Gervay-Hague, Castillón and coworkers carried out a glycosylation reaction with 
the same galactosyl iodide donor, yet with a 1,3-O-stannyl ether-protected ceramide 
moiety.
129
 
 
Scheme 1.3 Synthesis of α-GalCer by Gervay-Hague et al.  
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2 Objectives 
In view of the interesting iNKT-cell mediated responses induced by the aforementioned C-6”-
derivatised -GalCer analogues (summarized in Table 2.1), in particular NU-α-GalCer, we 
wish to further explore modifications at this position. Via the synthesis of a wide range of C-
5”- and C-6”-altered α-GalCer compounds, we aim to obtain new iNKT cell ligands with 
enhanced biological profiles. Furthermore, such compounds may contribute to our 
understanding of the cytokine polarization mechanism. Towards this end we want to develop 
a divergent synthetic approach that allows late-stage C-6”-functionalization as well as 
introduction of different acyl chains. As such, beneficial C-6” modifications can be combined 
with alternate acyl chains as in C6Ph (Table 2.1) to examine their mutual influence on the 
iNKT cell response. 
 
Glycolipid R1 R2 R3 Activity 
Gal(α1→6)GalCer 
 
(CH2)24CH3 (CH2)13CH3 
iNKT cell activation 
similar to α-GalCera 
PBS-57 
 
(CH2)13CH=CH(CH2)7CH3 (CH2)13CH3 
Antigenicity similar to   
α-GalCerb 
PEG-GalCer 
 
(CH2)24CH3 (CH2)13CH3 
Th2, stronger antigenicity 
than α-GalCerc 
RCAI-58 CH3 (CH2)24CH3 (CH2)13CH3 
More potent IFN-γ 
inducer than α-GalCerd 
RCAI-61 OCH3 (CH2)24CH3 (CH2)13CH3 
More potent IFN-γ 
inducer than α-GalCerd 
NU-α-GalCer 
 
(CH2)24CH3 (CH2)13CH3 
Th1, antigenicity similar 
to α-GalCerb 
C6Ph CH2-OH (CH2)5Ph (CH2)13CH3 
Th1, stronger antigenicity 
than α-GalCere 
OCH CH2-OH (CH2)22CH3 (CH2)4CH3 
Th2, weaker antigenicity 
than α-GalCerb 
Table 2.1 Summary of the SAR relevant to this work. 
a 
based on IL-2 measurement (mice, in vitro), 
b 
based on IL-4 and IFN-γ measurement (mice, in vivo), c based on 
IL-4 and IFN-γ measurement (mice, in vitro), d based on IFN- γ measurement (mice, in vivo), e based on IL-4 and 
IFN-γ measurement (human, in vitro). 
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At first, this method will be applied for the synthesis of -D-fucopyranosyl analogues 1 and 2, 
and galacturonic analogues 3 and 4 to prove its versatility (Figure 2.1). Compounds 1 and 3 
are two known Th1 polarizers, while 2 and 4 are novel derivatives thereof, in which the 
conventional acyl moiety is replaced by a C6Ph moiety. The latter is known to considerably 
enhance the overall production of both Th1 and Th2 type cytokines and to skew the balance 
toward a Th1 type response. 
 
Figure 2.1 Structures of the -D-fucopyranosyl and galacturonic analogues. 
In order to gain more insight into the importance of the third anchor induced by NU-α-
GalCer, and to determine the structural requirements to induce this anchor, we will explore 
closely related analogues, including C-6”-carbamates (5), uronamides (6) and C-5”-
carbamate/urea derivatives (7) (Figure 2.2). Substitution of the urea functionality by a 
carbamate group provides more flexibility to the linker. Introducing an amide or 
carbamate/urea group at the C-5” position alters the distance of the carbonyl oxygen and the 
aryl substituent with respect to the carbohydrate moiety. Such modifications might change the 
interaction with CD1d and/or the TCR and, as a consequence, might influence the outcome of 
iNKT cell activation. 
 
Figure 2.2 General structure of the envisioned C-6”-carbamates, uronamides and C5”-carbamate/urea 
derivatives. 
Additionally, we intend to replace the Th1-featuring C-6”-amide functionality by a 1,2,3-
triazole moiety (8, Figure 2.3). A 1,4-disubstituted triazole group, suggested as a bioisostere 
of a trans-amide bond, can be conveniently installed using a copper-catalyzed azide-alkyne 
cycloaddition reaction. Due to the commercial availability of a diverse array of aromatic-
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substituted alkynes, the linker length can be easily varied, allowing to investigate its influence 
on the iNKT cell activity. 
 
Figure 2.3 General structure of the C-6”-triazoles. 
Crystal structure studies of α-GalCer complexed to CD1d and the TCR demonstrated that the 
lipid chains of the ceramide part are buried into the binding groove of CD1d and thus do not 
contact the TCR. Yet, truncation of the lipid chains appears to be sensed by the TCR, as 
illustrated by the lower TCR affinity for analogues with shorter phytosphingosine chains. This 
is attributed to a different CD1d T cell recognition surface and is likely to affect the 
bioactivities of sugar-modified α-GalCer analogues. Therefore we will combine interesting C-
5” and C-6”-modifications with an OCH-like ceramide (9, Figure 2.4) and assess the effect on 
the iNKT cell response. Furthermore, glycolipids with shorter lipid chains are associated with 
an enhanced solubility in aqueous media, facilitating the biological experiments. 
 
Figure 2.4 General structure of C-5”- and C-6”-modified OCH derivatives. 
Finally, the established methodology will be exploited for the synthesis of C-6”-labeled α-
GalCer analogues 10 and 11 (Figure 2.5). Whereas the attached boron dipyrromethene 
(BODIPY) group in OCH derivative 10 is known for its excellent fluorescent properties, 
analogue 11 will serve as a reagent in the Chloramine-T method to obtain a radioiodine-
labeled molecule. Both labeled compounds represent valuable biological tools and will prove 
useful in the implementation of competition binding assays by other research groups. 
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Figure 2.5 Structure of C-6”-labeled α-GalCer analogues. 
In addition to the beneficial effects of activating iNKT cells, inappropriate or excessive 
activation can be detrimental for the host. For example, it can result in inflammatory or 
allergic disorders, such as bronchial asthma. In that regard, blockade of the iNKT cell 
response by a CD1d-dependent antagonist might be useful. Therefore we intend to synthesize 
a C-6”-naphthylureido-substituted α-mannosylceramide derivative (NU-α-ManCer, 12, Figure 
2.6), in which the naphthyl urea group is assumed to enhance the CD1d affinity, while the 
different orientation of the 2”-OH and 4”-OH groups of the mannosyl head group is expected 
to prevent interaction with the iNKT TCR. 
 
Figure 2.6 Structure of the known NU-α-GalCer and the envisaged NU-α-ManCer. 
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3 Development of a divergent approach 
towards C-5”- and C-6”-modified α-
GalCer analogues 
3.1 Introduction 
As outlined in the general introduction, several C-6”-modified α-GalCer analogues have 
already been synthesized. However, they concern mainly 6”-N-derivatized compounds, 
whereas we envisage both 6”-O- and 6”-N-alterations as well as 5”-modifications. This has 
crucial implications on the synthetic approach as the previously established methods are 
rather limited in their scope. 
 
Scheme 3.1 Top: Synthetic strategy used by Zhou et al. for the preparation of C-6”-fluorophore- and biotin-
labeled α-galactosylceramides VIa-c and adapted by Trappeniers et al. for the synthesis of C-6”-amides VIIa 
and urea derivatives VIIb. Middle: Synthetic strategy used by Wang et al. for the preparation of C-6”-biotin-
labeled α-GalCer XI. Bottom: Structures of fluorophores and biotin. 
For example, the strategy reported by Zhou et al. for the preparation of their C-6”-
fluorophore- and -biotin-labeled α-galactosylceramides VIa-c consists of coupling benzyl-
protected 6-azido-6-deoxy-galactosyl fluoride I with ceramide acceptor II followed by azide 
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reduction, deprotection and incorporation of the small fluorophores through amide bond 
formation (Scheme 3.1, top).
1
 A slightly modified version of this methodology using ceramide 
acceptor III has been adapted by our group for the synthesis of aromatic substituted C-6”-
amide and urea derivatives VIIa and VIIb.
2
 Similarly, Wang and coworkers used 6-azido-
galactosyl donor VIII in a glycosylation reaction with ceramide acceptor IX to produce C-6”-
biotin-labeled α-GalCer XI (Scheme 3.1, middle).3 Consequently, by incorporating the amine 
functionality early onto the carbohydrate masked as an azide, these strategies are restricted to 
6”-N-derivatized compounds. Therefore, we want to explore a more divergent synthetic 
approach giving access to a wide variety of C-5” and C-6”-modified α-GalCer analogues. 
An important aspect in our synthetic strategy is the stereoselective outcome in the 
glycosylation process, a major challenge in carbohydrate chemistry. In order to obtain optimal 
recognizable compounds for the iNKT TCR, an α-glycosidic bond is required. For galactose 
derivatives, this corresponds to the preparation of 1,2-cis glycosides which in general is more 
demanding than that of 1,2-trans glycosides. Yet, this linkage type can be formed by working 
in appropriate solvents under thermodynamic conditions.
4
 Moreover, the stereoselectivity can 
be greatly enhanced by using a suitable galactosyl donor, preferably with a non-participating 
protecting group at the C-2 hydroxyl such as a benzyl group. Concerning the anomeric 
leaving group, three commonly employed donors in the synthesis of α-GalCer and related 
compounds are galactosyl fluoride,
1, 5 , 6
 galactosyl trichloroacetimidate,
7 , 8 , 9
 and galactosyl 
iodide.
10,11
 The latter has recently gained more interest and was shown to be an excellent α-
directing donor in the glycosylation of unprotected ceramides by the group of Gervay-
Hague.
12
 However, previous elaboration of this methodology in our lab was found 
unsuccessful and therefore it is not considered in the current strategy. Finally, the desired late-
stage introduction of diverse C-5”- and C-6”-functionalities implicates the use of a 6”-O-
orthogonal protecting group, which is easily removable after the glycosylation process. 
Taken together, we consider general structure A in Scheme 3.2 an ideal intermediate towards 
C-5”- and C-6”-modifications, compelling the synthesis of an appropriate C-6”-O-orthogonal 
protected α-galactoside B. Towards this end, two methods coupling galactosyl fluoride C1 or 
trichloroacetimidate C2 with ceramide moiety D1 or its azido precursor D2, respectively, will 
be attempted and evaluated for their α-selectivity. 
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Scheme 3.2 General approach towards versatile intermediate A. 
3.2 Strategy involving Mukaiyama glycosylation 
Since 1981 glycosyl fluorides have been utilized for effective glycosylation reactions because 
of their enhanced stability, ease of handling and higher stereoselectivity compared with other 
glycosyl halides. In a method developed by Mukaiyama and coworkers these practical 
glycosyl donors are activated by stannous(II) chloride, known to give predominantly 1,2-cis 
glycosides especially in the presence of silver perchlorate as a copromotor.
13
 
Preparation of galactosyl fluoride donor 17 started by benzylation of the commercially 
available methyl-α-D-galactopyranoside 14 (Scheme 3.3). For the orthogonal C-6”-O-
protection, we relied on the well-established acetolysis of benzyl ethers initialized by sulfuric 
acid and acetic anhydride.
14
 Although Yang et al. reported that selective 6-O-debenzylation 
and simultaneous cleavage of the methyl glycosidic bond required a large excess of freshly 
fused ZnCl2,
15
 we similarly attained 16 by treatment with acetic anhydride, acetic acid and a 
catalytic amount of sulfuric acid. Subsequent introduction of the anomeric fluoride utilizing 
pyridinium polyhydrogen fluoride afforded exclusively the α-fluoride 17.16 
 
Scheme 3.3 Reagents and conditions: (a) NaH, BnBr, DMF, 0 °C-rt, overnight, 90%; (b) Ac2O, AcOH, H2SO4, 
0 °C-rt, overnight, 81%; (c) HF.pyridine, toluene, 0 °C-rt, 7 h, 74%. 
The synthesis of ceramide 23 started from the readily available D-ribo-phytosphingosine 18 
(Scheme 3.4). Metal-catalyzed diazotransfer afforded azidophytosphingosine 19, which was 
submitted to a protocol analogous to Kratzer et al.
17
 This consisted of selective tritylation of 
the primary OH followed by per-benzylation to give 21. Staudinger reduction and acylation of 
the resulting amine with hexacosanoic acid in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) as a condensing agent afforded 22. Final 
detritylation furnished the desired ceramide building block 23. 
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Scheme 3.4 Reagents and conditions: (a) i. NaN3, Tf2O, CH2Cl2, H2O, 0 °C, 2 h; ii. K2CO3, CuSO4, H2O, 
MeOH, rt, overnight, 76%; (b) TrCl, DMAP, pyridine, 70 °C, overnight, 85%; (c) NaH, BnBr, DMF, 0 °C-rt, 
overnight, 59%; (d) i. PMe3, THF, rt, 2 h; ii. NaOH 1M, rt, 2 h; (e) C25H51COOH, EDC, CH2Cl2, rt, overnight, 
83%; (f) ZnBr2, CH2Cl2/iPrOH (8.5/1.5), rt, overnight, 85%. 
With the galactosyl donor and ceramide acceptor in hand, Mukaiyama glycosylation could be 
performed resulting in the fully protected galactosylceramide 24 with an α/β ratio of 4/1 and a 
general yield of 69% (Scheme 3.5). Deacetylation under basic conditions then provided 
versatile intermediate 25, which enables introduction of a variety of C-6”-modifications. 
 
Scheme 3.5 Reagents and conditions: (a) SnCl2, AgClO4, THF, -10 °C, 1.5 h, 52%; (b) NH3, MeOH, CHCl3, rt, 
48 h, 89%. 
3.3 Strategy involving Schmidt glycosylation 
Glycosyl trichloroacetimidates, introduced by Schmidt and Michel in 1980,
18
 are currently 
among the most popular glycosyl donors for O-glycosylation.
19
 Depending on the nature of 
the protecting group, solvent and the catalyst, α- or β- glycosides are usually formed with high 
stereoselectivity.
4,22
 In particular for the synthesis of galactosyl cerebrosides, Schmidt 
demonstrated excellent α-selectivity by using a 4,6-O-benzylidene-protected galactosyl 
derivative.
7 
This has been attributed to the cis-decalin ring system with the equatorial phenyl 
group preventing attack from the β-face. 20  Since the selective ring opening of 4,6-O-
benzylidene-protected carbohydrates is a well-described method for obtaining protected 
saccharides having a free 6-OH group,
21
 we decided to exploit a 4,6-O-benzylidene-protected 
galactosyl donor for the synthesis of our target intermediate. Contrary to the Mukaiyama 
procedure, this method is preferentially used for coupling azidosphingosines rather than 
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ceramides to circumvent the low nucleophilicity of ceramides associated with poor 
glycosylation yields.
22,23
 
So, the synthesis of trichloroacetimidate intermediate 32 was started by treatment of penta-
acetylated α-D-galactose 26 with p-thiocresol and BF3.etherate yielding thiogalactoside 27, 
followed by global Zemplen deacetylation to give 28 (Scheme 3.6). Next, introduction of a 
4,6-O-benzylidene acetal was accomplished by treatment with benzaldehyde dimethylacetal 
and p-toluenesulfonic acid (p-TSA). Consecutive benzylation and removal of the anomeric 
thiotolyl group with N-iodosuccinimide (NIS) afforded 31, which was then reacted with 
trichloroacetonitrile and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to selectively furnish the 
desired trichloroacetimidate 32 as the α-anomer. 
 
Scheme 3.6 Reagents and conditions: (a) p-thiocresol, BF3.Et2O, CH2Cl2, 0 °C, 1 h, 80%; (b) NaOMe, MeOH, 
0 °C-rt, 3 h; (c) benzaldehyde dimethylacetal, p-TSA, CH3CN, rt, 5 h, 98% over 2 steps; (d) BnBr, NaH, DMF, 
0 C-rt, 2 h, 79%; (e) NIS, acetone, H2O, 0 °C-rt, 2.5 h, 95%; (f) Cl3CCN, DBU, CH2Cl2, 0 °C, 5 h, 83%. 
Azidophytosphingosine acceptor 33 could be easily obtained via detritylation of intermediate 
21 and was subsequently used for trimethylsilyl trifluoromethanesulfonate (TMSOTf)-
catalyzed coupling with galactosyl trichloroacetimidate 32 to acquire α-glycoside 34 in high 
yields (Scheme 3.7). Only a negligible amount of the β-anomer was observed, which could be 
easily removed by flash chromatography. 
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Scheme 3.7 Reagents and conditions: (a) ZnBr2, CH2Cl2/iPrOH (8.5/1.5), rt, overnight, 51%; (b) TMSOTf, THF, 
-30 °C, 80%; (c) BH3·THF, Cu(OTf)2,CH2Cl2, 78%. 
In order to address the 6”-position for further modifications, a regioselective opening of the 
benzylidene ring was required. This key step could be realized by treating 34 with BH3.THF 
and Cu(OTf)2, giving intermediate 35 (Scheme 3.7).
21
 The regioselective opening was 
confirmed by combination of a COSY and HSQC experiment (Figure 3.1), which 
unambiguously proved that the carbon attached to the hydroxyl group possesses two protons, 
indicating that the free hydroxyl group was connected to C-6”. 
 
Figure 3.1 COSY and HSQC experiment of compound 35. 
Conclusively, both methods efficiently allow to synthesize a versatile intermediate towards C-
5”- and C-6”-derivatized α-GalCer analogues through appropriate orthogonal C-6”-protection. 
However, the strategy involving Schmidt glycosylation affords more of the desired α-
galactoside owing to a higher general yield and a better stereoselectivity. Moreover, this 
procedure offers the opportunity for late-stage introduction of alternative acyl chains in the 
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phytosphingosine moiety, thereby extending its potential scope. Hence this seems an exquisite 
approach for the assessment of S.A.R. studies, which was further applied for the preparation 
of our target compounds. 
3.4 Proof-of-concept: synthesis of galacturonic acids and D-fucosyl 
analogues 
To demonstrate the versatility of our method, it was first used to gain access to the known -
D-fucopyranosyl analogue 1,
24
 the galacturonic analogue 3,
25
 and two related derivatives 2 
and 4 in which the conventional acyl moiety has been replaced by a 6-phenylhexanoyl (C6Ph) 
moiety, known to considerably enhance the overall production of both Th1 and Th2 type 
cytokines and to skew the balance toward a Th1 type response (Figure 3.2).
26
 Compound 3 
represents a synthetic analogue of GSL-1’ in which the ceramide part was replaced by that 
found in -GalCer. GSL-1’ was shown to induce a more Th1-based immunity and to suppress 
tumor growth and prolong survival of mice bearing lung cancer more effectively than -
GalCer at equal doses. In contrast to GSL-1’, i.v. administration of compound 3 results in a 
drastically lower secretion of IFN- than that caused by -GalCer administration. Despite this 
fact, it is more effective towards lung and breast cancer in mice compared to α-GalCer. 
Although 3 was reported for the first time in 2007 by Chang et al., its synthetic procedure has 
not been documented yet. 
 
Figure 3.2 Structure of the envisaged -D-fucopyranosyl analogues and galacturonic acid compounds. 
In this context, an additional advantage of our strategy concerns the glycosylation of 
galacturonic acid donors, which surprisingly is not well-precedented.
27,28,29
 This may be due 
to the deactivating effect of the electron-withdrawing C-5 carboxylic group, making the 
galacturonidation particularly challenging.
30
 In addition, in their efforts to assess the influence 
of a pyranosyl C-5 carboxylate ester on the stereochemical outcome of glycosylation 
reactions, van der Marel and coworkers demonstrated that a C-5 ester is 1,5-cis or β-directing 
as opposed to C-5 methylene oxybenzyl, which induces little selectivity.
31
 This selectivity 
arises from the 
3
H4 half-chair conformer, indicating that in the intermediate pyranosyl 
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oxacarbenium ion intermediate, a C-5 carboxylate ester prefers to occupy a pseudoaxial 
position (Figure 3.3, top). In the presence of conflicting substituent preferences on electronic 
grounds (Figure 3.3, bottom; the C-2 and C-4 alkoxy groups are favorably oriented in a 
4
H3 
half-chair oxacarbenium ion conformer, while the C-3 alkoxy and C-5 ester substituents adapt 
a preferred position in the 
3
H4 half-chair oxacarbenium ion conformer), the stereochemical 
outcome of per-benzyl-protected galacturonic ester donor remains speculative, but 
stereospecific α-glycosylation seems unattainable, despite the fact that destabilizing steric 
interactions predominate in the 
3
H4 half-chair. Accordingly, a report of Seeberger et al.
29
 on 
the synthesis of the Sphingomonas glycolipid GSL-1’ illustrates that even after extensive 
optimization (including galactose protecting groups), glycosylation was achieved with a 
maximum 4.2/1 ratio of the - and β-anomers, representing the most -selective 
glycosylation reaction between a galacturonic acid building block and a ceramide reported so 
far. 
 
Figure 3.3 Top: Stereoselectivity of C-5-functionalized pyranosides. Bottom: Structures of the half-chair 
oxacarbenium ions involved in galactosidation. Substituents occupying a favorable position are depicted in 
green, while those occurring in an unfavorable position are colored red. 
The synthesis of the α-D-fucosyl analogue RCAI-58 (1) by Mori and coworkers involved 
glycosylation under Mukaiyama conditions.
24
 Unfortunately, neither yield nor anomeric ratio 
were mentioned. In contrast to the scarce reports about D-fucosylation, L-fucosylation is more 
prevalent, with reasonable α-selectivities.32,33,34 Neglecting the potential influence on the α/β 
ratio due to the asymmetry of the sphingosine, glycosylation of this acceptor with D- and L-
fucose is expected to proceed with the same stereoselectivity. 
Scheme 3.8 summarizes the divergent route followed for the synthesis of both types of target 
analogues starting from versatile building block 35. Staudinger reduction of the azide 
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followed by acylation of the resulting amino group with the appropriate acids gave 
compounds 25 and 36. These in turn are useful intermediates primed for further C-5” and C-
6”-modifications. 
Towards the deoxygenation of the 6”-OH, 25 and 36 were first converted to the corresponding 
iodo analogues 37 and 38 by treatment with triphenylphosphine, imidazole and iodine. Our 
plan was to carry out the reductive dehalogenation and debenzylation in a single step. 
However, upon treatment with palladium black under hydrogen atmosphere, the reaction 
stopped at the stage of the deiodinated products still containing all benzyl groups, probably 
due to poisoning of the catalyst. After flash chromatography of the reaction mixture, the 
deiodinated intermediates were again subjected to catalytic hydrogenation (same conditions) 
to afford the target compounds 1 and 2. 
The galacturonic acid derivatives were prepared upon oxidation of the 6”-OH groups of 25 
and 36 into the corresponding carboxylic acids 39 and 40 via a TEMPO/BAIB oxidation.
35
 
Final deprotection was accomplished by Pd-catalyzed hydrogenation to afford the desired 
compounds 3 and 4. 
 
Scheme 3.8 Reagents and conditions: (a) i. PMe3, THF, NaOH, rt, 5 h; ii. EDC, RCOOH, CH2Cl2, rt, overnight, 
71-81%; (b) PPh3, I2, imidazole, toluene, 110 °C, 30 min., 85%; (c) TEMPO, BAIB, CH2Cl2, H2O, rt, overnight, 
81-97%; (d) Pd black, H2, rt, 49-86%. 
3.5 Biological evaluation 
To assess the biological activity of the galacturonic acid and α-D-fucopyranosyl analogues, 
serum levels of IFN-γ and IL-4 were measured after intraperitoneal injection of 5 μg of the 
corresponding glycolipids in mice (Collaboration with Prof. D. Elewaut). The cytokine 
secretion induced by these compounds is presented in Figure 3.4. Consistent with the results 
of Mori,
24
 6”-deoxy-analogue 1 is a superior IFN-γ inducer. However, where Mori and 
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coworkers only reported the IFN-γ secretion, we measured the IL-4 levels as well, revealing a 
strong Th2 response. Hence, we may infer that under these conditions 1 combines strong 
antigenicity with no net polarization. In combination with a C6Ph modified acyl chain, 
fucosyl analogue 2 induces only a weak cytokine secretion. So, combination of the two 
modifications known to enhance antigenic activity results in a remarkably decreased activity. 
In contrast to the in vitro response in human iNKT cells,
25 
galacturonic acid 3 shows a minor 
cytokine secretion in vivo in mice. Combination with the C6Ph modified acyl chain in 
compound 4 abolishes all activity.  
The low cytokine release of the C6Ph analogues 2 and 4 is surprising. Wong et al. 
demonstrated that this and related acyl moieties enhanced the stability for mCD1d, a finding 
that was further substantiated by cocrystal structures with that protein.
36
 Furthermore, 
introduction of this acyl group in α-GalCer afforded a compound that produced more IFN-γ 
and less IL-4 from human iNKT cells compared to α-GalCer. It remains to be investigated if 
the very low antigenicity found for 2 and 4 is due to the fact that this acyl moiety negatively 
influences cytokine secretion in the mouse system (despite good affinity for mCD1d). 
Alternatively, our results may also indicate that modification of the carbohydrate moiety can 
significantly alter the influence of the lipid moiety of the ligand on CD1d presentation and 
iNKT cell responses. This is in accordance with observations made by Besra and coworkers.
34
 
Figure 3.4 IL-4 and IFN-γ secretion, measured at respective 4 h and 16 h, after intraperitoneal injection of 5 μg 
of the glycolipids in mice. 
We also determined the equilibrium binding affinities of the mouse V14V8.2 NKT TCR 
toward the four CD1d-glycolipid complexes using surface plasmon resonance (SPR) 
(Table 3.1, Collaboration with Prof. D. Zajonc). Purified and biotinylated mouse CD1d was 
loaded with the four individual glycolipid ligands and coated on a Biacore sensor chip. 
Increasing concentrations of TCR were simultaneously passed over each flow channel of the 
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chip to measure real time binding kinetics. Interestingly, the binding phase (kass) of the TCR 
to each of the CD1d-presented glycolipids is similar, ranging from 0.8x10
5
-1.3x10
5
 (M
-1
s
-1
) 
while the dissociation of the TCR (kdiss) can differ up to 10-fold between α-GalCer and 3 
(compare 1.45x10
-3
 s
-1
 with 16.6x10
-3
 s
-1
), resulting in over 10-fold different binding affinities 
(KD=11.2nM-165nM). 
Table 3.1 Equilibrium binding affinity of the TCR to the indicated glycolipid/CD1d complex, measured by SPR. 
Glycolipid kass(M
-1
s
-1
) kdiss(s
-1
) KD(kdiss/kass) 
α-GalCer 1.3E+05 ± 1E+03 1.5E-03 ± 4.5E-05 11.2 ± 0.2 nM 
1 0.8E+05 ± 3E+03 5.3E-03 ± 2.9E-04 64.8 ± 6.0 nM 
2 1.0E+05 ± 2E+04 6.5E-03 ± 1.8E-03 74.4 ± 25.0 nM 
3 1.0E+05 ± 9E+03 16.6E-03 ± 5.5E-03 165.1 ± 38.3 nM 
4 1.1E+05 ± 6E+03 8.1E-03 ± 1.2E-03 75.3 ± 15.2 nM 
These data indicate that modifications of the galactose moiety and the acyl chain do affect 
iNKT TCR affinity but not to a degree that has been seen for weak microbial antigens, such as 
borrelial -galactosyl diacylglycerolipids (KD=6.2µM). As a result, the apparent discrepancy 
between relatively high affinity TCR interaction in vitro and weak iNKT cell activation in 
vivo, likely is a result of different pharmacokinetics of the lipids inside cells, rather than 
attributed by altered TCR binding kinetics. 
3.6 Conclusion 
We described a practical synthetic route to modify the 6”-position after the glycosidation, 
featuring the regioselective opening of a 4”,6”-O-benzylidene ring as the key step. As a proof-
of-concept this method was employed to prepare the 6”-deoxy-analogue of α-GalCer (1), as 
well as the otherwise not so accessible galacturonic acid analogue 3. The carboxylate group of 
the latter may be suitable for flexible substitution through an amide linkage and will be 
described in Chapter 4. An additional advantage of the reported procedure is that it allows to 
introduce alternative acyl moieties in the phytosphingosine moiety in the final stages of the 
synthesis, exploited for the preparation of compounds 2 and 4. 
During the course of this project, the group of Cox/Besra also reported a practical procedure 
to synthesize 6”-N-derivatized α-GalCer analogues relying on the orthogonal protection of the 
C-2 and C-6”-amino groups, and application of Gervay-Hague’s glycosylation methodology 
(Scheme 3.9).
37
 Selective C-6”-TMS-ether cleavage nicely allowed introduction of the C-6”-
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azido group and was followed by global deprotection prior to introduction of the acyl chain 
and further 6”-N-functionalization. Although not reported thus far, their synthetic route could 
also give access to 6”-O-derivatized compounds. 
 
Scheme 3.9 The Cox/Besra method towards C-6”-modified α-GalCer analogues illustrated for C-6”-amino 
derivative PBS-57. 
3.7 Experimental section 
General 
Precoated Macherey-Nagel SIL G/UV254 plates were used for TLC, and spots were examined 
under UV light at 254 nm and further visualized by sulfuric acid-anisaldehyde spray. Column 
chromatography was performed on Biosolve silica gel (63-200 m, 60 Å). NMR spectra were 
obtained with a Varian Mercury 300 Spectrometer or a Bruker Avance II 500 spectrometer. 
Chemical shifts are given in ppm () relative to the residual solvent signals, in the case of 
CDCl3:  = 7.26 ppm for 
1
H and  = 77.4 ppm for 13C, in the case of DMSO-d6:  = 2.54 ppm 
for 
1
H and  = 40.5 ppm for 13C, and in the case of pyridine-d5:  = 8.71, 7.56 and 7.18 ppm 
for 
1
H and  = 149.9, 135.5 and 123.5 ppm for 13C. Exact mass measurements were performed 
on a Waters LCT Premier XE TOF equipped with an electrospray ionization interface and 
coupled to a Waters Alliance HPLC system. Samples were infused in a CH3CN/HCOOH 
(1000/1) mixture at 10 mL/min. The purity of the target compounds was assessed by HPLC. 
An Agilent Technologies 1100 HPLC system (Agilent Technologies, Waldbronn, Germany) 
was coupled to a Varian 385-LC Evaporative Light Scattering Detector (ELSD)(Agilent 
Technologies). The compounds were subjected to an Xbridge Shield C18 column (Waters, 
Millford, MA, USA) operated at 65°C. Mobile phases, delivered at a flow rate of 2 mL/min, 
consisted of 25 mM ammonium formate pH 5 (solvent A) and methanol (solvent B). A linear 
gradient from 70 % B to 100 % B was applied. The target compounds were dissolved in 
pyridine and further diluted a hundred fold in acetonitrile prior to injecting 2 µl. 
2,3,4,6-tetra-O-benzyl-1-O-methyl-α-D-galactopyranoside (15) 
To a solution of 14 (10.30 g, 53.02 mmol) in DMF (500 mL) at 0 °C was added NaH (12.72 
g, 318.11 mmol). After stirring for 45 minutes, benzyl bromide (55.52 g, 318.11 mmol) was 
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added and the solution was stirred overnight at room temperature. Upon reaction completion, 
the mixture was quenched with brine and extracted with EtOAc. The organic layer was 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The resulting 
residue was purified by column chromatography (hexanes/EtOAc: 8.5/1.5) to afford 
compound 15 (26.37 g, 90 %) as a yellow oil. 
1
H-NMR (300 MHz, CDCl3): δ 7.43-7.26 (m, 20H, arom. H), 4.95 (d, J = 
11.5 Hz, 1H, CH2-Ph), 4.86 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.84 (d, J = 12.1 
Hz, 1H, CH2-Ph), 4.74 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.69 (d, J = 3.7 Hz, 
1H, H-1”), 4.69 (d, J = 12.7 Hz, 1H, CH2-Ph), 4.58 (d, J = 11.5 Hz, 1H, 
CH2-Ph), 4.49 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.40 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.05 (ddd, J 
= 0.9 Hz, 3.4 Hz and 10.8 Hz, 1H, H-2”), 3.97-3.89 (m, 3H, H-3”, H-4” and H-5”), 3.55 (d, J 
= 6.3 Hz, 2H, H-6), 3.40 (s, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 139.10, 138.91, 138.79, 138.25, 128.65, 128.60, 128.54, 
128.49, 128.38, 128.03, 127.96, 127.85, 127.76, 99.06, 79.39, 76.71, 75.41, 75.00, 73.84, 
73.75, 73.56, 69.49, 69.34, 55.63. 
Exact mass (ESI-MS) for C35H38O6 [M+H]
+
 found, 555.2759; calcd, 555.2741. 
Spectral data are consistent with the literature data. 
1,6-di-O-acetyl-2,3,4-tri-O-benzyl-D-galactopyranoside (16) 
A solution of 15 (23.59 g, 42.69 mmol) in AcOH (24 mL) and Ac2O (18 mL) was cooled to 
0 °C, followed by dropwise addition of H2SO4 (0.35 mL). The reaction mixture was allowed 
to warm to room temperature and was stirred overnight, then quenched with a saturated 
solution of NaHCO3 and extracted with CH2Cl2. The organic layer was washed with a 
saturated solution of NaHCO3 and brine, dried over MgSO4 and evaporated. Purification by 
column chromatography (hexanes/EtOAc: 7/3) resulted in an anomeric mixture of compound 
16 (18.49 g, 81 %) as a colorless oil. 
1
H-NMR (300 MHz, CDCl3): δ 7.41-7.16 (m, 15H, arom. H), 6.40 (d, J = 
3.7 Hz, 0.8H, H-1α”), 5.59 (d, J = 8.1 Hz, 0.2H, H-1β”), 4.97 (dd, J = 11.4 
Hz, 1H, CH2-Ph), 4.88 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.80 (d, J = 12.3 
Hz, 1H, CH2-Ph), 4.80 (d, J = 12.3 Hz, 1H, CH2-Ph), 4.72 (d, J = 11.4 Hz, 1H, CH2-Ph), 4.62 
(d, J = 11.2 Hz, 1H, CH2-Ph), 4.19 (dd, J = 3.78 Hz and 9.74 Hz, 0.8H, H-2α”), 4.13-3.87 (m, 
5.2H, H-2β”, H-3”, H-4”, H-5” and H-6”), 2.12 (s, 3H, OAc), 1.99 (s, 3H, OAc). 
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13
C-NMR (75 MHz, CDCl3): δ 170.81, 170.76, 169.65, 169.53, 138.72, 138.49, 138.28, 
138.25, 139.19, 138.13, 128.79, 128.73, 128.70, 128.67, 128.61, 128.60, 128.26, 128.19, 
128.09, 128.08, 128.02, 127.96, 127.89, 127.84, 127.66, 94.34, 90.89, 82.61, 78.82, 78.31, 
75.60, 75.57, 74.93, 74.62, 74.45, 73.66, 73.64, 73.57, 73.39, 73.03, 71.06, 63.31, 63.14, 
60.63, 21.37, 21.28, 21.24, 21.04, 21.02, 14.43. 
Exact mass (ESI-MS) for C31H34O6 [M+Na]
+
 found, 557.2119; calcd, 557.2151. 
6-O-acetyl-2,3,4-tri-O-benzyl-α-D-galactopyranosyl fluoride (17) 
To HF in pyridine (24 mL) at 0 °C was added a solution of 16 (2.00 g, 3.74 mmol) in toluene 
(10 mL). The reaction mixture was gradually warmed to room temperature and stirred for 7 
hours. The solution was poured into brine and extracted with CH2Cl2. The organic layer was 
washed with a saturated solution of NaHCO3 and brine, followed by drying over Na2SO4. 
After evaporation of the organic solvent, the residue was purified by column chromatography 
(hexanes/EtOAc: 4/1) to furnish compound 17 (1.36 g, 74 %) as a white solid. 
1
H-NMR (300 MHz, CDCl3): δ 7.42-7.27 (m, 15H, arom. H), 5.60 (dd, J = 2.6 
Hz and 53.5 Hz, 1H, H-1”), 4.99 (d, J = 11.2 Hz, 1H, CH2-Ph), 4.88 (d, J = 
11.8 Hz, 1H, CH2-Ph), 4.86 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.79 (d, J = 11.8 
Hz, 1H, CH2-Ph), 4.73 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.62 (d, J = 11.5 Hz, 1H, 
CH2-Ph), 4.17-3.93 (m, 6H, H-2”, H-3”, H-4”, H-5” and H-6”), 2.00 (s, 3H, OAc). 
13
C-NMR (75 MHz, CDCl3): δ 170.77, 138.47, 138.17, 138.12, 128.75, 128.72, 128.66, 
128.59, 128.53, 128.22, 128.16, 128.03, 127.81, 107.86, 104.86, 78.58, 76.10, 75.79, 74.89, 
74.36, 74.05, 73.70, 71.35, 71.31, 63.39, 60.62, 21.28, 21.02, 14.44. 
Exact mass (ESI-MS) for C29H31FO6 [M+Na]
+
 found, 517.1927; calcd, 517.1997. 
Spectral data are consistent with the literature data. 
(2S,3S,4R)-2-azidooctadecane-1,3,4-triol (19) 
To a suspension of NaN3 (40.96 g, 630.00 mmol) in CH2Cl2 (100 mL) and H2O (100 mL) at 
0 °C was slowly added Tf2O (22.5 mL). After stirring for 2 hours, the reaction mixture was 
separated. The aqueous layer was extracted with CH2Cl2 and the combined organic layer was 
washed with H2O. 
The freshly prepared TfN3-solution (200 mL in CH2Cl2) was added to a mixture of D-ribo-
phytosphingosine (20.00 g, 63.00 mmol), K2CO3 (17.40 g, 125.80 mmol) and CuSO4 (100 
mg, 0.64 mmol) in H2O (400 mL) and MeOH (1.2 L). After stirring overnight, the solvent was 
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evaporated under reduced pressure to furnish 400 mL of a white slurry. The precipitate was 
filtered, washed with H2O and lyophilized to yield 19 (16.37 g, 76 %) as a white solid. 
1
H-NMR (300 MHz, pyridine-d5): δ 7.03 (d, J = 5.5 Hz, 1H, 
OH), 6.90 (t, J = 6.1 Hz, 1H, OH), 6.35 (d, J = 6.1 Hz, 1H, OH), 
4.70 (ddd, J = 3.5 Hz, 5.0 Hz and 11.4 Hz, 1H, H-1), 4.58 (ddd, J 
= 5.6 Hz, 7.6 Hz and 11.4 Hz, 1H, H-1), 4.43 (ddd, J = 3.5 Hz, 4.1 Hz and 11.4 Hz, 1H, H-2), 
4.38-4.30 (m, 1H, H-3), 4.30-4.20 (m, 1H, H-4), 2.25-2.15 (m, 1H, CH2), 2.00-1.86 (m, 2H, 
CH2), 1.50-1.20 (m, 22H, CH2), 0.88 (t, J = 6.7 Hz, 3H, CH3). 
13
C-NMR (75 MHz, pyridine-d5): δ 106.65, 76.50, 72.88, 67.47, 50.14, 34.66, 32.59, 30.70, 
30.44, 30.39, 30.08, 26.86, 23.41, 14.75. 
Exact mass (ESI-MS) for C18H37N3O3 [M+Na]
+
 found, 366.2725; calcd, 366.2733. 
Spectral data are consistent with the literature data. 
(2S,3S,4R)-2-azido-1-O-trityloctadecane-1,3,4-triol (20) 
To a solution of 19 (7.50 g, 21.83 mmol) in pyridine (218 mL) was added TrCl (6.83 g, 24.01 
mmol) and DMAP (0.67 g, 5.46 mmol). After stirring overnight at 70 °C, the resulting orange 
reaction mixture was quenched with a saturated NaHCO3 solution and extracted with CH2Cl2. 
The combined organic layer was washed with brine, dried over Na2SO4 and evaporated to 
dryness. Purification by column chromatography (hexanes/EtOAc: 9/1) afforded 20 (10.59 g, 
85 %) as a yellow oil. 
1
H-NMR (300 MHz, CDCl3): δ 7.49-7.25 (m, 5H, arom. H), 
7.35-7.22 (m, 10H, arom. H), 3.67-3.62 (m, 2H, H-1 and H-3), 
3.57-3.52 (m, 2H, H-2 and H-4), 3.45 (dd, J = 5.7 Hz and 10.1 
Hz, 1H, H-1), 2.36 (d, J = 4.4 Hz, 1H, OH), 1.82 (t, J = 2.2 Hz, 1H, OH), 1.57-1.23 (m, 26H, 
CH2), 0.88 (t, J = 6.6 Hz, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 143.58, 128.78, 128.26, 128.14, 127.52, 127.48, 88.03, 74.44, 
72.43, 63.71, 62.54, 32.16, 29.93, 29.89, 29.60, 25.84, 22.93, 14.36. 
Exact mass (ESI-MS) for C36H51N3O3 [M+Na]
+
 found, 608.3853; calcd, 608.3828. 
Spectral data are consistent with the literature data. 
(2S,3S,4R)-2-azido-3,4-di-O-benzyl-1-O-trityloctadecane-1,3,4-triol (21) 
To a solution of 20 (10.58 g, 18.57 mmol) in DMF (190 mL) at 0 °C was added NaH (2.23 g, 
55.70 mmol). After stirring for 45 minutes, benzyl bromide (6.66 mL, 55.70 mmol) was 
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added and the solution was stirred overnight at room temperature. Upon reaction completion, 
the mixture was quenched with H2O and extracted with CH2Cl2. The combined organic layer 
was washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The 
resulting residue was purified by column chromatography (hexanes/EtOAc: 97/3) to afford 
compound 21 (8.43 g, 59 %) as a pale yellow oil. 
1
H-NMR (300 MHz, CDCl3): δ 7.46-7.43 (m, 5H, arom. H), 
7.38-7.34 (m, 2H, arom. H), 7.31-7.21 (m, 16H, arom. H), 7.10-
7.07 (m, 2H, arom. H), 4.58 (d, J = 11.3 Hz, 1H, CH2-Ph), 4.54 
(d, J = 12.8 Hz, 1H, CH2-Ph), 4.49 (d, J = 10.6 Hz, 1H, CH2-Ph), 4.45 (d, J = 11.6 Hz, 1H, 
CH2-Ph), 3.77 (ddd, J = 3.0 Hz, 5.6 Hz and 8.3 Hz, 1H, H-2), 3.63-3.44 (m, 3H, H-1, H-3 and 
H-4), 3.37 (dd, J = 8.1 and 10.0 Hz, 1H, H-1), 1.66-1.52 (m, 2H, CH2), 1.35-1.22 (m, 24H, 
CH2), 0.88 (t, J = 6.7 Hz, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 144.27, 138.89, 138.46, 129.27, 128.94, 128.85, 128.78, 
128.43, 128.37, 128.32, 128.22, 128.17, 128.13, 128.07, 127.57, 87.74, 79.97, 74.08, 72.66, 
72.58, 63.77, 32.48, 30.39, 30.31, 30.26, 30.25, 30.23, 30.22, 30.18, 30.15, 29.92, 25.89, 
23.24, 14.68. 
Exact mass (ESI-MS) for C36H51N3O3 [M+Na]
+
 found, 788.4774; calcd, 788.4767. 
Spectral data are consistent with the literature data. 
(2S,3S,4R)-3,4-di-O-benzyl-2-hexacosylamino-1-O-trityloctadecane-1,3,4-triol (22) 
To a solution of 21 (4.54 g, 5.92 mmol) in THF (5.3 mL) was added trimethylphosphine 
(29.62 mL, 29.62 mmol) dropwise. Upon stirring for 3.5 hours, NaOH was added and the 
reaction mixture was allowed to stir for an additional 2 hours. The aqueous layer then was 
extracted with EtOAc and the combined organic layers were washed with H2O and brine, 
dried over MgSO4 and evaporated to dryness to furnish the crude amine as a white slurry. 
A suspension of hexacosanoic acid (3.53 g, 8.89 mmol) and EDC (2.27 g, 11.85 mmol) in 
CH2Cl2 (30 mL) was stirred for 30 minutes. Subsequently, a solution of the crude amine in 
CH2Cl2 (60 mL) was added. After stirring overnight, the mixture was extracted with CH2Cl2 
and the organic layers were washed with H2O and brine, dried over MgSO4 and concentrated 
under reduced pressure. Purification by column chromatography (hexanes/EtOAc: 92/8) 
afforded 22 (5.48 g, 83 %) as a colorless oil. 
Development of a divergent approach towards C-5”- and C-6”-modified α-GalCer analogues 
63 
1
H-NMR (300 MHz, CDCl3): δ 7.32-7.12 (m, 25H, arom. H), 
5.50 (d, J = 9.1 Hz, 1H, NH), 4.73 (d, J = 11.4 Hz, 1H, CH2-Ph), 
4.41 (d, J = 10.8 Hz, 3H, CH2-Ph), 4.26-4.17 (m, 1H, H-2), 3.76 
(dd, J = 2.6 Hz and 6.7 Hz, 1H, H-3), 3.43-3.38 (m, 2H, H-1 and 
H-4), 3.23 (dd, J = 4.0 Hz and 9.5 Hz, 1H, H-1), 1.85 (t, J = 7.5 Hz, 2H, COCH2), 1.51-1.18 
(m, 72H, CH2), 0.81 (t, J = 6.6 Hz, 6H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 172.61, 144.07, 138.90, 138.81, 128.92, 128.58, 128.52, 
128.05, 127.95, 127.79, 127.69, 127.28, 86.88, 80.63, 79.69, 73.51, 72.20, 62, 65, 60.62, 
50.24, 37.14, 32.16, 30.16, 30.07, 29.96, 29.94, 29.89, 29.78, 29.67, 29.64, 29.61, 29.60, 
26.22, 25.92, 22.93, 14.43, 14.35. 
Exact mass (ESI-MS) for C77H115NO4 [M+Na]
+
 found, 1140.8667; calcd, 1140.8724; 
[M+K]
+
 found, 1156.8420; calcd, 1156.8463. 
Spectral data are consistent with the literature data. 
(2S,3S,4R)-3,4-di-O-benzyl-2-hexacosylamino-octadecane-1,3,4-triol (23) 
To a solution of 22 (5.48 g, 4.90 mmol) in CH2Cl2 (67 mL) and iPrOH (12 mL) was added 
ZnBr2 (17.66 g, 78.42 mmol). The mixture was stirred overnight, then quenched with H2O. 
After extraction with CH2Cl2, the combined organic layers were washed with H2O and brine, 
dried over Na2SO4 and evaporated to dryness. The resulting residue was purified by column 
chromatography (hexanes/EtOAc: 7.5/2.5) furnishing 23 (3.66 g, 85 %) as a white solid. 
1
H-NMR (300 MHz, CDCl3): δ 7.39-7.27 (m, 10H, arom. H), 
6.02 (d, J = 8.1 Hz, 1H, NH), 4.71 (d, J = 11.5 Hz, 1H, CH2-Ph), 
4.66 (d, J = 11.2 Hz, 1H, CH2-Ph), 4.60 (d, J = 11.5 Hz, 1H, CH2-
Ph), 4.45 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.16-4.11 (m, 1H, H-2), 
3.99 (dt, J = 3.7 Hz and 11.5 Hz, 1H, ,H-1), 3.72-3.66 (m, 2H, H-3 and H-4), 3.60 (ddd, J = 
3.9 Hz, 8.4 Hz and 11.8 Hz, 1H, H-1), 3.04 (dd, J = 4.3 Hz and 8.4 Hz, 1H, OH), 2.04-1.91 
(m, 2H, COCH2), 1.74-1.18 (m, 72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 172.99, 138.29, 137.96, 128.84, 128.59, 128.30, 128.24, 
128.10, 127.95, 82.39, 79.21, 73.19, 73.02, 63.10, 50.75, 36.85, 32.08, 30/96, 29.85, 29.82, 
29.80, 29.74, 29.67, 29.63, 29.57, 29.52, 29.46, 29.43, 26.18, 25.79, 22.84, 14.26. 
Exact mass (ESI-MS) for C58H101NO4 [M+Na]
+
 found, 898.7695; calcd, 898.7628. 
Spectral data are consistent with the literature data. 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(6-O-acetyl-2,3,4-tri-O-benzyl-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (24) 
To a solution of ceramide 23 (225 mg, 0.26 mmol) in THF (2.6 mL) under argon atmosphere, 
SnCl2 (115 mg, 0.60 mmol), AgClO4 (127 mg, 0.60 mmol) and powdered 4 Å molecular 
sieves were added. A solution of 17 (100 mg, 0.20 mmol) in THF (2.6 mL) then was added at 
-10 °C and the mixture was stirred for 1.5 hours. After filtration over celite and rinsing of the 
filter cake with Et2O, the organic solvent was evaporated under reduced pressure. Purification 
by column chromatography (hexanes/EtOAc: 8/2) yielded glycolipid 24 (143 mg, 52 %) as a 
white solid. 
1
H-NMR (300 MHz, CDCl3): δ 7.40-7.21 (m, 25H, 
arom. H), 5.84 (d, J = 8.4 Hz, NH), 4.95 (d, J = 11.5 
Hz, 1H, CH2-Ph), 4.88 (d, J = 3.4 Hz, 1H, H-1”), 4.83 
(d, J = 11.8 Hz, 1H, CH2-Ph), 4.78 (d, J = 11.5 Hz, 1H, 
CH2-Ph), 4.76 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.75 (d, J 
= 10.5 Hz, 1H, CH2-Ph), 4.62 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.61 (d, J = 11.5 Hz, 1H, CH2-
Ph), 4.57 (d, J = 10.6 Hz, 1H, CH2-Ph), 4.54 (d, J = 11.2 Hz, 1H, CH2-Ph), 4.46 (d, J = 11.2 
Hz, 1H, CH2-Ph), 4.28-4.20 (m, 1H, H-2), 4.11-3.87 (m, 6H, H-2”, H-3”, H-4”, H-5” and H-
6”), 3.82-3.78 (m, 3H, H-1 and H-3), 3.52-3.50 (m, 1H, H-4), 1.98-1.88 (m, 5H, OAc and 
COCH2), 1.63-1.23 (m, 72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 172.97, 170.76, 138.79, 138.72, 138.59, 138.35, 128.59, 
128.03, 127.99, 127.80, 127.65, 99.07, 80.07, 79.41, 79.22, 77.42, 74.78, 74.58, 73.76, 73.66, 
73.37, 72.01, 69.06, 68.24, 63.64, 56.22, 50.35, 36.94, 32.15, 30.22, 29.93, 29.68, 29.59, 
26.20, 25.93, 22.92, 20.97, 14.35. 
Exact mass (ESI-MS) for C87H131NO10 [M+H]
+
 found, 1350.9780; calcd, 1350.9851; 
[M+Na]
+
 found, 1372.9690; calcd, 1372.9671; [M+K]
+
 found, 1388.9348; calcd, 1388.9410. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-hydroxy-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (25) 
To a solution of 24 (1.12 g, 0.83 mmol) in CHCl3 (8mL) was added NH3 in MeOH (7 N, 
25 mL). The mixture was stirred during 48 hours at room temperature followed by 
evaporation of the organic solvent. The resulting residue was suspended in H2O and extracted 
with EtOAc. Subsequently, the organic layer was washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure. Purification by column chromatography 
(hexane/EtOAc: 7.2/2.5) provided compound 25 (967 mg, 89 %) as a colorless oil. 
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1
H-NMR (300 MHz, CDCl3): δ 7.39-7.25 (m, 25H, 
arom. H), 5.83 (d, J = 9.0 Hz, 1H, NH), 4.94 (d, J = 
11.5 Hz, 1H, CH2-Ph), 4.88 (d, J = 3.8 Hz, 1H, H-
1”), 4.82 (d, J = 12.7 Hz, 1H, CH2-Ph), 4.79 (d, J = 
11.8 Hz, 1H, CH2-Ph), 4.73 (d, J = 11.8 Hz, 1H, 
CH2-Ph), 4.71 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.64 (d, J = 12.1 Hz, 1H, CH2-Ph), 4.62 (d, J = 
11.8 Hz, 1H, CH2-Ph), 4.58 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.50 (d, J = 11.5 Hz, 1H, CH2-Ph), 
4.47 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.41-4.33 (m, 1H, H-2), 4.03 (dd, J = 3.7 Hz and 9.6 Hz, 
1H, H-2”), 3.95 (dd, J = 7.6 Hz and 11.6 Hz, 1H, H-1), 3.85-3.82 (m, 3H, H-1, H-3”, H-4”), 
3.70-3.62 (m, 3H, H-3, H-5”, H-6”), 3.55-3.50 (m, 1H, H-4), 3.48-3.42 (m, 1H, H-6”), 2.39 (t, 
J = 5.8 Hz, 1H, OH), 1.92-1.87 (m, 2H, COCH2), 1.69-1.14 (m, 72H, CH2), 0.88 (t, J = 6.8 
Hz, 6H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 173.37, 138.86, 138.79, 138.67, 138.65, 138.48, 128.66, 
128.64, 128.60, 128.17, 128.13, 128.06, 127.96, 127.94, 127.83, 127.67, 100.31, 80.68, 79.46, 
77.66, 77.44, 77.24, 76.91, 76.81, 75.09, 74.77, 73.77, 73.43, 73.32, 72.08, 71.50, 70.04, 
62.70, 50.90, 37.05, 32.16, 30.43, 29.95, 29.93, 29.89, 29.83, 29.66, 29.59, 26.01, 26.93, 
22.92, 14.43, 14.35. 
Exact mass (ESI-MS) for C85H129NO9 [M+H]
+
 found, 1308.9780; calcd, 1308.9746. 
p-methylphenyl-2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranoside (27) 
To a solution of galactose pentaacetate (10.00 g, 25.62 mmol) and p-thiocresol (3.5 g, 27.62 
mmol) in CH2Cl2 (26 mL) at 0 °C was slowly added BF3.Et2O (4 mL). After stirring for 1 
hour at 0 °C, the reaction mixture was diluted with CH2Cl2 and quenched with a saturated 
solution of NaHCO3. The organic layer was washed with H2O and brine, dried over Na2SO4 
and evaporated to dryness. The crude was purified by column chromatography 
(hexanes/EtOAc: 7/3) to afford compound 27 (9.29 g, 80 %) as a white solid. 
1
H-NMR (300 MHz, CDCl3): δ 7.39 (d, J = 8.1 Hz, 2H, arom. H), 7.11 
(d, J = 8.1 Hz, 2H, arom. H), 5.39 (dd, J = 1.0 Hz and 3.2 Hz, 1H, H-4”), 
5.20 (t, J = 10.0 Hz, 1H, H-2”), 5.02 (dd, J = 3.2 Hz and 10.0 Hz, 1H, H-
3”), 4.63 (d, J = 10.0 Hz, 1H, H-1”), 4.17 (dd, J = 6.8 Hz and 11.3 Hz, 1H, H-6”), 4.09 (dd, J 
= 6.1 Hz and 11.3 Hz, 1H, H-6”), 3.89 (ddd, J = 0.8 Hz and 6.6 Hz, 1H, H-5”), 2.32 (s, 3H, 
CH3), 2.09 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.02 (s, 3H, OAc), 1.95 (s, 3H, OAc). 
13
C-NMR (75 MHz, CDCl3): δ 170.43, 170.26, 170.12, 169.49, 138.52, 133.23, 129.71, 
128.71, 87.00, 74.44, 72.11, 67.38, 67.32, 61.67, 21.23, 20.93, 20.74, 20.70, 20.66. 
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Exact mass (ESI-MS) for C21H26O9S [M+Na]
+
 found, 477.1032; calcd, 477.1195. 
Spectral data are consistent with the literature data. 
p-methylphenyl-1-thio-β-D-galactopyranoside (28) 
To a suspension of 27 (9.28 g, 20.41 mmol) in MeOH (90 mL) at 0 °C was added NaOMe 
(0.58 g, 10.21 mmol) in small portions. The reaction was allowed to stir for 3 hours at room 
temperature. Subsequently, the mixture was neutralized with Amberlite IR 120 (H
+
 form) and 
diluted with MeOH. After filtration and rinsing with MeOH, the filtrate was concentrated 
under reduced pressure to yield compound 28 (6.06 g) as a white solid. 
1
H-NMR (300 MHz, DMSO-d6): δ 7.35 (d, J = 8.2 Hz, 2H, arom. H), 
7.11 (d, J = 7.9 Hz, 2H, arom. H), 5.06 (d, J = 5.9 Hz, 1H, OH), 4.83 (d, J 
= 5.6 Hz, 1H, OH), 4.60 (t, J = 5.6 Hz, 1H, OH) 4.49 (d, J = 9.1 Hz, 1H, 
H-1”), 4.43 (d, J = 4.4 Hz, 1H, OH), 3.70 (t, J = 3.8 Hz, 1H, H-3”), 3.30-3.55 (m, 5H, H-2”, 
H-4”, H-5” and H-6”), 2.27 (s, 3H, CH3). 
13
C-NMR (75 MHz, DMSO-d6): δ 136.46, 132.18, 130.83, 130.09, 88.84, 79.81, 75.39, 
69.92, 60.00, 61.20, 21.27. 
Exact mass (ESI-MS) for C13H18O5S [M+Na]
+
 found, 309.0804; calcd, 309.0773. 
Spectral data are consistent with the literature data. 
p-methylphenyl-4,6-O-benzylidene-1-thio-β-D-galactopyranoside (29) 
To a suspension of 28 (5.51 g, 19.25 mmol) in CH3CN (74 mL), was added benzaldehyde 
dimethylacetal (3.52 g, 23.10 mmol). Upon adjustment of the pH until 3 by addition of          
p-TSA, a clear solution was obtained. After stirring for 5 hours, the resulting white suspension 
was neutralized with Et3N and diluted with CH2Cl2. The organic layer was washed with H2O 
and brine, dried over Na2SO4 and evaporated to dryness. The crude was recrystallised 
furnishing 29 (7.05 g, 98 %) as white crystals. 
1
H-NMR (300 MHz, DMSO-d6): δ 7.45 (d, J = 8.3 Hz, 2H, arom. H), 
7.43-7.36 (m, 5H, arom. H), 7.09 (d, J = 7.9 Hz, 2H, arom. H), 5.54 (s, 
1H, CH-Ph), 5.09 (d, J = 5.5 Hz, 1H, OH), 5.00 (, J = 5.6 Hz, 1H, OH), 
4.58 (d, J =9.3 Hz, 1H, H-1”), 4.11 (app. d, J = 3.0 Hz, 1H, H-4”), 4.06-
3.99 (m, 2H, H-6”), 3.60 (br. S, 1H, H-5”), 3.54-3.38 (m, 2H, H-2” and H-3”), 2.28 (s, 3H, 
CH3). 
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13
C-NMR (75 MHz, DMSO-d6): δ 139.36, 136.96, 132, 28, 130.44, 130.02, 129.37, 128.54, 
127.13, 100.54, 87.57, 76.77, 73.80, 69.91, 69.32, 68.55, 21.36. 
Exact mass (ESI-MS) for C20H22O5S [M+H]
+
 found, 375.1273; calcd, 375.1266; [M+Na]
+
 
found, 397.1109; calcd, 397.1086. 
Spectral data are consistent with the literature data. 
p-methylphenyl-2,3-di-O-benzyl-4,6-O-benzylidene-1-thio-β-D-galactopyranoside (30) 
To a solution of 29 (7.00 g, 18.69 mmol) in DMF (94 mL) at 0 °C was added NaH (2.24 g, 
56.08 mmol). After stirring for 30 minutes, benzyl bromide (6.7 mL, 56.08 mmol) was added 
and the solution was stirred for 2 hours at room temperature. Upon reaction completion, the 
mixture was quenched with H2O and extracted with CH2Cl2. The combined organic layers 
were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The 
resulting residue was purified by column chromatography (hexanes/EtOAc: 6.5/3.5) to afford 
compound 30 (8.14 g, 79 %) as white crystals. 
1
H-NMR (300 MHz, CDCl3): δ 7.61 (d, J = 7.9 Hz, 2H, arom. H), 7.54-
7.26 (m, 15H, arom. H), 7.01 (d, J = 7.9 Hz, 2H, arom. H), 5.48 (s, 1H, 
CH-Ph), 4.72 (app. d, J = 3.5 Hz, 4H, CH2-Ph), 4.57 (d, J = 9.4 Hz, 1H, 
H-1”), 4.37 (dd, J = 1.5 Hz and 12.3 Hz, 1H, H-6”), 4.14 (dd, J = 0.6 Hz 
and 3.5 Hz, 1H, H-4”), 3.98 (dd, J = 1.6 Hz and 12.5 Hz, 1H, H-6”), 3.84 (t, J = 9.4 Hz, 1H, 
H-2”), 3.62 (dd, J = 3.4 Hz and 9.2 Hz, 1H, H-3”), 3.41 (app. d, J = 0.9 Hz, 1H, H-5”), 2.31 
(s, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 138.83, 138.36, 138.17, 137.90, 133.71, 129.87, 129.27, 
128.90, 128.63, 128.57, 128.42, 128.35, 128.06, 128.03, 127.91, 126.92, 101.59, 86.87, 81.70, 
75.58, 73.90, 72.07, 70.01, 69.70, 21.40. 
Exact mass (ESI-MS) for C34H34O5S [M+H]
+
 found, 555.2230; calcd, 555.2205; [M+Na]
+
 
found, 577.2017; calcd, 577.2025; [M+K]
+
 found, 593.1777; calcd, 593.1764. 
Spectral data are consistent with the literature data. 
2,3-di-O-benzyl-4,6-O-benzylidene-D-galactopyranoside (31) 
To a suspension of 30 (8.10 g, 14.60 mmol) in acetone (162 mL) and H2O (16.2 mL) at 0 °C 
was added N-iodosuccinimide (NIS) (3.60 g, 16.06 mmol). The reaction was allowed to stir 
for 2.5 hours at room temperature. Then a 0.5 M solution of Na2S2O3 was added and the 
reaction mixture was allowed to stir for an additional hour. The aqueous layer was extracted 
with CH2Cl2 and the combined organic layers were washed with a 0.5 M solution of Na2S2O3 
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and brine. After drying over Na2SO4 and evaporation of the solvent, the residue was purified 
by column chromatography (hexanes/EtOAc: 1/1) to afford 31 (6.25 g, 95 %) as a white solid. 
Exact mass (ESI-MS) for C27H28O6 [M+Na]
+
 found, 471.1788; calcd 
471,1784; [M+K]
+
 found, 487.1522; calcd, 487.1523. 
 
2,3-di-O-benzyl-4,6-O-benzylidene-α-D-galactopyranosyl trichloroacetimidate (32) 
To a solution of 31 (3.30 g, 7.36 mmol) in CH2Cl2 (80 mL) at 0 °C, DBU (0.5 mL, 
3.68 mmol) and trichloroacetonitrile (7.38 mL, 73.6 mmol) were added. The reaction mixture 
was stirred for 5 hours, diluted with CH2Cl2 and celite was added. The solvent was removed 
under reduced pressure and the residue was purified by column chromatography 
(hexanes/EtOAc: 8.5/1.5 + 1 V% Et3N) yielding 32 (3.62 g, 83 %) as white crystals. 
1
H-NMR (300 MHz, CDCl3): δ 8.57 (s, 1H, NH), 7.55-7.53 (m, 2H, 
arom. H), 7.40-7.26 (m, 13H, arom. H), 6.64 (d, J = 3.4 Hz, 1H, H-
1”), 5.52 (s, 1H, CH-Ph), 4.83-4.75 (m, 4H, CH2-Ph), 4.31-4.26 (m, 
3H, H-2”, H-6” and H-4”), 4.08 (dd, J = 3.3 Hz and 10.0 Hz, 1H, H-
3”), 4.01 (dd, J = 1.8 Hz and 12.6 Hz, 1H, H-6”), 3.84 (app. d, J = 0.9 
Hz, 1H, H-5”). 
13
C-NMR (75 MHz, CDCl3): δ 161.27, 138.63, 137.89, 129.21, 128.52, 128.47, 128.40, 
128.21, 127.70, 127.63, 126.60, 101.34, 95.85, 75.31, 74.95, 74.71, 73.37, 72.45, 69.31, 
65.50. 
Exact mass (ESI-MS) for C29H28Cl3NO6 [M+Na]
+
 found, 614.0919; calcd, 614.0880; 
[M+K]
+
 found, 630.0668; calcd, 630.0619. 
(2S,3S,4R)-2-azido-3,4-di-O-benzyl-octadecane-1,3,4-triol (33) 
To a solution of 21 (8.40 g, 10.97 mmol) in CH2Cl2 (149 mL) and iPrOH (26.32 mL) was 
added ZnBr2 (39.51 g, 175.44 mmol). The mixture was stirred overnight, then quenched with 
H2O. After extraction with CH2Cl2, the combined organic layers were washed with H2O and 
brine, dried over Na2SO4 and evaporated to dryness. The resulting residue was purified by 
column chromatography (hexanes/EtOAc: 9/1) furnishing 33 (2.92 g, 51 %) as a pale yellow 
oil. 
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1
H-NMR (300 MHz, CDCl3): δ 7.27-7.39 (m, 10H, arom.H), 
4.72 (d, J = 11.1 Hz, 1H, CH2-Ph), 4.67 (d, J = 10.2 Hz, 1H, CH2-
Ph), 4.63 (d, J = 10.5 Hz, 1H, CH2-Ph), 4.57 (d, J = 11.4 Hz, 1H, 
CH2-Ph), 3.89 (dd, J = 11.4 Hz and 5.9 Hz, 1H, H-1), 3.79 (ddd, J = 11.7 Hz, 6.7 Hz and 5.1 
Hz, 1H, H-1), 3.60-3.73 (m, 3H, H-2, H-3 and H-4), 2.49 (dd, J = 6.2 Hz and 6.8 Hz, 1H, 
OH), 1.58-1.23 (m, 26H, CH2), 0.88 (t, J = 6.8 Hz, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 147.10, 138.20, 137.87, 128.76, 128.69, 128.34, 128.25, 
128.23, 128.16, 128.08, 127.49, 80.75, 79.27, 77.45, 73.87, 72.79, 63.31, 62.50, 32.16, 30.47, 
29.94, 29.92, 29.90, 29.84, 29.80, 29.60, 25.72, 22.93, 14.36. 
Exact mass (ESI-MS) for C32H49N3O3 [M+H]
+
 found, 524.3843; calcd, 524.3852. 
Spectral data are consistent with the literature data. 
(2S,3S,4R)-2-azido-3,4-di-O-benzyl-1-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-
galactopyranosyl)-octadecane-1,3,4-triol (34) 
To a mixture of galactosyl donor 32 (170 mg, 0.29 mmol) in THF (1 mL) under argon 
atmosphere was added a solution of 33 (100 mg, 0.19 mmol) in THF (2.8 mL). The solution 
was cooled to -30 °C and TMSOTf (5 μL, 0.03 mmol) was added. After stirring for 1 hour, 
the reaction mixture was neutralized with Et3N and the solvent was evaporated under reduced 
pressure. The resulting residue was purified by column chromatography (hexanes/EtOAc: 9/1) 
affording glycolipid 34 (146 mg, 80 %) as a white solid. 
1
H-NMR (300 MHz, CDCl3): δ 7.53-7.51 (m, 2H, 
arom. H), 7.41-7.21 (m, 23H, arom. H), 5.45 (s, 1H, 
CH-Ph), 4.97 (d, J = 3.2 Hz, 1H, H-1”), 4.86 (d, J = 
12.0 Hz, 1H, CH2-Ph), 4.81 (d, J = 13.2 Hz, 1H, CH2-
Ph), 4.77 (d, J = 10.4 Hz, 1H, CH2-Ph), 4.74 (d, J = 
12.3 Hz, 1H, CH2-Ph), 4.67 (d, J = 11.7 Hz, 1H, CH2-
Ph), 4.60 (d, J = 11.4 Hz, 1H, CH2-Ph), 4.58 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.50 (d, J = 11.7 
Hz, 1H, CH2-Ph), 4.16 (app. d, J = 3.5 Hz, 1H, H-4”), 4.14-4.07 (m, 2H, H-2” and H-6”), 
4.04-3.99 (m, 2H, H-1 and H-3”), 3.88 (dd, J = 1.3 Hz and 12.6 Hz, 1H, H-6”), 3.73-3.69 (m, 
3H, H-1, H-2 and H-3), 3.62 (ddd, J = 3.5 Hz and 7.1 Hz, 1H, H-4), 3.57 (app. s, 1H, H-5”), 
1.65-1.26 (m, 26H, CH2), 0.88 (t, J = 6.4 Hz, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 139.00, 138.60, 138.26, 138.07, 129.90, 129.10, 128.62, 
128.59, 128.51, 128.47, 128.34, 128.15, 128.04, 128.00, 127.94, 127.91, 127.85, 127.75, 
127.70, 126.58, 121.12, 101.30, 99.38, 79.65, 79.20, 77.90, 77.44, 76.04, 75.69, 74.91, 74.02, 
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73.74, 72.44, 72.31, 72.28, 69.56, 68.69, 63.22, 62.04, 32.16, 30.26, 30.01, 29.94, 29.92, 
29.90, 29.88, 29.85, 29.72, 29.60, 29.47, 25.70, 22.92, 21.58, 14.35. 
Exact mass (ESI-MS) for C59H75N3O8 [M+H]
+
 found, 954.5652; calcd, 954.5627; [M+Na]
+
 
found, 976.5464; calcd, 976.5446; [M+K]
+
 found, 992.5109; calcd, 992.5186. 
(2S,3S,4R)-2-azido-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-hydroxy--D-
galactopyranosyl)-octadecane-1,3,4-triol (35) 
To a solution of 34 (50 mg, 0.05 mmol) in anhydrous CH2Cl2 (1.6 mL) under argon 
atmosphere was added copper(II) triflate (3 mg, 0.008 mmol) and BH3.THF (0.26 mL, 0.26 
mmol). After stirring for 1.5 hours at room temperature, the brown reaction mixture was 
quenched with methanol. Subsequently the mixture was diluted with EtOAc and washed with 
a saturated NaHCO3 solution, water and brine. The organic layer was dried over Na2SO4 and 
concentrated under reduced pressure. Purification by column chromatography 
(hexanes/EtOAc: 8.5/1.5) yielded 35 (37 mg, 73 %) as a colorless oil. 
1
H NMR (300 MHz, DMSO-d6): δ 7.38-7.7.22 (m, 
25H, arom. H), 4.97 (d, J = 2.25 Hz, 1H, H-1”), 4.82 (d, 
J = 11.4 Hz, 1H, CH2-Ph), 4.79-4.69 (m, 5H, CH2-Ph, 
OH), 4.60-5.54 (m, 4H, CH2-Ph), 4.44 (d, J = 11.6 Hz, 
1H, CH2-Ph), 4.08 (br. s, 1H, H-3”), 3.97-3.88 (m, 3H, 
H-1, H-3, H-2”), 3.79-3.73 (m, 3H, H-2, H-4”, H-5”), 3.67-3.62 (m, 2H, H-1, H-4), 3.52-3.46 
(m, 2H, H-6”), 2.49-1.20 (m, 26H, CH2) 0.85 (t, J = 6.6 Hz, 3H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 138.96, 138.88, 138.63, 138.43, 138.30, 128.82, 128.72, 
128.66, 128.63, 128.61, 128.54, 128.22, 128.13, 128.09, 128.00, 127.98, 127.86, 127.84, 
127.78, 98.84, 79.56, 79.46, 79.06, 76.69, 75.43, 74.73, 73.96, 73.69, 73.48, 72.30, 71.12, 
68.68, 62.70, 62.25, 32.19, 30.27, 30.02, 29.97, 29.93, 29.89, 29.87, 29.63, 25.61, 22.96, 
14.39. 
Exact mass (ESI-MS) for C59H77N3O8 [M+Na]
+
 found, 978.5695; calcd, 978.5603. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-hydroxy--D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (25) 
To a solution of 35 (157 mg, 0.16 mmol) in THF (1.6 mL) was added dropwise 
trimethylphosphine (0.8 mL, 0.82 mmol). After stirring for 2.5 hours, a NaOH solution 
(3 mL, 1 M) was added and the mixture was allowed to stir for an additional 2.5 hours. The 
reaction mixture was extracted with EtOAc and the organic layer was washed with brine, 
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dried over Na2SO4 and concentrated under reduced pressure. The crude amine was dissolved 
in CH2Cl2 (2 mL) and added to a solution of EDC (63 mg, 0.33 mmol) and hexacosanoic acid 
(97 mg, 0.25 mmol) in CH2Cl2 (0.5 mL). This reaction mixture was stirred overnight at room 
temperature after which it was extracted with CH2Cl2. The organic layer was washed with 
brine and dried over Na2SO4. After evaporation of the organic solvent, the residue was 
purified by column chromatography (hexanes/EtOAc: 6/4) affording compound 25 (167 mg, 
78 %) as a yellow oil. 
Spectral data are consistent with those of 25 on page 
62-63. 
 
 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-hydroxy--D-galactopyranosyl)-2-
(6-phenylhexanoyl)amino-octadecane-1,3,4-triol (36) 
To a solution of 35 (120 mg, 0.13 mmol) in THF (1.3 mL) was added dropwise 
trimethylphosphine (0.6 mL, 0.63 mmol). After stirring for 2.5 hours, a NaOH solution (2.3 
mL, 1 M) was added and the mixture was allowed to stir for an additional 2.5 hours. The 
reaction mixture was extracted with EtOAc and the organic layer was washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure. The crude amine was dissolved 
in CH2Cl2 (1.4 mL) and added to a solution of EDC (48 mg, 0.25 mmol) and 6-
phenylhexanoic acid (36 mg, 0.19 mmol) in CH2Cl2 (0.5 mL). This reaction mixture was 
stirred overnight at room temperature after which it was extracted with CH2Cl2. The organic 
layer was washed with brine and dried over Na2SO4. After evaporation of the organic solvent, 
the residue was purified by column chromatography (hexanes/EtOAc: 7/3) affording 
compound 36 (107 mg, 77 %) as a colorless oil. 
1
H-NMR (300 MHz, CDCl3): δ 7.38-7.15 (m, 30H, 
arom. H), 5.84 (d, J = 8.6 Hz, 1H, NH), 4.94 (d, J = 
11.4 Hz, 1H, CH2-Ph), 4.86 (d, J = 3.7 Hz, 1H, H-1”), 
4.83 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.80 (d, J = 11.7 Hz, 
1H, CH2-Ph), 4.74 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.69 
(d, J = 11.7 Hz, 1H, CH2-Ph), 4.66 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.60 (d, J = 11.7 Hz, 1H, 
CH2-Ph), 4.55 (d, J = 11.4 Hz, 1H, CH2-Ph), 4.52 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.48 (d, J = 
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11.4 Hz, 1H, CH2-Ph), 4.44 (d, J = 11.4 Hz, 1H, CH2-Ph), 4.37 (m, 1H, H-2), 4.02 (dd, J = 
9.9 Hz and 3.7 Hz, 1H, H-2”), 3.94 (dd, J = 11.4 Hz and 7.7 Hz, 1H, H-1), 3.85-3.82 (m, 3H, 
H-1, H-3”and H-4”), 3.70-3.62 (3H, H-3, H-5” and H-6”), 3.55-3.41 (m, 2H, H-4, H-6”), 2.57 
(t, J = 7.1 Hz, 2H, CH2-Ph), 1.97-1.80 (m, 2H, COCH2), 1.69-1.26 (m, 34H, CH2), 0.88 (t, J = 
6.6 Hz, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 173.26, 142.68, 138.84, 138.76, 138.66, 138.47, 128.68, 
128.65, 128.62, 128.60, 128.51, 128.17, 128.14, 128.09, 127.98, 127, 95, 127.86, 127.84, 
127.66, 125.93, 100.23, 80.57, 79.50, 79.43, 77.67, 77.45, 77.25, 76.82, 75.04, 74.76, 73.79, 
73.40, 73.33, 72.06, 71.51, 69.98, 62.69, 51.08, 50.89, 36.87, 35.95, 32.16, 31.36, 31.16, 
30.44, 30.02, 29.96, 29.92, 29.60, 29.12, 26.01, 25.73, 22.93, 14.36. 
Exact mass (ESI-MS) for C71H93NO9 [M+H]
+
 found, 1104.7063; calcd, 1104.6923. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-iodo-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (37) 
PPh3 (18 mg, 0.07 mmol) was added to a solution of 25 (74 mg, 0.06 mmol) in toluene (0.4 
mL) under argon followed by refluxing during 10 minutes. The mixture was cooled down to 
80 °C and imidazole (11 mg, 0.17 mmol) and I2 (19 mg, 0.07 mmol) were added. After 
refluxing for 20 minutes, the solution was concentrated under reduced pressure. The resulting 
residue was diluted with EtOAc and washed with a saturated Na2S2O3 solution and water. The 
organic layer was dried on Na2SO4 and evaporated to dryness. Purification by column 
chromatography (hexanes/EtOAc: 9/1) yielded 37 (68 mg, 85 %) as a white solid. 
1
H-NMR (300 MHz, CDCl3): δ 7.40-7.21 (m, 25H, 
arom. H), 5.84 (d, J = 8.6 Hz, 1H, NH), 5.03 (d, J = 
11.2 Hz, 1H, CH2-Ph), 4.84 (d, J = 11.7 Hz, 1H, CH2-
Ph), 4.83 (d, J = 3.4 Hz, 1H, H-1”), 4.79-4.72 (m, 3H, 
CH2-Ph), 4.65-4.58 (m, 3H, CH2-Ph), 4.52 (d, J = 11.7 
Hz, 1H, CH2-Ph), 4.49 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.30 (m, 1H, H-2), 4.08 (m, 1H, H-4”), 
4.02 (dd, J = 10.0 Hz and 3.5 Hz, 1H, H-2”), 3.91-3.87 (m, 2H, H-1, H-3”), 3.84-3.77 (m, 3H, 
H-1, H-3, H-5”), 3.53 (ddd, J = 7.2 Hz and 3.6 Hz, 1H, H-4), 3.18 (dd, J = 9.9 Hz and 7.1 Hz, 
1H, H-6”), 3.09 (dd, J = 9.9 Hz and 7.0 Hz, 1H, H-6”), 2.02-1.86 (m, 2H, COCH2), 1.72-1.06 
(m, 72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 169.41, 135.12, 135.05, 135.00, 134.87, 134.74, 124.95, 
124.90, 124.87, 124.39, 124.37, 124.30, 124.23, 124.16, 124.12, 124.08, 123.93, 101.28, 
95.36, 76.43, 75.71, 75.61, 73.94, 73.94, 73.72, 73.52, 73.10, 72.70, 71.88, 71.63, 69.97, 
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69.80, 69.70, 68.44, 64.81, 46.66, 33.29, 28.44, 26.63, 26.37, 26.24, 26.21, 26.17, 26.12, 
25.97, 25.91, 25.89, 25.87, 22.46, 22.26, 19.21, 10.63. 
Exact mass (ESI-MS) for C85H128INO8 [M+H]
+
 found, 1418.8851; calcd, 1418.8757. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-iodo-α-D-galactopyranosyl)-2-(6-
phenylhexanoyl)amino-octadecane-1,3,4-triol (38) 
PPh3 (20 mg, 0.08 mmol) was added to a solution of 36 (70 mg, 0.06 mmol) in toluene (0.4 
mL) under argon followed by refluxing during 10 minutes. The mixture was cooled down to 
80 °C and imidazole (13 mg, 0.19 mmol) and I2 (21 mg, 0.08 mmol) were added. After 
refluxing for 20 minutes, the solution was concentrated under reduced pressure. The resulting 
residue was diluted with EtOAc and washed with a saturated Na2S2O3 solution and water. The 
organic layer was dried on Na2SO4 and evaporated to dryness. Purification by column 
chromatography (hexanes/EtOAc: 8/2) yielded 38 (67 mg, 85 %) as a yellow oil. 
1
H-NMR (300 MHz, CDCl3): δ 7.42-7.16 (m, 30H, 
arom. H), 5.86 (d, J = 8.6 Hz, 1H, NH), 5.05 (d, J = 
11.2 Hz, 1H, CH2-Ph), 4.86 (d, J = 3.6 Hz, 1H, H-1”), 
4.85 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.79 (d, J = 11.7 Hz, 
1H, CH2-Ph), 4.78 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.76 
(d, J = 11.5 Hz, 1H, CH2-Ph), 4.66 (d, J = 11.1 Hz, 1H, CH2-Ph), 4.65 (d, J = 10.0 Hz, 1H, 
CH2-Ph), 4.62 (d, J = 12.0 Hz, 1H, CH2-Ph), 4.54 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.52 (d, J = 
11.7 Hz, 1H, CH2-Ph), 4.34 (m, 1H, H-2), 4.11-4.10 (m, 1H, H-4”), 4.05 (dd, J = 10.0 Hz and 
3.5 Hz, 1H, H-2”), 3.95-3.89 (m, 2H, H-1, H-3”), 3.87-3.85 (m, 1H, H-5”), 3.83-3.79 (m, 2H, 
H-1, H-3), 3.59-3.54 (m, 1H, H-4), 3.21 (dd, J = 10.0 Hz and 7.2 Hz, 1H, H-6”), 3.12 (dd, J = 
10.0 Hz and 6.9 Hz, 1H, H-6”), 2.60 (t, J = 7.6 Hz, 2H, CH2-Ph), 2.03-1.86 (m, 2H, COCH2), 
1.73-1.26 (m, 32H, CH2), 0.91 (t, J = 6.7 Hz, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 169.14, 138.98, 135.09, 135.02, 134.97, 134.84, 134.72, 
124.93, 124.88, 124.85, 124.76, 124.38, 124.36, 124.33, 124.29, 124.21, 124.14, 124.11, 
124.07, 123.90, 122.17, 95.31, 76.35, 75.71, 75.57, 73.96, 73.54, 73.12, 72.69, 71.83, 71.60, 
69.95, 69.75, 69.63, 68.39, 64.75, 56.87, 45.58, 33.11, 32.24, 28.42, 27.67, 26.62, 26.35, 
26.21, 26.16, 25.86, 25.42, 22.42, 22.00, 19.19, 17.53, 10.69, 10.63. 
Exact mass (ESI-MS) for C71H92INO8 [M+K]
+
 found, 1252.5511; calcd, 1252,5499. 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-α-D-galactopyranosyluronate)-2-
hexacosylamino-octadecane-1,3,4-triol (39) 
TEMPO (22 mg, 0.14 mmol) and BAIB (578 mg, 1.80 mmol) were added to a mixture of 25 
(940 mg, 0.72 mmol) in CH2Cl2 (4.7 mL) and H2O (2.4 mL). The emulsion was vigorously 
stirred overnight at room temperature and the reaction was quenched with Na2S2O3. After 
extraction of the aqueous layer with EtOAc, the organic layer was washed with a saturated 
NaHCO3 solution and brine, dried over Na2SO4 and evaporated. The residue was submitted to 
column chromatography (CH2Cl2/MeOH: 24/1 with 1% formic acid), affording compound 39 
(823 mg, 87 %) as a yellow oil. 
1
H-NMR (300 MHz, CDCl3): δ 7.32-7.19 (m, 25H, 
arom. H), 5.79 (br. s, 1H, NH), 4.97 (br. s, 1H, H-1”), 
4.86-4.28 (m, 13H, CH2-Ph, H-2, H-4”, H-5”), 4.02 (dd, 
J = 3.4 Hz and 9.9 Hz, 1H, H-2”), 3.90 (dd, J = 2.6 Hz 
and 10.0 Hz, 1H, H-3”), 3.88-3.83 (m, 1H, H-1), 3.76-3.69 (m, 2H, H-1 and H-3), 3.53-3.50 
(m, 1H, H-4), 1.93-1.74 (m, 2H, COCH2), 1.59-1.08 (m, 72H, CH2), 0.86 (t, J = 6.8 Hz, 6H, 
CH3). 
13
C-NMR (75 MHz, CDCl3): δ 173.30, 169.69, 138.59, 138.55, 138.38, 138.16, 128.70, 
128.66, 128.47, 128.38, 128.21, 128.14, 128.13, 128.09, 128.01, 127.98, 127.66, 99.32, 79.65, 
79.57, 78.14, 77.67, 77.45, 77.25, 76.82, 76.47, 75.84, 75.55, 74.07, 73.23, 73.10, 72.16, 
71.21, 68.97, 50.15, 36.90, 32.17, 30.47, 30.04, 29.97, 29.94, 29.91, 29.89, 29.87, 29.84, 
29.81, 29.67, 29.61, 29.60, 29.54, 25.99, 25.90, 22.93, 14.36. 
Exact mass (ESI-MS) for C85H127NO10 [M+Na]
+
 found, 1344.9396; calcd, 1344.9352. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-α-D-galactopyranosyluronate)-2-(6-
phenylhexanoyl)amino-octadecane-1,3,4-triol (40) 
TEMPO (3 mg, 0.02 mmol) and BAIB (77 mg, 0.2 mmol) were added to a mixture of 36 (106 
mg, 0.10 mmol) in CH2Cl2 (0.6 mL) and H2O (0.3 mL). The emulsion was vigorously stirred 
overnight at room temperature and the reaction was quenched with Na2S2O3. After extraction 
of the aqueous layer with EtOAc, the organic layer was washed with a saturated NaHCO3 
solution and brine, dried over Na2SO4 and evaporated. The residue was submitted to column 
chromatography (CH2Cl2/MeOH: 29/1 with 1% formic acid), affording compound 40 (104 
mg, 97 %) as a yellow oil. 
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1
H-NMR (300 MHz, CDCl3): δ 7.34-7.14 (m, 30H, 
arom. H), 5.80 (d, J = 8.2 Hz, 1H, NH), 4.95 (d, J = 3.4 
Hz, 1H, H-1”), 4.91-4.42 (m, 12H, CH2-Ph, H-4”, H-
5”), 4.42-4.31 (m, 1H, H-2), 4.06 (dd, J = 10.0 and 3.5 
Hz, 1H, H-2”), 3.93 (dd, J = 10.1 and 2.6 Hz, 1H, H-3”), 3.89 (dd, J = 10.5 and 4.9 Hz, 1H, 
H-1), 3.80 (m, 2H, H-1, H-3), 3.54 (m, 1H, H-4), 2.67 (t, J = 7.7 Hz, 2H, CH2-Ph), 1.92-1.77 
(m, 2H, COCH2), 1.67-1.19 (m, 34H, CH2), 0.90 (t, J = 6.7 Hz, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 173.33, 170.50, 142.73, 138.57, 138.55, 138.44, 138.42, 
138.25, 128.71, 128.70, 128.68, 128.66, 128.62, 128.52, 128.46, 128.32, 128.25, 128.18, 
128.16, 128.10, 128.02, 128.00, 127.96, 127.92, 127.64, 125.93, 99.93, 79.64, 79.45, 78.23, 
77.72, 77.29, 76.87, 76.18, 75.95, 75.43, 74.07, 73.22, 73.07, 72.12, 71.17, 69.03, 50.23, 
36.74, 35.98, 32.18, 31.38, 30.47, 30.06, 29.98, 29.93, 29.63, 29.12, 25.98, 25.72, 22.95, 
14.39. 
Exact mass (ESI-MS) for C71H97NO10 [M+H]
+
 found, 1118.6841; calcd, 1118.6716. 
(2S,3S,4R)-1-O-(6-deoxy-α-D-galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol 
(1) 
A solution of compound 37 (65 mg, 0.05 mmol) in MeOH (2.5 mL) was hydrogenated under 
atmospheric pressure in the presence of palladium black (20 mg). After consumption of the 
starting material, 1 spot was visible on TLC, corresponding with the deiodinated product. 
After a quick purification by column chromatography (hexanes/EtOAc: 7/3), the product was 
dissolved in MeOH (3 mL) and hydrogenated under atmospheric pressure in the presence of 
palladium black (15 mg). Upon completion of the reaction, the mixture was diluted with 
MeOH and filtered through celite. The filter cake was rinsed with MeOH and the filtrate was 
evaporated to dryness. After purification by column chromatography (CH2Cl2/MeOH:8/2), 
compound 1 (18 mg, 47 %) was afforded as a white powder. 
1
H-NMR (300 MHz, pyridine-d5): δ 8.43 (d, J = 8.7 Hz, 
1H, NH), 6.94 (d, J = 4.8 Hz, 1H, OH), 6.53 (d, J = 5.8 
Hz, 1H, OH), 6.42 (d, J = 6.5 Hz, 1H, OH), 6.16 (d, J = 
4.5 Hz, 1H, OH), 6.11 (d, J = 5.8 Hz, 1H, OH), 5.48 (d, J 
= 3.7 Hz, 1H, H-1”), 5.31 (m, 1H, H-2), 4.67 (dd, J = 10.5 Hz and 5.3 Hz, 1H, H-1), 4.59-
4.56 (m, 1H, H-2”), 4.42-4.29 (m, 5H, H-1, H-3, H-4, H-3”, H-5”), 4.09-4.04 (m, 1H, H-4”), 
2.47 (t, J = 7.4 Hz, COCH2), 2.31-1.27 (m, 72H, CH2), 1.11 (t, J = 7.1 Hz, 3H, CH3), 0.89 (t, 
J = 6.7 Hz, 6H, CH3). 
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13
C-NMR (75 MHz, pyridine-d5): δ 171.88, 100.25, 75.62, 72.08, 71.39, 70.44, 68.72, 67.34, 
66.32, 59.09, 50.02, 35.63, 33.30, 30.94, 29.20, 28.96, 28.85, 28.83, 28.75, 28.74, 28.69, 
28.64, 28.57, 28.44, 28.43, 25.31, 25.23, 21.76, 19.63, 16.03, 13.10. 
Exact mass (ESI-MS) for C50H99NO8 [M+H]
+
 found, 842.7474; calcd, 842,7444. 
(2S,3S,4R)-1-O-(6-deoxy-α-D-galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol 
(2) 
A solution of compound 38 (66 mg, 0.05 mmol) in MeOH (2.5 mL) was hydrogenated under 
atmospheric pressure in the presence of palladium black (20 mg). After consumption of the 
starting material, 1 spot was visible on TLC, corresponding with the deiodinated product. 
After a quick purification by column chromatography (hexanes/EtOAc: 7/3), the product was 
dissolved in MeOH (2.5 mL) and hydrogenated under atmospheric pressure in the presence of 
palladium black (15 mg). Upon completion of the reaction, the mixture was diluted with 
MeOH and filtered through celite. The filter cake was rinsed with MeOH and the filtrate was 
evaporated to dryness. After purification by column chromatography (CH2Cl2/MeOH: 
9.2/0.8), compound 2 (22 mg, 70 %) was afforded as a white powder. 
1
H-NMR (300 MHz, CD3OD): δ 7.88 (d, J = 8.9 Hz, 1H, 
NH), 7.26-7.10 (m, 5H, arom. H), 4.79 (app. s, 1H, H-
1”), 4.22-4.17 (m, 1H, H-2), 3.95 (dd, J = 13.3 Hz and 
6.7 Hz, 1H, H-5”), 3.84 (dd, J = 10.5 Hz and 4.4 Hz, 1H, 
H-1), 3.77-3.70 (m, 2H, H-2”, H-3”), 3.65-3.52 (m, 4H, 
H-1, H-3, H-4, H-4”), 2.61 (t, J = 7.7 Hz, 2H, CH2-Ph), 2.21 (t, J = 7.5 Hz, 2H, COCH2), 
1.69-1.24 (m, 32H, CH2), 1.20 (t, J = 6.7 Hz, 3H, CH3), 0.89 (t, J = 6.7 Hz, 3H, CH3). 
13
C-NMR (75 MHz, CD3OD): δ 174.47, 142.55, 128.21, 128.11, 125.52, 99.86, 74.20, 72.42, 
71.77, 70.50, 68.78, 66.81, 66.60, 50.59, 35.98, 35.57, 31.90, 31.85, 31.31, 29.64, 29.59, 
29.31, 28.77, 25.82, 25.77, 22.56, 15.52, 13.28. 
Exact mass (ESI-MS) for C36H63NO8 [M+H]
+
 found, 638.4659; calcd, 638.4626. 
(2S,3S,4R)-1-O-(α-D-galactopyranosyluronate)-2-hexacosylamino-octadecane-1,3,4-triol 
(3) 
A solution of compound 39 (105 mg, 0.08 mmol) in CHCl3 (1.3 mL) and EtOH (3.8 mL) was 
hydrogenated under atmospheric pressure in the presence of palladium black (15 mg). Upon 
reaction completion, the mixture was diluted with pyridine and filtered through celite. The 
filter cake was rinsed with CHCl3 and EtOH and the filtrate was evaporated to dryness. After 
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purification by column chromatography (CH2Cl2/MeOH:8/2), compound 3 (54 mg, 78 %) was 
afforded as a white powder. 
1
H-NMR (500 MHz, pyridine-d5): δ 8.46 (d, J = 8.7 Hz, 
1H, NH), 5.64 (d, J = 3.4 Hz, 1H, H-1”), 5.27-5.26 (m, 
1H, H-2), 5.15 (app. s, 1H, H-5”), 5.02 (app.s, 1H, H-
4”), 4.69-4.66 (m, 2H, H-2”, H-1), 4.50 (dd, J = 9.9 Hz 
and 3.1 Hz, 1H, H-3”), 4.37 (dd, J = 10.6 Hz and 4.5 Hz, 1H, H-3), 4.30 (app. s, 2H, H-1, H-
4), 2.46-2.41 (m, 2H, COCH2), 2.26-1.23 (m, 72H, CH2), 0.85 (t, J = 6.7 Hz, CH3). 
13
C-NMR (75 MHz, pyridine-d5): δ 171.93, 171.07, 152.04, 149.40, 105.00, 100.53, 75.48, 
71.51, 71.34, 70.99, 70.05, 68.64, 68.08, 49.98, 35.61, 33.18, 30.94, 29.48, 29.20, 28.97, 
28.86, 28.83, 28.76, 28.74, 28.69, 28.64, 28.60, 28.45, 28.43, 25.31, 25.22, 21.76, 13.10. 
Exact mass (ESI-MS) for C50H97NO10 [M-H]
-
 found, 870.7089; calcd, 870.7039. 
(2S,3S,4R)-1-O-(α-D-galactopyranosyluronate)-2-(6-phenylhexanoyl)amino-octadecane-
1,3,4-triol (4) 
A solution of compound 40 (35 mg, 0.03 mmol) in MeOH (2 mL) was hydrogenated under 
atmospheric pressure in the presence of palladium black (5 mg). Upon reaction completion, 
the mixture was diluted with MeOH and filtered through celite. The filter cake was rinsed 
with MeOH and the filtrate was evaporated to dryness. After purification by column 
chromatography (CH2Cl2/MeOH:8/2), compound 4 (14 mg, 68 %) was afforded as a white 
powder. 
1
H-NMR (500 MHz, DMSO-d6): δ 7.78 (d, J = 6.3 Hz, 
1H, NH), 7.28-7.14 (m, 5H, arom. H), 4.78 (d, J = 3.4 
Hz, 1H, H-1”), 4.07-3.93 (m, 3H, H-2, H-4”, H-5”), 3.74 
(app. s, 1H, H-1), 3.62-3.38 (m, 5H, H-2”, H-3”, H-1, H-
3, H-4), 2.57-2.52 (m, 4H, COCH2, CH2-Ph), 1.59-1.23 
(m, 32H, CH2), 0.86 (t, J = 6.9 Hz, CH3). 
13
C-NMR (75 MHz, DMSO-d6): δ 172.65, 142.97, 128.90, 128.86, 126.22, 100.10, 75.03, 
73.65, 71.45, 71.31, 70.51, 68.55, 67.90, 50.44, 36.09, 35.78, 32.86, 31.98, 31.59, 30.05, 
29.95, 29.86, 29.82, 29.79, 29.77, 29.71, 29.40, 29.12, 28.91, 26.09, 25.90, 22.78, 14.64. 
Exact mass (ESI-MS) for C36H61NO10 [M-H]
-
 found, 666.4213; calcd, 666.4223.  
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4 Synthesis of diverse C-5”- and C-6”-
modified α-GalCer analogues 
4.1 C-5”-amides, C-5”-urea/carbamate derivatives and C-6”-
carbamates 
As suggested at the end of the previous chapter, galacturonic acid 39, acquired upon 
TEMPO/BAIB-mediated oxidation of compound 25, is an excellent precursor for the 
synthesis of C-5”-amide-substituted α-GalCer analogues (Scheme 4.1). These compounds 
differ from the previously synthesized C-6”-amides in that the amide functionality is inversed 
and located one position closer to the galactose moiety. In analogy, C-5”-modified 
compounds related to the known C-6”-urea derivatives can be prepared by submitting the 
same carboxylate 39 to a Curtius rearrangement reaction with relevant amines. A similar 
reaction with primary alcohols gives access to C-5”-carbamates. The corresponding C-6”-
carbamates on the other hand can be obtained via treatment of 25 with the appropriate 
isocyanates. Together, biological evaluation of these compounds allows to investigate the 
influence of the linker type and length on the iNKT cell response. 
 
Scheme 4.1 Retrosynthetic scheme for the synthesis of C-5”-amides, C-5”-urea/carbamate derivatives and C-6”-
carbamates. 
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4.1.1 Synthesis 
Scheme 4.2 illustrates the synthesis of C-6”-carbamates 5a-5c and C-5”-amides 6a-6g starting 
from the common intermediate 25. Reaction of the primary hydroxyl group with the 
appropriate isocyanate allowed introduction of the C-6”-carbamate group, affording 41a and 
41b. Since pyridin-4-yl isocyanate was not commercially available, compound 41c was 
obtained by treating 25 with 4-aminopyridine and 1,1’-carbonyldiimidazole (CDI). On the 
other hand, oxidation of the primary hydroxyl group of 25 via a TEMPO/BAIB reaction, 
followed by coupling with the appropriate amine using 2-(6-Chloro-1-H-benzotriazole-1-yl)-
1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) afforded C-5”-amides 42a-42g. 
Finally, the desired carbamates 5a-5c and amides 6a-6e were obtained after global 
deprotection involving a palladium-catalyzed hydrogenation. Unfortunately, this deprotection 
method was inconvenient for sulfur-containing compound 42f, even under high pressure 
(50 bar). In addition, during hydrogenation of derivatives 41b and 42g, overreduction of the 
naphthyl group occurred. In case of naphthyl carbamate 41b, carefully monitoring of the 
reaction yet allowed obtaining the final product. For the naphthyl amide compound, however, 
this undesired reduction was observed in the early stage of the reaction, impeding isolation of 
the envisaged analogue. Consequently, compounds 42f and 42g were alternatively 
deprotected in the presence of aluminium chloride and dimethylaniline, rendering the desired 
products 6f and 6g in low yields. 
 
Scheme 4.2 Reagents and conditions: (a) i. RNCO, DMF, 67%-74% or ii. RNH2, CDI, DMF, 70 °C, 33%; (b) Pd 
black, H2, EtOH/CHCl3, 49%-86%; (c) TEMPO, BAIB, CH2Cl2/H2O, 87%; (d) RNH2, HCTU, DIPEA, DMF, 
53%-87 %; (e) AlCl3, dimethylaniline, CH2Cl2, 11%-15%. 
Synthesis of diverse C-5” and C-6”-modified α-GalCer analogues 
 
85 
For the preparation of C-5”-urea derivative 7, a Curtius rearrangement reaction was carried 
out involving refluxing of galacturonic acid 39 in toluene in the presence of Et3N, 
diphenylphosphorazidate (DPPA), Ag2CO3 and aniline (Scheme 4.3). Regrettably, palladium-
catalyzed hydrogenation of 43 to remove the benzyl groups appeared to be destructive for this 
compound, as no product formation could be observed and only low-molecular mass 
fragments were detected. 
 
Scheme 4.3 Reagents and conditions: (a) Et3N, DPPA, aniline, Ag2CO3, toluene, 110 °C, 3.5 h, 50%; (b) H2, Pd 
black, EtOH, CHCl3. 
4.1.2 Biological evaluation 
Similar to the galacturonic acid and α-D-fucopyranosyl analogues, the biological activity of 
the C-6”-carbamates and C-5”-amides was assessed by measurement of IFN-γ and IL-4 serum 
levels after intraperitoneal injection of 5 μg of the corresponding glycolipids in mice 
(Collaboration with Prof. D. Elewaut). The cytokine secretion induced by these compounds is 
presented in Figure 4.1. These data demonstrate that the C-5”-amides are weaker agonists 
than α-GalCer, except 6a and 6f which are equally potent IFN-γ inducers. The C-5”-amides 
generally induce a Th1 polarization, although less pronounced compared to NU-α-GalCer. 
The C-6”-carbamates on the other hand result in a much stronger iNKT cell response, with 5a 
and 5c skewing the balance towards a Th1 response, while 5b has rather a Th2 polarizing 
effect. 
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Figure 4.1 IFN-γ and IL-4 secretion, measured at respective 16 h and 4 h, after intraperitoneal injection of 5 μg 
of the glycolipids in mice. 
In order to reveal a contingent relation between the nature of the linker and the observed 
differences in iNKT cell response, C-5”- amide 6c, further referred to as BnNH-GSL-1’, was 
studied in more detail and compared to NU-α-GalCer. SPR experiments demonstrated that the 
TCR binding affinity toward BnNH-GSL-1’ is much weaker than to NU-α-GalCer (Table 4.1, 
Collaboration with Prof. D. Zajonc). Whereas the association rate of TCR binding is 
comparable, the dissociation of BnNH-GSL-1’ is much faster than NU-α-GalCer. This 
indicates that the chemical differences between both glycolipids mostly affect the dissociation 
rate and thus the stability of the CD1d/glycolipid/TCR complex. 
Table 4.1 Equilibrium binding affinity of the TCR to the indicated glycolipid/CD1d complex, measured by SPR. 
Glycolipid kass(M
-1
s
-1
) kdiss(s
-1
) KD(kdiss/kass) 
α-GalCer 1.3E+05 ± 1.2E+03 1.5E-03 ± 4.5E-05 11.2 ± 0.2 nM 
NU-α-GalCer  9.9E+04 ± 2.0E+04 3.8E-03 ± 8.7E-04 39.6 ± 13.5 nM 
BnNH-GSL-1’  1.2E+05 ± 9.2E+03 2.2E-02 ± 2.8E-04 187.3 ± 17.0 nM 
 
To clarify the decreased stability of the ternary complex with BnNH-GSL-1’, its crystal 
structure was elucidated and compared to the one of NU-α-GalCer and α-GalCer (Figure 4.2). 
Analogous to NU-α-GalCer, an additional hydrogen bond is formed between the carbonyl 
oxygen of the amide linker and Thr159 of CD1d. However, as the carbonyl oxygen of BnNH-
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GSL-1’ is located closer to the galactose part, the galactose is tilted slightly down toward 
CD1d, moving the 4”-OH away from the TCR. This results in a loss of the hydrogen bond 
between this hydroxyl group and Asn30 of the TCR, accounting for weaker TCR binding. 
Moreover, the C-5”-aromatic substituent of BnNH-GSL-1’ is exposed into the solvent, in 
contrast to NU-α-GalCer where the naphthyl ring induces an additional hydrophobic pocket in 
CD1d. This suggests a lower binding affinity toward CD1d and, together with the reduced 
TCR affinity, explains the decreased stability of the ternary complex. 
 
Figure 4.2 Crystal structure comparison of the ternary complexes with NU-α-GalCer (top, yellow) and BnNH-
GSL-1’ (bottom, green), both superimposed on α-GalCer (blue). 
Subsequently, we turned our attention to the C-6”-carbamate class, characterized by a 
remarkably high IFN-γ release. It is well-established that optimal IFN-γ production by iNKT 
cells requires APC-derived IL-12. For example, the IFN-γ level of the prototypical Th1 
polarizer α-C-GalCer was shown to be greatly reduced in IL-12-deficient mice.1 Therefore, 
we also examined the IL-12 production induced by these new glycolipids. The results, 
represented in Figure 4.3, show significantly higher IL-12 production for all three analogues 
compared to α-GalCer, with 5c markedly exceeding the IL-12 amount induced by NU-α-
GalCer. A similar trend was seen for the IFN-γ and IL-12 secretion when bone marrow 
dendritic cells (BMDCs) pulsed with these glycolipids were injected in mice (Figure 4.3, 
right) and for 5c these cytokine levels were even increased up to 24 hours. Importantly, 5c 
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was also able to induce a Th1-biased cytokine secretion in cultures of purified human iNKT 
cells. 
Figure 4.3 Top: IL-12 secretion, measured at 16 h after intraperitoneal injection of 5 μg of the glycolipids in 
mice. Bottom: IFN-γ and IL-12 levels at different time points after injection of glycolipid-pulsed BMDCs. 
The equilibrium dissociation constant (KD) of the TCR towards the different carbamate-based 
glycolipids presented by CD1d was assessed using SPR. For all three compounds, similar 
TCR affinities were observed, with 5c equaling α-GalCer (Table 4.2). This indicates that they 
may follow an analogous binding mode with the TCR as α-GalCer. 
Table 4.2 Equilibrium binding affinity of the TCR to the indicated glycolipid/CD1d complex, measured by SPR. 
Glycolipid kass(M
-1
s
-1
) kdiss(s
-1
) KD(kdiss/kass) 
α-GalCer 5.06E+04 ± 6.60E+03 1.34E-03 ± 9.00E-05 26.45 ± 4.55 nM 
5a 5.27E+04 ± 1.47E+04 2.62E-03 ± 7.20E-04 49.30 ± 0.30 nM 
5b 
 
3.83E+04 ± 5.30E+03 1.50E-03 ± 7.35E-04 37.10 ± 14.10 nM 
5c 6.61E+04 ± 1.21E+04 1.61E-03 ± 1.10E-04 25.00 ± 3.00 nM 
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The CD1d/glycolipid stability on the other hand was investigated via a lipid decay 
experiment, measuring the IL-2 production as a surrogate marker for the remaining binary 
complexes. Parallel to C-GalCer and NU-α-GalCer, the IL-2 levels of the C-6”-carbamate 
antigens were longer-lasting than that of α-GalCer and additionally were very similar to each 
other (Figure 4.4). Hence, we can conclude that the CD1d/glycolipid stability is comparable 
for all tested Th1 polarizing analogues and that it is significantly higher than that of CD1d/α-
GalCer. 
 
Figure 4.4 Stability analysis of the glycolipid/CD1d complexes. 
To rationalize the observed binding kinetics, crystal structures of the ternary complexes with 
5a and 5c were elucidated (Figure 4.5, Collaboration with Prof. D. Zajonc). Concerning the 
interactions with the TCR, the hydrogen bonds with the 2”-OH and 3”-OH groups are 
maintained, while for the 4”-OH group this contact is lost. The pyridine ring of 5c makes 
intimate van der Waals (VDW) contact with Gln52 of the TCR (3.5-3.8 Å), an interaction 
previously unseen in any other structure. This might compensate for the lost hydrogen bond 
with the 4”-OH group and, as a consequence, explains the comparable TCR affinity to α-
GalCer. By contrast, the C-6”-aryl groups of 5a and NU-α-GalCer are more distant from the 
Gln52 residue, at 6.4-6.9 Å and 8.0-12.9 Å respectively, which is in agreement with the 
observed TCR affinity hierarchy. 
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Figure 4.5 Crystal structures of the ternary complexes with 5c (top) and 5a (bottom). The left panel shows the 
overall binding by mCD1d and the TCR. The middle panel illustrates the interactions with the TCR, while the 
right panel illustrates those with CD1d. 
Regarding the binding with CD1d, all hydrogen bonds found for α-GalCer are conserved. In 
contrast to NU-α-GalCer, neither the aromatic substituents of 5a and 5c, nor their carbonyl 
oxygen were found to induce additional interactions with CD1d. Nevertheless, analysis of the 
buried surface areas (BSA) between the glycolipids and CD1d indicates that 5a binds as 
extensively to CD1d as NU-α-GalCer (1.124 vs 1.145 Å²), mostly attributed to novel VDW 
interactions with CD1d, in particular involving Met69, Met162 and Thr159. This is in 
accordance with its enhanced CD1d stability observed in the lipid decay experiment. 
Although 5c showed a similar CD1d stability, its crystal structure indicates that it interacts 
less extensively with CD1d (1.045 Å²), comparable to α-GalCer (1.027 Å²). This suggests that 
in this case, factors other than the binding kinetics might play a role in the overall stability of 
the CD1d/glycolipid complex. Concerning the binding mode of 5b in the ternary complex, we 
know from personal communication that it parallels that of NU-α-GalCer (Figure 4.6). In 
particular, it also induces an additional hydrophobic pocket in CD1d. 
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Figure 4.6 Crystal structure of 5b bound to CD1, compared with that of NU-α-GalCer. 
Finally, the high IFN-γ and IL-12 levels of the C-6”-carbamate analogues led us to investigate 
their anti-metastatic potential in a B16 lung melanoma model (Collaboration with Prof. D. 
Elewaut). All three compounds were able to reduce the quantity of lung nodules significantly 
more than α-GalCer (Figure 4.7). In analogy with its ability to induce high levels of IFN-γ and 
IL-12 secretion, 5c was superior in preventing tumor metastases, even in comparison with 
NU-α-GalCer. 
 
Figure 4.7 Left: number of long noduli in a B16 mouse melanoma model upon injection of 10 000 BMDCs 
loaded with the corresponding glycolipid (each dot represents an individual mouse). Right: pictures of the most 
representative lung for each glycolipid. 
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4.1.3 Conclusion 
Starting from intermediate 25, we could furnish a series of C-5”-amides and C-6”-carbamates 
in only a few steps, highlighting the versatility of our established synthetic route. Although 
the preparation of C-5”-carbamates and C-5”-urea derivatives could not be realized, data 
comparison of the succeeded C-5”-amide and C-6”-carbamate compounds with that of NU-α-
GalCer does provide some insights concerning the influence of the linker and the aromatic 
substituent on the iNKT cell response. The possible effect of the C-5” or C-6” substituents is 
twofold. At first, C-6”-substitution with certain aromatic groups can result in novel 
interactions with the TCR, as illustrated by the VDW contacts between Gln52 and the 
pyridine ring of 5c. However, this analogue also loses an H-bond between the 4”-OH and 
Asn30, resulting in no net TCR affinity enhancement. Secondly, increased interactions with 
CD1d may arise, such as the induction of an additional hydrophobic pocket and the formation 
of an extra hydrogen bond with Thr159, both increasing the stability of the binary complex. 
For the induction of the additional hydrophobic pocket, the size of the aromatic group seems 
to be the key determinant rather than the linker type or length. Indeed, this so-called third 
anchor is thus far only observed with NU-α-GalCer and 5b, two naphthyl-containing 
derivatives. On the other hand, the linker length might affect the orientation of the 
carbohydrate moiety and thus the recognition of the CD1d/glycolipid epitope by the TCR, as 
shown for BnNH-GSL-1’. However, whether all these different interactions are related with 
the Th1 polarization induced by these compounds, and if so, what underlies their different 
potencies, is not yet clear and definitively needs further research. Furthermore, the apparently 
contradicting cytokine secretion induced by 5b raises a lot of questions. 
4.2 C-6”-triazoles 
The copper-catalyzed azide–alkyne cycloaddition (CuAAC) variant of Huisgen’s 1,3-dipolar 
cycloaddition provides an easy and reliable method to link two building blocks via a 1,2,3-
triazole moiety. Besides being a rigid linking unit, the 1,4-disubstituted triazole also possesses 
desirable pharmacological properties.
2
 It is metabolically stable and, due to its high aromatic 
stabilization, resistant towards acid and basic hydrolysis and towards reductive and oxidation 
conditions. It has a large dipole moment (about 5 D) and is able to participate in hydrogen 
bond formation, dipole-dipole and π-stacking interactions. Since the aforementioned crystal 
structure of NU-α-GalCer and BnNH-GSL-1’ revealed an extra hydrogen bond between the 
carbonyl oxygen of the substituent and Thr159 of CD1d, the capacity of a triazole moiety to 
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act as H-bonding acceptor is most appealing. Moreover, a 1,4-disubstituted triazole group is 
suggested as a bioisostere of a trans-amide bond, which is interesting in view of the distinct 
Th1 profile of α-GalCer analogues with aromatic amides on C-6”, including a phenyl-
substituted amide (PhA-α-GalCer). 3  Hence, its corresponding triazole compound 9c is 
synthesized and evaluated for comparative reasons. Finally, a docking experiment of C-6”-
(1,2,3-triazol-1-yl)-substituted α-GalCer (8a) in the structure of the ternary complex indicates 
that introduction of aromatic substituents in position 4 of the triazole ring might favorably 
occupy the cleft that accommodates the naphthyl group of NU-α-GalCer (Figure 4.8, 
Performed by dr. H. De Winter). Hence, such aromatic substituents may induce a similar 
hydrophobic pocket in CD1d. This led us to select a homologous series of aromatic alkynes, 
allowing us to investigate the inﬂuence of the linker length between the triazole ring and the 
aromatic group on the iNKT cell activity. 
 
Figure 4.8 Docking of a 6”-triazole-substituted α-GalCer analogue (green: triazole compound; purple: NU-α-
GalCer). 
Incorporation of a triazole unit at the C-6” position has very recently been described by the 
group of Besra for the synthesis of homodimeric α-GalCer analogues.4 Pegylated as well as 
alkylene spacers of varying lengths were used to link the two α-GalCer units (Figure 4.9). 
Depending on the linker length, the pegylated dimers showed similar or lower iNKT cell 
stimulation as α-GalCer. By contrast, the alkylene derivatives were only marginally active, 
regardless the length of the linker. 
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Figure 4.9 General structure of homodimeric α-GalCer analogues synthesized by the group of Besra. 
4.2.1 Synthesis 
The synthesis of the desired triazoles started from intermediate 25 (Scheme 4.4). Conversion 
of the primary hydroxyl group to an azide group via a Mitsunobu reaction with DPPA 
afforded compound 44 in excellent yield. Initial attempts to convert 44 to triazole 45b using a 
CuAAC reaction at ambient temperature did not result in triazole formation, even after 48 
hours. Based on a report by Carvalho and co-workers
5
 and our own lab experiences, we then 
performed the CuAAC reaction under microwave conditions (70 °C) in the presence of the 
appropriate alkyne, successfully obtaining compounds 45b-45f in good yields. Due to 
solubility reasons, DMF was chosen as a solvent, rather than common mixtures such as 
H2O/tBuOH or H2O/THF. Aberrantly, the unsubstituted triazole 45a was acquired by 
treatment with neat vinylacetate (120 °C). This procedure provides an improved and simple 
method compared to other reported alternatives such as the use of TMS-acetylene or acetylene 
gas.
6
 Final debenzylation by catalytic hydrogenolysis afforded the desired analogues 8a-8f in 
moderate yields. 
 
Scheme 4.4 Reagents and conditions: (a) Ph3P, DEAD, DPPA, THF, -20 °C, 92%; (b) appropriate alkyne, 
sodium ascorbate, CuSO4, DMF, μW (70-120 °C, 250 W), 60%-97%; (c) Pd black, H2, EtOH/CHCl3, rt, 22%-
53%. 
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During the course of this work, Besra and co-workers reported the synthesis of structurally 
related triazoles including phenyl-substituted triazole 8c. In contrast to our method, they 
performed the CuAAC reaction on an unprotected 6’’-azido-6’’-deoxy-α-GalCer derivative, 
applying conventional heating (Scheme 4.5).
7
 
 
Scheme 4.5 Synthetic overview of the related 1,4-disubstituted triazoles prepared by Besra and coworkers. 
4.2.2 Biological evaluation 
To assess the antigenic activity of the final compounds, BMDCs were loaded during 20 hours 
with 100 ng/mL glycolipid. After 16 hours of coculture with 2C12 cells (iNKT cell 
hybridoma), IL-2 secretion was determined by ELISA (Collaboration with Prof. D. Elewaut). 
8a-8f showed an efficacy to release IL-2 that was higher or comparable to α-GalCer (Figure 
4.10). The analogues in which an n-butyl (8b) or phenyl (8c) substituent is directly attached to 
the triazole ring tend to induce the highest IL-2 secretion. Strikingly, the response of phenyl-
substituted triazole 8c contrasts with the in vitro results obtained by Besra and co-workers, 
where a remarkably reduced iNKT cell stimulatory activity is observed for this compound.
7
 A 
possible explanation for this discrepancy is the direct incubation of glycolipids, BMDCs and 
iNKT cell hybridomas in their assay, while we used glycolipid-loaded BMDCs. Introduction 
of varying linker lengths between the triazole and the phenyl moieties doesn’t seem to 
significantly influence the antigenic activity. Hence we speculated that the mere presence of a 
triazol-1-yl ring at position 6” suffices to cause a superior antigenic activity than α-GalCer. 
Affirmatively, DCs loaded with the unsubstituted triazole analogue 8a were even better in 
stimulating iNKT cells to release IL-2. This is consistent with the potent iNKT cell activity of 
the precursor azide reported in the publication of Besra and co-workers.
7
 The IL-2 secretion 
induced by n-butyl containing analogue 8b is in line with the alkyl-substituted triazoles of 
Besra, where the one with an octyl chain is far more active than the one with a longer undecyl 
chain. Contradictory to the docking experiment, however, these data indicate that 1,4-
substitution of the triazole moiety doesn’t significantly impact on the interaction with CD1d 
and the TCR, provided that the attached group doesn’t exceed a certain size. 
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Figure 4.10 IL-2 secretion after coculture of 2C12 cells (iNKT cell hybridoma) with glycolipid (100 ng/mL) 
loaded BMDCs. 
4.2.3 Conclusion 
In summary, a series of phenyl-substituted C-6”-triazolyl α-GalCer analogues as well as a     
n-butyl- and non-substituted triazole analogue have been synthesized using a copper-
catalyzed azide-alkyne cycloaddition reaction. Compared to our approach, the almost 
simultaneously published method by Besra and coworkers, using an unprotected 6”-azido 
precursor, is attractive in that it allows diversification at the very end of the synthesis. 
Evaluation of the in vitro IL-2 secretion induced by these compounds reveals them to act as 
potent iNKT cell stimulating ligands. We suggest that the observed increase in antigenic 
activity is mainly due to the triazole functionalization whereby further substitution at C-4 of 
this heterocycle with small groups is tolerated. 
4.3 OCH-variants of NU-α-GalCer and BnNH-GSL-1’ 
As evidenced by several polymodified α-GalCer analogues, including the herein reported 
C6Ph derivative of α-D-FucCer (2), combination of two favorable modifications does not 
necessarily afford compounds with enhanced biological profiles. Furthermore, it is unlikely 
that differing CD1d/glycolipid complex stabilities and TCR affinities alone determine the 
outcome of iNKT cell activation. Therefore we decided to combine two contradictory 
modifications, i.e. a C-6”-naphthyl urea substituent known to enhance the CD1d affinity, and 
an OCH-like ceramide moiety associated with a decreased half-life of binding to CD1d and a 
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reduced TCR affinity. Introduction of such an OCH ceramide is also expected to improve the 
solubility of the glycolipid in aqueous mixtures, facilitating biological experiments. As a 
comparison, the OCH variant of BnNH-GSL-1’ is also included. Towards this end, a similar 
strategy as for the previous C-6”- and C-5”-modified α-GalCer compounds can be applied, 
using the same galactosyl donor 32 in a Schmidt glycosylation procedure (Scheme 4.6). Yet, a 
shorter phytosphingosine base is required, which, in contrast to the C18-phytosphinsosine 
base, is not commercially available and is therefore prepared following a chiral pool 
approach. 
 
Scheme 4.6 Retrosynthesis of NU-OCH (9a) and BnNH-GSL-1’-OCH (9b). 
4.3.1 Synthesis 
The C9-phytosphingosine building block was prepared relying on a method reported by Niu et 
al., starting from tri-O-benzyl-D-galactal 46 (Scheme 4.7).
8
 Hydrolysis of the galactal 
building block in the presence of HBr and triphenylphosphine resulted in the corresponding 2-
deoxysugar 47. The latter was treated with the appropriate Wittig reagent, derived from 
reacting n-propyl triphenylphosphonium bromide in the presence of n-BuLi at -12 °C, leading 
to alkene 48 as a mixture of two isomers. In order to facilitate the NMR spectral analysis of 
the following compounds, we have decided to reduce the double bond at this stage, in contrast 
to Niu et al. who combined this with the global deprotection at the end of the synthesis. The 
selective reduction was accomplished quantitatively by a palladium-catalyzed hydrogenation 
in the presence of small amounts ammonia, affording alkane 49.
9
 Next, the hydroxyl group 
was converted to an azido group under Mitsunobu conditions, thereby generating the desired 
configuration. Primary debenzylation of the obtained azide 50 by treatment with ZnCl2 in a 
mixture of acetic anhydride and acetic acid, followed by deacetylation under Zemplen 
conditions furnished the desired azidophytosphingosine precursor 52. 
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Scheme 4.7 Reagents and conditions: (a) HBr, PPh3, CH2Cl2, rt, 24 h; (b) [n-PrPPh3]
+
Br
-
, BuLi, THF, -12 °C, 
3 h, 55% over 2 steps; (c) Pd/C, H2, NH3, MeOH, rt, 16 h, 99%; (d) Ph3P, DEAD, DPPA, THF, -20 °C-rt, 
overnight, 89%; (e) ZnCl2, Ac2O, AcOH, rt, 5 h; (f) NaOMe, MeOH, rt, overnight, 69% over 2 steps. 
Having obtained the appropriate acceptor 52, Schmidt glycosylation with galactosyl donor 32 
was successfully realized (Scheme 4.8). Regioselective opening of the benzylidene ring, as 
described earlier for intermediate 35, allowed to introduce the proposed C-5”- and C-6”-
modifications. For the envisaged benzylamide derivative, this implicated conversion to 
carboxylic acid 56 by a TEMPO/BAIB oxidation reaction, followed by condensation with 
benzylamine in the presence of DIPEA and HCTU. Debenzylation by a catalytic 
hydrogenation then afforded the final C-5”-amide-substituted OCH derivative 9a. 
 
Scheme 4.8 Reagents and conditions: (a) TMSOTf, THF, -30 °C, 2 h, 61%; (b) Cu(OTf)2, BH3.THF, CH2Cl2, rt, 
5 h, 68%; (c) i. PMe3, NaOH, THF, 6.5 h; ii. EDC, C23H47COOH, CH2Cl2, rt, overnight, 79%; (d) TEMPO, 
BAIB, CH2Cl2, H2O, rt, overnight, 98%; (e) DIPEA, HCTU, benzylamine, DMF, CH2Cl2, rt, overnight, 88%; (f) 
H2, Pd Black, CHCl3, EtOH, rt, 74%. 
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The C-6”-urea-substituted OCH derivative on the other hand could be easily accessed starting 
from intermediate 55 (Scheme 4.9). Mitsunobu reaction converted the primary hydroxyl 
group to an azido group, giving compound 58. Staudinger reduction followed by reaction of 
the obtained amine 59 with 1-naphthylisocyanate resulted in urea compound 60. Final 
deprotection under the usual hydrogenation conditions furnished the desired C-6”-
naphthylurea OCH analogue 9b. 
 
Scheme 4.9 Reagents and conditions: (a) PPh3, DEAD, DPPA, THF, -20 °C-rt, overnight, 98%; (b) PMe3, 
NaOH, THF, rt, 6 h; (c) naphthylisocyanate, DMF, 0 °C-rt, overnight, 60% over 2 steps; (d), H2, Pd black, 
CHCl3, EtOH, 26%. 
4.3.2 Biological evaluation 
The in vivo cytokine secretion measured upon intraperitoneal injection of 5 μg of the 
truncated glycolipids in mice is shown in Figure 4.11. Despite the combination with a Th2-
featuring OCH-ceramide, the C-5”- and C-6”-altered compounds still induce a Th1 
polarization. However, their capacity to release IFN-γ is clearly lower compared to the parent 
compounds, rendering a nice trend of increasing Th1 profiles. Neglecting other possible 
influencing factors, this might suggest that the additional hydrogen bond between the 
carbonyl oxygen of both C-6”-linkers and CD1d compensates for the decreased VDW 
interactions due to the shorter lipid chains. Further investigation is required to evaluate this 
hypothesis, including crystal structure elucidation of the corresponding ternary complexes and 
affinity measurements. 
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Figure 4.11 INF-γ and IL-4 secretion, measured at respective 16 h and 4 h, after intraperitoneal injection of 5 μg 
of the glycolipids in mice. 
4.4 Binding assay in a human setting 
The aforementioned in vivo and in vitro experiments were mainly accomplished in a mouse 
setting. However, mouse and human CD1d have been proven to be slightly different due to 
species polymorphisms. In particular, a glycine-tryptophane mutation leads to a small shift of 
the galactose ring (see Chapter 1). Therefore, in a final experiment, human CD1d-expressing 
cells were pulsed for 3 hours at 37 °C with the different C-5” and C-6”-modified α-GalCer 
analogues followed by staining with fluorescently-conjugated human iNKT TCR tetramers 
for 20 minutes at room temperature (Collaboration with Prof. S. Gadola). The TCR-staining is 
dependent on different factors, i.e. the "bioavailability" of the compound or how well it gets 
loaded onto CD1d, how stable it is kept in the CD1d binding groove, and the headgroup 
structure of the compound. The latter may help stabilizing the CD1d-binding of the glycolipid 
and may influence binding of the TCR to the combined CD1d/glycolipid epitope. However, 
with α-galactosylceramides the key factors are the binding to CD1d and the stability of the 
CD1d/glycolipid complex. Hence, the observed mean fluorescence intensity (MFI), 
normalized to α-GalCer, mainly gives an indication of the degree of CD1d/glycolipid 
complex formation (Figure 4.12). Two compounds that bind markedly better to CD1d than α-
GalCer are 2 and 4, both containing a CD1d affinity-enhancing C6Ph acyl chain. In contrast 
to the herein reported cytokine secretions in mice, these date do follow the human findings 
with the corresponding C6Ph compound reported by Wong et al. Furthermore, galacturonic 
acid 3 binds hCD1d at least equivalent to α-GalCer, whereas in mice only minor cytokine 
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release was observed. Surprisingly, the C-6”-naphthyl-substituted analogues NU-α-GalCer 
and 5b, characterized by induction of an additional pocket in mouse CD1d, appear to bind less 
efficient to human CD1d compared to α-GalCer. Nevertheless, both compounds were 
previously found to induce a Th1 polarization in a human setting. On the other hand, 5c 
results in a higher fluorescence intensity, while in mCD1d less intimate contacts were 
observed for this compound. 
 
Figure 4.12 iNKT TCR tetramer staining of glycolipid-pulsed CD1d molecules. 
Together, these data suggest that the minor structural differences between human and mouse 
CD1d can result in a different degree of glycolipid binding to CD1d, in turn influencing 
complex formation with the TCR. This may explain some of the discrepancies between 
human and mouse iNKT cell responses observed for certain glycolipids. Furthermore, the 
decreased hCD1d binding by NU-α-GalCer is in conflict with the observed Th1 polarization 
induced by this compound. This indicates that, at least for this compound, other 
predominating factors are probably involved in the outcome of human iNKT cell activation. 
4.5 C-6”-labeled analogues 
In the context of collaborations with other research groups, synthesis of two labeled α-GalCer 
analogues was desired. On the one hand, a BODIPY (boron-dipyrromethene)-labeled OCH 
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derivative was envisaged for the implementation of a fluorescence polarization assay, 
allowing real-time measurement of ligand binding and competition binding experiments. A 
convenient way to append the fluorescent group was via a C-6”-triazole linker (10, Figure 
4.13). On the other hand, a radioactive glycolipid that strongly binds to CD1d was needful for 
another competition binding assay. Towards this end, we provided a tyrosine-like precursor 
with the p-hydroxyphenyl group connected through a C-6”-amide bond (11, Figure 4.13). 
This derivative offers easy access to a iodine-labeled molecule via the Chloramine-T method. 
 
Figure 4.13 Structure of the C-6”-labeled α-GalCer derivatives. 
4.5.1 Synthesis of a C-6”-BODIPY-triazole OCH analogue 
The synthetic pathway of C-6”-BODIPY analogue 10 is outlined in scheme 4.10. Intermediate 
55 served as starting material. A slightly different approach compared to the previously 
synthesized C-6”-triazole derivatives was applied since the BODIPY core is not compatible 
with catalytic hydrogenation conditions. Therefore, the primary hydroxyl group was first 
tosylated followed by global deprotection of the secondary hydroxyl groups. Treatment of 62 
with sodium azide then afforded azide 64, in addition to a considerable amount of the 
undesired elimination product 63. Finally, a CuACC click reaction with the alkyne-
functionalized BODIPY furnished the envisaged BODIPY derivative 10.
10
 As microwave 
conditions could be harmfull for the BODIPY core, this reaction was performed at room 
temperature in the presence of tris-(benzyltriazolylmethyl)amine (TBTA). 
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Scheme 4.10 Reagents and conditions: (a) TsCl, pyridine, 0 °C-rt, overnight, 98%; (b) H2, Pd black, CHCl3, 
EtOH, 79%; (c) NaN3, DMF, 60 °C, 2 days, 38%; (d) CuI, TEA, TBTA, alkyne, DMF, H2O, 3 h, 91%. 
4.5.2  Synthesis of a C-6”-radioactive precursor 
Intermediate 44, obtained in the synthesis of the C-6”-triazole derivatives, was submitted to 
Staudinger reduction (Scheme 4.11). Next, the resulting amine 65 was reacted with 
(benzyloxy)phenylacetic acid in the presence of DIPEA and HCTU to yield amide 66. Global 
debenzylation gave the final compound 11. 
 
Scheme 4.11 Reagents and conditions: (a) PMe3, NaOH, THF, 5.5 h; (b) (benzyloxy)phenylacetic acid, DIPEA, 
HCTU, DMF, CH2Cl2, overnight, 93% over 2 steps; (c) H2, Pd black, CHCl3, EtOH, 48%. 
Chapter 4 
104 
4.6 Experimental part 
General 
Precoated Macherey-Nagel SIL G/UV254 plates were used for TLC, and spots were examined 
under UV light at 254 nm and further visualized by sulfuric acid-anisaldehyde spray. Column 
chromatography was performed on Biosolve silica gel (63-200 µm, 60 Å). NMR spectra were 
obtained with a Varian Mercury 300 Spectrometer. Chemical shifts are given in ppm () 
relative to the residual solvent signals, in the case of CDCl3:  = 7.26 ppm for 
1
H and  = 77.4 
ppm for 
13
C and in the case of pyridine-d5:  = 8.74, 7.58 and 7.22 ppm for 
1
H and  = 149.9, 
135.5 and 123.5 ppm for 
13
C. IR spectra were recorded on a Varian Scimitar 800 FT-IR 
spectrometer as KBr pellets. The absorption peaks are reported in cm
-1
. Exact mass 
measurements were performed on a Waters LCT Premier XE TOF equipped with an 
electrospray ionization interface and coupled to a Waters Alliance HPLC system. Samples 
were infused in a CH3CN/HCOOH (1000/1) mixture at 10 mL/min. 
Procedure for the synthesis of carbamates 41a and 41b 
To a solution of compound 25 (0.07 mmol) in DMF (1 mL) was added the appropriate 
isocyanate (0.18 mmol). After stirring overnight, the reaction mixture was evaporated to 
dryness under reduced pressure. Purification by column chromatography (hexanes/EtOAc: 
8/2) afforded carbamates 41a (74 %) and 41b (67 %). 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-O-(4-chlorophenylcarbamoyl)-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (41a) 
1
H NMR (300 MHz, CDCl3): δ 8.29 (s, 1H, NH), 7.31-
7.10 (m, 29H, arom. H), 5.71 (d, J = 6.6 Hz, 1H, NH), 
4.88 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.79 (d, J = 3.9 Hz, 
1H, H-1”), 4.75 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.67 (d, J 
= 12.0 Hz, 1H, CH2-Ph), 4.61 (d, J = 11.8 Hz, 1H, CH2-
Ph), 4.62 (d, J = 11.9 Hz, 1H, CH2-Ph ), 4.57 (d, J = 
11.6 Hz, 1H, CH2-Ph), 4.52 (d, J = 11.4 Hz, 1H, CH2-Ph), 4.51 ( d, J = 11.8 Hz, 1H, CH2-Ph), 
4.42 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.41 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.33-4.26 (m, 2H, H-2, 
H-6”), 4.01-3.90 (m, 3H, H-2”, H-1), 3.86-3.75 (m, 4H, H-3, H-3”, H-4”, H-5”), 3.69 (dd, J = 
1.6 Hz and 11.4 Hz, 1H, H-6”), 3.51-3.46 (m, 1H, H-4), 1.96-1.84 (m, 2H, COCH2), 1.58-
1.06 (m, 72H, CH2), 0.77 (t, J = 6.9 Hz, 6H, CH3). 
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13
C NMR (75 MHz, CDCl3): δ 173.93, 153.51, 138.79, 138.73, 138.69, 138.47, 138.22, 
137.63, 129.90, 128.96, 128.68, 128.64, 128.60, 128.57, 128.13, 128.04, 127.99, 127.90, 
127.84, 127.73, 127.66, 119.69, 100.52, 80.54, 79.72, 79.48, 77.67, 77.45, 77.25, 76.83, 
76.65, 75.20, 74.52, 73.88, 73.66, 73.62, 72.38, 70.26, 70.17, 65.87, 60.62, 52.34, 37.04, 
32.17, 32.16, 30.88, 29.97, 29.96, 29.94, 29.92, 29.89, 29.79, 29.61, 29.60, 29.48, 26.17, 
25.81, 22.93, 21.28, 14.43, 14.36. 
Exact mass (ESI-MS) for C92H133ClN2O10 [M+H]
+
 found, 1461.9786; calcd, 1461.9727. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-O-(1-naphthylcarbamoyl)-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (41b) 
1
H NMR (300 MHz, pyridine-d5): δ 10.66 (s, 1H, NH), 
8.99 (d, J = 8.4 Hz, 1H, NH), 8.84 (d, J = 8.4 Hz, 1H, 
arom. H), 8.37 (d, J = 7 Hz, 1H, arom. H), 7.96 (d, J = 
7.9 Hz, 1H, arom. H), 7.78 (d, J = 8.1 Hz, 1H, arom. H), 
7.66-7.58 (m, 2H, arom. H), 7.55-7.29 (m, 26H, arom. 
H), 5.43 (d, J = 3.4 Hz, 1H, H-1”), 5.17 (d, J = 11.1 Hz, 
1H, CH2-Ph), 5.13 (d, J = 10.2 Hz, 1H, CH2-Ph), 5.00-
4.82 (m, 4H, CH2-Ph, H-6”, H-2), 4.78-4.68 (m, 5H, H-6”, CH2-Ph), 4.64-4.58 (m, 2H, H-5”, 
CH2-Ph ), 4.54 (dd, J = 2.0 and 8.4 Hz, 1H, H-3), 4.48-4.43 (m, 3H, H-1, H-2”, CH2-Ph), 4.34 
(dd, J = 2.7 Hz and 10.2 Hz, 1H, H-3”), 4.25-4.20 (m, 2H, H-1, H-4”), 3.97-3.93 (m, 1H, H-
4), 2.66-2.56 (m, 2H, COCH2), 2.15-1.18 (m, 72H, CH2), 0.90 (t, J = 6.7 Hz, 3H, CH3), 0.89 
(t, J = 6.4 Hz, 3H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 172.21, 154.34, 138.55, 138.41, 138.21, 138.12, 127.65, 
127.50, 127.29, 126.89, 126.80, 126.75, 126.58, 125.16, 125.11, 97.63, 80.00, 78.76, 77.89, 
76.09, 74.88, 73.94, 73.24, 72.26, 71.67, 70.70, 68.77, 61.38, 50.13, 49.97, 48.02, 38.95, 
35.66, 34.03, 30.97, 28.99, 28.87, 28.80, 28.74, 28.66, 28.43, 25.62, 25.27, 23.71, 21.78, 
13.12. 
Exact mass (ESI-MS) for C96H136N2O10 [M+H]
+
 found, 1478.0220; calcd, 1478.0273. 
Procedure for the synthesis of carbamate 41c 
To a solution of compound 25 (50 mg, 0.04 mmol) in DMF (0.5 mL) was added CDI (31 mg, 
0.18 mmol). After stirring overnight, the reaction mixture was heated until 70 °C and 4-
aminopyridine was added. The reaction mixture was stirred at 70 °C during 48 hours followed 
by evaporation to dryness under reduced pressure. Purification by column chromatography 
(hexanes/EtOAc: 7/3) afforded carbamate 41c (26 mg, 33 %). 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-O-(4-pyridinylcarbamoyl)-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (41c) 
1
H NMR (300 MHz, CDCl3): δ 7.87 (s, 1H, NH), 7.35-
7.15 (m, 28H, arom. H), 6.93 (s, 1H, arom. H), 5.69 (d, 
J = 8.2 Hz, 1H, NH), 4.90 (d, J = 11.7 Hz, 1H, CH2-Ph), 
4.81 (d, J = 3.7 Hz, 1H, H-1”), 4.76 (d, J = 11.1 Hz, 1H, 
CH2-Ph), 4.73 (d, J = 11.3 Hz, 1H, CH2-Ph), 4.69 (d, J 
= 11.3 Hz, 1H, CH2-Ph), 4.65 (d, J = 11.7 Hz, 1H, CH2-
Ph), 4.58 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.55 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.48 (d, J = 11.7 
Hz, 1H, CH2-Ph), 4.40 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.39 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.29-
4.20 (m, 2H, H-2, H-6”), 4.12-4.06 (m, 1H, H-6”), 3.99 (dd, J= 3.3 Hz and 9.8 Hz, 1H, H-2”), 
3.94 (m, 1H, H-5”), 3.85 (dd, J = 2.5 Hz and 10.1 Hz, 1H, H-3”), 3.81 (dd, J = 4.91 Hz and 
11.0 Hz, 1H, H-1), 3.75 (app. s, 1H, H-4”), 3.68-3.64 (m, 1H, H-3), 3.62-3.56 (m, 1H, H-1), 
3.48-3.43 (m, 1H, H-4), 1.86-1.74 (m, 2H, COCH2), 1.54-1.09 (m, 72H, CH2), 0.83-0.76 (m, 
6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 173.09, 148.33, 138.68, 138.62, 138.52, 138.01, 137.32, 
130.68, 128.76, 128.73, 128.68, 128.66, 128.64, 128.60, 128.54, 128.16, 128.07, 128.05, 
127.97, 127.82, 127.78, 127.68, 117.33, 99.09, 80.11, 79.67, 79.13, 74.56, 73.83, 73.48, 
72.12, 68.33, 68.16, 66.68, 60.63, 56.66, 50.42, 36.97, 32.16, 31.82, 30.51, 30.04, 29.96, 
29.93, 29.89, 29.84, 29.67, 29.64, 29.60, 29.59, 26.02, 25.94, 22.92, 22.88, 21.27, 14.22, 
14.35. 
Exact mass (ESI-MS) for C91H133N3O10 [M+H]
+
 found, 1429.0229; calcd, 1429.0064. 
General procedure for the synthesis of amides (42a-42g) 
To a solution of 39 (150 mg, 0.11 mmol) in DMF (0.3 mL) and CH2Cl2 (0.7 mL) was added 
DIPEA (22 mg, 0.17 mmol). After stirring for 10 minutes at room temperature, HCTU 
(72 mg, 0.17 mmol) was added and the mixture was stirred for 30 minutes. Then the 
appropriate amine (0.17 mmol) was added and the solution was continued stirring overnight. 
After completion of the reaction, the mixture was evaporated to dryness. The residue was 
partitioned between H2O and EtOAc and the aqueous layer was extracted with EtOAc. The 
organic layer was washed with brine and dried over Na2SO4. Purification by column 
chromatography and concentration under reduced pressure furnished the desired amides 42a 
(87 %), 42b (84 %), 42c (53 %), 42d (82 %), 42e (82 %), 42f (85 %) and 42g (82 %). 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-5-phenylamide-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (42a) 
1
H NMR (300 MHz, CDCl3): δ 8.20 (s, 1H, NH), 7.53 
(d, J = 1.0 Hz, 2H, arom. H), 7.39-7.08 (m, 28H, arom. 
H), 5.73 (d, J = 8.2 Hz, 1H, NH), 4.98 (d, J = 3.5 Hz, 
1H, H-1”), 4.87 (d, J = 10.8 Hz, 1H, CH2-Ph), 4.84 (d, J 
= 11.6 Hz, 1H, CH2-Ph), 4.79 (d, J = 12.7 Hz, 1H, CH2-
Ph), 4.71 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.66 (d, J = 
11.6 Hz, 1H, CH2-Ph), 4.62 (d, J = 12.0 Hz, 1H, CH2-Ph), 4.58 (d, J = 10.8 Hz, 1H, CH2-Ph), 
4.55 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.51-4.45 (m, 3H, CH2-Ph and H-4”), 4.37 (app. d, J = 1.1 
Hz, 1H, H-5”), 4.26 (m, 1H, H-2), 4.07 (dd, J = 3.5 Hz and 10.1 Hz, 1H, H-2”), 3.98 (dd, J = 
2.7 Hz and 10.0 Hz, 1H, H-3”), 3.90-3.76 (m, 3H, H-1, H-3), 3.55-3.49 (m, 1H, H-4), 1.92-
1.78 (m, 2H, COCH2), 1.68-1.22 (m, 72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 173.07, 166.69, 138.73, 138.70, 138.55, 138.50, 138.40, 
137.44, 129.16, 128.67, 128.65, 128.63, 128.61, 128.45, 128.35, 128.15, 128.07, 128.03, 
128.01, 127.92, 127.90, 127.81, 127.70, 124.76, 120.19, 99.21, 79.97, 79.20, 78.55, 76.63, 
76.10, 75.91, 74.10, 73.38, 72.72, 72.24, 72.14, 68.46, 50.19, 36.90, 32.16, 30.41, 30.05, 
29.96, 29.94, 29.89, 29.82, 29.65, 29.61, 29.60, 26.11, 25.85, 22.93, 14.36. 
Exact mass (ESI-MS) for C91H132N2O9 [M+Na]
+
 found, 1419.9889; calcd, 1419,9831. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-5-(3,4-dichlorophenylamide)-α-
D-galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (42b) 
1
H NMR (300 MHz, CDCl3): δ 8.17 (s, 1H, NH), 7.74 
(d, J = 2.2 Hz, 1H, arom. H), 7.40-7.14 (m, 27H, arom. 
H), 5.70 (d, J = 8.2 Hz, 1H, NH), 4.95 (d, J = 3.4 Hz, 
1H, H-1”), 4.89-4.46 (m, 11H, CH2-Ph and H-4”), 4.35 
(d, J = 1.2 Hz, 1H, H-5”), 4.31-4.25 (m, 1H, H-2), 4.04 
(dd, J = 3.4 Hz and 10.0 Hz, 1H, H-2”), 3.96 (dd, J = 
2.6 Hz and 10.2 Hz, 1H, H-3”), 3.91 (dd, J = 4.9 Hz and 
10.6 Hz, 1H, H-1), 3.80-3.74 (m, 2H, H-1 and H-3), 3.56-3.52 (m, 1H, H-4), 1.94-1.77 (m, 
2H, COCH2), 1.60-1.08 (m, 72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 173.09, 167.17, 138.68, 138.66, 138.50, 138.43, 138.28, 
136.81, 132.93, 130.62, 128.70, 128.68, 128.65, 128.64, 128.42, 128.40, 128.11, 128.09, 
128.06, 128.01, 127.97, 127.94, 127.87, 127.70, 121.80, 119.37, 99.25, 79.92, 79.69, 78.49, 
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75.99, 74.11, 73.32, 72.94, 72.29, 68.67, 53.64, 50.20, 36.89, 32.16, 30.61, 30.05, 29.96, 
29.94, 29.91, 29.89, 29.82, 29.66, 29.61, 29.59, 26.12, 25.85, 22.92, 14.35. 
Exact mass (ESI-MS) for C91H130Cl2N2O9 [M+Na]
+
 found, 1487.9138; calcd, 1487.9046. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-5-benzylamide-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (42c) 
1
H NMR (300 MHz, CDCl3): δ 7.37-7.17 (m, 30H, 
arom. H), 6.79 (app. t, J = 5.9 Hz, 1H, NH), 5.74 (d, J = 
8.1 Hz, 1H, NH), 4.88 (d, J = 3.7 Hz, 1H, H-1”), 4.85-
4.42 (m, 12H, CH2-Ph, H-4”, NH-CH2), 4.35-4.28 (m, 
2H, H-5” and NH-CH2), 4.26-4.18 (m, 1H, H-2), 4.04 
(dd, J = 3.4 Hz and 9.9 Hz, 1H, H-2”), 3.95 (dd, J = 2.6 
Hz and 10.0 Hz, 1H, H-3”), 3.82-3.71 (m, 3H, H-1 and H-3), 3.49 (m, 1H, H-4), 1.93-1.78 (m, 
2H, COCH2), 1.65-1.14 (m, 72H, CH2), 0.87 (t, J = 6.6 Hz, 6H, CH3). 
13
 C NMR (75 MHz, CDCl3): δ 173.05, 168.75, 138.80, 138.76, 138.74, 138.51, 137.76, 
128.87, 128.63, 128.59, 128.40, 128.25, 128.15, 128.06, 128.01, 127.96, 127.87, 127.84, 
127.75, 127.67, 99.05, 80.00, 78.98, 78.61, 76.26, 76.03, 75.60, 74.04, 73.47, 72.59, 72.01, 
71.92, 68.18, 60.61, 50.12, 43.37, 36.88, 32.16, 31.82, 31.14, 30.27, 30.06, 29.96, 29.94, 
29.89, 29.84, 29.68, 29.61, 29.59, 26.16, 25.87, 22.92, 22.88, 14.43, 14.35. 
Exact mass (ESI-MS) for C92H134N2O9 [M+Na]
+
 found, 1433.9846; calcd, 1433.9982. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-5-(3,4-
dichlorophenmethylamide)-α-D-galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol 
(42d) 
1
H NMR (300 MHz, CDCl3): δ 7.38-7.22 (m, 26H, 
arom. H), 7.14 (d, J = 8.2 Hz, 1H, arom. H), 6.98 (dd, J 
= 1.9 Hz and 8.2 Hz, 1H, arom. H), 6.82 (t, J = 6.1 Hz, 
1H, NH), 5.75 (d, J = 8.0 Hz, 1H, NH), 4.92 (d, J = 3.3 
Hz, 1H, H-1”), 4.89 (d, J = 11.0 Hz, 1H, CH2-Ph), 4.82 
(d, J = 11.6 Hz, 1H, CH2-Ph), 4.79 (d, J = 12.1 Hz, 1H, 
CH2-Ph), 4.74 (d, J = 12.1 Hz, 1H, CH2-Ph), 4.72 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.65 (d, J = 
11.6 Hz, 1H, CH2-Ph), 4.56 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.55 (d, J = 11.0 Hz, 1H, CH2-Ph), 
4.50-4.43 (m, 4H, CH2-Ph, NH-CH2 and H-4”), 4.30-4.26 (m, 2H, H-5” and H-2), 4.20 (dd, J 
= 5.4 Hz and 15.1 Hz, 1H, NH-CH2), 4.05 (d, J = 3.4 Hz and 10.1 Hz, 1H, H-2”), 3.96 (d, J = 
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2.5 Hz and 10.0 Hz, 1H, H-3”), 3.88-3.73 (m, 3H, H-1 and H-3), 3.55-3.58 (m, 1H, H-4), 
1.99-1.80 (m, 2H, COCH2), 1.72-1.16 (m, 72H, CH2), 0.89 (t, J = 6.6 Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 173.06, 168.95, 138.73, 138.69, 138.50, 138.47, 138.24, 
132.72, 131.67, 130.87, 129.97, 128.66, 128.64, 128.62, 128.43, 128.13, 128.10, 128.03, 
127.96, 127.91, 127.84, 127.68, 127.33, 99.14, 79.96, 79.33, 78.60, 77.69, 77.27, 76.84, 
76.24, 75.98, 75.60, 74.06, 73.44, 72.73, 72.12, 71.97, 68.28, 50.18, 42.19, 36.91, 32.17, 
30.42, 30.06, 29.97, 29.95, 29.90, 29.85, 29.69, 29.62, 29.60, 26.15, 25.88, 22.94, 14.37. 
Exact mass (ESI-MS) for C92H132Cl2N2O9 [M+H]
+
 found, 1479.9365; calcd, 1479.9388. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-5-phenethylamide-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (42e) 
1
H NMR (300 MHz, CDCl3): δ 7.38-7.12 (m, 30H, 
arom. H), 6.61 (t, J = 6.0 Hz, 1H, NH), 5.78 (d, J = 8.3 
Hz, 1H, NH), 4.89 (d, J = 3.3 Hz, 1H, H-1”), 4.87 (d, J 
= 10.8 Hz, 1H, CH2-Ph), 4.82 (d, J = 11.7 Hz, 1H, CH2-
Ph), 4.77 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.73 (d, J = 
10.5 Hz, 1H, CH2-Ph), 4.72 (d, J = 11.8 Hz, 1H, CH2-
Ph), 4.64 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.59 (d, J = 
10.8 Hz, 1H, CH2-Ph), 4.56 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.51-4.49 (m, 1H, H-4”), 4.48 (d, J 
= 11.8 Hz, 1H, CH2-Ph), 4.46 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.27-4.29 (m, 2H, H-2 and H-
5”), 4.03 (dd, J = 3.5 Hz and 10.0 Hz, 1H, H-2”), 3.94 (dd, J = 2.7 Hz and 10.1 Hz, 1H, H-
3”), 3.82 (dd, J = 2.9 Hz and 6.5 Hz, 1H, H-3), 3.79-3.71 (m, 2H, H-1), 3.53-3.45 (m, 3H, 
NH-CH2 and H-4), 2.73 (ddd, J = 7.2 Hz, 13.5 Hz and 28.0 Hz, 2H, CH2), 1.98-1.80 (m, 2H, 
COCH2), 1.65-1.19 (m, 72H, CH2), 0.88 (t, J = 6.8 Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 172.99, 168.65, 138.88, 138.80, 138.77, 138.75, 138.53, 
138.51, 128.92, 128.78, 128.64, 128.62, 128.61, 128.39, 128.37,128.14, 128.06, 127.99, 
127.95, 127.88, 127.85, 127.70, 126.70, 98.97, 80.11, 78.92, 78.61, 77.68, 77.45, 77.25, 
76.83, 76.31, 76.03, 75.73, 74.06, 73.47, 72.53, 72.04, 71.81, 68.03, 50.11, 40.61, 36.91, 
36.03, 32.16, 30.29, 30.07, 29.97, 29.94, 29.92, 29.89, 29.85, 29.69, 29.64, 29.61, 29.60, 
26.21, 25.88, 22.93, 14.36. 
Exact mass (ESI-MS) for C93H136N2O9 [M+H]
+
 found, 1426.0337; calcd, 1426.0324; 
[M+Na]
+
 found, 1448.0142; calcd, 1448.0144; [M+K]
+
 found, 1463.9927; calcd, 1463.9882. 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-5-thiofuranmethylamide-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (42f) 
1
H NMR (300 MHz, CDCl3): δ 7.30-7.13 (m, 25H, 
arom. H), 7.07 (dd, J = 1.4 Hz and 5.0 Hz, 1H, arom. 
H), 6.81 (dd, J = 1.3 Hz and 3.4 Hz, 1H, arom. H), 6.79-
6.75 (m, 2H, arom. H and NH), 5.66 (d, J = 8.3 Hz, 1H, 
NH), 4.81 (d, J = 3.3 Hz, 1H, H-1”), 4.77 (d, J  = 11.0 
Hz, 1H, CH2-Ph), 4.73 (d, J = 12.5 Hz, 1H, CH2-Ph), 
4.68 (d, J = 12.0 Hz, 1H, CH2-Ph), 4.64 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.58-4.42 (m, 7H, 
CH2-Ph, NH-CH2, H-4”), 4.40 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.37 (d, J = 11.6 Hz, 1H, CH2-
Ph), 4.20 (d, J = 0.8 Hz, 1H, H-5”), 4.18-4.12 (m, 1H, H-2), 3.95 (dd, J = 3.4 Hz and 10.0 Hz, 
1H, H-2”), 3.87 (dd, J = 2.6 Hz and 10.0 Hz, 1H, H-3”), 3.75-3.63 (m, 3H, H-1 and H-3), 
3.48-3.40 (m, 1H, H-4), 1.88-1.69 (m, 2H, COCH2), 1.58-1.07 (m, 72H, CH2), 0.81 (t, J = 6.7 
Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 173.02, 168.56, 140.27, 138.77, 138.76, 138.54, 138.52, 
128.65, 128.63, 128.62, 128.39, 128.33, 128.19, 128.07, 128.01, 127.90, 127.88, 127.77, 
127.69, 127.12, 126.52, 125.44, 99.06, 79.96, 79.01, 78.57, 77.70, 77.28, 76.86, 76.23, 76.03, 
75.61, 74.05, 73.45, 72.58, 72.02, 71.89, 68.21, 50.10, 38.03, 36.90, 32.18, 32.17, 30.29, 
30.08, 29.98, 29.96, 29.93, 29.91, 29.86, 29.70, 29.63, 29.61, 26.15, 25.88, 22.95, 14.38. 
Exact mass (ESI-MS) for C90H132N2O9S [M+H]
+
 found, 1417.9757; calcd, 1417,9732; 
[M+Na]
+
 found, 1439.9514; calcd, 1439,9551; [M+K]
+
 found, 1455.9220; calcd, 1455,9291. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-5-(1-naphthalenmethylamide)-α-
D-galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (42g) 
1
H NMR (300 MHz, CDCl3): δ 7.98 (d, J = 8.2 Hz, 1H, 
arom. H), 7.85 (d, J = 7.8 Hz, 1H, arom. H), 7.77 (d, J = 
8.2 Hz, 1H, arom. H), 7.50-7.23 (m, 29H, arom. H), 
6.85 (t, J = 5.6 Hz, 1H, NH), 5.78 (d, J = 8.4 Hz, 1H, 
NH), 4.92-4.36 (m, 15H, H-1”, CH2-Ph, NH-CH2, H-4”, 
H-5”), 4.28-4.20 (m, 1H, H-2), 4.04 (dd, J = 3.2 Hz and 
10.0 Hz, 1H, H-2”), 3.98 (dd, J = 2.0 Hz and 10.0 Hz, 
1H, H-3”), 3.82-3.69 (m, 3H, H-1 and H-3), 3.53-3.47 (m, 1H, H-4), 1.97-1.79 (m, 2H, 
COCH2), 1.62-1.18 (m, 72H, CH2), 0.90 (t, J = 6.5 Hz, 6H, CH3). 
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13
C NMR (75 MHz, CDCl3): δ 173.05, 168.73, 138.84, 138.75, 138.73, 138.53, 138.50, 
134.02, 133.14, 131.56, 128.98, 128.95, 128.69, 128.65, 128.60, 128.43, 128.28, 128.18, 
128.08, 127.98, 127.88, 127.84, 127.77, 127.71, 126.84, 126.51, 126.15, 125.67, 123.50, 
99.02, 79.94, 78.89, 78.59, 77.71, 77.29, 76.86, 76.30, 79.06, 75.61, 74.06, 73.47, 72.59, 
72.00, 71.95, 68.20, 50.07, 41.30, 36.88, 32.18, 30.22, 30.08, 29.99, 29.96, 29.91, 29.87, 
29.71, 29.64, 29.62, 26.15, 25.89, 22.95, 14.39. 
Exact mass (ESI-MS) for C96H136N2O9 [M+H]
+
 found, 1462.0370; calcd, 1462,0324; 
[M+Na]
+
 found, 1484.0066; calcd, 1484,0144; [M+K]
+
 found, 1499.9858; calcd, 1499,9883. 
General procedure for debenzylation: method A (5a-5c and 6a-6e) 
A solution of the protected amide/carbamate (0.03 mmol) in CHCl3 (0.4 mL) and EtOH 
(1.2 mL) was hydrogenated under atmospheric pressure in the presence of palladium black 
(10 mg). Upon reaction completion, the mixture was diluted with pyridine and filtered 
through celite. The filter cake was rinsed with CHCl3 and EtOH and the filtrate was 
evaporated to dryness. After purification by column chromatography, final compounds 5a 
(81 %), 5b (68 %), 5c (86 %), 6a (86 %), 6b (63 %), 6c (49 %), 6d (80 %) and 6e (79 %) 
were afforded as white powders. 
(2S,3S,4R)-1-O-(6-O-(4-chlorophenylcarbamoyl)-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (5a) 
1
H NMR (300 MHz, pyridine-d5): δ 10.73 (s, 1H, NH), 
8.58 (d, J = 8.2 Hz, 1H, NH), 7.91 (d, J = 8.7 Hz, 2H, 
arom. H), 7.40 (d, J = 8.9 Hz, 2H, arom. H), 6.99 (br. s, 
1H, OH), 6.75 (br. s, 1H, OH), 6.62 (d, J = 3.7 Hz, 1H, 
OH), 6.45 (d, J = 6.6 Hz, 1H, OH), 6.27 (d, J = 6.8 Hz, 
1H, OH), 5.51 (d, J = 3.9 Hz, 1H, H-1”), 5.21-5.18 (m, 
1H, H-2), 5.03 (dd, J = 8.1 and 11.0 Hz, 1H, H-6”), 4.79 (dd, J = 3.5 Hz and 11.0 Hz, 1H, H-
6”), 4.66-4.57 (m, 3H, H-1, H-2”, H-5”), 4.39-4.24 (m, 5H, H-3”, H-4”, H-1, H-3, H-4), 2.46 
(t, J = 7.5 Hz, 2H, COCH2), 1.98-1.18 (m, 72H, CH2), 0.88 (t, J = 6.3 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 172.33, 153.39, 138.14, 128.14, 128.05, 126.14, 119.21, 
100.24, 74.89, 71.53, 70.08, 69.72, 69.27, 68.86, 67.57, 64.78, 50.50, 35.64, 32.88, 30.96, 
30.94, 29.31, 29.18, 28.98, 28.87, 28.84, 28.76, 28.74, 28.70, 28.63, 28.57, 28.45, 28.43, 
25.37, 25.18, 21.77, 13.11. 
Exact mass (ESI-MS) for C57H103ClN2O10 [M+H]
+
 found, 1011.7393; calcd, 1011.7374. 
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(2S,3S,4R)-1-O-(6-O-(1-naphthylcarbamoyl)-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (5b) 
1
H NMR (300 MHz, pyridine-d5): δ 10.68 (s, 1H, NH), 
8.74-8.70 (m, 1H, arom H), 8.58 (d, J = 8.6 Hz, 1H, 
NH), 8.26 (d, J = 7.3 Hz, 1H, arom. H), 7.94 (d, J = 7.5 
Hz, 1H, arom. H), 7.74 (d, J = 8.4 Hz, 1H, arom. H), 
7.62-7.51 (m, 3H, arom. H), 5.58 (d, J = 3.9 Hz, 1H, H-
1”), 5.28-5.22 (m, 1H, H-2), 5.17-5.06 (m, 1H, H-6”), 
4.94 (dd, J = 4.2 Hz and 11.2 Hz, 1H, H-6”), 4.84-4.65 
(m, 3H, H-1, H-5”, H-2”), 4.48-4.37 (m, 4H, H-1, H-3, H-3”, H-4”), 4.33-4.28 (m, 1H, H-4), 
2.51-2.46 (m, 2H, COCH2), 1.93-1.23 (m, 72H, CH2), 0.91-0.86 (m, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 172.27, 154.65, 149.43, 135.00, 133.63, 127.56, 125.15, 
125.11, 125.04, 123.71, 100.24, 75.11, 71.50, 70.10, 69.75, 69.29, 68.90, 64.83, 50.45, 35.66, 
30.95, 30.94, 29.19, 28.95, 28.86, 28.83, 28.76, 28.74, 28.68, 28.62, 28.58, 28.45, 28.43, 
25.32, 25.22, 21.76, 13.10. 
Exact mass (ESI-MS) for C61H106N2O10 [M+H]
+
 found, 1027.7919; calcd, 1027.7926. 
(2S,3S,4R)-1-O-(6-O-(4-pyridinylcarbamoyl)-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (5c) 
1
H NMR (300 MHz, pyridine-d5): δ 11.18 (s, 1H, NH), 
8.83 (d, J = 8.3 Hz, 1H, NH), 8.67 (dd, J = 1.4 Hz and 
4.8 Hz, 2H, arom. H), 7.93 (dd, J = 1.4 Hz and 4.8 Hz, 
2H, arom. H), 5.55 (d, J = 3.8 Hz, 1H, H-1”), 5.26-5.20 
(m, 1H, H-2), 5.08 (dd, J = 8.2 Hz and 11.0 Hz, 1H, H-
6”), 4.77 (dd, J = 3.4 Hz and 11.0 Hz, 1H, H-6”), 4.72-
4.62 (m, 3H, H-1, H-2”, H-5”), 4.45-4.30 (m, 5H, H-3”, H-4”, H-1, H-3, H-4), 2.53 (t, J = 7.5 
Hz, 2H, COCH2), 1.95-1.23 (m, 72H, CH2), 0.88 (t, J = 6.5 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 173.94, 154.68, 151.19, 147.76, 113.56, 101.56, 76.57, 
72.96, 71.66, 70.43, 53.40, 46.06, 37.19, 32.45, 30.72, 30.50, 30.38, 30.34, 30.27, 30.24, 
30.17, 30.09, 29.94, 26.89, 26.75, 23.26, 14.61. 
Exact mass (ESI-MS) for C56H103N3O10 [M+H]
+
 found, 978.7662; calcd, 978.7722. 
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(2S,3S,4R)-1-O-(6-deoxy-5-phenylamide-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (6a) 
1
H NMR (300 MHz, pyridine-d5): δ 9.88 (s, 1H, NH), 
8.49 (d, J = 8.8 Hz, 1H, NH), 8.12 (dd, J = 1.1 Hz and 
8.6 Hz, 2H, arom. H), 7.36-7.30 (m, 3H, arom. H and 
OH), 7.10 (t, J = 7.3 Hz, 1H, arom. H), 6.79 (d, J = 5.2 
Hz, 1H, OH), 6.43 (d, J = 5.9 Hz, 1H, OH), 6.12 (d, J = 
5.4 Hz, 1H, OH), 5.47 (d, J = 3.8 Hz, 1H, H-1”), 5.27-
5.24 (m, 1H, H-2), 5.02-4.99 (m, 3H, OH, H-4” and H-5”), 4.66-4.55 (m, 2H, H-1 and H-2”), 
4.44 (app. d, J = 9.2 Hz, 1H, H-3”), 4.32-4.21 (m, 3H, H-1, H-3, H-4), 2.49-2.44 (m, 2H, 
COCH2), 1.40-1.12 (m, 72H, CH2), 0.88 (t, J = 6.6 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 173.77, 169.23, 139.70, 129.36, 120.95, 101.60, 76.53, 
74.21, 72.76, 71.71, 71.36, 69.97, 69.18, 51.49, 37.07, 34.44, 32.44, 32.43,  30.67, 30.45, 
30.35, 30.31, 30.24, 30.22, 30.19, 30.11, 30.07, 29.93, 29.91, 26.80, 26.71, 23.25, 14.60. 
Exact mass (ESI-MS) for C56H102N2O9 [M+H]
+
 found, 947.7612; calcd, 947.7658. 
(2S,3S,4R)-1-O-(6-deoxy-5-(3,4-dichlorophenylamide)-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (6b) 
1
H NMR (300 MHz, pyridine-d5): δ 10.19 (s, 1H, NH), 
8.52 (d, J = 8.7 Hz, 1H, NH), 8.46 (d, J = 2.4 Hz, 1H, 
arom. H), 7.92 (dd, J = 2.4 Hz and 9.0 Hz, 1H, arom. H), 
7.39 (d, J = 9.0 Hz, 1H, arom. H), 7.28 (bs, 1H, OH), 
6.85 (bs, 1H, OH), 6.45 (d, J = 4.2 Hz, 1H, OH), 6.13 
(bs, 1H, OH), 5.40 (d, J = 3.6 Hz, 1H, H-1”), 5.27-5.23 
(m, 1H, H-2), 5.03-4.96 (m, 3H, H-4”, H-5” and OH), 
4.62 (dd, J = 3.6 Hz and 10.5 Hz, 1H, H-2”), 4.57 (dd, J = 5.1 Hz and 10.8 Hz, 1H, H-3), 4.44 
(dd, J = 1.8 Hz and 9.6 Hz, 1H, H-3”), 4.26-4.21 (m, 3H, H-1 and H-4), 2.49-2.44 (m, 2H, 
COCH2), 2.29-1.18 (m, 72H, CH2), 0.89 (t, J = 6.6 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 171.94, 168.21, 138.12, 131.03, 129.39, 125.19, 121.60, 
121.10, 119.06, 100.22, 75.33, 72.80, 71.31, 70.27, 68.78, 68.42, 49.86, 35.56, 33.15, 30.95, 
30.94, 29.17, 28.95, 28.86, 28.83, 28.76, 28.74, 28.70, 28.64, 28.58, 28.45, 28.43, 25.29, 
25.21, 21.76, 13.10. 
Exact mass (ESI-MS) for C56H100Cl2N2O9 [M+Na]
+
 found, 1015.6865; calcd, 1015,6884. 
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(2S,3S,4R)-1-O-(6-deoxy-5-benzylamide-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (6c) 
1
H NMR (300 MHz, pyridine-d5): δ 8.69 (dd, J = 5.9 Hz 
and 6.8 Hz, 1H, NH), 8.47 (d, J = 8.7 Hz, 1H, NH), 7.59 
(d, J = 5.9 Hz, 2H, arom. H), 7.30-7.17 (m, 4H, arom. H 
and OH), 6.40 (bs, 1H, OH), 5.58 (d, J = 3.9 Hz, 1H, H-
1”), 5.03-5.00 (m, 2H, H-2 and OH), 4.98-4.95 (m, 4H, 
H-4”, OH and NH-CH2), 4.69 (dd, J = 3.8 Hz and 9.9 
Hz, 1H, H-2”), 4.63-4.56 (m, 2H, H-3 and H-5”), 4.44 (dd, J = 3.1 Hz and 10.0 Hz, 1H, H-
3”), 4.34-4.27 (m, 3H, H-1 and H-4), 2.48-2.43 (m, 2H, COCH2), 1.93-1.09 (m, 72H, CH2), 
0.89 (t, J = 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 172.12, 169.18, 138.92, 127.50, 126.55, 125.87, 123.04, 
121.66, 100.15, 75.12, 72.52, 71.26, 70.08, 69.96, 68.61, 67.55, 49.94, 41.71, 35.57, 32.98, 
30.96, 30.94, 29.20, 28.98, 28.87, 28.83, 28.76, 28.74, 28.70, 28.63, 28.58, 28.45, 28.43, 
25.32, 25.22, 21.77, 13.11. 
Exact mass (ESI-MS) for C57H104N2O9 [M+H]
+
 found, 961.7808; calcd, 961.7815; [M+Na]
+
 
found, 983.7621; calcd, 983.7634; [M+H]
+
 found, 999.7262; calcd, 999.7373. 
(2S,3S,4R)-1-O-(6-deoxy-5-(3,4-dichlorophenmethylamide)-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (6d) 
1
H NMR (300 MHz, pyridine-d5): δ 8.96 (dd, J = 5.7 Hz 
and 7.1 Hz, 1H, NH), 8.48 (d, J = 8.6 Hz, 1H, NH), 7.77 
(d, J = 1.9 Hz, 1H, arom. H), 7.41 (dd, J = 2.0 Hz and 
8.3 Hz, 1H, arom. H), 7.32 (d, J = 8.2 Hz, 1H, arom. H), 
6.75 (app. s, 1H, OH), 6.43 (d, J = 5.7 Hz, 1H, OH), 6.13 
(d, J = 4.8 Hz, 1H, OH), 5.60 (d, J = 3.8 Hz, 1H, H-1”), 
5.26 (app. d, J = 4.6 Hz, 1H, H-2), 5.01-4.92 (m, 3H, NH-CH2, H-4” and H-5”), 4.69-4.56 (m, 
H2, H-2” and H-1), 4.49-4.42 (m, 2H, H-3” and NH-CH2), 4.33-4.29 (m, 3H, H-1, H-3 and H-
4), 2.46 (app. t, J = 7.5 Hz, 2H, COCH2), 1.97-1.16 (m, 72H, CH2), 0.89 (t, J = 6.7 Hz, 6H, 
CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 173.43, 170.90, 141.50, 132.57, 130.84, 130.65, 130.10, 
127.77, 101.72, 76.86, 74.10, 72.75, 71.68, 71.44, 70.08, 51.32, 42.16, 37.07, 34.66, 32.45, 
32.46, 30.71, 30.48, 30.38, 30.34, 30.27, 30.25, 30.20, 30.14, 30.10, 29.96, 29.94, 26.80, 
26.72, 23.28, 14.61. 
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Exact mass (ESI-MS) for C57H102Cl2N2O9 [M+H]
+
 found, 1029,7021; calcd, 1029.7041. 
(2S,3S,4R)-1-O-(6-deoxy-5-phenethylamide-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (6e) 
1
H NMR (300 MHz, pyridine-d5): δ 8.50 (d, J = 8.7 Hz, 
1H, NH), 8.13 (t, J = 6.0 Hz, 1H, NH), 7.32-7.18 (m, 5H, 
arom. H), 7.03 (br. s, 1H, OH), 6.41 (br. s, 1H, OH), 6.13 
(br. s, 1H, OH), 5.54 (d, J = 3.9 Hz, 1H, H-1”), 5.27 
(app. d, J = 4.4 Hz, 1H, H-2), 4.99-4.91 (m, 2H, H-4” 
and H-5”), 4.65 (dd, J = 3.8 Hz and 10.0 Hz, 1H, H-2”), 
4.60 (dd, J = 5.4 Hz and 10.7 Hz, 1H, H-1), 4.41 (dd, J = 
3.1 Hz and 10.0 Hz, 1H, H-3”), 4.39-4.31 (m, 1H, H-4), 4.30 (dd, J = 4.2 Hz and 10.7 Hz, 1H, 
H-1), 3.72 (dd, J = 6.5 Hz and 14.4 Hz, 2H, NH-CH2), 2.94 (app. t, J = 7.5 Hz, 2H, CH2), 
2.48 (t, J = 7.1 Hz, 2H, COCH2), 1.97-1.18 (m, 72H, CH2), 0.89 (t, J = 6.6 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 173.42, 170.26, 140.50, 136.52, 129.67, 129.16, 126.87, 
123.50, 101.65, 76.91, 73.90, 72.78, 71.53, 71.49, 70.11, 69.17, 51.29, 41.44, 37.08, 36.72, 
34.66, 32.46, 32.45, 30.71, 30.48, 30.37, 30.34, 30.27, 30.25, 30.21, 30.15, 30.11, 29.96, 
29.94, 26.81, 26.73, 23.27, 14.61. 
Exact mass (ESI-MS) for C58H106N2O9 [M+H]
+
 found, 975.7974; calcd, 975.7977; [M+Na]
+
 
found, 997.7779; calcd, 997.7796. 
General procedure for debenzylation: method B (6f and 6g) 
To a solution of the protected amide (0.07 mmol) in CH2Cl2 (1 mL) was added aluminum 
chloride (109 mg, 0.82 mmol) and dimethylaniline (0.13 mL, 1.00 mmol). Upon stirring for 8 
hours, the reaction mixture was quenched with a 1N solution of HCl (1.5 mL) followed by 
extraction with EtOAc. Next, the combined organic layers were washed with a saturated 
NaHCO3 solution and brine, dried over Na2SO4 and evaporated to dryness. The resulting 
residue was submitted to column chromatography (CH2Cl2/MeOH: 28/2), yielding amides 6f 
(10 mg, 15 %) and 6g (8.5 mg, 11 %). 
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(2S,3S,4R)-1-O-(6-deoxy-5-thiofuranmethylamide-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (6f) 
1
H NMR (300 MHz, pyridine-d5): δ 8.86 (t, J = 6.2 Hz, 
1H, NH), 8.45 (d, J = 8.5 Hz, 1H, NH), 7.25 (app. dd, J 
= 1.2 Hz and 5.2 Hz, 2H, arom. H), 7.11 (br. s, 1H, OH), 
6.91 (dd, J = 3.6 Hz and 5.1 Hz, 1H, arom. H), 6.68 (br. 
s, 1H, OH), 6.39 (br. s, 1H OH), 6.12 (br. s, 1H, OH), 
5.55 (d, J = 3.8 Hz, 1H, H-1”), 5.28-5.21 (m, 1H, H-2), 
5.0-4.82 (m, 4H, NH-CH2, H-4” and H-5”), 4.66 (dd, J = 3.8 Hz and 9.9 Hz, 1H, H-2”), 4.56 
(dd, J = 5.4 Hz and 10.5 Hz, 1H, H-1), 4.41 (d, J = 3.2 Hz and 9.9 Hz, 1H, H-3”), 4.35-4.19 
(m, 2H, H-3 and H-4), 4.25 (dd, J = 4.2 Hz and 10.6 Hz, 1H, H-1), 2.44 (app. t, J = 7.4 Hz, 
2H, COCH2), 1.92-1.19 (m, 72H, CH2), 0.89 (t, J = 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 171.87, 168.91, 141.99, 125.87, 124.66, 123.74, 100.23, 
75.37, 72.51, 71.25, 70.01, 69.97, 68.60, 67.72, 53.86, 49.76, 36.91, 35.55, 33.13, 30.95, 
30.94, 29.20, 28.97, 28.87, 28.83, 28.75, 28.74, 28.69, 28.63, 28.58, 28.45, 28.43, 25.29, 
25.20, 21.76, 13.10. 
Exact mass (ESI-MS) for C55H102N2O9S [M+H]
+
 found, 967.7431; calcd, 967.7379; [M+Na]
+
 
found, 989.7236; calcd, 967.7198; [M+K]
+
 found, 1005.7026; calcd, 1005.6938. 
(2S,3S,4R)-1-O-(1-naphthaleneamide-α-D-galactopyranosyl)-2-hexacosylamino-octadecane-
1,3,4-triol (6g) 
1
H NMR (300 MHz, pyridine-d5): δ 8.49 (d, J = 8.7 Hz, 
1H, NH), 8.29 (dd, J = 2.7 Hz and 6.7 Hz, 1H, NH), 7.94 
(d, J = 7.2 Hz, 1H, arom. H), 7.87 (dd, J = 3.1 Hz and 
6.3 Hz, 1H, arom. H), 7.77 (d, J = 8.3 Hz, 1H, arom. H), 
7.59-7.38 (m, 4H, arom. H), 5.54 (d, J = 3.7 Hz, 1H, H-
1”), 5.44 (dd, J = 6.7 Hz and 15.6 Hz, 1H, NH-CH2), 
5.29-5.21 (m, 1H, H-2), 5.13-4.95 (m, 3H, NH-CH2, H-
4” and H-5”), 4.68 (dd, J = 3.7 Hz and 9.8 Hz, 1H, H-
2”), 4.60 (dd, J = 5.4 Hz and 10.6 Hz, 1H, H-1), 4.45 (dd, J = 3.1 Hz and 10.0 Hz, H-3”), 
4.43-4.29 (m, 2H, H-3 and H-4), 4.28 (dd, J = 4.4 Hz and 10.7 Hz, 1H, H-1), 2.46 (app. t, J = 
7.1 Hz, 2H, COCH2), 1.97-1.19 (m, 72H, CH2), 0.89 (t, J = 6.6 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 173.42, 170.60, 134.50, 132.12, 129.31, 128.21, 126.85, 
126.35, 126.27, 125.92, 101.77, 76.84, 74.18, 72.79, 71.63, 71.50, 70.12, 69.29, 55.37, 51.34, 
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41.33, 37.07, 34.62, 32.47, 30.82, 30.71, 30.48, 30.38, 30.34, 30.27, 30.25, 30.21, 30.15, 
30.11, 29.96, 29.94, 26.81, 26.73, 23.28, 14.62. 
Exact mass (ESI-MS) for C61H106N2O9 [M+H]
+
 found, 1011.7974; calcd, 1011.7971; 
[M+Na]
+
 found, 1033.7747; calcd, 1033,7796; [M+K]
+
 found, 1049.7509; calcd, 1049,7535. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-5-phenylureido-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (43) 
To a solution of 39 (96 mg, 0.07 mmol) in toluene (1 mL) was added Et3N (0.02 mL, 0.15 
mmol) and DPPA (0.03 mL, 0.15 mmol). The mixture was stirred while refluxing for 1.5 
hours followed by addition of Ag2CO3 (2 mg, 0.01 mmol) and aniline (7 mg, 0.07 mmol). 
Upon additional refluxing during 3 hours, the reaction mixture was cooled to 0 °C, quenched 
with NH4Cl and extracted with EtOAc. The organic layer was washed with brine, dried over 
Na2SO4 and evaporated to dryness. Purification by column chromatography (hexanes/EtOAc: 
8.2/1.8) yielded derivative 43 (52 mg, 50 %) as a pale yellow oil. 
1
H NMR (300 MHz, CDCl3): δ 7.43-7.05 (m, 31H, 
arom. H, NH), 5.98 (s, 1H, NH), 5.47 (app. d, J = 10.0 
Hz, 1H, H-5”), 5.33 (d, J = 9.7 Hz, 1H, NH), 5.01 (d, J 
= 11.8 Hz, 1H, CH2-Ph), 4.88 (d, J = 10.9 Hz, 1H, CH2-
Ph), 4.87 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.77 (d, J = 
11.5 Hz, 1H, CH2-Ph), 4.75-4.70 (m, 3H, H-1”, CH2-
Ph), 4.67 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.65 (d, J = 
11.5 Hz, 1H, CH2-Ph), 4.56-4.47 (m, 4H, CH2-Ph, H-1), 3.99-3.92 (m, 3H, H-2, H-2”, H-3”), 
3.78 (app. s, 1H, H-4”), 3.61-3.55 (m, 2H, H-3, H-4), 2.09-2.03 (m, 2H, COCH2), 1.70-1.16 
(m, 72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 172.51, 153.26, 138.12, 137.98, 137.39, 137.34, 137.32, 
136.79, 128.12, 127.81, 127.78, 127.42, 127.26, 127.23, 127.17, 127.15, 126.99, 126.75, 
126.66, 126.43, 126.26, 123.06, 119.42, 99.38, 79.38, 77.41, 76.61, 75.71, 73.75, 73.61, 
72.85, 72.75, 72.39, 72.14, 70.55, 49.78, 35.42, 30.93, 30.91, 28.73, 28.69, 28.64, 28.51, 
28.40, 28.37, 28.35, 28.23, 25.23, 24.82, 21.68, 13.11. 
Exact mass (ESI-MS) for C91H133N3O9 [M+H]
+
 found, 1413.0187; calcd, 1413.0120. 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (25). 
 
IR: 3485, 3319, 3036, 2922, 2851, 1647 
(Other spectral data and preparation: see Chapter 3, 
p62-63) 
 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(6-azido-2,3,4-tri-O-benzyl-6-deoxy-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (44). 
To a solution of intermediate 25 (500 mg, 0.38 mmol) and triphenylphosphine (400 mg, 1.53 
mmol) in THF (25 mL) at -20 °C were added DEAD (0.7 mL, 2.2 M) and DPPA (0.33 mL, 
1.53 mmol). The reaction mixture was stirred overnight and after completion of the reaction, 
the solvent was removed under reduced pressure. Purification by column chromatography 
(hexanes/EtOAc: 9/1) resulted in azide 44 (471 mg, 92 %) as a white solid. 
1
H NMR (300 MHz, CDCl3): δ 7.42-7.26 (m, 25H, 
arom. H), 5.87 (d, J = 8,6 Hz, 1H, NH), 4.98 (d, J = 
11.4 Hz, 1H, CH2-Ph), 4.84 (d, J = 3.8 Hz, 1H, H-1”), 
4.82-4.72 (m, 4H, CH2-Ph), 4.64 (d, J = 11.9 Hz, 1H, 
CH2-Ph), 4.61-4.57 (m, 2H, CH2-Ph), 4.51 (d, J = 11.5 
Hz, 1H, CH2-Ph), 4.49 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.32-4.24 (m, 1H, H-2), 4.02 (dd, J = 
3.5 Hz and 10.1 Hz, 1H, H-2”), 3.91-3.83 (m, 3H, H-3”, H-1, H-4”), 3.81-3.74 (m, 3H, H-3, 
H-1, H-5”), 3.55-3.51 (m, 1H, H-4), 3.47 (dd, J = 8.1 Hz and 12.4 Hz, 1H, H-6”), 2.99 (dd, J 
= 6.2 Hz and 12.4 Hz, 1H, H-6”), 2.01-1.85 (m, 2H, COCH2), 1.64-0.98 (m, 72H, CH2), 0.88 
(t, J = 6.6 Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 173.01, 150.14, 150.03, 138.89, 138.78, 138.73, 138.60, 
138.32, 130.30, 130.28, 128.68, 128.66, 128.63, 128.61, 128.57, 128.15, 128.06, 128.04, 
127.97, 127.91, 127.84, 127.77, 127.69, 126.36, 126.34, 120.49, 120.43, 99.34, 80.09, 79.56, 
79.04, 77.66, 77.44, 77.24, 76.81, 75.07, 74.87, 73.68, 73.51, 72.06, 70.25, 69.04, 51.61, 
50.37, 36.98, 32.16, 30.06, 29.96, 29.94, 29.89, 29.84, 29.69, 29.64, 29.61, 29.59, 26.16, 
25.95, 22.92, 14.35. 
IR: 3312, 2978, 2918, 2849, 2097, 1645. 
Exact mass (ESI-MS) for C85H128N4O8 [M+H]
+
 found, 1333.9846; calcd, 1333.9805. 
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General procedure for CuAAC click reaction 
To a solution of azide 44 (80 mg, 0.06 mmol) in DMF (2 mL) was added the appropriate 
alkyne, sodium ascorbate and copper(II) sulfate. The reaction mixture was stirred for 
20 minutes at 70 °C in the microwave. After extraction with EtOAc, the organic phase was 
washed with brine and dried over Na2SO4, followed by evaporation of the solvent. 
Purification by column chromatography (hexanes/EtOAc: 7.5/2.5) afforded the desired 
triazoles 45b (74 %), 45c (60 %), 45d (95 %), 45e (80 %) and 45f (97 %). 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(4-butyltriazol-1-yl)-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (45b). 
1
H NMR (300 MHz, CDCl3): δ 7.27-7.03 (m, 26H, 
arom. H), 5.63 (d, J = 8.5 Hz, 1H, NH), 4.94 (d, J = 
11.1 Hz, 1H, CH2-Ph), 4.78 (d, J = 3.5 Hz, 1H, H-1”), 
4.73 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.71 (d, J = 11.7 Hz, 
1H, CH2-Ph), 4.64 (d, J = 11.7 Hz, 2H, CH2-Ph), 4.57 
(d, J = 11.7 Hz, 1H, CH2-Ph), 4.56 (d, J = 11.1 Hz, 1H, 
CH2-Ph), 4.48 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.40 (d, J 
= 11.7 Hz, 1H, CH2-Ph), 4.39 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.31 (dd, J = 5.9 Hz and 13.7 Hz, 
1H, H-6”), 4.21-4.15 (m, 1H, H-2), 4.12 (dd, J = 5.9 Hz and 13.1 Hz, 1H, H-6”), 4.00-3.96 
(m, 2H, H-2”, H-5”), 3.80 (dd, J = 2.6 Hz and 10.2 Hz, 1H, H-3”), 3.68-3.59 (m, 3H, H-4”, 
H-3, H-1), 3.52-3.41 (m, 2H, H-1, H-4), 2.57 (app. t, J = 7.7 Hz, 2H, CH2), 1.88-1.71 (m, 2H, 
COCH2), 1.56-1.05 (m, 76H, CH2), 0.84 (t, J = 7.3 Hz, 3H, CH3), 0.81 (t, J = 6.8 Hz, 6H, 
CH3). 
13
C NMR (75 MHz, CDCl3): δ 173.01, 148.40, 138.82, 138.77, 138.56, 138.49, 138.44, 
128.76, 128.68, 128.65, 128.62, 128.57, 128.16, 128.11, 128.09, 127.99, 127.92, 127.81, 
127.66, 122.29, 99.41, 79.87, 79.78, 79.25, 77.67, 77.45, 77.25, 76.82, 76.47, 74.95, 74.76, 
73.81, 73.51, 73.41, 72.08, 70.17, 50.28, 36.87, 32.16, 31.75, 30.43, 30.08, 29.96, 29.94, 
29.91, 29.89, 29.85, 29.70, 29.61, 29.59, 26.06, 25.88, 25.52, 22.92, 22.55, 14.35, 14.05. 
Exact mass (ESI-MS) for C91H138N4O8 [M+H]
+
 found, 1416.0526; calcd, 1416.0593. 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(4-phenyltriazol-1-yl)-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (45c). 
1
H NMR (300 MHz, CDCl3): δ 7.93-7.72 (m, 3H, arom. 
H), 7.31-7.18 (m, 28H), 5.55 (d, J = 8.2 Hz, 1H, NH), 
4.95 (d, J = 10.9 Hz, 1H, CH2-Ph), 4.78 (app. s, 1H, H-
1”), 4.73-4.55 (m, 6H, CH2-Ph), 4.47-4.34 (m, 4H, CH2-
Ph, H-6”), 4.25-4.18 (m, 2H, H-2, H-6”), 4.06-3.97 (m, 
2H, H-5”, H-2”), 3.79 (app. d, J = 10.0 Hz, 1H, H-3”), 
3.69-3.52 (m, 4H, H-4”, H-3, H-1), 3.42-3.41 (m, 1H, 
H-4), 1.82-1.66 (m, 2H, COCH2), 1.49-0.99 (m, 72H, 
CH2), 0.80 (t, J = 6.5 Hz, 6H, CH3).  
13
C NMR (75 MHz, CDCl3): δ 173.19, 162.87, 138.76, 138.68, 138.58, 138.51, 138.48, 
130.85, 129.03, 128.82, 128.69, 128.68, 128.63, 128.58, 128.28, 128.21, 128.13, 128.01, 
127.98, 127.91, 127.81, 127.68, 125.88, 121.47, 99.69, 80.15, 79.45, 79.27, 77.70, 77.49, 
77.28, 76.86, 76.45, 75.06, 74.75, 73.80, 73.60, 73.40, 72.00, 70.10, 68.90, 50.41, 36.86, 
36.73, 32.17, 31.69, 30.50, 30.08, 29.95, 29.90, 29.84, 29.65, 29.60, 25.86, 22.93, 14.37. 
Exact mass (ESI-MS) for C93H134N4O8 [M+H]
+
 found, 1436.0295; calcd, 1436.0274, 
[M+Na]
+
 found 1458.0104; calcd, 1458.0094, [M+K]
+ 
found 1473.9843, calcd, 1473.9833. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(4-benzyltriazol-1-yl)-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (45d) 
1
H NMR (300 MHz, CDCl3): δ 7.30-7.09 (m, 31H, 
arom. H), 5.63 (d, J =8.6 Hz, 1H, NH), 4.92 (d, J = 11.1 
Hz, 1H, CH2-Ph), 4.74 (d, J = 2.9 Hz, 1H, H-1”), 4.70 
(d, J = 11.8 Hz, 1H, CH2-Ph), 4.69 (d, J = 13.0 Hz, 1H, 
CH2-Ph), 4.66 (d, J = 12.1 Hz, 1H, CH2-Ph), 4.64 (d, J 
= 11.6 Hz, 1H, CH2-Ph), 4.56 (d, J = 11.8 Hz, 1H, CH2-
Ph), 4.50 (d, J = 11.1 Hz, 1H, CH2-Ph), 4.48 (d, J = 
11.8 Hz, 1H, CH2-Ph), 4.39 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.38 (d, J = 11.6 Hz, 1H, CH2-Ph), 
4.25 (dd, J = 5.6 Hz and 13.8 Hz, 1H, H-6”), 4.16-4.09 (m, 2H, H-2, H-6”), 3.98-3.93 (m, 4H, 
CH2-Ph, H-2”, H-5”), 3.79 (dd, J = 2.4 Hz and 10.1 Hz, 1H, H-3”), 3.68 (app. s, 1H, H-4”), 
3.64 (dd, J = 3.5 Hz and 5.7 Hz, 1H, H-3), 3.55 (dd, J = 6.1 Hz and 10.7 Hz, 1H, H-1), 3.45-
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3.38 (m, 2H, H-4, H-1), 1.89-1.70 (m, 2H, COCH2), 1.54-1.18 (m, 72H, CH2), 0.80 (t, J = 6.7 
Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 172.98, 147.54, 139.32, 138.82, 138.53, 138.46, 138.34, 
128.85, 128.83, 128.71, 128.69, 128.64, 128.62, 128.58, 128.17, 128.11, 128.06, 128.04, 
128.00, 127.95, 127.88, 127.81, 127.68, 126.97, 123.19, 99.27, 79.97, 79.58, 79.21, 77.67, 
77.45, 77.25, 76.83, 76.42, 74.90, 74.71, 73.82, 73.49, 73.39, 72.04, 70.06, 68.41, 50.52, 
50.17, 36.89, 32.38, 32.16, 30.34, 30.10, 29.97, 29.94, 29.89, 29.86, 29.71, 29.61, 29.60, 
26.11, 25.90, 22.93, 14.36. 
Exact mass (ESI-MS) for C94H136N4O8 [M+H]
+
 found, 1450.0453; calcd, 1450.0431, 
[M+Na]
+
 found 1472.0304; calcd, 1472.0250. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(4-ethylphenyltriazol-1-yl)-α-
D-galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (45e). 
1
H NMR (300 MHz, CDCl3): δ 7.30-7.06 (m, 31H, 
arom. H), 5.64 (d, J = 8.5 Hz, 1H, NH), 4.93 (d, J = 
11.3 Hz, 1H, CH2-Ph), 4.77 (d, J = 3.7 Hz, 1H, H-1”), 
4.73-4.62 (m, 3H, CH2-Ph), 4.60 (d, J = 10.9 Hz, 1H, 
CH2-Ph), 4.57 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.52 (d, J 
= 9.2 Hz, 1H, CH2-Ph), 4.48 (d, J = 9.6 Hz, 1H, CH2-
Ph), 4.40 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.39 (d, J = 
11.5 Hz, 1H, CH2-Ph), 4.29 (dd, J = 5.92 Hz and 13.7 
Hz, 1H, H-6”), 4.22-4.15 (1H, H-2), 4.14 (dd, J = 6.7 Hz and 13.9 Hz, 1H, H-6”), 4.01-3.95 
(m, 2H, H-2”, H-5”), 3.79 (dd, J = 2.6 Hz and 10.2 Hz, 1H, H-3”), 3.65-3.57 (m, 3H, H-4”, 
H-3, H-1), 3.51-3.41 (m, 2H, H-1, H-4), 2.96-2.82 (m, 4H, CH2-CH2-Ph), 1.88-1.70 (m, 2H, 
COCH2), 1.53-1.04 (m, 72H, CH2), 0.81 (t, J = 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 173.04, 147.29, 141.38, 138.80, 138.76, 138.56, 138.48, 
138.41, 128.76, 128.69, 128.66, 128.61, 128.58, 128.17, 128.11, 128.09, 128.01, 127.93, 
127.82, 127.65, 126.31, 122.61, 99.37, 79.84, 79.25, 77.67, 77.45, 77.25, 76.83, 76.48, 74.93, 
74.71, 73.82, 73.54, 73.42, 72.08, 70.09, 68.50, 50.36, 50.28, 36.88, 35.71, 32.16, 30.45, 
30.08, 29.96, 29.89, 29.86, 29.70, 29.61, 29.59, 27.61, 26.05, 25.89, 22.93, 21.28, 14.43, 
14.36. 
Exact mass (ESI-MS) for C95H138N4O8 [M+H]
+
 found, 1464.0540; calcd, 1464.0593. 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(4-propylphenyltriazol-1-yl)-
α-D-galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (45f). 
1
H NMR (300 MHz, CDCl3): δ 7.36-7.17 (m, 31H, 
arom. H), 5.73 (d, J = 8.5 Hz, 1H, NH), 5.03 (d, J = 
11.9 Hz, 1H, CH2-Ph), 4.87 (d, J = 3.5 Hz, 1H, H-1”), 
4.82 (d, J =11.8 Hz, 1H, CH2-Ph), 4.80 (d, J = 11.8 Hz, 
1H, CH2-Ph), 4.73 (d, J = 12.0 Hz, 2H, CH2-Ph), 4.66 
(d, J = 11.8 Hz, 1H, CH2-Ph), 4.65 (d, J = 11.27 Hz, 
1H, CH2-Ph), 4.57 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.49 
(d, J = 11.8 Hz, 1H, CH2-Ph), 4.47 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.40 (dd, J = 6.0 Hz and 
13.8 Hz, 1H, H-6”), 4.32-4.20 (m, 2H, H-2, H-6”), 4.11-4.05 (m, 2H, H-5”, H-2”), 3.89 (dd, J 
= 2.6 Hz and 10.0 Hz, 1H, H-3”), 3.76 (app. d, J = 1.5 Hz, 1H, H-4”), 3.74-3.66 (m, 2H, H-3, 
H-1), 3.59 (dd, J = 4.6 Hz and 10.7 Hz, 1H, H-1), 3.54-3.50 (m, 1H, H-4), 2.77-2.64 (m, 4H, 
CH2-CH2-Ph), 2.05-1.81 (m, 4H, CH2, CH2, COCH2), 1.61-1.28 (m, 72H, CH2), 0.90 (t, J = 
6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 173.04, 147.93, 142.09, 138.84, 138.79, 138.57, 138.51, 
138.44, 128.79, 128.76, 128.72, 128.70, 128.66, 128.64, 128.61, 128.58, 128.18, 128.13, 
128.10, 128.02, 127.94, 127.83, 127.68, 126.17, 126.07, 122.41, 99.43, 79.80, 79.26, 77.73, 
77.30, 76.88, 76.50, 74.96, 74.75, 73.84, 73.54, 73.44, 72.08, 70.15, 68.94, 50.31, 36.88, 
35.65, 34.87, 32.18, 31.29, 30.42, 30.30, 30.09, 29.98, 29.96, 29.94, 29.91, 29.87, 29.72, 
29.63, 26.06, 25.91, 25.39, 22.95, 18.06, 14.38. 
Exact mass (ESI-MS) for C96H140N4O8 [M+H]
+
 found, 1478.0772; calcd, 1478,0749. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(triazol-1-yl)-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (45a). 
Azide 44 was dissolved in vinyl acetate and stirred at 120 °C in the microwave. After 6 hours, 
the reaction mixture was evaporated to dryness. Purification by column chromatography 
(hexanes/EtOAc: 7.5/2.5) afforded the desired triazole 45a (93 mg, 71 %). 
1
H NMR (300 MHz, CDCl3): δ 7.53 (dd, J = 0.9 and 
7.3 Hz, 2H, arom. H), 7.36-7.22 (m, 25H, arom. H), 
5.68 (d, J = 8.5 Hz, 1H, NH), 5.01 (d, J = 11.2 Hz, 1H, 
CH2-Ph), 4.84 (d, J = 3.6 Hz, 1H, H-1”), 4.80 (d, J = 
11.8 Hz, 1H, CH2-Ph), 4.78 (d, J = 11.8 Hz, 1H, CH2-
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Ph), 4.71 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.70 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.64 (d, J = 11.7 
Hz, 1H, CH2-Ph), 4.63 (d, J = 11.2 Hz, 1H, CH2-Ph), 4.55 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.47 
(d, J = 11.8 Hz, 1H, CH2-Ph), 4.45 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.39 (dd, J = 5.2 Hz and 
13.9 Hz, 1H, H-6”), 4.29 (dd, J = 7.7 Hz and 13.9 Hz, 1H, H-6”), 4.23-4.17 (m, 1H, H-2), 
4.07-4.01 (m, 2H, H-2”, H-5”), 3.87 (dd, J = 2.6 Hz and 10.1 Hz, 1H, H-3”), 3.77 (app. d, J = 
1.3 Hz, 1H, H-4”), 3.68 (dd, J = 3.6 Hz and 5.2 Hz, 1H, H-3), 3.62 (dd, J = 6.9 Hz and 10.6 
Hz, 1H, H-1), 3.55-3.47 (m, 2H, H-1, H-4), 1.95-1.77 (m, 2H, COCH2), 1.61-1.13 (m, 72H, 
CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ 172.95, 149.61, 138.59, 138.49, 138.33, 138.27, 138.08, 
133.65, 128.57, 128.51, 128.48, 128.45, 128.41, 128.37, 128.03, 127.89, 127.88, 127.85, 
127.79, 127.73, 127.62, 127.47, 124.77, 116.19, 99.01, 79.69, 79.61, 78.96, 76.25, 74.73, 
74.63, 73.58, 73.38, 73.11, 71.96, 69.94, 50.40, 50.04, 36.69, 31.94, 30.28, 29.83, 29.74, 
29.69, 29.67, 29.62, 29.46, 29.39, 29.37, 25.86, 25.67, 22.70, 14.13. 
Exact mass (ESI-MS) for C87H130N4O8 [M+H]
+
 found, 1359.9907; calcd, 1359.9967, 
[M+Na]
+
 found, 1381.9797; calcd, 1381.9786. 
General procedure for debenzylation of the C-6”-triazoles 
A solution of the protected triazole (0.06 mmol) in CHCl3 (0.4 mL) and EtOH (1.2 mL) was 
hydrogenated under atmospheric pressure in the presence of palladium black (10 mg). Upon 
reaction completion, the mixture was diluted with pyridine and filtered through celite. The 
filter cake was rinsed with CHCl3 and EtOH and the filtrate was evaporated to dryness. After 
purification by column chromatography (CH2Cl2/MeOH: 8/2), final compounds 8a (31 %), 8b 
(50 %), 8c (40 %), 8d (22 %), 8e (31 %) and 8f (53 %) were obtained as white powders. 
(2S,3S,4R)-1-O-(6-deoxy-6-(triazol-1-yl)-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (8a). 
1
H NMR (300 MHz, pyridine-d5): δ 8.42 (d, J = 8.9 Hz, 
1H, NH), 8.21 (d, J = 0.9 Hz, 1H, arom. H), 7.92 (d, J = 
0.9 Hz, 1H, arom. H), 5.5 (d, J = 3.7 Hz, 1H, H-1”), 
5.26-5.19 (m, 1H, H-2), 5.14-4.99 (m, 2H, H-6”), 4.67-
4.61 (m, 2H, H-2”, H-5”), 4.38-4.30 (3H, H-1, H-3”, H-
3), 4.26-4.21 (m, 2H, H-4, H-4”), 4.09 (dd, J = 4.9 Hz 
and 10.6 Hz, 1H, H-1), 2.50-2.36 (m, 2H, COCH2), 2.01-1.09 (m, 72H, CH2), 0.88 (t, J = 6.7 
Hz, 6H, CH3). 
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13
C NMR (75 MHz, pyridine-d5): δ 171.92, 149.07, 148.72, 148.36, 147.99, 135.00, 134.66, 
134.33, 134.00, 133.64, 132.60, 124.24, 122.98, 122.65, 122.32, 121.99, 121.61, 99.98, 75.54, 
71.23, 69.78, 69.67, 69.47, 68.57, 67.06, 50.30, 49.77, 35.57, 33.34, 30.94, 29.21, 28.97, 
28.86, 28.83, 28.75, 28.69, 28.63, 28.58, 28.43, 25.27, 25.20, 21.76, 13.10. 
IR: 3462, 3451, 3335, 2922, 2850, 1653. 
Exact mass (ESI-MS) for C52H100N4O8[M+H]
+
 found, 909.7681; calcd, 909.7619, [M+Na]
+
 
found, 931.7450; calcd, 931.7439. 
(2S,3S,4R)-1-O-(6-deoxy-6-(4-butyltriazol-1-yl)-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (8b). 
1
H NMR (300 MHz, pyridine-d5): δ 8.42 (d, J = 8.7 Hz, 
1H, NH), 7.93 (s, 1H, arom. H), 6.83 (br. s, 1H, OH), 
6.37 (br. s, 1H, OH), 6.05 (br. s, 1H, OH), 5.52 (d, J = 
3.9 Hz, 1H, H-1”), 5.26-5.19 (m, 1H, H-2), 5.03 (app. d, 
J = 6.5 Hz, 2H, H-6”), 4.70-4.62 (m, 2H, H-5”, H-2”), 
4.41 (dd, J = 5.4 Hz and 10.7 Hz, 1H, H-1), 4.32 (dd, J = 
3.2 Hz and 9.9 Hz, 1H, H-3”), 4.27-4.22 (m, 3H, H-3, H-
4”, H-4), 4.16 (dd, J = 4.9 Hz and 10.6 Hz, 1H, H-1), 2.83 (t, J = 7.6 Hz, 2H, CH2), 2.48-2.39 
(m, 2H, COCH2), 1.94-1.11 (m, 76H, CH2), 0.93-0.86 (m, 9H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 171.94, 100.11, 75.56, 71.24, 69.83, 69.72, 69.41, 68.62, 
67.25, 50.21, 49.90, 35.58, 33.32, 30.94, 30.81, 29.24, 28.98, 28.86, 28.83, 28.75, 28.74, 
28.71, 28.64, 28.61, 28.44, 28.43, 25.29, 25.21, 24.59, 21.76, 21.39, 13.10, 12.82. 
Exact mass (ESI-MS) for C56H108N4O8 [M+H]
+
 found, 965.8295; calcd, 965.8240, [M+Na]
+
 
found, 987.8087; calcd, 987.8059, [M+K]
+
 found, 1003.7825; calcd, 1003.7799. 
(2S,3S,4R)-1-O-(6-deoxy-6-(4-phenyltriazol-1-yl)-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (8c). 
1
H NMR (300 MHz, pyridine-d5): δ 8.66 (s, 1H, arom. 
H), 8.40 (d, J = 8.7 Hz, 1H, NH), 8.21-8.18 (m, 2H, 
arom. H), 7.50-7.45 (m, 2H, arom. H), 7.38-7.33 (m, 1H, 
arom. H), 5.55 (d, J = 3.7 Hz, 1H, H-1”), 5.28-5.19 (m, 
1H, H-2), 5.10 (app. d, J = 5.5 Hz, 2H, H-6”), 4.75 (t, J = 
6.6 Hz, 1H, H-5”), 4.66 (dd, J = 3.7 Hz and 9.8 Hz, 1H, 
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H-2”), 4.45 (dd, J = 5.6 Hz and 10.6 Hz, 1H, H-1), 4.35 (dd, J = 3.2 Hz and 9.9 Hz, 1H, H-
3”), 4.27-4.22 (m, 3H, H-3, H-4, H-4”), 4.15 (dd, J = 4.9 Hz and 10.8 Hz, 1H, H-1), 2.45-2.22 
(m, 2H, COCH2), 1.90-1.17 (m, 72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 171.95, 149.40, 149.07, 148.71, 148.35, 146.54, 134.66, 
134.33, 134.00, 130.91, 128.07, 126.94, 124.95, 122.99, 122.66, 122.33, 122.00, 121.60, 
121.01, 100.05, 75.56, 71.22, 69.79, 69.54, 69.25, 68.60, 67.07, 50.34, 49.83, 35.54, 33.32, 
30.94, 29.23, 28.97, 28.87, 28.83, 28.75, 28.74, 28.70, 28.61, 28.58, 28.44, 28.43, 25.26, 
25.18, 21.76, 13.10. 
Exact mass (ESI-MS) for C58H104N4O8 [M+H]
+
 found, 985.7953; calcd, 985.7927, [M+Na]
+
 
found, 1007.7729; calcd, 1007.7746. 
(2S,3S,4R)-1-O-(6-deoxy-6-(4-benzyltriazol-1-yl)-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (8d) 
1
H NMR (300 MHz, pyridine-d5): δ 8.41 (d, J = 8.7 Hz, 
1H, NH), 7.91 (s, 1H, arom. H), 7.47-7.45 (m, 2H, arom. 
H), 7.41-7.36 (m, 2H, arom. H), 7.28-7.26 (m, 1H, arom. 
H), 5.48 (d, J = 3.7 Hz, 1H, H-1”), 5.23-5.19 (m, 1H, H-
2), 5.01-4.99 (m, 2H, H-6”), 4.64-4.59 (m, 2H, H-2”, H-
5”), 4.36 (dd, J = 5.2 Hz and 10.7 Hz, 1H, H-1), 4.32-
4.25 (m, 3H, H-4, H-4”, H-3, CH2-Ph), 4.21 (app. d, J = 
2.4 Hz, 1H, H-3”), 4.14 (dd, J = 4.6 Hz and 10.7 Hz, 1H, H-1), 2.48-2.41 (m, 2H, COCH2), 
1.93-1.26 (m, 72H, CH2), 0.88 (t, J = 6.6 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 171.92, 149.06, 148.70, 148.35, 147.98, 146.06, 139.26, 
135.00, 134.66, 134.33, 133.99, 133.64, 128.02, 127.78, 125.45, 122.98, 122.65, 122.32, 
122.20, 121.99, 100.13, 75.55, 71.30, 69.79, 69.71, 69.47, 68.56, 67.44, 50.37, 49.83, 35.58, 
33.29, 31.33, 30.95, 29.24, 28.98, 28.87, 28.83, 28.75, 28.74, 28.71, 28.64, 28.61, 28.55, 
28.44, 28.43, 28.37, 25.31, 25.22, 21.76, 13.10. 
Exact mass (ESI-MS) for C59H106N4O8 [M+H]
+
 found, 999.8134; calcd, 999.8089, [M+Na]
+
 
found, 1021.7906; calcd, 1021.7908, [M+K]
+
 found, 1037.7676; calcd, 1037.7648. 
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(2S,3S,4R)-1-O-(6-deoxy-6-(4-ethylphenyltriazol-1-yl)-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (8e). 
1
H NMR (300 MHz, pyridine-d5): δ 8.43 (d, J = 8.7 Hz, 
1H, NH), 7.88 (s, 1H, arom. H), 7.36-7.31 (m, 3H, arom. 
H), 7.27-7.25 (m, 2H, arom. H), 5.50 (d, J = 3.9 Hz, 1H, 
H-1”), 5.26-5.19 (m, 1H, H-2), 5.01-4.96 (m, 2H, H-2”, 
H-5”), 4.67-4.61 (m, 2H, H-6”), 4.39 (dd, J = 5.3 Hz and 
10.6 Hz, 1H, H-1), 4.61 (dd, J = 3.2 Hz and 9.9 Hz, 1H, 
H-3” or H-4”) 4.56 (m, 2H, H-3, H-4), 4.49 (app. d, J = 
2.4 Hz, H-3” or H-4”), 4.15 (dd, J = 5.0 Hz and 10.7 Hz, 
1H, H-1), 3.22-3.11 (m, 4H, CH2), 2.47-2.40 (m, 2H, COCH2), 1.94-1.24 (m, 72H, CH2), 0.89 
(t, J = 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 173.49, 150.58, 150.21, 149.86, 147.64, 142.41, 136.17, 
135.84, 135.51, 129.24, 129.12, 126.72, 124.49, 124.16, 123.83, 123.50, 123.18, 123.12, 
101.57, 77.11, 72.76, 71.34, 71.22, 70.91, 70.14, 51.76, 51.42, 37.10, 36.35, 34.85, 32.46, 
32.45, 30.75, 30.49, 30.38, 30.34, 30.27, 30.25, 30.21, 30.14, 30.11, 29.96, 29.94, 28.44, 
26.80, 26.72, 23.27, 14.61. 
Exact mass (ESI-MS) for C60H108N4O8 [M+H]
+
 found, 1013.8259; calcd, 1013.8240. 
(2S,3S,4R)-1-O-(6-deoxy-6-(4-propylphenyltriazol-1-yl)-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (8f). 
1
H NMR (300 MHz, pyridine-d5): δ 8.38 (d, J = 8.7 Hz, 
1H, NH), 7.93 (s, 1H, arom. H), 7.37-7.24 (m, 5H, arom. 
H), 7.11 (br. s, 1H, OH), 6.94 (br. s, 1H, OH), 6.82 (d, J 
= 2.9 Hz, 1H, OH), 6.36 (d, J = 5.0 Hz, 1H, OH), 6.04 
(d, J = 3.9 Hz, 1H, OH), 5.51 (d, J = 3.7 Hz, 1H, H-1”), 
5.26-5.18 (m, 1H, H-2), 5.03 (d, J = 5.03 Hz, 2H, H-6”), 
4.71-4.62 (m, H-5”, H-2”), 4.41 (dd, J = 5.4 Hz and 10.4 
Hz, 1H, H-1), 4.33-4.20 (m, 5H, H-3”, H-3, H-4, H-4”), 4.15 (dd, J = 5.0 Hz and 10.7 Hz, 1H, 
H-1), 2.86 (t, J = 7.6 Hz, 2H, CH2), 2.72 (t, J = 7.6 Hz, 2H, CH2), 2.41 (ddd, J = 3.0 Hz and 
7.5 Hz, 2H, COCH2), 2.10 (m, 2H, CH2), 1.90-1.18 (m, 72H, CH2), 0.87 (t, J = 6.6 Hz, 6H, 
CH3). 
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13
C NMR (75 MHz, pyridine-d5): δ 173.43, 150.58, 150.22, 149.87, 149.49, 148.06, 142.91, 
136.51, 136.17, 135.84, 135.51, 135.14, 129.33, 129.10, 126.51, 124.49, 124.16, 123.83, 
123.50, 123.10, 101.63, 77.07, 72.75, 71.34, 71.21, 70.88, 70.13, 68.79, 51.70, 51.40, 37.08, 
35.92, 34.83, 32.46, 32.45, 31.95, 30.75, 30.50, 30.38, 30.34, 30.27, 30.25, 30.22, 30.15, 
30.12, 29.96, 29.94, 26.79, 26.72, 25.92, 23.28, 14.62. 
Exact mass (ESI-MS) for C61H110N4O8 [M+H]
+
 found, 1027.8478; calcd, 1027.8402. 
Computational modeling of C-6”-triazole 8a (performed by Dr. H. De Winter) 
The starting conformation of the triazole was generated using OpenBabel version 2.3.1
11
 and 
graphical visualisation of the complex was done with PyMol.
12
 The structure was 
subsequently positioned into the binding pocket of Nu-α-GalCer (crystal structure was taken 
from the PDB, code 3QUZ) by superimposing the sugar ring of the triazole compound onto 
the corresponding ring of Nu-α-GalCer. Torsion angles were rotated to adopt a low energy 
conformation. 
3,4,6-tri-O-benzyl-2-deoxy-D-galactopyranose (47) 
To a solution of 3,4,6-tri-O-benzyl-D-galactal (2 g, 4.80 mmol) in CH2Cl2 (30 mL), a mixture 
of 48 % HBr (8.0 mL) and PPh3 (17.6 g, 67.22 mmol) in CH2Cl2 (80 mL) was slowly added. 
The solution was vigorously stirred for 24 hours and the reaction mixture then was extracted 
with EtOAc. The combined organic layers were washed with a saturated NaHCO3 solution 
and brine, dried over Na2SO4 and evaporated to dryness to afford the crude product 47. 
Exact mass (ESI-MS) for C27H30O5 [M+H]
+
 found, 435.2198; calcd, 
435.2166, [M+Na]
+
 found, 457.1977; calcd, 457.1986, [M+K]
+
 found, 
473.1725; calcd, 473.1725. 
(2R,3S,4R,6E/Z)-1,3,4-tri-O-benzyl-non-6-en-2-ol (48) 
n-Propyl triphenylphosphonium bromide (9.3 g, 24.01 mmol) was dissolved in THF (60 mL). 
The mixture was cooled to -12 °C, followed by dropwise addition of n-BuLi (12 mL, 1.6 M in 
hexane). After stirring for 1 hour at room temperature, the reaction mixture was again cooled 
to -12 °C and a solution of the crude galactopyranose 47 in anhydrous THF (90 mL) was 
added. After stirring for 2 hours at -12 °C, the reaction was quenched by addition of a 
saturated NH4Cl solution. The mixture was extracted with CH2Cl2 and the organic layer was 
washed with brine, dried over Na2SO4 and evaporated. Column chromatography 
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(hexanes/EtOAc: 9/1) resulted in an isomeric mixture of the desired product 48 (1.22 g, 55 % 
over 2 steps) as a colorless oil. 
1
H-NMR (300 MHz, CDCl3): 7.28-7.18 (m, 15H, arom. H), 
5.44-5.33 (m, 2H, H-6, H-7), 4.57-4.37 (m, 6H, CH2-Ph), 4.03-
3.99 (m, 1H, H-2), 3.70-3.65 (m, 1H, H-4), 3.55-3.51 (m, 1H, 
H-3), 3.47-3.45 (m, 2H, H-1), 3.04-3.02 (m, 1H, OH), 2.39-2.30 (m, 2H, H-5), 2.04-1.91 (m, 
2H, H-8), 0.91-0.83 (m, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3):  138.38, 138.34, 138.30, 135.47, 134.26, 132.41, 132.27, 
132.15, 128.81, 128.62, 128.59, 128.31, 128.17, 128.12, 128.08, 128.04, 127.92, 128.89, 
124.85, 124.61, 79.93, 79.82, 79.02, 78.76, 73.75, 73.66, 73.58, 73.56, 72.86, 72.71, 71.35, 
69.96, 69,90, 34.24, 29.94, 28.94, 25.94, 14.34. 
Exact mass (ESI-MS) for C30H36O4 [M+H]
+
 found, 461.2701; calcd, 461.2686, [M+Na]
+
 
found, 483.2522; calcd, 483.2506, [M+K]
+
 found, 499.2265; calcd, 499.2245. 
Spectral data are consistent with the literature data. 
(2R,3S,4R)-1,3,4-tri-O-benzyl-non-2-ol (49) 
Palladium on carbon (41 mg) was added to a solution of compound 48 (822 mg, 1.79 mmol) 
in 0.1 M NH3 in MeOH (8.22 mL). The suspension was stirred for 16 hours under hydrogen 
atmosphere followed by filtration through celite and rinsing of the filter cake with MeOH. 
The product was concentrated under reduced pressure to obtain 49 (821 mg, 99 %) as a 
colorless oil. 
1
H-NMR (300 MHz, CDCl3): 7.28-7.18 (m, 15H, arom. H), 
4.62 (d, J = 11.3 Hz, 1H, CH2-Ph), 4.58 (d, J = 11.1 Hz, 1H, 
CH2-Ph), 4.49-4.38 (m, 4H, CH2-Ph), 3.96 (m, 1H, H-2), 3.64-
3.58 (m, 1H, H-4), 3.54 (dd, J = 3.2 Hz and 4.1 Hz, 1H, H-3), 3.48-3.45 (m, 2H, H-1), 3.09 
(d, J = 4.6 Hz, 1H, OH), 1.61-1.12 (m, 8H, CH2), 0.80 (t, J = 6.8 Hz, CH3). 
13
C-NMR (75 MHz, CDCl3):  138.51, 138.37, 138.33, 128.64, 128.62, 128.60, 128.34, 
128.18, 128.08, 128.05, 127.92, 127.91, 80.17, 79.27, 73.78, 73.61, 73.05, 71.32, 70.10, 
32.14, 31.22, 25.52, 22.83, 14.27. 
Exact mass (ESI-MS) for C30H38O4 [M+H]
+
 found, 463.2861; calcd, 463.2843, [M+Na]
+
 
found, 485.2627; calcd, 485.1662. 
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(2S,3S,4R)-2-azido-1,3,4-tri-O-benzyl-nonane-1,3,4-triol (50) 
To a solution of compound 49 (874 mg, 1.89 mmol) in THF (160 mL) were added Ph3P (1.98 
g, 7.56 mmol), DEAD (3.45 mL (2.2 M), 7.56 mmol) and DPPA (1.7 mL, 7.56 mmol) at -20 
°C. The mixture was stirred for 6 hours at this temperature followed by stirring at room 
temperature overnight. The solvent was evaporated under reduced pressure and the residue 
was directly submitted to column chromatography (hexanes/EtOAc: 9.5/0.5) to give 
compound 50 (821 mg, 89 %) as a clear oil. 
1
H-NMR (300 MHz, CDCl3): 7.36-7.26 (m, 15H, arom. H), 
4.71 (d, J = 11.1 Hz, 1H, CH2-Ph), 4.62 (d, J = 11.5 Hz, 1H, 
CH2-Ph), 4.58 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.56 (d, J = 12.4 Hz, 
1H, CH2-Ph), 4.53 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.52 (d, J = 12.1 Hz, 1H, CH2-Ph), 3.83-
3.76 (m, 2H, H-1 and H-2), 3.73-3.67 (m, 2H, H-1 and H-3), 3.62 (ddd, J = 3.8 Hz and 7.6 
Hz, 1H, H-4), 1.83-1.27 (m, 8H, CH2), 0.89 (t, J = 6.8 Hz, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3):  128.66, 128.61, 128.25, 128.16, 127.99, 127.94, 127.91, 
127.88, 79.47, 79.38, 74.05, 73.59, 72.27, 70.43, 62.32, 32.21, 30.06, 25.24, 22.86, 14.30. 
Exact mass (ESI-MS) for C30H37N3O3 [M+H]
+
 found, 488.29907; calcd, 488.2908, [M+Na]
+
 
found, 510.2726; calcd, 510.2727, [M+K]
+
 found, 526.2469; calcd, 526.2467. 
(2S,3S,4R)-1-O-acetyl-2-azido-3,4-di-O-benzyl-nonane-1,3,4-triol (51) 
Compound 50 (820 mg, 1.68 mmol) was dissolved in 27 mL Ac2O/AcOH (2:1 v/v) followed 
by addition of ZnCl2 (4.6 g, 33.62 mmol). After stirring for 5 hours at room temperature, the 
reaction mixture was poured into water and extracted with CH2Cl2. The organic layer was 
washed with water and a saturated Na2CO3 solution, dried over Na2SO4 and evaporated under 
reduced pressure to afford the crude product 51 (849 mg) as an orange-brown oil.  
Exact mass (ESI-MS) for C25H33N3O4 [M+H]
+
 found, 440.2539; 
calcd, 440.2544, [M+Na]
+
 found, 462.2356; calcd, 462.2363, 
[M+K]
+ 
found, 478.2153; calcd, 478.2103. 
(2S,3S,4R)-2-azido-3,4-di-O-benzyl-nonane-1,3,4-triol (52) 
The crude compound 51 (848 mg) was dissolved in MeOH (45 mL) and the pH was adjusted 
to 10 by addition of NaOMe. After stirring overnight, the pH of the reaction mixture was 
neutralized by addition of Amberlite IR 120 (H
+
 form) resin. The mixture was filtered and the 
solvent was evaporated under reduced pressure. Co-evaporation with water and toluene, 
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followed by column chromatography (hexanes/EtOAc: 8/2) yielded compound 52 (443 mg, 
69 % over 2 steps) as a yellow oil. 
1
H-NMR (300 MHz, CDCl3): 7.39-7.26 (m, 10H, arom. H), 4.72 
(d, J = 11.1 Hz, 1H, CH2-Ph), 4.67 (d, J = 9.3 Hz, 1H, CH2-Ph), 
4.63 (d, J = 9.6 Hz, 1H, CH2-Ph), 4.57 (d, J = 11.5 Hz, 1H, CH2-
Ph), 3.90 (dd, J = 5.3 Hz and 11.8 Hz, 1H, H-1), 3.79 (dd, J = 5.1 Hz and 11.6 Hz, 1H, H-1), 
3.73-3.61 (m, 3H, H-2, H-3 and H-4), 1.71-1.23 (m, 8H, CH2), 0.89 (t, J = 7.0 Hz, CH3). 
13
C-NMR (75 MHz, CDCl3):  138.20, 137.87, 128.76, 128.69, 128.34, 128.25, 128.23, 
128.08, 80.74, 79.27, 73.87, 72.79, 63.30, 62.49, 32.12, 30.44, 25.40, 22.82, 14.26. 
Exact mass (ESI-MS) for C23H31N3O3 [M+H]
+
 found, 398.2436; calcd, 398.2438, [M+Na]
+
 
found, 420.2256; calcd, 420.2258, [M+K]
+
 found, 436.2001; calcd, 436.1997. 
(2S,3S,4R)-2-azido-3,4-di-O-benzyl-1-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-
galactopyranosyl)-nonane-1,3,4-triol (53) 
To a solution of compound 32 (1.03 g, 1.74 mmol) in THF (9 mL) under argon atmosphere 
was added a solution of 52 (506 mg, 1.33 mmol) in THF (10 mL). The mixture was cooled to 
-30 °C and TMSOTf (0.04 mL, 0.20 mmol) was added. After stirring for 2 hours, the reaction 
mixture was neutralized with Et3N followed by concentration under reduced pressure. 
Purification by column chromatography (hexanes/EtOAc: 8.5/1.5) resulted in compound 53 
(677 mg, 61 %) as a white solid. 
1
H NMR (300 MHz, CDCl3): 7.38-7.35 (m, 2H, arom. 
H), 7.26-7.06 (m, 23H, arom. H), 5.30 (s, 1H, CH-Ph), 
4.81 (d, J = 3.3 Hz, 1H, H-1”), 4.70 (d, J = 12.0 Hz, 1H, 
CH2-Ph), 4.62 (d, J = 10.1 Hz, 1H, CH2-Ph), 4.58 (d, J = 
12.4 Hz, 1H, CH2-Ph), 4.56 (d, J = 11.3 Hz, 1H, CH2-
Ph), 4.51 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.45 (d, J = 11.1 
Hz, 1H, CH2-Ph), 4.43 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.34 (d, J = 11.5 Hz, CH2-Ph), 4.00 (dd, 
J = 0.7 Hz and 3.13 Hz, 1H, H-4”), 3.98-3.94 (m, 1H, H-2”), 3.93-3.84 (m, 3H, H-6”, H-3”, 
H-1), 3.73 (dd, J = 1.6 Hz and 12.6 Hz, 1H, H-6”), 3.60-3.53 (m, 3H, H-3, H-1, H-2), 3.51-
3.45 (m, 1H, H-4), 3.42 (app. d, J = 0.7 Hz, 1H, H-5”), 1.51-1.05 (m, 8H, CH2), 0.73 (t, J = 
7.0 Hz, 3H, CH3). 
13
C NMR (75 MHz, CDCl3):  139.01, 139.00, 138.60, 138.26, 138.07, 129.11, 128.63, 
128.60, 128.52, 128.47, 128.35, 128.16, 128.05, 128.01, 127.95, 127.92, 127.87, 127.76, 
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127.71, 126.59, 101.31, 99.39, 79.66, 79.18, 77.68, 76.04, 75.69, 74.91, 74.02, 73.75, 72.31, 
72.29, 69.56, 68.70, 63.23, 62.05, 32.18, 30.23, 25.38, 22.86, 14.30. 
Exact mass (ESI-MS) for C50H57N3O8 [M+H]
+
 found, 828.4247; calcd, 828.4218, [M+Na]
+
 
found, 850.4062; calcd, 850.4038, [M+K]
+
 found, 66.3802; calcd, 866.3777. 
(2S,3S,4R)-2-azido-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-hydroxy-α-D-
galactopyranosyl)-nonane-1,3,4-triol (54) 
To a solution of compound 53 (677 mg, 0.82 mmol) in anhydrous CH2Cl2 (25 mL) under 
argon atmosphere was added copper(II) triflate (45 mg, 0.12 mmol) and BH3.THF (1 M, 
4.1 mL). After stirring for 5 hours at room temperature, the reaction was quenched with 
MeOH. The mixture was extracted with EtOAc and the organic layer was washed with a 
saturated NaHCO3 solution, water and brine followed by drying over Na2SO4 and evaporation 
until dryness. The residue was submitted to column chromatography (hexanes/EtOAc: 8/2) to 
afford the desired compound 54 (464 mg, 68 %) as a clear colorless oil. 
1
H NMR (300 MHz, CDCl3): 7.41-7.21 (m, 25H, 
arom. H), 4.97 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.92 (d, J = 
3.4 Hz, 1H, H-1”), 4.88 (d, J = 11.8 Hz, 1H, CH2-Ph), 
4.81 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.75 (d, J = 11.8 Hz, 
1H, CH2-Ph), 4.70 (d, J = 12.1 Hz, 1H, CH2-Ph), 4.67 (d, 
J = 10.9 Hz, 1H, CH2-Ph), 4.63 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.62 (d, J = 11.2 Hz, 1H, CH2-
Ph), 4.59 (d, J = 11.8 Hz, CH2-Ph), 4.51 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.08 (dd, J = 3.6 Hz 
and 10.1 Hz, 1H, H-2”), 4.00-3.95 (m, 2H, H-3”, H-1), 3.86 (app. d, J = 1.6 Hz, 1H, H-4”), 
3.73-3.67 (m, 4H, H-5”, H-1, H-2, H-3), 3.67-3.61 (m, 2H, H-4, H-6”), 3.42 (dd, J = 4.4 Hz 
and 11.2 Hz, 1H, H-6”), 1.67-1.21 (m, 8H, CH2), 0.87 (t, J = 7.0 Hz, 3H, CH3). 
13
C NMR (75 MHz, CDCl3):  138.94, 138.87, 138.61, 138.40, 138.28, 128.81, 128.71, 
128.64, 128.61, 128.59, 128.52, 128.21, 128.10, 128.07, 127.98, 127.95, 127.85, 127.83, 
127.82, 127.76, 98.83, 79.55, 79.44, 79.05, 76.66, 75.40, 74.70, 73.94, 73.67, 73.45, 72.28, 
71.09, 68.68, 62.69, 62.23, 60.63, 32.17, 30.22, 25.28, 22.85, 21.29, 14.44, 14.29. 
Exact mass (ESI-MS) for C50H57N3O8 [M+H]
+
 found, 828.4247; calcd, 828.4218, [M+Na]
+
 
found, 850.4062; calcd, 850.4038, [M+K]
+
 found, 66.3802; calcd, 866.3777. 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-hydroxy-α-D-galactopyranosyl)-2-
tetracosylamino-nonane-1,3,4-triol (55) 
To a solution of 54 (463 mg, 0.56 mmol) in THF (5.6 mL) was added dropwise 
trimethylphosphine (2.8 mL, 2.79 mmol). After stirring for 3.5 hours, a NaOH solution 
(10.3 mL, 1 M) was added and the mixture was allowed to stir for an additional 3 hours. The 
reaction mixture was extracted with EtOAc and the organic layer was washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure. The crude amine was dissolved 
in CH2Cl2 (7 mL) and added to a solution of EDC (214 mg, 1.12 mmol) and tetracosanoic 
acid (308 mg, 0.84 mmol) in CH2Cl2 (1.5 mL). This reaction mixture was stirred overnight at 
room temperature after which it was extracted with CH2Cl2. The organic layer was washed 
with brine and dried over Na2SO4. After evaporation of the organic solvent, the residue was 
purified by column chromatography (hexanes/EtOAc: 7/3) affording compound 55 (509 mg, 
79 %) as a yellow oil. 
1
H NMR (300 MHz, CDCl3): 7.39-7.26 (m, 25H, 
arom. H), 5.85 (d, J = 9.0 Hz, 1H, NH), 4.95 (d, J = 11.5 
Hz, 1H, CH2-Ph), 4.85 (d, J = 4.0 Hz, 1H, H-1”), 4.83 (d, 
J = 12.7 Hz, 1H, CH2-Ph), 4.80 (d, J = 11.8 Hz, 1H, 
CH2-Ph), 4.73 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.72 (d, J = 
11.8 Hz, 1H, CH2-Ph), 4.64 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.63 (d, J = 11.5 Hz, 1H, CH2-Ph), 
4.59 (d, J = 12.1 Hz, 1H, CH2-Ph), 4.55 (d, J = 12.1 Hz, 1H, CH2-Ph), 4.47 (d, J = 11.5 Hz, 
1H, CH2-Ph), 4.42-4.33 (m, 1H, H-2), 4.03 (dd, J = 3.7 Hz and 9.6 Hz, 1H, H-2”), 3.95 (dd, J 
= 7.8 Hz and 11.5 Hz, 1H, H-1), 3.87-3.82 (m, 3H, H-1, H-3”, H-4”), 3.70-3.63 (m, 3H, H-3, 
H-5”, H-6”), 3.56-3.51 (m, 1H, H-4), 3.47 (dd, J = 7.8 Hz and 13.4 Hz, 1H, H-6”), 1.93-1.87 
(m, 2H, COCH2), 1.69-1.24 (m, 50H, CH2), 0.90-0.84 (m, 6H, CH3). 
13
C NMR (75 MHz, CDCl3):  173.42, 138.86, 138.80, 138.68, 138.65, 138.48, 128.67, 
128.65, 128.18, 128.13, 128.07, 127.97, 127.95, 127.85, 127.68, 100.31, 80.70, 79.49, 79.45, 
77.45, 76.82, 75.08, 74.78, 73.78, 73.42, 73.33, 72.10, 71.51, 70.02, 62.69, 60.63, 50.90, 
37.05, 32.16, 30.38, 29.94, 29.89, 29.83, 29.66, 29.59, 25.94, 25.68, 22.92, 22.87, 21.28, 
14.43, 14.35, 14.30. 
Exact mass (ESI-MS) for C74H107NO9 [M+H]
+
 found, 1154.8068; calcd, 1154,8024. 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-α-D-galactopyranosyluronate)-2-
tetracosylamino-nonane-1,3,4-triol (56) 
TEMPO (2.7 mg, 0.02 mmol) and BAIB (70 mg, 0.22 mmol) were added to a mixture of 55 
(100 mg, 0.09 mmol) in CH2Cl2 (0.6 mL) and H2O (0.3 mL). The emulsion was vigorously 
stirred overnight at room temperature and the reaction was quenched with Na2S2O3. After 
extraction of the aqueous layer with EtOAc, the organic layer was washed with a saturated 
NaHCO3 solution and brine, dried over Na2SO4 and evaporated. The residue was submitted to 
column chromatography (CH2Cl2/MeOH: 29/1 with 1% formic acid), affording compound 56 
(99 mg, 98 %) as a yellow oil. 
1
H NMR (300 MHz, CDCl3): 7.34-7.26 (m, 25H, 
arom. H), 5.91 (d, J = 8.0 Hz, 1H, NH), 5.00 (d, J = 3.7 
Hz, 1H, H-1”), 4.88 (d, J = 10.9 Hz, 1H, CH2-Ph), 4.79 
(d, J = 11.8 Hz, 1H, CH2-Ph), 4.75 (d, J = 9.4 Hz, 1H, 
CH2-Ph), 4.72 (d, J = 11.2 Hz, 1H, CH2-Ph), 4.65 (d, J = 10.9 Hz, 1H, CH2-Ph), 4.63 (d, J = 
11.8 Hz, 1H, CH2-Ph), 4.61 (d, J = 10.9 Hz, 1H, CH2-Ph), 4.54 (d, J = 11.8 Hz, 1H, CH2-Ph), 
4.49 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.48 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.40-4.33 (m, 3H, H-
4”, H-5”, H-2), 4.04 (dd, J = 3.3 Hz and 10.1 Hz, 1H, H-2”), 3.93 (dd, J = 2.6 Hz and 10.1 
Hz, 1H, H-3”), 3.88 (dd, J = 5.0 Hz and 10.7 Hz, 1H, H-1), 3.79 (dd, J = 6.7 Hz and 10.7 Hz, 
1H, H-1), 3.72 (dd, J = 3.7 Hz and 5.0 Hz, 1H, H-3), 3.55-3.50 (m, 1H, H-4), 1.94-1.82 (m, 
2H, COCH2), 1.66-1.24 (m, 50H, CH2), 0.91-0.84 (m, 6H, CH3). 
13
C NMR (75 MHz, CDCl3):  173.59, 171.47, 170.89, 138.61, 138.59, 138.48, 138.42, 
138.22, 128.66, 128.64, 128.43, 128.35, 128.21, 128.14, 128.06, 127.96, 127.92, 127.65, 
99.21, 79.77, 79.35, 78.23, 77.48, 76.31, 76.00, 75.42, 74.02, 73.21, 73.02, 72.11, 69.06, 
60.66, 53.66, 50.18, 36.89, 32.16, 30.34, 29.94, 29.90, 29.85, 29.67, 29.60, 25.92, 25.65, 
22.93, 22.89, 21.27, 14.42, 14.36, 14.21. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-5-benzylamide-6-deoxy-α-D-
galactopyranosyl)-2-tetracosylamino-nonane-1,3,4-triol (57) 
To a solution of 56 (99 mg, 0.09 mmol) in DMF (0.3 mL) and CH2Cl2 (0.7 mL) was added 
DIPEA (0.04 mL, 0.22 mmol). The solution was stirred for 10 minutes followed by addition 
of HCTU (90 mg, 0.22 mmol). After stirring for another 30 minutes, benzylamine (0.02 mL, 
0.22 mmol) was added and the reaction mixture was allowed to stir overnight. Upon reaction 
completion, the organic solvent was removed by evaporation and the resulting residue was 
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submitted to column chromatography (hexanes/EtOAc: 6/4) to yield compound 57 (94 mg, 88 
%) as a yellow solid. 
1
H NMR (300 MHz, CDCl3): 7.39-7.16 (m, 30H, 
arom. H), 6.80 (t, J = 5.8 Hz, 1H, NH), 5.78 (d, J = 8.3 
Hz, 1H, NH), 4.89 (d, J = 3.7 Hz, 1H, H-1”), 4.88 (d, J = 
10.7 Hz, 1H, CH2-Ph), 4.81 (d, J = 11.6 Hz, 1H, CH2-
Ph), 4.78 (d, J = 10.3 Hz, 1H, CH2-Ph), 4.73 (d, J = 11.9 
Hz, 1H, CH2-Ph), 4.72 (d, J = 11.6 Hz, 1H, CH2-Ph), 
4.63 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.59 (d, J = 11.3 Hz, 
1H, CH2-Ph), 4.55 (d, J = 12.0 Hz, 1H, CH2-Ph), 4.54-4.51 (m, 2H, H-4”, CH2-Ph), 4.51 (d, J 
= 10.7 Hz, 1H, CH2-Ph), 4.47 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.45 (d, J = 11.6 Hz, 1H, CH2-
Ph), 4.35-4.29 (m, 2H, CH2-Ph, H-5”), 4.27-4.19 (m, 1H, H-2), 4.04 (dd, J = 3.4 Hz and 10.1 
Hz, 1H, H-2”), 3.96 (dd, J = 2.7 Hz and 10.1 Hz, 1H, H-3”), 3.83-3.77 (m, 2H, H-1, H-3), 
3.74 (dd, J = 5.6 Hz and 10.3 Hz, 1H, H-1), 3.52-3.48 (m, 1H, H-4), 1.97-1.79 (m, 2H, 
COCH2), 1.68-1.13 (m, 50H, CH2), 0.88 (t, J = 6.6 Hz, 3H, CH3), 0.86 (t, J = 6.7 Hz, 3H, 
CH3). 
13
C NMR (75 MHz, CDCl3):  172.81, 168.48, 138.56, 138.52, 138.50, 138.28, 137.53, 
128.64, 128.40, 128.36, 128.17, 128.02, 127.91, 127.84, 127.77, 127.76, 127.72, 127.64, 
127.61, 127.52, 127.45, 127.42, 98.81, 79.77, 78.75, 78.36, 77.21, 76.00, 75.80, 75.37, 73.82, 
73.22, 72.33, 71.78, 71.69, 67.93, 49.87, 43.14, 36.65, 31.94, 31.92, 29.97, 29.70, 29.65, 
29.60, 29.43, 29.38, 29.35, 25.63, 25.56, 22.68, 22.66, 14.11, 14.08. 
Exact mass (ESI-MS) for C81H112N2O9 [M+H]
+
 found, 1257.8498; calcd, 1257.8441. 
(2S,3S,4R)-1-O-(5-benzylamide-6-deoxy-α-D-galactopyranosyl)-2-tetracosylamino-
nonane-1,3,4-triol (9a) 
A solution of 57 (92 mg, 0.07 mmol) in CHCl3 (1 mL) and EtOH (3 mL) was hydrogenated 
under atmospheric pressure in the presence of palladium black (10 mg). Upon reaction 
completion, the mixture was diluted with pyridine and filtered through celite. The filter cake 
was rinsed with CHCl3 and EtOH and the filtrate was evaporated to dryness. After 
purification by column chromatography (CH2Cl2/MeOH: 28/2), final compound 9a (44 mg, 
74 %) was obtained as a white powder. 
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1
H NMR (300 MHz, pyridine-d5): 8.71-8.67 (m, 1H, 
NH), 8.46 (d, J = 8.7 Hz, 1H, NH), 7.31-7.19 (m, 5H, 
arom. H), 6.71 (br. s, 1H, OH), 6.39 (d, J = 5.6 Hz, 1H, 
OH), 6.10 (br. s, 1H, OH), 5.59 (d, J = 3.9 Hz, 1H, H-1”), 
5.29-5.21 (m, 1H, H-2), 5.03-4.89 (m, 3H, H-4”, H-5”, 
CH2-Ph), 4.68 (dd, J = 3.5 Hz and 9.8 Hz, 1H, H-2”), 
4.63-4.56 (m, 2H, H-1, CH2-Ph), 4.44 (dd, J = 2.6 Hz and 
9.5 Hz, 1H, H-3”), 4.31-4.26 (m, 3H, H-1, H-3, H-4), 2.47-2.42 (m, 2H, COCH2), 2.30-1.19 
(m, 50H, CH2), 0.88 (t, J = 6.8 Hz, 3H, CH3), 0.82 (t, J = 7.1 Hz, 3H, CH3). 
13
C NMR (75 MHz, pyridine-d5):  173.40, 170.58, 140.50, 135.14, 128.99, 128.04, 127.35, 
124.49, 123.11, 101.74, 76.92, 74.10, 72.73, 71.61, 71.49, 70.11, 69.17, 51.26, 43.20, 37.06, 
34.62, 32.77, 32.45, 30.36, 30.33, 30.24, 30.18, 30.12, 30.08, 29.94, 26.71, 26.38, 23.34, 
23.27, 14.61, 14.59. 
Exact mass (ESI-MS) for C46H82N2O9 [M+H]
+
 found, 807.6121; calcd, 807.6093. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(6-azido-2,3,4-tri-O-benzyl-6-deoxy-α-D-
galactopyranosyl)-2-tetracosylamino-nonane-1,3,4-triol (58) 
Compound 55 (78 mg, 0.07 mmol) was dissolved in THF (6 mL) and the solution was cooled 
to -20 °C. PPh3 (71 mg, 0.27 mmol), DEAD (0.12 mL, 0.27 mmol) and DPPA (0.06 mL, 0.27 
mmol) were added and the mixture was stirred for 6 hours, after which it was allowed to 
warm up to room temperature. After stirring overnight, the reaction mixture was evaporated 
and the residue was submitted to column chromatography (hexanes/EtOAc: 8.5/1.5) resulting 
in compound 58 (78 mg, 98 %) as a clear yellow oil. 
1
H NMR (300 MHz, CDCl3): 7.42-7.17 (m, 25H, 
arom. H), 5.91 (d, J = 8.8 Hz, 1H, NH), 4.99 (d, J = 11.6 
Hz, 1H, CH2-Ph), 4.86 (d, J = 3.8 Hz, 1H, H-1”), 4.84 (d, 
J = 11.6 Hz, 1H, CH2-Ph), 4.82 (d, J = 11.6 Hz, 1H, 
CH2-Ph), 4.78 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.75 (d, J = 
11.3 Hz, 1H, CH2-Ph), 4.65 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.60 (d, J = 11.9 Hz, 1H, CH2-Ph), 
4.59 (d, J =  11.6 Hz, 1H, CH2-Ph), 4.52 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.50 (d, J = 11.6 Hz, 
1H, CH2-Ph), 4.32-4.25 (m, 1H, H-2), 4.03 (dd, J = 3.4 Hz and 10.0 Hz, 1H, H-2”), 3.92-3.84 
(m, 3H, H-3”, H-1), 3.82-3.76 (m, 3H, H-4”, H-5”, H-3), 3.55 (dd, J = 3.8 Hz and 7.2 Hz, 1H, 
H-4), 3.48 (dd, J = 8.0 Hz and 12.4 Hz, 1H,H-6”), 2.32 (dd, J = 5.0 Hz and 12.5 Hz, 1H, H-
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6”), 2.00-1.89 (m, 2H, COCH2), 1.70-1.24 (m, 50H, CH2), 0.89 (t, J = 6.6 Hz, 3H, CH3), 0.87 
(t, J = 6.9 Hz, 3H, CH3).  
13
C NMR (75 MHz, CDCl3):  173.10, 150.14, 150.03, 138.89, 138.78, 138.73, 138.58, 
138.32, 130.30, 130.29, 128.69, 128.68, 128.64, 128.61, 128.58, 128.17, 128.15, 128.07, 
127.99, 127.92, 127.85, 127.79, 127.71, 126.37, 126.35, 120.50, 120.43, 99.31, 80.10, 79.54, 
79.04, 77.69, 76.72, 75.06, 74.88, 73.72, 73.52, 73.49, 72.07, 70.27, 68.98, 51.61, 50.38, 
36.99, 32.19, 32.16, 30.23, 29.95, 29.90, 29.83, 29.69, 29.64, 29.60, 25.97, 25.81, 22.93, 
22.90, 14.36, 14.32. 
Exact mass (ESI-MS) for C74H106N4O8 [M+H]
+
 found, 1179.8011; calcd, 1179.8083. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(6-amino-2,3,4-tri-O-benzyl-α-D-galactopyranosyl)-2-
tetracosylamino-nonane-1,3,4-triol (59) 
To a solution of 58 (77 mg, 0.07 mmol) in THF (1 mL) was added PMe3 (0.33 mL, 
0.33 mmol) dropwise. After stirring for 4 hours, NaOH (2 mL, 1 M) was added, followed by 
an additional stirring for 2 hours. Upon reaction completion, the mixture was extracted with 
EtOAc. The organic layer was washed with brine, dried over Na2SO4 and evaporated to 
dryness to give the crude amine 59 (85 mg) as a yellow oil. 
Exact mass (ESI-MS) for C74H108N2O8 [M+H]
+
 found, 
1153.8164; calcd, 1153,8184. 
 
 
 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(3-(1-naphthyl)ureido-α-D-
galactopyranosyl)-2-tetracosylamino-nonane-1,3,4-triol (60) 
To a solution of the crude amine 59 in DMF (1 mL) at 0 °C was added naphthylisocyanate 
(0.01 mL, 0.08 mmol). The reaction mixture was allowed to stir at room temperature 
overnight followed by evaporation to dryness. Purification by column chromatography 
(hexanes/EtOAc: 7/3) resulted in compound 60 (52 mg, 60 %) as a yellow oil. 
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1
H NMR (300 MHz, pyridine-d5):  9.42 (s, 1H, NH), 
9.04 (d, J = 8.9 Hz, 1H, NH), 8.64 (d, J = 6.6 Hz, 1H, 
arom. H), 8.51 (d, J = 8.3 Hz, 1H, arom. H), 8.29 (d, J = 
8.1 Hz, 1H, 1H, arom. H), 7.94-7.91 (m, 1H, arom. H), 
7.72-7.27 (m, 28H, arom. H), 7.01 (dd, J = 3.6 Hz and 
6.3 Hz, 1H, NH), 5.34 (d, J = 3.3 Hz, 1H, H-1”), 5.15 (d, 
J = 11.3 Hz, 2H, CH2-Ph), 4.97-4.85 (m, 3H, CH2-Ph, H-
2), 4.81-4.71 (m, 5H, CH2-Ph), 4.53 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.47-4.42 (m, 2H, H-3, H-
5”), 4.41-4.37 (m, 2H, H-2”, H-1), 4.31 (dd, J = 2.5 Hz and 10.1 Hz, 1H, H-3”), 4.24 (d, J = 
5.3 Hz and 10.6 Hz, 1H, H-1), 4.19 (app. d, J = 1.7 Hz, 1H, H-4”), 4.16-4.12 (m, 1H, H-6”), 
3.97-3.91 (m, 2H, H-4, H-6”), 2.69-2.54 (m, 2H, COCH2), 2.06-1.09 (m, 50H, CH2), 0.89 (t, J 
= 6.5 Hz, 3H, CH3), 0.79 (t, J = 6.8 Hz, 3H, CH3). 
13
C NMR (75 MHz, pyridine-d5):  174.14, 157.54, 151.05, 140.04, 139.29, 139.80, 139.74, 
136.56, 135.23, 129.25, 129.13, 129.05, 128.97, 128.79, 128.32, 128.22, 128.08, 128.01, 
126.95, 126.79, 126.56, 126.44, 126.37, 126.25, 124.74, 122.76, 122.64, 120.48, 119.50, 
99.81, 81.31, 80.24, 79.89, 77.55, 77.21, 75.58, 74.58, 73.77, 73.05, 72.30, 71.58, 51.54, 
37.12, 32.56, 32.46, 30.45, 30.37, 30.26, 30.17, 29.94, 26.80, 26.59, 23.28, 14.59. 
(2S,3S,4R)-1-O-(6-deoxy-6-(3-(1-naphthyl)ureido-α-D-galactopyranosyl)-2-
tetracosylamino-nonane-1,3,4-triol (9b) 
A solution of 60 (51 mg, 0.04 mmol) in CHCl3 (0.4 mL) and EtOH (1.2 mL) was 
hydrogenated under atmospheric pressure in the presence of palladium black (5 mg). Upon 
reaction completion, the mixture was diluted with pyridine and filtered through celite. The 
filter cake was rinsed with CHCl3 and EtOH and the filtrate was evaporated to dryness. After 
purification by column chromatography (CH2Cl2/MeOH: 28/2), final compound 9b (9 mg, 26 
%) was obtained as a white powder. 
1
H NMR (300 MHz, pyridine-d5):  9.52 (s, 1H, NH), 
8.71 (d, J = 8.7 Hz, 1H, NH), 8.50 (d, J = 7.6 Hz, 1H, 
arom. H), 8.46 (dd, J = 3.4 Hz and 6.2 Hz, 1H, arom. H), 
7.90 (dd, J = 3.3 Hz and 6.1 Hz, 1H, arom. H), 7.65 (d, J 
= 8.2 Hz, 1H, arom. H), 7.54 (d, J = 7.8 Hz, 1H, arom. 
H), 7.50-7.45 (m, 2H, arom. H), 7.26-7.15 (m, 1H, NH), 
5.55 (d, J = 3.9 Hz, 1H, H-1”), 5.36-5.28 (m, 1H, H-2), 
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4.67 (dd, J = 4.7 Hz and 10.9 Hz, 1H, H-2”), 4.61 (dd, J = 3.7 Hz and 9.5 Hz, 1H, H-1), 4.53 
(dd, J = 5.2 Hz and 7.6 Hz, 1H, H-5”), 4.43-4.35 (m, 3H, H-1, H-3, H-3”), 4.33-4.20 (m, 3H, 
H-4, H-4”, H-6”), 4.15-4.07 (m, 1H, H-6”), 2.49-2.45 (m, 2H, COCH2), 2.25-1.19 (m, 50H, 
CH2), 0.88 (t, J = 6.7 Hz, 3H, CH3), 0.79 (t, J = 7.0 Hz, 3H, CH3). 
13
C NMR (75 MHz, pyridine-d5):  172.57, 156.45, 147.97, 135.03, 133.68, 127.66, 126.68, 
125.34, 124.91, 124.70, 122.98, 121.61, 121.33, 118.26, 100.68, 75.57, 71.50, 70.12, 70.05, 
68.93, 67.99, 50.61, 41.02, 35.68, 33.31, 31.24, 30.94, 28.86, 28.82, 28.80, 28.73, 28.66, 
28.57, 28.43, 25.26, 24.90, 21.81, 21.75, 13.10, 13.06. 
Exact mass (ESI-MS) for C50H85N3O9 [M+H]
+
 found, 872.6391; calcd, 872,6364. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-O-tosyl-α-D-
galactopyranosyl)-2-tetracosylamino-nonane-1,3,4-triol (61) 
To a solution of 55 (407 mg, 0.35 mmol) in pyridine at 0 °C was added tosyl chloride (82 mg, 
0.43 mmol). The reaction mixture was allowed to stir overnight at room temperature. Upon 
reaction completion, the solvent was removed by evaporation. Purification by column 
chromatography (hexanes/EtOAc: 8.5/1.5) afforded 61 (452 mg, 98 %) as a clear colorless oil. 
1
H NMR (300 MHz, CDCl3): 7.69 (d, J = 8.1 Hz, 2H, 
arom. H), 7.36-7.20 (m, 27H, arom. H), 5.85 (d, J = 8.5 
Hz, 1H, NH), 4.91 (d, J = 11.3 Hz, 1H, CH2-Ph), 4.81 (d, 
J = 11.3 Hz, 1H, CH2-Ph), 4.79 (d, J = 3.2 Hz, 1H, H-
1”), 4.76 (d, J = 12.1 Hz, 1H, CH2-Ph), 4.75 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.74 (d, J = 11.7 
Hz, 1H, CH2-Ph), 4.62 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.59 (d, J = 11.9 Hz, 1H, CH2-Ph), 4.50 
(d, J = 11.5 Hz, 1H, CH2-Ph), 4.49 (d, J = 11.5 Hz, 2H, CH2-Ph), 4.28-4.19 (m, 1H, H-2), 
4.02-3.83 (m, 6H, H-2”, H-3”, H-4”, H-5”, H-6”), 3.82-3.77 (m, 2H, H-1, H-3), 3.71 (dd, J = 
4.6 Hz and 10.5 Hz, 1H, H-1), 3.56-3.51 (m, 1H, H-4), 2.41 (s, 3H, CH3), 2.00-1.86 (m, 2H, 
COCH2), 1.69-1.18 (m, 50H, CH2), 0.88 (t, J = 5.8 Hz, 3H, CH3), 0.86 (t, J = 6.1 Hz, 3H, 
CH3). 
13
C NMR (75 MHz, CDCl3):  172.84, 144.96, 138.70, 138.61, 138.38, 138.28, 138.03, 
132.49, 129.87, 128.44, 128.36, 128.32, 128.26, 127.96, 127.92, 127.78, 127.73, 127.67, 
127.57, 127.51, 127.41, 104.76, 99.07, 79.90, 78.85, 78.54, 77.21, 76.36, 74.63, 74.13, 73.51, 
73.36, 73.12, 71.75, 68.76, 78.65, 49.94, 36.67, 31.97, 31.92, 29.86, 29.70, 29.65, 29.61, 
29.46, 29.39, 29.35, 25.67, 25.56, 22.68, 21.63, 14.11, 14.10. 
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Exact mass (ESI-MS) for C81H113NO11S [M+H]
+
 found, 1308.8115; calcd, 1308.8113; 
[M+Na]
+
 found, 1330.8131; calcd, 1330.8188. 
(2S,3S,4R)-1-O-(6-deoxy-6-O-tosyl-α-D-galactopyranosyl)-2-tetracosylamino-nonane-
1,3,4-triol (62) 
A solution of 61 (451 mg, 0.34 mmol) in CHCl3 (1.6 mL) and EtOH (4.8 mL) was 
hydrogenated under atmospheric pressure in the presence of palladium black (45 mg). Upon 
reaction completion, the mixture was diluted with pyridine and filtered through celite. The 
filter cake was rinsed with CHCl3 and EtOH and the filtrate was evaporated to dryness. After 
purification by column chromatography (CH2Cl2/MeOH: 28/2), compound 62 (234 mg, 79 %) 
was obtained as a white powder. 
1
H NMR (300 MHz, CD3OD): 7.79 (d, J = 8.4 Hz, 2H, 
arom. H), 7.43 (d, J = 8.1 Hz, 2H, arom. H), 4.77 (app. s, 
1H, H-1”), 4.20-4.14 (m, 3H, H-1, H-5”), 4.01 (t, J = 6.1 
Hz, 1H, H-2), 3.79-3.71 (m, 4H, H-2”, H-3”, H-6”, H-3), 
3.62-3.57 (m, 2H, H-4, H6”), 3.53 (dd, J = 2.3 Hz and 6.0 
Hz, 1H, H-4”), 2.45 (s, 3H, CH3), 2.22 (ddd, J = 2.6 Hz and 7.5 Hz, 2H, COCH2), 1.64-1.21 
(m, 50H, CH2), 0.91 (t, J = 6.7 Hz, 3H, CH3), 0.89 (t, J = 6.6 Hz, 3H, CH3). 
13
C NMR (75 MHz, CD3OD):  174.60, 145.32, 133.18, 129.87, 127.95, 99.62, 74.11, 71.75, 
69.89, 69.81, 69.48, 68.90, 68.67, 67.06, 50.36, 36.08, 31.95, 31.89, 31.68, 29.61, 29.57, 
29.49, 29.37, 29.29, 29.24, 25.92, 25.53, 22.61, 22.55, 20.44, 13.31, 13.26. 
Exact mass (ESI-MS) for C46H83NO11S [M+H]
+
 found, 858.5725; calcd, 858.5765; [M+Na]
+
 
found, 880.5571; calcd, 880.5585. 
(2S,3S,4R)-1-O-(6-azido-6-deoxy-α-D-galactopyranosyl)-2-tetracosylamino-nonane-1,3,4-
triol (64) 
To a solution of 62 (233 mg, 0.27 mmol) in DMF (1 mL) was added NaN3. The reaction 
mixture was heated to 60 °C and was stirred for 2 days. The resulting white suspension was 
filtered, followed by evaporation of the solvent under reduced pressure. The residue was 
purified by column chromatography (CH2Cl2/MeOH: 96/4), giving 64 (75 g, 38 %) as a white 
solid. 
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1
H NMR (300 MHz, CD3OD): 4.89 (d, J = 3.1 Hz, 1H, 
H-1”), 4.23-4.17 (m, 1H, H-2), 3.96 (dd, J = 4.8 Hz and 
8.8 Hz, 1H, H-5”), 3.90 (dd, J = 4.4 Hz and 10.5 Hz, 1H, 
H-1), 3.81-3.76 (m, 3H, H-2”, H-3”, H-4”), 3.70 (dd, J = 
4.2 Hz and 10.3 Hz, 1H, H-1), 3.64-3.52 (m, 3H, H-3, H-
4, H-6”), 3.26 (dd, J = 4.4 Hz and 12.7 Hz, 1H, H-6”), 2.22 (app. t, J = 7.2 Hz, 2H, COCH2), 
1.64-1.22 (m, 50H, CH2), 0.91 (t, J = 6.7 Hz, 3H, CH3), 0.90 (t, J = 6.7 Hz, 3H, CH3). 
13
C NMR (75 MHz, CD3OD):  174.59, 99.72, 74.08, 71.77, 70.42, 70.16, 70.03, 68.78, 
67.04, 51.41, 50.44, 36.06, 31.93, 31.90, 31.67, 29.61, 29.57, 29.48, 29.38, 29.29, 29.22, 
25.92, 25.53, 22.60, 22.56, 13.30, 13.26. 
Exact mass (ESI-MS) for C39H76N4O8 [M+H]
+
 found, 729.5774; calcd, 729.5741; [M+Na]
+
 
found, 751.5574; calcd, 751.5561. 
(2S,3S,4R)-1-O-(6-deoxy-6-(4-BODIPY-triazol-1-yl))-α-D-galactopyranosyl)-2-
tetracosylamino-nonane-1,3,4-triol (10) 
To a solution of 64 (22 mg, 0.03 mmol) in DMF (0.8 mL) and H2O (0.2 mL) was added TEA 
(50 μL), CuI (4 mg, 0.02 mmol), TBTA (2 mg, 0.004 mmol) and the alkyne (17 mg, 0.06 
mmol). After stirring for 3 hours, the solvent was removed by evaporation. The resulting 
residue was purified by preparative TLC (CH2Cl2/MeOH: 27/3) to furnish final compound 10 
(29 mg, 91 %) as an orange powder. 
1
H NMR (300 MHz, CD3OD): 7.75 (s, 1H, arom. H), 
6.12 (s, 2H, arom. H), 4.81 (d, J = 3.4 Hz, 1H, H-1”), 
4.62-4.55 (m, 2H, H-6”), 4.19 (app. t, J = 6.3 Hz, 1H, H-
5”), 4.10 (dd, J = 4.6 Hz and 10.6 Hz, 1H, H-2), 3.82 (dd, 
J = 1.3 Hz and 2.7 Hz, 1H, H-4”), 3.77 (dd, J = 3.4 Hz 
and 8.5 Hz, 1H, H-2”), 3.74 (dd, J = 3.2 Hz and 9.9 Hz, 
1H, H-3”), 3.54-3.45 (m, 3H, H-1, H-3, H-4), 3.38 (dd, J 
= 4.5 Hz and 10.3 Hz, 1H, H-1), 3.07-3.02 (m, 2H, CH2), 
2.78 (t, J = 7.4 Hz, 2H, CH2), 2.44 (s, 6H, CH3), 2.42 (s, 6H, CH3), 2.15 (t, J = 7.5 Hz, 2H, 
CH2), 1.90 (t, J = 7.4 Hz, 2H, CH2), 1.75-1.22 (m, 52H, CH2), 0.91-0.87 (m, 6H, CH3). 
Exact mass (ESI-MS) for C58H99BF2N6O8 [M+H]
+
 found, 1057.7662; calcd, 1057.7664; 
[M+Na]
+
 found, 1079.7499; calcd, 1079.7483. 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(6-amino-2,3,4-tri-O-benzyl-6-deoxy-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (65). 
To a solution of 44 (126 mg, 0.09 mmol) in THF (1.4 
mL) was added trimethylphosphine (0.47 mL, 1M) 
dropwise. After stirring for 3 hours, NaOH (2.8 mL, 
1M) was added and the reaction mixture was allowed to 
stir for an additional 2.5 hours. The solution was 
extracted with EtOAc, followed by washing of the organic layer with brine, drying over 
Na2SO4 and evaporation of the solvent to afford amine 65 as a yellow oil.  
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-(4-O-benzyl)-benzylamido-6-deoxy-
α-D-galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (66). 
To a solution of (benzyloxy)phenylacetic acid (60 mg, 0.24 mmol) in DMF (0.3 mL) and 
CH2Cl2 (0.7 mL) was added DIPEA (0.04 mL, 0.24 mmol). After stirring for 10 minutes, 
HCTU (99 mg, 0.24 mmol) was added and the solution was allowed to stir for an additional 
30 minutes. The mixture was then added to a solution of the crude amine 65 in DMF (0.3 mL) 
and CH2Cl2 (0.7 mL). Upon stirring overnight, the solvent was removed by evaporation and 
the resulting residue was submitted to column chromatography (hexanes/EtOAc: 7/3) giving 
66 (134 mg, 93%) as a white solid. 
1
H NMR (300 MHz, CDCl3): 7.41-7.19 (m, 30H, 
arom. H), 7.08-7.04 (m, 2H, arom. H), 6.90-6.86 (m, 
2H, arom. H), 5.96 (d, J = 8.8 Hz, 1H, NH), 5.67 (dd, J 
= 4.2 Hz and 7.4 Hz, 1H, NH), 5.01 (d, J = 16.0 Hz, 2H, 
COCH2-Ph), 4.91 (d, J = 11.4 Hz, 1H, CH2-Ph), 4.80 (d, 
J = 11.6 Hz, 1H, CH2-Ph), 4.79 (d, J = 3.7 Hz, 1H, H-
1”), 4.77 (d, J = 12.9 Hz, 1H, CH2-Ph), 4.76 (d, J = 10.8 Hz, 1H, CH2-Ph), 4.72 (d, J = 11.7 
Hz, 1H, CH2-Ph), 4.62 (d, J = 11.4 Hz, 2H, CH2-Ph), 4.58 (d, J = 11.2 Hz, 1H, CH2-Ph), 4.57 
(d, J = 11.4 Hz, 1H, CH2-Ph), 4.48 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.46 (d, J = 11.7 Hz, 1H, 
CH2-Ph), 4.25-4.17 (m, 1H, H-2), 3.99 (dd, J = 3.7 Hz and 10.1 Hz, 1H, H-2”), 3.86-3.74 (m, 
4H, H-3”, H-4”, H-1, H-3), 3.69 (app. t, J = 6.2 Hz, 1H, H-5”), 3.59 (dd, J = 4.3 Hz and 10.3 
Hz, 1H, H-1), 3.53-3.32 (m, 2H, H-4, H-6”), 3.10 (ddd, J = 4.1 Hz, 7.5 Hz and 13.6 Hz, 1H, 
H-6”), 2.04-1.87 (m, 2H, COCH2), 1.68-1.08 (m, 72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3). 
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13
C NMR (75 MHz, CDCl3):  173.11, 171.75, 158.21, 138.87, 138.84, 138.69, 138.56, 
138.50, 137.13, 130.63, 130.60, 128.81, 128.77, 128.66, 128.62, 128.58, 128.16, 128.10, 
128.06, 127.98, 127.95, 127.89, 127.83, 127.68, 127.65, 127.40, 115.40, 115.23, 99.32, 80.08, 
79.40, 79.17, 77.44, 76.59, 75.07, 74.78, 73.80, 73.75, 73.24, 71.96, 70.20, 69.26, 68.64, 
50.49, 42.86, 36.92, 32.16, 30.09, 30.04, 29.97, 29.94, 29.89, 29.74, 29.66, 29.61, 29.59, 
26.25, 25.97, 22.92, 14.35. 
Exact mass (ESI-MS) for C100H142N2O10 [M+H]
+
 found, 1532.0707; calcd, 1532.0743; 
[M+Na]
+
 found, 1554.0514; calcd, 1554.0562; [M+K]
+
 found, 1570.0314; calcd, 1570.0302. 
(2S,3S,4R)-1-O-(6-benzylamido-6-deoxy-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (11). 
A solution of 11 (120 mg, 0.0.8 mmol) in CHCl3 (1 mL) and EtOH (3 mL) was hydrogenated 
under atmospheric pressure in the presence of palladium black (12 mg). Upon reaction 
completion, the mixture was diluted with pyridine and filtered through celite. The filter cake 
was rinsed with CHCl3 and EtOH and the filtrate was evaporated to dryness. After 
purification by column chromatography (CH2Cl2/MeOH: 27/3), compound 11 (39 mg, 48 %) 
was obtained as a white powder. 
1
H NMR (300 MHz, pyridine-d5):  8.68 (t, J = 5.7 Hz, 
1H, NH), 8.50 (d, J = 8.7 Hz, 1H, NH), 7.50 (d, J = 8.5 
Hz, 2H, arom. H), 7.18 (d, J = 8.5 Hz, 2H, arom. H), 
5.50 (d, J = 3.9 Hz, 1H, H-1”), 5.28-5.26 (m, 1H, H-2), 
4.61-4.56 (m, 2H, H-2”, H-1), 4.48-4.44 (m, 1H, H-5”), 
4.36-4.26 (m, 5H, H-1, H-3, H-4, H-3”, H-4”), 3.95-3.89 
(m, 1H, H-6”), 3.87-3.81 (m, 3H, H-6”, CH2-Ph), 2.55-2.41 (m, 2H, COCH2), 1.94-1.14 (m, 
72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5):  173.36, 172.48, 157.89, 131.09, 127.34, 116.51, 101.42, 
76.92, 72.60, 71.25, 70.70, 70.10, 68.60, 51.32, 43.17, 41.49, 36.91, 32.22, 30.51, 30.27, 
30.14, 30.11, 30.03, 30.01, 29.98, 29.93, 29.88, 29.72, 29.70, 26.61, 26.53, 23.03, 14.37. 
Exact mass (ESI-MS) for C58H106N2O10 [M+H]
+
 found, 991.7939; calcd, 991.7926; [M+Na]
+
 
found, 1013.7784; calcd, 1013.7745. 
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5 Synthesis of a potential iNKT cell 
antagonist 
5.1 Introduction 
There is emerging evidence that iNKT cells play an important pathogenic role in allergic 
diseases, such as contact hypersensitivity
1
 and asthma.
2 , 3
 Particularly in the latter, their 
function has been extensively studied over the past few years. This has provided new insights 
into the disease mechanism, opening the door to novel therapeutic strategies. 
The most elementary explanation of asthma, characterized by airway inflammation and 
airway hyperreactivity (AHR), involves an interaction between mast cells, eosinophils and 
CD4
+
 Th2 cells.
2,4
 The first phase, allergen sensitization, results from an adaptive immune 
response to common aeroallergens, leading to the development of allergen-specific CD4
+
 Th2 
cells and IgE. Subsequent challenge with allergen activates these CD4
+
 Th2 cells, in turn 
enhancing the growth, differentiation and recruitment of eosinophils, basophils, B cells and 
mast cells via the secretion of IL-4, IL-5, IL-9 and IL-13 (Figure 5.1). B cell-derived IgE 
stimulates mast cells to rapidly release chemical mediators such as leukotrienes and 
histamine, increasing the airway resistance. The produced IL-4 and IL-13 on the other hand 
give rise to AHR. 
So clearly, MHC class II-restricted CD4
+
 Th2 cells play an important role in the pathogenesis 
of bronchial asthma. However, a number of clinical observations cannot be explained by this 
paradigm, suggesting that several additional processes and pathways must be involved.
2
 
Indeed, different murine models of asthma indicate the requirement of iNKT cells producing 
IL-4 and IL-13 in the development of AHR.
5,6
 Moreover, respiratory administration of α-
GalCer has been demonstrated to rapidly induce AHR and airway inflammation in naive 
mice, even in MHC class II-deficient types.
7
 Although in human asthma more functional 
studies are required, the currently available findings also support the clinical relevance of 
iNKT cells. For example, an increased number of pulmonary CD4
+
 iNKT cells is observed in 
many but not all asthmatic patients.
2,8
 These iNKT cells might be activated by substances 
naturally occurring in our environment such as pathogen- or pollen-derived glycolipids and 
ozone, thereby inducing AHR either directly or by licensing Th2 cells (Figure 5.1).
3,4,5,7
 In 
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addition, it has been shown that pro-Th2 cytokines like IL-25, IL-33 and TSLP (thymic 
stromal lymphopoietin) act on iNKT cells to exacerbate the allergic symptoms. 
In accordance with these findings, the CD1d-dependent iNKT cell antagonist DPPE-PEG (di-
palmitoyl-phosphatidyl-ethanolamine covalently attached to polyethyleneglycol) completely 
abrogates the development of AHR in OVA- and α-GalCer-induced murine models.9 Hence, 
blockade of iNKT cells with an iNKT cell-specific antagonist might be highly effective in the 
treatment of asthma. 
Figure 5.1 Activated CD4+ Th2 cells and iNKT cells in the development of AHR and airway inflammation. 
Apart from DPPE-PEG, only two other CD1d-dependent antagonists have been described 
thus far. In 2009, the group of Vasella synthesized a thioamide-substituted 1,4-triazole 
derivative of 7-oxaceramide (Figure 5.2).
10
 This compound was able to compete with α-
GalCer for binding to plate-bound human CD1d, thereby reducing the α-GalCer-mediated 
iNKT cell activation. However, this competition was only achieved at a 15-fold molar excess 
over α-GalCer and could not be observed in living cells. The latter is in all probability due to 
the instability of the thioamide moiety inside living cells. More recently, the natural 
ganglioside GD3 (Figure 5.2) was identified as a high-affinity, competitive CD1d-ligand that 
inhibits the activation of iNKT cells both in vitro and in vivo.
11
 Taking into account the 
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abundant presence of GD3 in ovarian cancer-associated ascites fluid, this suggests that 
ovarian cancer tumors may use GD3 to inhibit the antitumor iNKT cell response as an early 
mechanism of tumor immune evasion. Contrary to this observation, another group reported 
earlier that mice immunized with GD3
+
 human melanoma or with GD3-loaded DCs 
developed a GD3-mediated CD1d-restricted iNKT cell response, characterized by IL-4, IL-10 
and IFN-γ secretion and polarized toward Th2 upon further immunization. 12  As the 
information currently available concerning iNKT cell inhibition is thus rather scarce, the 
synthesis of new iNKT cell antagonists is highly desirable. 
 
Figure 5.2 Structures of CD1d-dependent iNKT cell antagonists. 
As outlined in the introduction, the 2”-, 3”- and 4”-OH groups of the α-GalCer carbohydrate 
moiety are involved in the interaction with the TCR. Consequently, α-ManCer is unable to 
significantly activate iNKT cells due to the loss of hydrogen bonds with the 2”-OH and 4”-
OH group. On the other hand, NU-α-GalCer, designed earlier in our laboratory, induces a 
potent Th1 polarization, which has been related to increased interactions with CD1d, namely 
the induction of an additional binding pocket by the naphthylurea substituent and an extra 
hydrogen bond. Via the synthesis of NU-α-ManCer derivative 12 (Figure 5.3) we envisage to 
obtain an iNKT cell antagonist which may be useful in the treatment of allergic inflammatory 
responses such as asthma and other disorders characterized by inappropriate iNKT cell 
activation. 
 
Figure 5.3 Structure of NU-α-GalCer and NU-α-ManCer. 
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5.2 Synthesis of NU-α-ManCer 
The retrosynthesis of our first attempt towards the preparation of NU-α-ManCer 12 is shown 
in Scheme 5.1. We intended to couple glycosyl donor 77 and acceptor 71 under Schmidt’s 
conditions, whereby the 2”-acetyl group favors α-selectivity through neighbouring group 
participation. Staudinger reduction of the obtained C-6”-azido-mannosylceramide 80 followed 
by reaction with 1-naphthylisocyanate permits to introduce the desired naphthylurea 
substituent. Final deprotection of the acetyl and silyl groups then gives the envisaged NU-α-
ManCer 12. 
 
Scheme 5.1 Retrosynthesis of the first strategy towards NU-α-ManCer 12. 
For the synthesis of ceramide building block 71, a procedure similar to that of Kim et al. was 
employed.
13
 First an N-hydroxysuccinimide ester of hexacosanoic acid 67 was prepared as 
acyl donor for condensation with phytosphingosine to afford the unprotected ceramide 69 
(Scheme 5.2). Next, the free hydroxyl groups were silylated with TBSOTf in the presence of 
2,6-lutidine giving intermediate 70. Upon regioselective removal of the primary silyl group 
with HF.pyridine, ceramide acceptor 71 was obtained. 
 
Scheme 5.2 Reagents and conditions: (a) NHS, CH2Cl2, 40 °C, overnight; (b) phytosphingosine, Et3N, THF, 
50 °C, overnight; (c) TBSOTf, 2,6-lutidine, CH2Cl2, 0 °C-rt, 6 h, 37% over 3 steps; (d) HF.pyridine, THF, 
pyridine, 0 °C, 1.5 h, 70%. 
Synthesis of a potential iNKT cell antagonist 
151 
Preparation of the mannosyl donor started from the commercially available methyl-α-D-
mannopyranoside 72 (Scheme 5.3). After selective tosylation of the primary alcohol giving 
73, an azide group at the 6”-position was introduced to furnish 74. Subsequent acetylation of 
the remaining hydroxyl groups and the anomeric position under acidic conditions produced 
intermediate 75. 
 
Scheme 5.3 Reagents and conditions: (a) TsCl, pyridine, 0 °C, 20 min, 71%; (b) NaN3, DMF, 60 °C, 3 days, 
93%; (c) Ac2O, AcOH, H2SO4, 0 °C-rt, 2 days, 83%. 
Removal of the anomeric acetyl group in 75 using benzylamine, followed by substitution with 
trichloroacetonitrile in the presence of DBU afforded trichloroacetimidate 77 (Scheme 5.4). 
Unfortunately, glycosylation of 71 with 77 could not be realized, probably due to the low 
nucleophilicity of the ceramide. To compensate for this, the more reactive mannosyl fluoride 
donor 78 was used for glycosylation under Mukaiyama conditions. This didn’t result in the 
expected mannosylceramide derivative either. Instead, conversion of ceramide 71 to an 
undesired oxazoline derivative was observed (81). Subsequently, several other mannosyl 
donors and activator systems were applied, again without success (Scheme 5.4). 
 
Scheme 5.4 Reagents and conditions: (a) BnNH2, THF, 50 °C, 24 h, 94%; (b) CCl3CN, DBU, CH2Cl2, 0 °C, 5 h, 
49%; (c) 71, TMSOTf, THF, -30 °C, 24 h; (d) HF.pyridine, pyridine, toluene, -20 °C-rt, overnight, 73%; (e) 71, 
SnCl2, AgClO4, THF, -10 °C for 1 h-rt for 27 h; (f) 71, Hg(CN)2, nitromethane, 90 °C, 3-20 h; (g) AcOH, AcBr, 
MeOH, rt, overnight; (h) 71, BF3.Et2O, CH2Cl2, 0 °C-rt, 5 h. 
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Therefore, we decided to follow a new strategy which allows coupling of the more reactive 
azidosphingosine 33 with glycosyl donor 86 (Scheme 5.5). This implicates introduction of the 
acyl chain after Schmidt’s glycosylation as opposed to the first attempt, followed by global 
deprotection to yield 12. 
 
Scheme 5.5 Retrosynthesis of the second strategy towards NU-α-ManCer 12. 
The preparation of mannosyl donor 86 started with the Staudinger reduction of azide 
intermediate 74 and subsequent reaction of the resulting amine 82 with 1-naphthylisocyanate 
to produce the corresponding naphthylurea derivative 83 (Scheme 5.6). Yet, during the 
following acetylation of the free hydroxyl groups under acidic conditions, the NH groups of 
the urea functionality were acetylated as well, resulting in compounds 84a-c instead of the 
desired product 85. 
 
Scheme 5.6 Reagents and conditions: (a) i. PMe3, THF, 2 h; ii. H2O, 3 h; (b) 1-naphthylisocyanate, DMF, 0 °C-
rt, 1 h, 89% over 2 steps; (c) Ac2O, AcOH, H2SO4, 0 °C-rt, overnight. 
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In order to circumvent the unwanted N-acetylation of 83, the free OH groups were acetylated 
under mild basic conditions, furnishing 88 (Scheme 5.7). Then, anomeric demethylation prior 
to incorporation of the trichloroacetimidate group was attempted using several methods       
(b-d).
14,15,16
 Regrettably, none of these efforts were successful. 
 
Scheme 5.7 Reagents and conditions: (a) Ac2O, pyridine, 0 °C-rt, 1 h, 50%; (b) H2SO4, AcOH, 0 °C-rt (c) i. 
BCl3, CH2Cl2, -78 °C; ii. Ag2CO3, CH3CN, H2O; (d) TrBF4, CH2Cl2, rt. 
To overcome the aforementioned difficulties, a third alternative synthetic route was developed 
exploiting a glycosyl donor with a 1,2-orthoester functionality (Scheme 5.8). Sugar 1,2-
orthoesters are often considered undesired side products in the Koenigs-Knorr glycosylation.
17
 
However, by slightly changing the experimental conditions they may become the predominant 
product, which may subsequently be used for glycosylation as pioneered by Kochetkov and 
co-workers, leading stereospecifically to 1,2-trans-glycosides.
18 ,19
 Similar to the previous 
attempt, introduction of the acyl chain takes place after the glycosylation process followed by 
removal of the benzyl groups to acquire NU-α-ManCer 12. 
 
Scheme 5.8 Retrosynthesis of the third strategy towards NU-α-ManCer 12. 
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Generally, the synthesis of sugar 1,2-orthoesters starts from an acylated glycosyl halide, an 
alcohol and a base. Here, peracetylated α-D-mannopyranosyl bromide 91, prepared from the 
commercially available penta-O-acetyl-α-D-mannose 90 was used in the presence of methanol 
and 2,6-lutidine (Scheme 5.9). This resulted in the formation of two inseparable 
diastereoisomers of orthoester 92 in a ratio 9:1 (exo:endo), consistent with data found in 
literature.
20
 
 
Scheme 5.9 Reagents and conditions: (a) HBr, Ac2O, AcOH, 0 °C-rt, overnight, (b) 2,6-lutidine, MeOH, 
CH2Cl2, rt, overnight, 67% over 2 steps; (c) NH3, MeOH, rt, overnight; (d) TBDMSCl, imidazole, THF, rt, 30 h, 
76% over 2 steps; (e) NaH, BnBr, DMF, 0 °C-rt, overnight, 76%; (f) TBAF, THF, -78 °C-rt, 3 h; (g) McCl, 
pyridine, 0 °C, 30 min.; (h) NaN3, DMF, 80 °C, overnight, 39% over 3 steps; (i) i. PMe3, THF, 2 h; ii. H2O, 2.5 
h; (j) 1-naphthylisocyanate, DMF, 0 °C-rt, 1 h, 68% over 2 steps; (k) 33, TMSOTf, CH2Cl2, 0 °C, 1 h, 17-34 %; 
(l) NaOMe, MeOH, 0 °C-rt, 3 days, 50%; (m) PMe3, THF, 2h; ii. H2O, 2.5 h; (n); EDC, CH2Cl2, rt, overnight, 
64% over 2 steps; (o) Pd black, H2, EtOH/CHCl3, 5 h, 34%. 
Once the 1,2-orthoester functionality was introduced, the remaining acetyl groups were 
removed with a mixture of ammonia in methanol. Selective silylation at the primary position 
using tert-butyldimethylsilyl chloride (TBDMSCl) followed by benzylation of the secondary 
hydroxyl groups afforded compound 95. Next, orthogonal deprotection of the silyl group with 
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tetra(n-butyl)ammonium fluoride (TBAF) provided product 96, allowing subsequent selective 
manipulation of the 6”-position. After nucleophilic displacement of the corresponding 
monochloromesylate 97 with sodium azide, the resulting 6-azido derivative 98 was submitted 
to Staudinger reduction, giving amine 99. Reaction with 1-naphthylisocyanate then yielded 
the desired naphthylurea intermediate 100 to be used as glycosyl donor. 
The orthoester glycosylation consisted of reacting compound 100 with acceptor 33 in the 
presence of catalytic amounts TMSOTf. Unfortunately, the desired glycoside 101 could only 
be obtained in very low yield (17%), owing to competing glycosylation of the extruded 
methanol from the initial orthoester. Since the undesired methyl glycoside and the isomeric 
starting compound 100 have the same Rf, distinction was only possible by NMR analysis, 
impeding easy monitoring of the reaction. In order to reduce the formation of this side 
product, molecular sieves were employed, leading to a doubling of the reaction yield (34%). 
In the following step, the 2”-O-acetyl group regenerated during the glycosylation reaction was 
removed under basic conditions to give intermediate 102. Next, introduction of the acyl chain 
was achieved by Staudinger reduction and subsequent coupling with cerotic acid in the 
presence of EDC. Lastly, palladium-catalyzed hydrogenolysis of compound 104 provided the 
desired NU-α-ManCer derivative 12. 
5.3 Synthesis of NU-α-GlcCer 
Having obtained mannose intermediate 104 possessing a C-2” free hydroxyl group, we turned 
our attention to invert the stereochemistry of this group to acquire the corresponding glucose 
derivative 13 (Scheme 5.10). Compared to α-GalCer, α-GlcCer shows an activity level that is 
only slightly reduced. Similarly, α-GlcCer compounds containing a C24:0 or C20:2 acyl tail 
are equally potent in inducing iNKT cell expansion than the corresponding α-GalCer 
compounds.
21
 By comparing the biological activity of NU-α-GlcCer 13 with that of NU-α-
GalCer and NU-α-ManCer, additional information could be gained concerning the importance 
of the C-4” hydroxyl group. 
 
 
Chapter 5 
156 
 
Scheme 5.10 Retrosynthesis of NU-α-GlcCer 13. 
Towards this end, a Mitsunobu reaction with benzoic acid was carried out, known as a 
synthetic tool for alcohol inversion (Scheme 5.11). Subsequent removal of benzoyl and 
benzyl groups of 105 would then deliver the envisioned NU-α-GlcCer 13. However, the stated 
Mitsunobu conditions didn’t result in any product formation, neither when the more reactive 
p-nitrobenzoic acid was used.
22
 Difficulties associated with nucleophilic displacement 
reactions at the 2-position of hexoses have been reported earlier.
23,24,25 
 
Scheme 5.11 Reagents and conditions: (a) PPh3, DEAD, benzoic acid or p-nitrobenzoic acid, THF, 0 °C-rt, 24 h. 
In a second attempt, epimerization of the C-2” center via an oxidation-reduction sequence was 
explored. This strategy is most commonly used for the synthesis of β-mannosides but there 
are also some reports on the construction of α-glucosides. 26 , 27 , 28  Oxidation of the C-2” 
hydroxyl group first was performed using Dess Martin reagent (Scheme 5.12). However, 
under these conditions oxidation of the naphthyl system was observed, leading to a mixture of 
106a-d. Therefore, oxidation according to Swern was tried, successfully resulting in 2”-keto-
derivative 107, which was then reduced with sodium borohydride to furnish a mixture of 
glucoside 108 and the initial mannoside 104. Both epimers could be separated by column 
chromatography and the manno-derivative was recycled. Finally, debenzylation afforded the 
proposed NU-α-GlcCer 13. 1H-NMR analysis of this compound showed an anomeric coupling 
constant of 3.8 Hz, in line with other related α-GlcCer analogues and thus confirming the 
nature of the carbohydrate moiety.
21
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Scheme 5.12 Reagents and conditions: (a) DMP, CH2Cl2, 2 h, rt; (b) oxalyl chloride, DMSO, CH2Cl2, Et3N,        
-78 °C, 2 h; (c) NaBH4, THF, 0 °C-rt, 5 h, 16% over 2 steps; (d) Pd black, H2, EtOH/CHCl3, rt, 33%. 
5.4 Biological evaluation 
So far, only NU-α-ManCer has been evaluated for its antagonistic potential, providing some 
preliminary results. A first experiment aimed at determining whether NU-α-ManCer acts as 
an inhibitor of iNKT TCR binding. Towards this end, human CD1d-expressing T2 
lymphoblast cells were pulsed with vehicle, α-GalCer, OCH, GD1a or NU-α-ManCer (12), 
prior to staining with iNKT TCR tetramers (Collaboration with Prof. S. Gadola). As shown in 
Figure 5.4, the intensity of the tetramer stains between CD1d-expressing T2 lymphoblasts 
pulsed with vehicle alone or NU-α-ManCer were comparable, suggesting that NU-α-ManCer 
does allow some iNKT TCR binding to CD1d. 
 
Figure 5.4 Inhibition of iNKT TCR binding. 
To investigate whether NU-α-ManCer acts as a competitor of lipid binding, human CD1d-
expressing T2 lymphoblasts were pulsed for 1 hour with varying concentrations of OCH, 
followed by pulsing for 2 hours with vehicle, disialoganglioside 1a (GD1a) or NU-α-ManCer 
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as competitor ligands. Staining with iNKT TCR tetramers allowed to determine OCH lipid 
displacement. The results are presented in Figure 5.5 and demonstrate that, while GD1a could 
displace OCH, NU-α-ManCer was comparable to the vehicle background control. 
 
Figure 5.5 Lipid binding competition experiment. 
5.5 Conclusion 
The synthesis of NU-α-ManCer proved to be less straightforward than initially expected due 
to several difficulties encountered during, or in anticipation of the glycosylation reaction. 
Through application of a 1,2-orthoester-based glycosylation strategy, the intended mannosyl 
derivative could eventually be attained. This approach also allowed late-stage conversion to 
the corresponding glucosyl derivative via an oxidation-reduction sequence. Based on the 
preliminary results of the competition assays with NU-α-ManCer, we assume that this 
compound does not act as an iNKT cell antagonist. Additional experiments to extend and 
rationalize these findings as well as evaluation of NU-α-GlcCer are in progress. 
5.6 Experimental section 
N-succinimidyl hexacosanoate (68) 
To a solution of hexacosanoic acid (4.50 g, 11.34 mmol) in CH2Cl2 was added N-
hydroxysuccinimide (NHS) (1.57 g, 13.61 mmol). The mixture was heated to 40 °C and 
stirred overnight. After being poured in water and extraction with Et2O, the combined organic 
layers were washed with brine, dried over MgSO4 and evaporated to dryness to furnish 69 
(3.61 g) as a white powder. 
1
H-NMR (300 MHz, CDCl3): δ 2.83 (br. s, 2H, COCH2), 2.59 (t, J 
= 7.4 Hz, 2H, COCH2), 1.74 (ddd, J = 7.5 Hz and 15.2 Hz, 2H, 
CH2), 1.43-1.18 (m, 44H, CH2), 0.88 (t, J = 6.7 Hz, 3H, CH3). 
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13
C-NMR (75 MHz, CDCl3): δ 169.14, 168.65, 31.91, 30.92, 29.68, 29.61, 29.54, 29.34, 
29.07, 28.78, 25.57, 24.56, 22.67, 14.09. 
Spectral data are consistent with the literature data. 
(2S,3S,4R)-2-hexacosylamino-octadecane-1,3,4-triol (69) 
To a solution of 68 (3.61 g) in THF (100 mL) was added phytosphingosine (1.93 g, 6.10 
mmol) and Et3N (3 mL, 21.96 mmol). The resulting suspension was heated to 50 °C. After 
stirring overnight, a clear solution was obtained, which was allowed to cool down to room 
temperature. The solution was then diluted with EtOAc (50 mL), resulting in a white 
suspension. After centrifugation for 30 minutes, the supernatant was removed and the white 
residue was evaporated to dryness to afford 69 (3.99 g) as a white powder. 
1
H-NMR (300 MHz, pyridine-d5): δ 8.28 (d, J = 8.5 Hz, 1H, 
NH), 5.06 (dt, J = 4.8 Hz and 9.6 Hz, 1H, H-2), 4.53-4.43 (m, 2H, 
H-1 and H-3), 4.37 (dd, J = 4.8 Hz and 6.4 Hz, 1H, H-1), 4.30-
4.26 (m, 1H, H-4), 2.47 (t, J = 7.4 Hz, 2H, COCH2), 2.31-1.19 
(m, 72H, CH3). 
13
C-NMR (75 MHz, pyridine-d5): δ 176.96, 75.65, 71.96, 63.95, 52.63, 35.70, 32.85, 30.93, 
29.11, 28.93, 28.81, 28.79, 28.71, 28.66, 28.60, 28.55, 28.39, 25.43, 25.19, 21.72, 13.04. 
Exact mass (ESI-MS) for C44H89NO4 [M+H]
+
 found, 696.6869; calcd, 696,6870; [M+Na]
+
 
found, 718.6682; calcd 718,6689. 
Spectral data are consistent with the literature data. 
(2S,3S,4R)-1,3,4-tri-O-tert-butyldimethylsilyl-2-hexacosylamino-octadecane-1,3,4-triol 
(70) 
To a solution of 69 (1.50 g) in CH2Cl2 (12 mL), 2,6-lutidine (2.3 mL, 19.41 mmol) was 
added. The mixture was cooled to 0 °C and TBSOTf (3.0 mL, 12.94 mmol) was added. The 
reaction mixture was allowed to stir for 6 hours at room temperature. After quenching with a 
saturated NaHCO3 solution, the aqueous layer was extracted with CH2Cl2. Then, the 
combined organic layers were washed with a 1M HCl solution, a saturated NaHCO3 solution 
and brine, followed by drying over Na2SO4 and removal of the solvent under reduced 
pressure. Purification by column chromatography (hexanes/EtOAc: 97/3) yielded compound 
70 (1.65 g, 37 % over 3 steps) as a clear colorless oil. 
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1
H-NMR (300 MHz, CDCl3): δ 5.78 (d, J = 8.5 Hz, 1H, NH), 
3.94-3.87 (m, 1H, H-2), 3.83 (dd, J = 4.2 Hz and 9.9 Hz, 1H, 
H-1), 3.78 (dd, J = 1.4 Hz and 7.3 Hz, 1H, H-3), 3.66-3.57 (m, 
2H, H-1 and H-4), 2.01 (t, J = 7.5 Hz, 2H, COCH2), 1.60-1.15 
(m, 72H, CH2), 0.93-0.80 (m, 33H, CH3), 0.10-0.08 (m, 3H, CH3), 0.05-0.01 (m, 15H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 177.81, 80.96, 80.92, 66.94, 58.10, 42.71, 37.75, 37.49, 35.55, 
35.26, 35.23, 35.22, 35.18, 35.02, 34.98, 34.95, 34.93, 34.92, 31.91, 31.66, 31.63, 31.43, 
31.34, 31.25, 28.25, 23.91, 23.80, 23.70, 19.67, 2.61, 2.05, 1.74, 0.93, 0.37, 0.34. 
Exact mass (ESI-MS) for C62H131NO4Si3 [M+H]
+
 found, 1038.9584; calcd, 1038.9459; 
[M+Na]
+
 found, 1060.9448; calcd 1060.9278; [M+K]
+
 found, 1076.9200; calcd, 1076.9017. 
Spectral data are consistent with the literature data. 
(2S,3S,4R)-3,4-di-O-tert-butyldimethylsilyl-2-hexacosylamino-octadecane-1,3,4-triol (71) 
Compound 70 (411 mg, 0.40 mmol) was dissolved in THF (4.1 mL) in a polyethylene vial 
and cooled to 0 °C. Then, 2.4 mL of a stock solution consisting of pyridine (3.0 mL) and 
HF.pyridine (2.7 mL) in THF (7.5 mL) was added. After stirring for 1.5 hours, the reaction 
mixture was quenched with a saturated NaHCO3 solution and extracted with EtOAc. The 
combined organic layers were washed with a saturated NaHCO3 solution, dried over MgSO4 
and evaporated to dryness. The resulting residue was purified by column chromatography 
(hexanes/EtOAc: 9/1) to afford 71 (237 mg, 70 %) as a clear colorless oil. 
1
H-NMR (300 MHz, CDCl3): δ 6.17 (d, J = 7.8 Hz, 1H, NH), 
4.12 (app. d, J = 11.2 Hz, 1H, H-1), 4.01-3.95 (m, 1H, H-2), 3.83 
(t, J = 2.8, 1H, H-3), 3.68 (ddd, J = 2.6 Hz and 6.4 Hz, 1H, H-4), 
3.51 (app. t, J = 7.7 Hz, 1H, H-1), 3.09 (d, J = 6.7 Hz, 1H, OH), 
2.12-2.04 (m, 2H, COCH2), 1.58-1.08 (m, 72H, CH2), 0.88-0.77 (m, 24H, CH3), 0.02-0.00 (m, 
12H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 177.58, 68.52, 56.16, 41.85, 39.33, 36.84, 34.71, 34.61, 34.59, 
34.57, 34.54, 34.45, 34.39, 34.28, 30.91, 30.87, 30.74, 30.52, 27.60, 23.06, 23.03, 19.03, 1.15, 
0.84, 0.39, 0.00. 
Exact mass (ESI-MS) for C56H117NO4Si2 [M+H]
+
 found, 924.8608; calcd, 924.8594. 
Spectral data are consistent with the literature data. 
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6-O-toluenesulfonyl-1-O-methyl-α-D-mannopyranoside (73) 
Tosylchloride (5.98 g, 31.44 mmol) was added in small portions to a solution of methyl-α-D-
mannopyranoside 72 (5.00 g, 25.77 mmol) in pyridine (50 mL) at 0 °C. The mixture was 
stirred for 20 minutes, followed by evaporation of the solvent. Purification by column 
chromatography (CH2Cl2/MeOH: 96/4) afforded 73 (6.34 g, 71 %) as a white foam. 
1
H-NMR (300 MHz, CDCl3): δ 7.80 (d, J = 8.4 Hz, 2H, arom. H), 7.34 (d, 
J = 8.1 Hz, 2H, arom. H), 4.67 (d, J = 1.3 Hz, 1H, H-1), 4.35 (dd, J = 4.2 
Hz and 10.9 Hz, 1H, H-6), 4.28 (dd, J = 1.6 Hz and 11.0 Hz 1H, H-6), 
3.91 (app. s, 1H, H-2), 3.75-3.71 (m, 3H, H-3, H-4 and H-5), 3.30 (s, 3H, 
OCH3), 2.43 (s, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 145.23, 132.90, 130.12, 128.25, 101.17, 71.86, 70.74, 70.18, 
69.71, 67.33, 55.31, 21.87. 
Exact mass (ESI-MS) for C14H20O8S [M+H]
+
 found, 349.0992; calcd, 349.0952; [M+Na]
+
 
found, 371.0795; calcd 371.0771; [M+K]
+
 found, 387.0534; calcd, 387.0510. 
Spectral data are consistent with the literature data. 
6-azido-6-deoxy-1-O-methyl-α-D-mannopyranoside (74) 
To a solution of 73 (6.33 g, 18.18 mmol) in DMF (55 mL) at 60 °C was added NaN3 (13.12 g, 
201.80 mmol) in several portions. After stirring for 3 days, the resulting white suspension was 
filtered, followed by evaporation of the solvent under reduced pressure. The residue was 
purified by column chromatography (CH2Cl2/MeOH: 96/4), giving 74 (3.70 g, 93 %) as a 
colorless syrup. 
1
H-NMR (300 MHz, CDCl3): δ 4.68 (d, J = 1.5 Hz, 1H, H-1), 3.88 (dd, J 
= 1.5 Hz and 3.2 Hz, 1H, H-2), 3.74-3.62 (m, 3H, H-3, H-4 and H-5), 
3.49-3.48 (m, 2H, H-6), 3.35 (s, 3H, OCH3). 
13
C-NMR (75 MHz, CDCl3): δ 101.23, 71.86, 71.60, 70.93, 68.41, 55.41, 
51.60. 
Exact mass (ESI-MS) for C7H13N3O5 [M+Na]
+
 found, 242.0767; calcd 242.0747; [M+K]
+
 
found, 258.0511; calcd, 258.0487. 
Spectral data are consistent with the literature data. 
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1,2,3,4-tetra-O-acetyl-6-azido-6-deoxy-1-O-methyl-α-D-mannopyranoside (75) 
To a solution of 74 (4.42 g, 20.17 mmol) in AcOH (210 mL) and Ac2O (210 mL) at 0 °C was 
added concentrated H2SO4 (4.5 mL) dropwise. The reaction mixture was allowed to stir at 
room temperature for 2 days and then quenched with iced water. After extraction with 
CH2Cl2, the combined organic layers were washed with iced water and a saturated solution of 
NaHCO3, dried over MgSO4 and co-evaporated with toluene twice. Purification by column 
chromatography (hexanes/EtOAc: 6/4) yielded compound 75 (6.22 g, 83 %) as a colorless 
syrup. 
1
H-NMR (300 MHz, CDCl3): δ 6.09 (d, J = 1.7 Hz, 1H, H-1), 5.35-5.33 
(m, 2H, H-3 and H-4), 5.2-5.24 (m, 1H, H-2), 4.02-3.98 (m, 1H, H-5), 3.39 
(dd, J = 3.0 Hz and 13.5 Hz, 1H, H-6), 3.31 (dd, J = 5.5 Hz and 13.5 Hz, 
1H, H-6), 2.18 (s, 3H, CH3), 2.17 (s, 3H, CH3), 2.06 (s, 3H, CH3), 2.01 (s, 
3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 170.24, 170.00, 169.81, 168.25, 90.57, 72.08, 68.78, 68.50, 
66.71, 50.94, 21.27, 21.06, 20.97, 20.90, 20.86. 
Exact mass (ESI-MS) for C14H19N3O9 [M+Na]
+
 found, 396.1037; calcd 396.1014; [M+K]
+
 
found, 412.0786; calcd, 412.0753. 
Spectral data are consistent with the literature data. 
2,3,4-tri-O-acetyl-6-azido-6-deoxy-methyl-α-D-mannopyranoside (76) 
To a solution of compound 75 (262 mg, 0.70 mmol) in dry THF (3.6 mL) was added 
benzylamine (0.1 mL). The reaction mixture was allowed to stir at 50 °C for 24 hours under 
argon atmosphere. Since both starting material and desired product had the same Rf 
(hexanes/EtOAc: 6/4), mass spectrometry was needed to determine reaction completion. 
Subsequently, the solvent was evaporated under reduced pressure followed by purification by 
column chromatography (hexanes/EtOAc: 6/4) to give compound 76 (219 mg, 94 %) as a pale 
yellow syrup. 
1
H-NMR (300 MHz, CDCl3): δ 5.42 (dd, J = 3.1 Hz and 10.1 Hz, 1H, H-3), 
5.29-5.26 (m, 3H, H-1, H-2 and H-4), 4.19 (ddd, J = 4.8 Hz and 9.5 Hz, 1H, 
H-5), 3.36-3.34 (m, 2H, H-6), 2.16 (s, 3H, CH3), 2.05 (s, 3H, CH3), 2.00 (s, 
3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 170.43, 170.24, 170.14, 92.28, 70.24, 70.12, 68.73, 67.43, 
51.37, 20.96, 20.92, 20.79. 
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Exact mass (ESI-MS) for C12H17N3O8 [M+Na]
+
 found, 354.0923; calcd 354.0908; [M+K]
+
 
found, 370.0663; calcd, 370.0647. 
2,3,4-tri-O-acetyl-6-azido-6-deoxy-α-D-mannopyranosyl trichloroacetimidate (77) 
To a solution of 76 (194 mg, 0.59 mmol) in CH2Cl2 (6 mL) at 0 °C, DBU (0.05 mL, 
0.29 mmol) and trichloroacetonitrile (0.5 mL, 5.87 mmol) were added. The reaction mixture 
was stirred for 5 hours, diluted with CH2Cl2 and celite was added. After filtration, the solvent 
was removed under reduced pressure and the residue was purified by column chromatography 
(hexanes/EtOAc: 7.5/2.5 + 1 V% Et3N) yielding 77 (136 mg, 49 %) as a pale yellow syrup. 
1
H-NMR (300 MHz, CDCl3): δ 8.81 (s, 1H, NH), 6.39 (d, J = 2.0 
Hz, 1H, H-1), 5.47 (d, J = 1.9 Hz and 3.2 Hz, 1H, H-2), 5.41-5.38 
(m, 2H, H-3 and H-4), 4.18-4.11 (m, 1H, H-5), 3.38-3.36 (m, 2H, H-
6), 2.20 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.01 (s, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 170.03, 169.97, 169.88, 159.93, 
94.44, 72.70, 68.82, 68.04, 66.55, 50.94, 20.98, 20.93, 20.85. 
Exact mass (ESI-MS) for C14H17Cl3N4O8 [M+Na]
+
 found, 497.0020; calcd 497.0004; 
[M+K]
+
 found, 512.9760; calcd, 512.9744. 
2,3,4-tri-O-acetyl-6-azido-6-deoxy-α-D-mannopyranosyl fluoride (78) 
Anhydrous pyridine (1.0 mL) and a HF solution in pyridine (12.3 mL) were placed in a 
polyethylene vessel. The solution was cooled to -20 °C and a solution of 75 (256 mg, 0.69 
mmol) in toluene (2.6 mL) was added. The reaction mixture was gradually warmed to room 
temperature and stirred overnight, then quenched with a saturated NaHCO3 solution. The 
aqueous layer was extracted with CH2Cl2 followed by washing of the combined organic layer 
with a saturated NaHCO3 solution and brine. After drying over Na2SO4 and removal of the 
solvent under reduced pressure, the residue was purified by column chromatography 
(hexane/EtOAc: 7/3) to furnish compound 78 (167 mg, 73%) as a colorless syrup. 
1
H-NMR (300 MHz, CDCl3): δ 5.60 (dd, J = 1.9 Hz and 48.6 Hz, 1H, H-1), 
5.41-5.39 (m, 1H, H-2), 5.38-5.33 (m, 2H, H-3 and H-4), 4.16-4.09 (m, 1H, 
H-5), 3.46 (dd, J = 2.8 Hz and 13.6 Hz, 1H, H-6), 3.34 (dd, J = 5.4 Hz and 
13.6 Hz, 1H, H-6), 2.19 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.02 (s, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 169.76, 169.71, 169.59, 106.04, 103.07, 72.05, 72.02, 68.00, 
67.98, 67.87, 67.35, 65.94, 60.40, 50.68, 21.06, 20.70, 20.69, 20.67, 20.59, 14.21. 
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2,3,4-tri-O-acetyl-6-azido-6-deoxy-α-D-mannopyranosyl bromide (79) 
To a solution of 75 (200 mg, 0.53 mmol) in AcOH (1.9 mL), AcBr (0.32 
mL, 4.29 mmol) and MeOH (0.07 mL, 1.72 mmol) were added. After 
stirring overnight, the reaction mixture was co-evaporated twice with 
toluene, affording compound 79 as an orange syrup. 
 
(2S,3S,4R)-3,4-di-O-tert-butyldimethylsilyl-1-O-(2,3,4-tri-O-acetyl-6-azido-6-deoxy-α-D-
mannopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (80) 
Procedure 1 
To a mixture of mannosyl donor 77 (126 mg, 0.20 mmol) in THF (0.8 mL) was added a 
solution of ceramide 71 (187 mg, 0.26 mmol) in THF (2.1 mL). The solution was cooled to    
-30 °C and TMSOTf (5 μL, 0.03 mmol) was added. The reaction mixture was stirred under 
argon atmosphere but even after 24 hours, formation of the desired product could not be 
observed.  
Procedure 2 
To a solution of ceramide 71 (284 mg, 0.31 mmol) in THF (0.94 mL) under argon 
atmosphere, SnCl2 (135 mg, 0.71 mmol), AgClO4 (148 mg, 0.71 mmol) and powdered 4 Å 
molecular sieves were added. A solution of 78 (80 mg, 0.24 mmol) in THF (0.94 mL) was 
then added at -10 °C and the mixture was stirred for 1 hour. Since the majority of both 
starting materials remained unchanged, the solution was gradually warmed to room 
temperature. After stirring for 27 hours, complete conversion of ceramide 71 to a more apolar 
product was observed, while mannosyl donor 78 was still intact. The mixture was filtered 
over celite and the filter cake was washed with Et2O. The combined filtrates were evaporated 
to dryness and the resulting residue was purified by column chromatography (hexanes/EtOAc: 
95/5), affording oxazoline 81 (15 mg, 6%) as a colorless oil. However, no desired product 
could be obtained.  
1
H-NMR (300 MHz, CDCl3): δ 4.35 (app. t, J = 7.5 Hz, 1H, H-1), 
4.22-4.16 (m, 1H, H-2), 4.09 (dd, J = 7.5 Hz and 9.9 Hz, 1H, H-1), 
3.92 (app. s, 1H, H-3), 3.63-3.59 (m, 1H, H-4), 2.23-2.08 (m, 2H, 
COCH2), 1.66-0.93 (m, 72H, CH2), 0.91-0.62 (m, 24H, CH3), 0.07-
0.01 (m, 12H, CH3). 
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13
C-NMR (75 MHz, CDCl3): δ 39.92, 36.70, 36.00, 35.08, 34.62, 34.47, 34.44, 34.43, 34.39, 
34.35, 34.32, 34.22, 34.17, 34.13, 34.03, 32.98, 30.75, 30.68, 30.38, 27.46, 22.88, 22.83, 
18.88, 4.75, 1.01, 0.85, 0.71, 0.23. 
Exact mass (ESI-MS) for C56H115NO3Si2 [M+H]
+
 found, 906.8552; calcd 906.8494. 
Procedure 3 
To a solution of ceramide 71 (411 mg, 0.44 mmol) in THF (1.37 mL) under argon 
atmosphere, SnCl2 (197 mg, 1.04 mmol), AgClO4 (216 mg, 1.04 mmol) and powdered 4 Å 
molecular sieves were added. A solution of 79 (139 mg, 0.35 mmol) in THF (0.94 mL) was 
then added at -10 °C. After stirring for 2 hours, mass spectrometry revealed formation of 
oxazoline 81. Unfortunately, no desired product could be detected. 
Procedure 4 
A solution of 79 (188 mg, 0.48 mmol) in nitromethane (15 mL) was added dropwise to a 
solution of ceramide 71 (220 mg, 0.24 mmol) in nitromethane (5 mL). Hg(CN)2 (121 mg, 
0.48 mmol) was added. After stirring for 3 hours at 90 °C under argon atmosphere, TLC 
showed several spots including the one corresponding to oxazoline 81. The mixture was 
cooled to room temperature and diluted with EtOAc, followed by washing with water, a 
saturated NaHCO3 solution and brine. Next, the solution was dried over MgSO4 and 
evaporated to dryness. Unfortunately, mass spectrometry of the crude mixture could not 
detect the envisaged product. 
Procedure 5 
A solution of 78 (153 mg, 0.46 mmol) in nitromethane (7.5 mL) was added dropwise to a 
solution of ceramide 71 (212 mg, 0.23 mmol) in nitromethane (2.5 mL). Hg(CN)2 (116 mg, 
0.46 mmol) was added. After stirring for 20 hours at 90 °C under argon atmosphere, again no 
formation of the desired product could be observed and the reaction was stopped.  
Procedure 6 
A solution of mannosyl derivative 76 (40 mg, 0.11 mmol) in CH2Cl2 (4 mL) was added to a 
solution of ceramide 71 (100 mg, 0.11 mmol) in CH2Cl2 (12 mL). The solution was cooled to 
0 °C followed by dropwise addition of BF3.Et2O. The mixture was allowed to stir for 5 hours 
at room temperature under argon atmosphere. TLC revealed several spots, however mass 
spectrometric analysis could not identify the desired product. 
 
Chapter 5 
166 
6-amino-6-deoxy-1-O-methyl-α-D-mannopyranoside (82) 
To a solution of azide 74 (500 mg, 2.28 mmol) in THF (20 mL) was added a 1 M solution of 
trimethylphosphine in THF (22 mL). After stirring for 2 hours, H2O (20 mL) was added and 
the reaction mixture was allowed to stir for an additional 3 hours. The solvent was then 
removed by co-evaporation with toluene, yielding amine 82, which was used without further 
purification. 
Exact mass (ESI-MS) for C7H15NO5 [M+H]
+
 found, 194.1024; calcd, 
194.1029; [M+Na]
+
 found, 216.0849; calcd, 216.0848; [M+K]
+
 found, 
232.0589; calcd, 232.0587. 
 
6-deoxy-6-(1-naphthyl)ureido-1-O-methyl-α-D-mannopyranoside (83) 
To a solution of the crude amine 82 (100 mg) in DMF (5 mL) at 0 °C was added 1-
naphthylisocyanate (1.18 mL, 0.40 mmol). The mixture was allowed to stir for 1 hour at room 
temperature, followed by removal of the organic solvent by evaporation. Purification by 
column chromatography (CH2Cl2/MeOH: 95/5) afforded 83 (109 mg, 89 % over 2 steps). 
1
H-NMR (300 MHz, CDCl3): δ 7.81-7.77 (m, 1H, arom. H), 7.63-7.60 
(m, 1H, arom. H), 7.49 (dd, J = 0.9 Hz and 7.5 Hz, 1H, arom. H), 7.42 (d, 
J = 8.3 Hz, 1H, arom. H), 7.30-7.18 (m, 3H, arom. H), 6.10 (t, J = 5.6 Hz, 
1H, NH),4.42 (d, J = 1.4 Hz, 1H, H-1), 3.64 (dd, J = 1.8 Hz and 3.3 Hz, 
1H, H-2), 3.56-3.47 (m, 2H, H-6 and H-3), 3.41 (app. t, J = 9.3 Hz, 1H, 
H-4), 3.35-3.29 (m, 1H, H-5), 3.21 (ddd, J = 3.4 Hz, 6.1 Hz and 14.3 Hz, 
1H, H-6), 3.09 (s, 3H, OCH3). 
13
C-NMR (75 MHz, CDCl3): δ 158.83, 134.69, 133.99, 128.78, 128.38, 126.38, 126.29, 
126.05, 125.24, 121.78, 120.86, 101.68, 71.94, 71.07, 70.88, 68.01, 55.01, 40.80. 
Exact mass (ESI-MS) for C18H22N2O6 [M+H]
+
 found, 363.1549; calcd, 363.1556; [M+Na]
+
 
found, 385.1360; calcd, 385.1376; [M+K]
+
 found, 401.1115; calcd, 401.1115. 
1,2,3,4-tetra-O-acetyl-6-deoxy-6-(1-naphthyl)ureido-α-D-mannopyranose (85) 
A solution of 83 (98 mg, 0.27 mmol) in Ac2O (2.8 mL) and AcOH (2.8 mL) was cooled to 
0 °C, followed by addition of concentrated H2SO4 (0.06 mL). After stirring overnight at room 
temperature, one major polar spot was observed on TLC. The reaction mixture was poured 
into iced water and extracted with CH2Cl2. The combined organic layers were washed with a 
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saturated NaHCO3 solution and brine, dried over Na2SO4 and evaporated to dryness. Mass 
spectrometric analysis identified 84a-c, yet no desired product could be detected. Repeating 
the reaction under more careful monitoring of the reaction temperature and time didn’t change 
the result. 
Exact mass (ESI-MS) for C27H30N2O11 (a-b) [M+Na]
+
 found, 581.1769; 
calcd, 581.1747; [M+K]
+
 found, 597.1496; calcd, 597.1487. 
Exact mass (ESI-MS) for C29H32N2O12 (c) [M+Na]
+
 found, 623.1876; 
calcd, 623.1853; [M+K]
+
 found, 639.1507; calcd, 389.1592. 
 
 
 
2,3,4-tri-O-acetyl-6-deoxy-6-(1-naphthyl)ureido-1-O-methyl-α-D-mannopyranoside (88) 
83 (66 mg, 0.18 mmol) was dissolved in pyridine (4 mL), the mixture was cooled to 0 °C and 
Ac2O (2 mL) was added. The reaction was allowed to stir at room temperature for 1 hour. 
After removal of the organic solvent, the crude was purified by column chromatography 
(hexanes/EtOAc: 1/1) to afford 88 (44 mg, 50 %). 
1
H-NMR (300 MHz, CDCl3): δ 8.09-8.06 (m, 1H, arom. H), 7.89-7.86 
(m, 1H, arom. H), 7.78 (d, J = 8.2 Hz, 1H, arom. H), 7.59-7.44 (m, 4H, 
arom. H), 5.24 (dd, J = 3.4 Hz and 10.1 Hz, 1H, H-3), 5.14 (dd, J = 1.7 
Hz and 3.4 Hz, 1H, H-2), 5.13 (app. s, 1H, NH), 5.08 (app. t, J = 10.0 
Hz, 1H, H-4), 4.46 (d, J = 1.7 Hz, 1H, H-1), 3.80-3.73 (m, 1H, H-5), 3.69 
(ddd, J = 2.8 Hz, 7.3 Hz and 14.2 Hz, 1H, H-6), 3.21 (ddd, J = 4.6 Hz, 
7.3 Hz and 14.2 Hz, 1H, H-6), 3.07 (s, 3H, OCH3), 2.03 (s, 3H, OAc), 
2.01 (s, 3H, OAc), 1.97 (s, 3H, OAc). 
13
C-NMR (75 MHz, CDCl3): δ 170.35, 170.10, 170.08, 157.03, 134.74, 133.24, 130.04, 
128.71, 127.44, 127.10, 126.85, 125.96, 124.05, 122.30, 98.53, 69.75, 69.69, 69.12, 67.34, 
55.11, 41.04, 20.98, 20.96, 20.90. 
Exact mass (ESI-MS) for C24H28N2O9 [M+H]
+
 found, 489.1875; calcd, 489.1868; [M+Na]
+
 
found, 511.1697; calcd, 511.1687; [M+K]
+
 found, 527.1445; calcd, 527.1426. 
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2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl bromide (91) 
To a solution of 90 (20.00 g, 51.24 mmol) in Ac2O (15 mL) at 0 °C was 
added a solution of HBr in AcOH (45 mL). After stirring overnight, the 
reaction was quenched with ice, followed by extraction with CH2Cl2. The 
combined organic layers were washed with a saturated NaHCO3 solution, 
dried over Na2SO4 and co-evaporated twice with toluene to afford compound 91 as a pale 
yellow syrup. 
3,4,6-tri-O-acetyl-1,2-O-(1-methoxyethylidene)-β-D-mannopyranose (92) 
To a solution of intermediate 91 in CH2Cl2 (110 mL) was added a mixture of 2,6-lutidine (16 
mL) in MeOH (110 mL). After stirring overnight, the reaction mixture was extracted with 
CH2Cl2. The combined organic layers were washed with H2O and a saturated NaHCO3 
solution, followed by drying over Na2SO4 and evaporation to dryness. The resulting residue 
was purified by column chromatography (hexanes/EtOAc: 6.5/3.5 + 1 V% Et3N) to yield 
compound 92 (11.83 g, 67 % over 2 steps) as a yellow powder. 
1
H-NMR (300 MHz, CDCl3): δ 5.50 (d, J = 2.6 Hz, 1H, H-1), 5.30 (t, J 
= 9.8 Hz, 1H, H-4), 5.15 (dd, J = 4.0 Hz and 9.9 Hz, 1H, H-3), 4.62 
(dd, J = 2.6 Hz and 4.0 Hz, 1H, H-2), 4.25 (dd, J = 4.9 Hz and 12.2 Hz, 
1H, H-6), 4.14 (dd, J = 2.7 Hz and 12.1 Hz, 1H, H-6), 3.68 (ddd, J = 2.8 Hz, 4.8 Hz and 9.5 
Hz, 1H, H-5), 3.28 (s, 3H, OCH3), 2.12 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.06 (s, 3H, OAc), 
1.52 (s, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 170.66, 170.39, 169.43, 124.52, 97.40, 71.36, 70.64, 65.51, 
62.34, 49.94, 24.36, 20.77, 20.73, 20.68. 
Exact mass (ESI-MS) for C15H22O10 [M+Na]
+
 found, 385.1121; calcd, 385.1111; [M+K]
+
 
found, 401.0873; calcd, 401.0850. 
Spectral data are consistent with the literature data. 
1,2-O-(1-methoxyethylidene)-β-D-mannopyranose (93) 
To a suspension of compound 92 (11.77 g, 34.98 mmol) in MeOH (120 mL) was added a 
solution of NH3 in MeOH (7 N, 60 mL). After stirring overnight, the reaction mixture was 
evaporated to dryness, giving the crude 93 as a pale yellow syrup. 
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Exact mass (ESI-MS) for C9H16O7 [M+Na]
+
 found, 259.0790; calcd, 
259.0794; [M+K]
+
 found, 275.0532; calcd, 275.0533. 
 
6-O-tert-butyldimethylsilyl-1,2-O-(1-methoxyethylidene)-β-D-mannopyranose (94) 
To a suspension of 93 in THF (164 mL) was added imidazole (4.64 g, 68.16 mmol), giving a 
clear solution. Adding TBDMSCl (5.65 g, 37.49 mmol) again led to a white suspension. After 
stirring for 30 hours, the reaction mixture was filtered over celite, followed by rinsing of the 
filter cake with Et2O. Evaporation of the solvent and purification of the residue by column 
chromatography (CH2Cl2/MeOH: 9.5/0.5 + 1 V% Et3N) gave compound 94 (8.70 g, 76 % 
over 2 steps) as off-white crystals. 
1
H-NMR 5.45 (d, J = 2.4 Hz, 1H, H-1), 4.50 (dd, J = 2.6 Hz and 3.8 Hz, 
1H, H-2), 3.96 (dd, J = 4.4 Hz en 10.6 Hz, 1H, H-6), 3.85 (app. t, J = 9.2 
Hz, 1H, H-4), 3.81 (dd, J = 5.9 Hz and 10.5 Hz, 1H, H-6), 3.78-3.75 (m, 
1H, H-3), 3.31 (s, 3H, OMe), 3.28 (ddd, J = 1.3 Hz, 4.4 Hz and 5.8 Hz, 1H, H-5), 1.68 (s, 3H, 
CH3), 0.90 (s, 9H, CH3), 0.10 (s, 6H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 124.22, 97.73, 78.54, 73.06, 72.73, 70.35, 64.52, 49.80, 25.95, 
25, 91, 24.90, 18.35, -5.37, -5.41. 
Exact mass (ESI-MS) for C15H30O7Si [M+Na]
+
 found, 373.1664; calcd, 373.1658; [M+K]
+
 
found, 389.1405; calcd, 389.1398. 
3,4-di-O-benzyl-6-O-tert-butyldimethylsilyl-1,2-O-(1-methoxyethylidene)-β-D-
mannopyranose (95) 
To a solution of 94 (8.70 g, 26.01 mmol) in DMF (262 mL) at 0 °C was added NaH (3.12 g, 
78.03 mmol). After stirring for 30 minutes, benzyl bromide (9 mL, 78.03 mmol) was added 
and the solution was stirred overnight at room temperature. Upon reaction completion, the 
mixture was quenched with H2O and extracted with EtOAc. The combined organic layers 
were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The 
resulting residue was purified by column chromatography (hexanes/EtOAc: 8/2 + 1 V% Et3N) 
to afford compound 95 (10.54 g, 76 %) as a pale yellow syrup. 
1
H-NMR (300 MHz, CDCl3): δ 7.41-7.26 (m, 10H, arom. H), 5.30 (d, J 
= 2.3 Hz, 1H, H-1), 4.93 (d, J = 10.7 Hz, 1H, CH2-Ph), 4.80-4.75 (m, 
2H, CH2-Ph), 4.73 (d, J = 10.7 Hz, 1H, CH2-Ph), 4.36 (dd, J = 2.5 Hz 
and 3.9 Hz, 1H, H-2), 4.00 (app. d, J = 9.3 Hz, 1H, H-4) 3.94 (dd, J = 3.0 and 10.9 Hz, 1H, H-
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6), 3.81 (dd,
 
J = 1.9 Hz and 11.1 Hz, 1H, H-6), 3.72 (dd, J = 4.0 Hz and 9.3 Hz, 1H, H-3), 
3.28 (s, 3H, OCH3), 3.22 (dt, J = 2.5 Hz en 9.2 Hz, 1H, 5), 1.74 (s, 3H, CH3), 0.90 (s, 9H, 
CH3), 0.07 (s, 6H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 138.6, 138.0, 128.5, 128.4, 128.0, 127.9, 127.7, 124.0, 97.6, 
79.2, 77.3, 75.2, 74.8, 73.8, 72.5, 62.0, 49.6, 25.9, 24.5, 18.2, -5.3, -5.4. 
Exact mass (ESI-MS) for C29H42O7Si [M+Na]
+
 found, 553.2608; calcd, 553.2597; [M+K]
+
 
found, 569.2346; calcd, 569.2337. 
Spectral data are consistent with the literature data. 
3,4-di-O-benzyl-1,2-O-(1-methoxyethylidene)-β-D-mannopyranose (96) 
To a solution of 95 (10.54 g, 19.86 mmol) in THF (108 mL) at -78 °C was added a 1M 
solution of TBAF in THF (24 mL). After stirring for 1 hour, the solution was allowed to stir at 
room temperature. 2 hours later, the reaction mixture was diluted with EtOAc, washed with 
brine and dried over  Na2SO4. Evaporation to dryness afforded compound 96 as a syrup. 
Exact mass (ESI-MS) for C23H28O7 [M+Na]
+
 found, 439.1737; calcd, 
439.1733; [M+K]
+
 found, 455.1493; calcd, 455.1472. 
 
3,4-di-O-benzyl-1,2-O-(1-methoxyethylidene)-6-monochloromethylsulfonyl-β-D-
mannopyranose (97) 
To a solution of the crude 96 in pyridine (79 mL) at 0 °C was added 
chloromethanesulfonylchloride (2 mL, 19.86 mmol). After stirring for 30 minutes, the red-
brown reaction mixture was quenched with iced water and extracted with CH2Cl2. The 
combined organic layers were washed with a 1M solution of HCl, a saturated solution of 
NaHCO3 and H2O. Drying over Na2SO4 and concentration under reduced pressure resulted in 
97 as a brown syrup. 
Exact mass (ESI-MS) for C24H30ClO9S [M+Na]
+
 found, 551.1120; 
calcd, 551.1119; [M+K]
+
 found, 567.0857; calcd, 567.0858. 
 
6-azido-3,4-di-O-benzyl-6-deoxy-1,2-O-(1-methoxyethylidene)-β-D-mannopyranose (98) 
A solution of the crude 97 in DMF (53 mL) was heated to 80 °C followed by addition of 
NaN3 (2.58 g, 39.72 mmol). Upon reaction completion, the mixture was quenched with H2O 
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and extracted with Et2O. The combined organic layers were washed with H2O, dried over 
Na2SO4 and concentrated under reduced pressure. The resulting residue was purified by 
column chromatography (hexanes/EtOAc: 8/2 + 1 V% Et3N), yielding compound 98 (3.45 g, 
39 % over 3 steps) as a yellow syrup. 
1
H-NMR (300 MHz, CDCl3): δ 7.42-7.26 (m, 10 H, arom. H), 5.34 (d, 
J = 2.5 Hz, 1H, H-1), 4.97 (d, J = 10.9 Hz, 1H, CH2-Ph), 4.78 (app. s, 
2H, CH2-Ph), 4.66 (d, J = 10.9 Hz, 1H, CH2-Ph), 4.42 (dd, J = 2.4 Hz 
en 4.0 Hz, 1H, H-2), 3.88 (app. t, J = 8.9 Hz, 1H, H-4), 3.73 (dd, J = 4.0 Hz en 9.3 Hz, 1H, H-
3), 3.51 (dd, J = 3.4 Hz en 8.2 Hz, 1H, H-6), 3.42 (dd, J = 2.6 Hz en 4.4 Hz, 1H, H-6), 3.38 
(m, 1H, H-5), 3.29 (s, 3H, OCH3), 1.76 (s, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 137.98, 137.60, 128.59, 128.56, 128.52, 128.12, 128.10, 
128.06, 127.98, 124.11, 97.54, 78.88, 76.90, 75.43, 74.34, 73.40, 72.24, 51.19, 49.98, 24.12. 
Exact mass (ESI-MS) for C23H27N3O6 [M+Na]
+
 found, 464.1796; calcd, 464.1798; [M+K]
+
 
found, 480.1539; calcd, 480.1537. 
6-amino-3,4-di-O-benzyl-6-deoxy-1,2-O-(1-methoxyethylidene)-β-D-mannopyranose (99) 
To a solution of 98 (3.45 g, 7.81 mmol) in THF (64 mL), a 1M solution of trimethylphosphine 
in THF (39 mL) was added dropwise. After stirring for 2 hours, H2O (64 mL) was added and 
the reaction mixture was allowed to stir for an additional 2.5 hours. The solution was 
extracted with EtOAc, followed by washing of the organic layer with brine, drying over 
Na2SO4 and evaporation of the solvent to afford amine 99 as a yellow oil.  
Exact mass (ESI-MS) for C23H29NO6 [M+H]
+
 found, 416.2086; calcd, 
416.2073; [M+Na]
+
 found, 438.1905; calcd, 438.1893. 
 
3,4-di-O-benzyl-6-deoxy-6-(3-(1-naphthyl)ureido-1,2-O-(1-methoxyethylidene)-β-D-
mannopyranose (100) 
To a solution of 99 in DMF (110 mL) at 0 °C, 1-naphthylisocyanate was added. After stirring 
for 1 hour at room temperature, the solvent was evaporated under reduced pressure. 
Purification of the residue by column chromatography (hexanes/EtOAc: 6/4 + 1 V% Et3N) 
resulted in compound 100 (3.04 g, 68 % over 2 steps) as a white powder. 
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1
H-NMR (300 MHz, CD3OD): δ 8.02-7.99 (m, 1H, arom. H), 7.87-7.84 
(m, 1H, arom. H), 7.69-7.63 (m, 2H, arom. H), 7.52-7.25 (m, 13H, 
arom. H), 5.43 (d, J = 2.1 Hz, 1H, H-1), 4.87 (d, J = 12.6 Hz, 1H, CH2-
Ph), 4.77 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.72 (d, J = 10.5 Hz, 1H, CH2-
Ph), 4.69 (d, J = 11.4 Hz, 1H, CH2-Ph), 4.57 (app. t, J = 3.0 Hz, 1H, H-
2), 3.88 (dd, J = 4.0 Hz and 9.1 Hz, 1H, H-3), 3.80 (app. d, J = 11.6 Hz, 
1H, H-6), 3.60 (app. t, J = 8.9 Hz, 1H, H-4) 3.48-3.43 (m, 1H, H-5), 3.38 (app. d, J = 12.9 Hz, 
1H, H-6), 3.25 (s, 3H, OCH3), 1.60 (s, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 162.85, 157.17, 138.18, 137.90, 134.67, 133.49, 129.35, 
128.77, 128.69, 128.31, 128.14, 126.80, 126.60, 126.07, 123.96, 122.86, 122.19, 97.69,  
79.08, 75.44, 74.68, 73.59, 72.66, 50.05, 41.09, 36.72, 31.69, 29.92, 24.37, 14.43. 
Exact mass (ESI-MS) for C34H36N2O7 [M+H]
+
 found, 585.2607; calcd, 585.2601; [M+Na]
+
 
found, 607.2421; calcd, 607.2420; [M+K]
+
 found, 623.2146; calcd, 623.2160. 
(2S,3S,4R)-2-azido-3,4-di-O-benzyl-1-O-(2-O-acetyl-3,4-di-O-benzyl-6-deoxy-6-(3-(1-
naphthyl)ureido-α-D-mannopyranosyl)-octadecane-1,3,4-triol (101) 
Procedure 1 
A solution of (2S,3S,4R)-2-azido-3,4-di-benzyl-octadecane-1,3,4-triol (0.45g, 0.86 mmol) in 
CH2Cl2 (0.5 mL) was added to a suspension of mannosyldonor 100 (0.10g, 0.17 mmol) in 
CH2Cl2 (1.6 mL) at 0 °C. After stirring for 15 minutes under argon atmosphere, TMSOTf 
(0.01 mL, 0.05 mmol) was added, followed by stirring for an additional hour. The reaction 
mixture then was diluted with CH2Cl2, washed with a saturated solution of NaHCO3 and H2O, 
dried over Na2SO4 and evaporated to dryness. Purification by column chromatography 
(hexanes/EtOAc: 7.5/2.5) afforded compound 101 (0.03 g, 17 %) as a white powder.  
Procedure 2 
To a mixture of mannosyl donor 100 (0.10 g, 0.17 mmol) and powdered 4 Å molecular sieves 
in CH2Cl2 (1.6 mL) at 0 °C was added a solution of (2S,3S,4R)-2-azido-3,4-di-benzyl-
octadecane-1,3,4-triol (0.45g, 0.86 mmol). After stirring for 15 minutes under argon 
atmosphere, TMSOTf (0.01 mL, 0.05 mmol) was added, followed by stirring for an additional 
hour. The reaction mixture then was diluted with CH2Cl2, washed with a saturated solution of 
NaHCO3 and H2O, dried over Na2SO4 and evaporated to dryness. Purification by column 
chromatography (hexanes/EtOAc: 7.5/2.5) afforded compound 101 (0.06 g, 34 %) as a white 
powder. 
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1
H-NMR (300 MHz, CD3Cl3): δ 7.98-7.86 (m, 1H, 
arom. H), 7.85-7.81 (m, 1H, arom. H), 7.69-7.66 (m, 
1H, arom. H), 7.55-7.42 (m, 4H, arom. H), 7.41-7.20 
(m, 20H, arom. H), 6.62 (s, 1H, NH), 5.32 (dd, J = 1.9 
Hz and 3.4 Hz, 1H, H-2”), 4.87-4.82 (m, 1H, NH), 
4.66 (d, J = 11.0 Hz, 1H, CH2-Ph), 4.64 (d, J = 11.2 
Hz, 1H, CH2-Ph), 4.64 (J = 3.2 Hz, 1H, H-1”), 4.63-
4.58 (m, 3H, CH2-Ph), 4.56 (d, J = 11.4 Hz, 1H, CH2-
Ph), 4.51-4.48 (m, 2H, CH2-Ph), 3.94 (dd, J = 3.2 Hz and 8.3 Hz, 1H, H-3”), 3.83 (dd, J = 2.4 
Hz and 10.3 Hz, 1H, H-1), 3.67-3.52 (m, 6H, H-2, H-3, H-4, H-4”, H-5” and H-6”), 3.44 (dd, 
J = 8.1 Hz and 10.3 Hz, H-1), 3.38 (dd, J = 4.8 Hz and 11.5 Hz, 1H, H-6”), 1.99 (s, 3H, CH3), 
1.63-1.17 (m, 26H, CH2), 0.88 (t, J =  6.8 Hz, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 173.77, 172.53, 157.00, 155.76, 138.48, 137.95, 137.25, 
134.54, 133.31, 128.73, 128.06, 127.50, 126.83, 126.21, 124.92, 123.70, 122.05, 120.74, 
119.51, 99.65, 98.43, 80.24, 79.86, 79.38, 79.01, 78.64, 78.16, 76.46, 76.04, 75.61, 74.24, 
73.12, 72.25, 71.88, 71.55, 71.02, 70.32, 68.53, 67.67, 67.30, 66.46, 50.00, 48.77, 41.52, 
40.28, 37.12, 35.88, 32.17, 30.94, 30.57, 29.94, 28.74, 28.38, 26.02, 24.79, 22.93, 21.70, 
14.37, 13.14. 
Exact mass (ESI-MS) for C65H81N5O9 [M+H]
+
 found, 1076.6069; calcd, 1076.6113; 
[M+Na]
+
 found, 1098.5884; calcd, 1098.5932; [M+K]
+
 found, 1114.5629; calcd, 1114.5671. 
(2S,3S,4R)-2-azido-3,4-di-O-benzyl-1-O-(3,4-di-O-benzyl-6-deoxy-6-(3-(1-
naphthyl)ureido-α-D-mannopyranosyl)-octadecane-1,3,4-triol (102) 
A 30 % solution of NaOMe in MeOH (0.4 mL, 2.10 mmol) was added to a solution of 101 
(0.45 g, 0.42 mmol) in MeOH (1.7 mL) at 0 °C. The mixture was allowed to stir at room 
temperature but after 2 days, a lot of starting material remained and an additional amount of 
NaOMe in MeOH was added (0.4 mL, 2.10 mmol). After stirring overnight, the reaction 
mixture was neutralized with Amberlite IR 120 (H
+
 form). Filtration and rinsing with MeOH 
and CH2Cl2 was followed by evaporation of the solvent under reduced pressure. Purification 
by column chromatography (hexanes/EtOAc: 7/3) furnished 102 (0.22 g, 50 %) as a yellow 
syrup. 
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1
H-NMR (300 MHz, CD3Cl3): δ 7.99-7.97 (m, 1H, 
arom. H), 7.84-7.80 (m, 1H, arom. H), 7.66-7.59 (m, 
2H, arom. H), 7.45-7.23 (m, 23H, arom. H), 6.84 (br. 
s, 1H, NH), 5.10 (br. s, 1H, NH), 4.82 (d, J = 10.6 Hz, 
1H, CH2-Ph), 4.69 (d, J = 1.5 Hz, 1H, H-1”), 4.67 (d, 
J = 10.4 Hz, 1H, CH2-Ph), 4.63 (d, J = 11.1 Hz, 2H, 
CH2-Ph), 4.59 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.57-4.50 
(m, 3H, CH2-Ph), 3.94 (dd, J = 1.7 Hz and 3.0 Hz, 1H, 
H-2”), 3.86-3.83 (m, 2H, H-1 and H-3”), 3.68-3.59 (m, 4H, H-2, H-3, H-5” and H-6”), 3.57-
3.48 (m, 2H, H-4 and H-4”), 3.49 (dd, J = 8.3 Hz and 10.1 Hz, 1H, H-1), 3.39-3.34 (m, 1H, 
H-6”), 1.63-1.23 (m, 26 H, CH2), 0.88 (t, J = 6.8 Hz, 3H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 171.40, 157.16, 138.39, 138.36, 138.02, 137.96, 134.63, 
133.74, 129.17, 128.80, 128.69, 128.66, 128.63, 128.55, 128.27, 128.23, 128.21, 128.11, 
128.07, 128.01, 126.63, 126.40, 126.22, 126.12, 122.58, 122.17, 99.81, 79.99, 79.42, 79.22, 
76.84, 75.46, 74.56, 73.90, 72.34, 72.31, 70.96, 68.58, 68.17, 62.18, 60.63, 40.92, 32.16, 
30.14, 30.01, 29.94, 29.91, 29.87, 29.82, 29.60, 25.37, 22.93, 21.28, 14.43, 14.36. 
Exact mass (ESI-MS) for C63H79N5O8 [M+H]
+
 found, 1034.6049; calcd, 1034.6007; 
[M+Na]
+
 found, 1056.5845; calcd, 1056.5826; [M+K]
+
 found, 1072.5543; calcd, 1072.5566. 
(2S,3S,4R)-2-amino-3,4-di-O-benzyl-1-O-(3,4-di-O-benzyl-6-deoxy-6-(3-(1-
naphthyl)ureido-α-D-mannopyranosyl)-octadecane-1,3,4-triol (103) 
To a suspension of 102 (0.37 g, 0.36 mmol) in THF (2.9 mL), a 1M solution of 
trimethylphosphine in THF (1.8 mL) was added dropwise. After stirring for 2 hours, H2O 
(2.9 mL) was added and the reaction mixture was allowed to stir for an additional 2.5 hours. 
The solution was extracted with EtOAc, followed by washing of the organic layer with brine, 
drying over Na2SO4 and evaporation of the solvent to afford amine 103. 
Exact mass (ESI-MS) for C63H81N3O8 [M+H]
+
 found, 
1008.6169; calcd, 1008.6102; [M+Na]
+
 found, 
1030.5984 calcd, 1030.5921; [M+K]
+
 found, 
1046.5747; calcd, 1046.5661. 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(3,4-di-O-benzyl-6-deoxy-6-(3-(1-naphthyl)ureido-α-D-
mannopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (104) 
Hexacosanoic acid (0.28 g, 0.72 mmol) was added to a 
suspension of EDC (0.17 g, 0.90 mmol) in CH2Cl2 
(1.5 mL). After stirring for 30 minutes, a suspension 
of 103 was added and the solution was allowed to stir 
overnight. The reaction mixture was diluted with 
CH2Cl2, washed with H2O and brine, dried over 
Na2SO4 and evaporated to dryness. The resulting 
residue was purified by column chromatography 
(hexanes/EtOAc: 6.5/3.5) to yield compound 104 (0.32 g, 64 % over 2 steps) as a yellow 
syrup. 
1
H-NMR (300 MHz, CD3Cl3): δ 8.08-8.04 (m, 1H, arom. H), 7.82-7.78 (m, 2H, arom. H), 
7.64-7.58 (m, 2H, arom. H), 7.45-7.24 (m, 22H, arom. H), 5.81 (d, J = 8.5 Hz, 1H, NH ), 5.56 
(br. s, 1H, NH), 4.79 (d, J = 10.6 Hz, 1H, CH2-Ph), 4.71 (d, J = 1.9 Hz, 1H, H-1”), 4.71-4.54 
(m, 6H, CH2-Ph), 4.45 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.40-4.36 (m, 1H, H-2), 3.82 (app. d, J = 
1.5 Hz, 1H, H-2”),  3.79-3.70 (m, 2H, H-3” and H-1), 3.65-3.57 (m, 6H, H-1, H-6”, H-3, H-4, 
H-4” and H-5”), 3.50-3.44 (m, 1H, H-6”), 2.53 (br. s, 1H, OH), 1.99-1.83 (m, 2H, COCH2), 
1.64-1.11 (m, 72H, CH2), 0.89 (t, J = 6.5 Hz, 6H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 173.77, 157.04, 138.48, 138.40, 138.23, 137.96, 134.55, 
134.30, 128.80, 128.74, 128.73, 128.66, 128.49, 128.27, 128.19, 128.16, 128.10, 128.07, 
126.22, 126.16, 126.08, 124.94, 122.07, 120.77, 99.69, 80.24, 79.87, 79.37, 77.49, 75.48, 
75.39, 73.13, 72.35, 72.25, 71.56, 68.53, 67.67, 50.00, 41.50, 37.12, 32.18, 30.57, 29.98, 
29.96, 29.91, 29.77, 29.63, 29.61, 29.54, 29.52, 26.12, 26.03, 22.95, 14.38. 
Exact mass (ESI-MS) for C89H131N3O9 [M+H]
+
 found, 1386.9740; calcd, 1386.9964; 
[M+Na]
+
 found, 1408.9675; calcd, 1408.9783; [M+K]
+
 found, 1424.9347; calcd, 1424.9522. 
(2S,3S,4R)-1-O-(6-deoxy-6-(3-(1-naphthyl)ureido-α-D-mannopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (12) 
A solution of compound 104 (0.15 g, 0.11 mmol) in EtOH/CHCl3 (3.6 mL/1.2 mL) was 
hydrogenated under atmospheric pressure for 5 hours in the presence of palladium black 
(15 mg). The solution then was filtered through celite, followed by rinsing of the filter cake 
with MeOH and evaporation of the solvent under reduced pressure. Purification by column 
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chromatography (CH2Cl2/MeOH: 28/2) afforded compound 12 (0.04 g, 34 %) as a white 
powder. 
1
H-NMR (300 MHz, pyridine-d5): δ 9.48 (s, 1H, NH), 
8.94 (d, J = 8.3 Hz, 1H, NH), 8.53 (dd, J = 7.4 Hz, 1H, 
arom. H), 8.45-8.42 (m, 1H, arom. H), 7.89 (m, 1H, 
arom. H), 7.64 (d, J = 8.2 Hz, 1H, arom. H), 7.53-7.44 
(m, 3H, arom. H), 7.22 (s, 1H, NH (under pyridine)), 
5.45 (app. s, 1H, H-1”), 5.24-5.14 (m, 1H, H-2), 4.63 
(dd, J = 3.1 Hz en 10.4 Hz, 1H, H-1), 4.54-4.53 (m, 3H, 
H-2”, H-3” and H-4”), 4.45-4.37 (m, 2H, H-3 and H-
5”), 4.35-4.28 (m, 3H, H-1, H-4 and H-6”), 4.20-4.14 (m, 1H, H-6”), 2.48 (dd, J = 5.0 Hz and 
7.3 Hz, 2H, COCH2), 1.97-1.22 (m, 72H, CH2), 0.88 (t, J = 6.6 Hz, 6H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 172.93, 156.50, 135.10, 133.62, 127.63, 126.28, 125.32, 
124.81, 124.60, 121.61, 121.28, 117.61, 101.57, 74.58, 72.78, 71.66, 71.23, 70.94, 68.53, 
66.72, 51.65, 41.27, 35.73, 32.60, 30.96, 30.94, 29.15, 28.96, 28.89, 28.84, 28.77, 28.74, 
28.68, 28.58, 28.54, 28.46, 28.43, 25.41, 25.33, 21.77, 21.76, 13.11. 
Exact mass (ESI-MS) for C61H107N3O9 [M+H]
+
 found, 1026.8130; calcd, 1026.8086; 
[M+Na]
+
 found, 1048.7919; calcd, 1048.7905; [M+K]
+
 found, 1064.7678; calcd, 1064.7644. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(3,4-di-O-benzyl-6-deoxy-6-(3-(1-naphthyl)ureido-α-D-
mannopyran-2-on)-2-hexacosylamino-octadecane-1,3,4-triol (107) 
Dess-Martin oxidation 
To a solution of 104 in CH2Cl2 was added Dess Martin periodinane. After stirring for 2 hours 
at room temperature, the reaction mixture was diluted with CH2Cl2 and sequentially washed 
with Na2S2O3 and brine. The organic layer then was dried over Na2SO4 followed by 
concentration under reduced pressure to give a mixture containing mainly the undesired 106a-
d. 
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Exact mass (ESI-MS) for C89H129N3O10 (a) [M+H]
+
 
found, 1400.9719; calcd, 1400.9756; [M+Na]
+
 found, 
1422.9591; calcd, 1422.9576; [M+K]
+
 found, 
1438.9343; calcd, 1438.9315. 
Exact mass (ESI-MS) for C89H127N3O10 (b) [M+H]
+
 
found, 1398.9630; calcd, 1398.9600; [M+Na]
+
 found, 
1420.9406; calcd, 1420.9419; [M+K]
+
 found, 
1436.9088; calcd, 1436.9159. 
Exact mass (ESI-MS) for C79H125N3O9 (c) [M+H]
+
 
found, 1260.9498; calcd, 1260.9494; [M+Na]
+
 found, 
1282.9339; calcd, 1282.9314; [M+K]
+
 found, 
1298.9089; calcd, 1298.9053. 
Exact mass (ESI-MS) for C79H123N3O9 (d) [M+H]
+
 
found, 1258.9302; calcd, 1258.9338; [M+Na]
+
 found, 
1280.9169; calcd, 1280.9157; [M+K]
+
 found, 
1296.8853; calcd, 1296.8896. 
Swern oxidation 
Dimethylsulfoxide (0.05 mL, 0.67 mmol) was added to a solution of oxalyl chloride 
(0.03 mL; 0.32 mmol) in CH2Cl2 (3 mL) at -78 °C. After stirring for 30 minutes, a solution of 
104 (320 mg, 0.23 mmol) in CH2Cl2 (3 mL) was added to the reaction and the stirring was 
continued for another 45 minutes. Et3N (0.14 mL, 0.99 mmol) was then added to the reaction 
and the cooling bath was removed. After another hour of stirring, the reaction was diluted 
with CH2Cl2 and the organic layer was sequentially washed with 5 % HCl, saturated NaHCO3 
and brine. Subsequent drying over Na2SO4 and evaporation to dryness provided the crude 
ketone 107 (303 mg), which was used without any further purification. 
Exact mass (ESI-MS) for C89H129N3O9 [M+H]
+
 
found, 1384.9815; calcd, 1384.9807; [M+Na]
+
 found, 
1406.9630; calcd, 1406.9627; [M+K]
+
 found, 
1422.9333; calcd, 1422.9366. 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(3,4-di-O-benzyl-6-deoxy-6-(3-(1-naphthyl)ureido-α-D-
glucopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (108) 
To a solution of 107 in THF (6 mL) at 0 °C was added NaBH4 (21 mg, 0.25 mmol). After 
stirring for 5 hours at room temperature, the reaction mixture was concentrated under reduced 
pressure. Purification by column chromatography (CH2Cl2/EtOAc: 8.7/1.3) furnished 108 (56 
mg, 16 % over 2 steps) as an orange solid. 
1
H-NMR (300 MHz, CD3Cl3): δ 7.98-7.95 (m, 1H, 
arom. H), 7.76-7.71 (m, 1H, arom. H), 7.68 (d, J = 7.3 
Hz, 1H, arom. H), 7.55 (d, J = 8.2 Hz, 1H, arom. H), 
7.42-7.14 (m, 24H, arom. H and NH), 5.76 (d, J = 8.8 
Hz, 1H, NH), 5.14 (br. s, 1H, NH), 4.79 (d, J = 11.1 
Hz, 1H, CH2-Ph), 4.74 (d, J = 10.5 Hz, 1H, CH2-Ph), 
4.66 (d, J = 11.1 Hz, 1H, CH2-Ph), 4.62 (d, J = 11.7 
Hz, 1H, CH2-Ph), 4.57 (d, J = 10.8 Hz, 1H, CH2-Ph), 4.50 (d, J = 3.8 Hz, 1H, H-1”), 4.47 (br. 
s, 2H, CH2-Ph), 4.33 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.35-4.31 (m, 1H, H-2), 3.71 (dd, J = 3.5 
Hz and 11.4 Hz, 1H, H-1), 3.59-3.50 (m, 5H, H-1, H-3, H-4, H-3” and H-5”), 3.48-3.44 (m, 
1H, H-6”), 3.42-3.32 (m, 2H, H-2” and H-6”), 3.16 (app. t, J = 9.2 Hz, 1H, H-4”), 2.39 (d, J = 
8.5 Hz, 1H, OH), 1.98-1.78 (m, 2H, COCH2), 1.66-1.10 (m, 72H, CH2), 0.81 (t, J = 6.7 Hz, 
6H, CH3). 
13
C-NMR (75 MHz, CDCl3): δ 173.85, 156.93, 138.88, 138.33, 138.15, 138.07, 134.57, 
134.10, 128.89, 128.71, 128.69, 128.64, 128.62, 128.58, 128.53, 128.41, 128.37, 128.34, 
128.29128.14, 128.12, 128.09, 127.90, 126.35, 126.25, 126.18, 125.34, 121.98, 121.04, 99.95, 
83.40, 81.11, 79.06, 78.70, 77.47, 75.53, 75.46, 73.53, 73.19, 72.25, 71.00, 69.79, 50.13, 
41.45, 37.09, 32.18, 30.69, 29.97, 29.95, 29.92, 29.90, 29.88, 29.78, 29.62, 29.60, 29.57, 
25.96, 25.78, 22.94, 14.37. 
Exact mass (ESI-MS) for C63H79N5O8 [M+H]
+
 found, 1387.0018; calcd, 1386.9964; 
[M+Na]
+
 found, 1408.9834; calcd, 1408.9783; [M+K]
+
 found, 1424.9579; calcd, 1424.9522. 
(2S,3S,4R)-1-O-(6-deoxy-6-(3-(1-naphthyl)ureido-α-D-glucopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (13) 
A solution of compound 108 (56 mg, 0.038 mmol) in EtOH/CHCl3 (1.2 mL/0.4 mL) was 
hydrogenated under atmospheric pressure for 16 hours in the presence of palladium black 
(5 mg). The solution then was filtered through celite, followed by rinsing of the filter cake 
with MeOH and evaporation of the solvent under reduced pressure. Purification by column 
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chromatography (CH2Cl2/MeOH: 28/2) afforded compound 13 (13 mg, 33 %) as a white 
powder. 
1
H-NMR (300 MHz, pyridine-d5): δ 9.51 (s, 1H, NH), 
8.67 (d, J = 8.5 Hz, 1H, NH), 8.56 (d, J = 6.7 Hz, 1H, 
arom. H), 8.43 (dd, J = 2.6 Hz and 9.4 Hz, 1H, arom. 
H), 7.90 (dd, J = 3.2 Hz and 6.2 Hz, 1H, arom. H), 7.65 
(d, J = 8.2 Hz, 1H, arom. H), 7.54 (d, J = 7.9 Hz, 1H, 
arom. H), 7.50-7.42 (m, 2H, arom. H), 7.13 (t, J = 5.3 
Hz, 1H, NH), 6.55 (br. s, 1H, OH), 6.23 (br. s, 1H, 
OH), 5.48 (d, J = 3.8 Hz, 1H, H-1”), 5.32-5.31 (m, 1H, H-2), 4.67 (dd, J = 5.1 Hz and 11.3 
Hz, 1H, H-1), 4.52 (app. t, J = 9.1 Hz, 1H, H-3”), 4.43-4.38 (m, 1H, H-5”), 4.36-4.28 (m, 4H, 
H-3, H-4, H-1 and H-6”), 4.11 (dd, J = 5.9 Hz and 13.5 Hz, 1H, H-6”), 4.04 (dd, J = 3.8 Hz 
and 9.7 Hz, 1H, H-2”), 3.97 (app. t, J = 9.2 Hz, 1H, H-4”) 2.44 (t, J = 7.6 Hz, 2H, COCH2), 
1.90-1.21 (m, 72H, CH2), 0.88 (t, J = 6.6 Hz, 6H, CH3). 
13
C-NMR (75 MHz, pyridine-d5): δ 172.62, 156.41, 135.11, 133.66, 127.68, 126.32, 125.35, 
124.86, 124.63, 121.99, 121.59, 117.65, 100.09, 75.42, 73.59, 72.31, 71.83, 71.69, 67.64, 
50.46, 41.31, 35.69, 33.35, 30.95, 30.94, 29.18, 28.94, 28.87, 28.82, 28.75, 28.74, 28.66, 
28.57, 28.44, 28.43, 25.27, 21.76, 13.10. 
Exact mass (ESI-MS) for C61H107N3O9 [M+H]
+
 found, 1026.8115; calcd, 1026.8086. 
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6 General conclusion 
We developed an efficient route towards the synthesis of a wide variety of C-5” and C-6”-
modified α-GalCer analogues. This method also allows the late-stage incorporation of 
alternative acyl chains. A summary of the acquired data of the synthesized compounds is 
represented in Table 6.1. Consistent with earlier reports in literature we showed via the 
synthesis of deoxy compound 2 and galacturonic acid 4 that combination of two favorable 
modifications does not necessarily lead to compounds with an enhanced biological profile. 
Instead, we observed a remarkably decreased iNKT cell activity for these compounds. 
 
Glycolipid R1 R2 R3 Activity 
1 CH3 (CH2)24CH3 (CH2)13CH3 
No net polarization, strong 
antigenicitya  
2 CH3 (CH2)5Ph (CH2)13CH3 Very weak antigenicity
a 
3 COOH (CH2)24CH3 (CH2)13CH3 Very weak antigenicity
a 
4 COOH (CH2)5Ph (CH2)13CH3 Very weak antigenicity
a 
5c 
 
(CH2)24CH3 (CH2)13CH3 Th1, strong antigenicity
a 
6c 
 
(CH2)24CH3 (CH2)13CH3 
Weak Th1, weaker 
antigenicity than α-GalCera 
8 
 
(CH2)24CH3 (CH2)13CH3 
Similar iNKT cell 
activation than α-GalCerb  
9a 
 
(CH2)22CH3 (CH2)4CH3 
Th1, weaker antigenicity 
than 6ca 
9b 
 
(CH2)22CH3 (CH2)4CH3 
Th1, weaker antigenicity 
than NU-α-GalCera 
Table 6.1 Summary of the acquired data. 
a 
based on IL-4 and IFN-γ measurement (mice, in vivo), b based on  IL-2 measurement (mice, in vitro). 
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The introduction of several aromatic groups via different linker types at C-5” or C-6” showed 
that the effect can be twofold. Certain aromatic groups can result in novel interactions with 
the TCR as illustrated by 4-pyridyl substituted carbamate 5c. On the other hand, increased 
interactions with CD1d might arise, for example by the formation of an extra hydrogen bond 
and/or by the induction of an additional hydrophobic pocket. As the latter has only been 
observed for the two naphthyl-containing compounds (NU-α-GalCer and 5b), it is likely that 
the size of the aromatic group is the key determinant rather than the linker type or length. 
However, the linker length might affect the orientation of the carbohydrate moiety as has been 
shown for BnNH-GSL-1’ (6c). 
Regarding the therapeutic potential, we identified the carbamate-based glycolipids 5 as a new 
class of iNKT cell ligands with superior anti-tumor effects. 
Based on the preliminary results of the competition assays with NU-α-ManCer (12) we 
assume that this compound does not act as an iNKT cell antagonist, hence will not be useful 
in the treatment of allergic inflammatory disorders. 
The promising results of the C-6”-carbamates encourage further exploration of this class of 
compounds by substituting the C-6”-linker with other aromatic and non-aromatic groups. On 
the other hand, combination with other modifications, for example with C-type glycosides, 
might also lead to interesting findings. Finally, more research with regard to the human 
system is urgently awaited. 
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Tot slot kom ik bij de belangrijkste persoon in mijn leven. Davy, ik denk niet dat ik met 
woorden kan beschrijven hoezeer ik je dankbaar ben voor je steun en hulp tijdens de voorbije 
jaren. In gelijk welke gemoedstoestand ik van het labo thuiskwam - enthousiast, ongeduldig, 
zenuwachtig of teleurgesteld - steeds was je er om naar mij te luisteren, samen een 
vreugdedansje te doen of om mij op te peppen. Bedankt voor alles! 
  
 
